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Abstract 
Survival after acute paediatric (0–14 years), adolescent (15–19 years) and 
young adult (20–39 years) leukaemia has improved substantially over the last 
five decades, particularly for acute lymphoblastic leukaemia (ALL) and acute 
promyelocytic leukaemia, a subtype of acute myeloid leukaemia. This progress 
represents one of the most successful achievements in the history of medicine 
and has been attributed to the development of effective chemotherapy 
regimens, improvement in supportive care, better risk stratification, use of 
targeted therapies, and advances in haematopoietic stem cell transplantation.  
 Currently, long-term survival for children diagnosed with acute 
lymphoblastic leukaemia is 80%–90% in developed countries. Strikingly, 
survival among adolescents and young adults with this disease is about 60% 
and 40% respectively. In addition, in these countries, 5-year survival for young 
patients with acute myeloid leukaemia (excluding acute promyelocytic 
leukaemia) remains approximately 60% in the modern era of treatment. 
 This project aimed to evaluate how survival and, when appropriate, 
early death (death occurring within 30 days of diagnosis) after acute leukaemia 
varied during almost 25 years in California, the most populous and 
racially/ethnically diverse state in the United States (US). A second aim was to 
investigate the association between sociodemographic and selected clinical 
factors and outcomes. Using high-quality data from the California Cancer 
Registry, I evaluated survival trends from acute lymphoblastic leukaemia 
among patients aged 0–19 years, and survival and early death trends after 
acute myeloid leukaemia among patients aged 0–39 years. I also investigated 
whether early death has decreased among young patients after the approval 
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by the US Food and Drug Administration of all-trans retinoic acid (ATRA) for 
the treatment of acute promyelocytic leukaemia. 
 The overall results of this thesis showed improvement in survival over 
time for all age groups and subtypes of leukaemia. Early death after acute 
promyelocytic and myeloid leukaemias declined during the study period. 
However, these outcomes varied widely by age at diagnosis and were 
associated with sociodemographic and clinical factors. 
 Racial/ethnical survival inequalities were identified and found to persist 
even after adjustment for other covariates. These inequalities were more 
marked among patients of Hispanic (acute lymphoblastic leukaemia) and black 
race/ethnicity (for acute lymphoblastic and myeloid leukaemias). Patients living 
in lower socioeconomic neighbourhoods had worse survival than those living in 
higher socioeconomic neighbourhoods (for acute lymphoblastic and myeloid 
leukaemias).  
 Early death and worse survival were associated with initial care at 
hospitals not affiliated with National Cancer Institute-designated cancer 
centres (for acute myeloid leukaemia) and lack of health insurance (for acute 
myeloid and promyelocytic leukaemias). Intriguingly, over the 25-year study 
period, adolescents and young adults with acute leukaemia continued to have 
worse survival than children. These results suggest that lack of timely access 
to treatment and suboptimal care have influenced outcome among vulnerable 
patients.  
 In conclusion, survival and early death after acute leukaemia has greatly 
improved among young patients in California. However, inequalities in 
outcomes remain and are likely a result of multiple factors. My studies highlight 
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the importance of population-based data to reveal the actual burden of the 
disease in this population and help clinicians, policy makers, government, and 
researchers better understand the predictors of outcomes. I expect my work to 
contribute to the development of strategies aimed at improving survival from 
acute leukaemia, especially among vulnerable and disadvantaged patients. 
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“The loss of a child in any culture or country, for 
whatever reason, is a societal tragedy.” 
 
Professors Kathy Pritchard-Jones and Richard Sullivan1 
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Chapter 1 Introduction 
1.1 Background  
Acute leukaemia is the leading cause of cancer death among patients aged 39 
or younger.2, 3 Survival from acute leukaemia has improved dramatically over 
the last five decades, mainly due to intensive chemotherapeutic regimens, 
comprehensive supportive care and risk-adapted therapeutic regimens. 
Among children living in the United States (US) and Europe, 5-year overall 
survival after acute lymphoblastic (ALL) increased from less than 5% in the 
early 1960s4 to 80%–90% at present.5-7 Survival also increased substantially 
for children, adolescents and young adults with acute myeloid leukaemia 
(AML), mostly for specific subtypes of disease, such as acute promyelocytic 
leukaemia (APL) and core-binding factor (CBF) leukaemias.8-10  
 Survival among adolescents and young adults has been considerably 
lower than that observed for children with acute leukaemias.10 One explanation 
for this may be that the biology of cancers affecting adolescents and young 
adults is markedly different than the biology of paediatric cancers, even when 
the malignancies appear clinically and histopathologically similar.11 Another 
possibility is that adolescents and young adults have inferior participation in 
clinical trials than children, and this factor contributes to worse outcomes 
among these patients.12 
 Collaborative national and international clinical trials have played a key 
role in identifying more efficient and less toxic therapeutic regimens for patients 
from different age groups and subtypes of disease, and are considered the 
“gold standard” practice for the remarkable success of survival improvement 
after acute leukaemia.13 Clinical trials commonly report relatively short 
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outcomes such as early death (death within 30 days after cancer diagnosis), 
event-free survival and 1- to 5-year overall survival. Overall survival has been 
long recognised as the most relevant clinical end point in clinical trials,14 along 
with event-free survival. Event-free survival corresponds to the length of time 
that a patient remains free of complications or ‘events’ after cancer treatment. 
The event may be death, disease progression or severe drug toxicity.15  
 Despite their relevance, clinical trials, in general, provide data for less 
than 3% to 5% of the cancer population,16 although this proportion is much 
higher among paediatric patients. For example, in the United Kingdom, during 
1998–2002, 89% of children with cancer were referred to specialised cancer 
centres and treated on national protocols by the Children’s Cancer and 
Leukaemia Group.17 This proportion varies between and within countries, e.g., 
between 2000 and 2005, only about 40% of patients with acute lymphoblastic 
leukaemia aged 20 years or younger were enrolled in the Children’s Oncology 
Group (COG) trials, which are mostly conducted in the United States and 
Canada.12, 18 However, in these countries, children may be enrolled in clinical 
trials in other institutions, which use their own therapeutic protocols, such as 
Dana-Farber Cancer Institute and St. Jude Children’s Research Hospital in the 
United States. 
 Whereas clinical trials usually select patients based on their risk 
stratification, performance status and comorbidities, population-based studies 
can provide information on virtually all patients with a specific cancer and 
therefore, are frequently representative of the entire population. Moreover, 
population-based studies can estimate both short-term (mentioned above) and 
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long-term outcomes (10 to 40 years or more), providing critical information on 
excess mortality after cancer treatment. 
 Despite substantial improvement over time, survival from acute leukaemia 
varies widely between and within countries.5, 19 Survival is considered a 
fundamental measure of the effectiveness of health care systems, along with 
incidence and mortality trends.20 In addition, the examination of early death 
(death occurring within 30 days of leukaemia diagnosis) is highly relevant for 
acute myeloid leukaemia, particularly for acute promyelocytic leukaemia, 
because patients with APL have an elevated risk of developing fatal 
haemorrhage, thrombosis and sepsis in the first days after diagnosis and 
induction of treatment.21, 22 Epidemiological studies that investigate the factors 
associated with disease outcomes can reveal potential areas for improvement 
and help the development of health policies aimed at reducing childhood and 
young adult mortality after acute leukaemia. This is the main goal of my thesis. 
 
1.2 Research aims  
Using data from the State of California, my thesis had four main aims, 
described as follows.  
 The first aim was to perform a literature review on acute paediatric, 
adolescent and young adult leukaemia in order to identify the most important 
advances in disease outcomes and potential areas for improvement.  
 My second aim was to examine survival trends in children (0–14 years) 
and adolescents (15–19 years) diagnosed with acute lymphoblastic leukaemia 
during 1988–2011, and to investigate the association between survival and 
sociodemographic and selected clinical factors. These factors included age at 
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diagnosis, sex, race/ethnicity, health insurance status, type of treatment 
facility, and neighbourhood socioeconomic status (SES).  
 During my literature review, I learned that patients with acute 
promyelocytic leukaemia have a much better prognosis than patients with 
other subtypes of acute myeloid leukaemia, and therefore this entity should be 
studied separately. This directed me to my third aim, which was to evaluate 
survival and early death in children, adolescents and young adults (0–39 
years) diagnosed with acute promyelocytic leukaemia during 1988–2011, and 
examine the association between survival and the sociodemographic factors 
and clinical factors mentioned in aim 2. 
 My fourth aim was to investigate survival and early death trends after 
acute myeloid leukaemia (excluding acute promyelocytic leukaemia) among 
patients aged 0–39 years during 1988–2011 and also examine factors 
associated with outcomes. This malignancy is more common in older adults 
but also occurs in younger patients, for whom there is a lack of population-
based studies examining outcomes.10 
 The focus of this thesis was survival, but incidence rates and annual 
percentage change of acute leukaemias in California are also provided 
because of relevance, particularly to previous reports of increased incidence 
rates of certain types of leukaemias in the US6, 23 and Europe over time.24, 25 
Leukaemia incidence is presented in this thesis for each subtype of disease, 
by race/ethnicity and over time, covering the studies’ period of 1988–2011. 
Appendix 1 shows comparative charts of the distribution of each subtype of 
acute leukaemia by race/ethnicity in California. 
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1.3 Thesis structure 
This is a research paper style thesis. The chapters have been structured as 
follows. 
 Chapter 2 provides information on the burden of paediatric and young 
adult acute leukaemia and presents an overview of the haematopoiesis and 
leukaemogenesis as well as leukaemia definition, classification, aetiology, risk 
stratification, diagnosis, treatment, and prognosis. 
 Chapter 3 provides a review of the literature, assessing how survival 
and, when appropriate, early death after acute leukaemia have changed in the 
last half-century, among paediatric and young adult patients. 
 Chapter 4 includes the Materials and Methods I used in this thesis. The 
first section gives detailed information on the data source and variables I have 
used. The second section describes the statistical methods I have applied and 
discusses some sources of bias that may occur when using population-based 
studies.  
 Chapters 5 to 7 contain three research papers, each introduced with a 
preamble, followed by the incidence data for each leukaemia subtype. 
Chapter 5 provides information on how survival from acute lymphoblastic 
leukaemia varied over a 25-year period among children and adolescents in 
California. This study investigates the main factors associated with disease 
outcome and also provides descriptive information on leukaemia treatment 
(including chemotherapy and radiation), patient’s cause of death, and 
secondary malignancies. 
 Chapter 6 contains the results of the evaluation of early death (7-day 
and 30-day mortality) among children, adolescents and young adults with 
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acute promyelocytic leukaemia before and after the introduction of all-trans 
retinoic acid (ATRA). This study looks at three calendar periods: the pre-ATRA 
era and the earlier and later ATRA eras. The cut point was the year 1995 when 
the US Food and Drug Administration (FDA) approved ATRA. This study also 
investigates survival after acute promyelocytic leukaemia and the main factors 
associated with disease outcomes. In addition, I present descriptive 
information on chemotherapy and cause of death. 
 Chapter 7 provides trends in early death and survival after acute 
myeloid leukaemia in children, adolescents and young adults in California over 
25 years. This study also reveals the predictors of worse outcomes after acute 
myeloid leukaemia and provides descriptive information on treatment 
(chemotherapy and haematopoietic stem cell transplantation) and patient’s 
cause of death. 
 Chapter 8 offers an overview of the thesis, the main findings, 
contribution of my work to the field of paediatric and young adult haematology 
and limitations. In this chapter I also provide information on my future research 
plans and present the concluding remarks. 
 
1.4 Contribution of the candidate to the thesis 
All research was performed as part of my PhD studies and took place during 
the period of my registration at the London School of Hygiene and Tropical 
Medicine (January 2013 to January 2016). Two papers have been published 
in, and one accepted by peer-reviewed journals based on the work undertaken 
for this thesis (Chapters 5, 6, and 7). I am the first and corresponding author of 
the three papers, carried out all the analyses, prepared all drafts, and 
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answered the reviewers’ comments and suggestions. The co-authors’ 
contributions to the manuscripts were limited to providing statistical advice and 
comments on the drafts that I had prepared, as well as on the responses to the 
reviewers, when applicable. The co-authors reviewed and approved the final 
version of my three papers, and also approved the three posters I have 
presented at national (United States) and international conferences. The 
papers were sent to scientific editors for proofreading before the submission to 
the journals. Each editor has been acknowledged in the corresponding paper.  
 The first paper was published in Pediatric Blood and Cancer in April 
(online) and October 2015 (printed). This work was presented at three 
conferences: World Cancer Congress in Melbourne, Australia in December 
2014 (oral presentation); Global Cancer Research conference in Boston, 
United States in March 2015 (poster presentation); and GRELL Ascension 
meeting, Reus, Spain in May 2015 (poster presentation). I presented this work 
in Australia and in the United States, and my collaborator, Dr Rafael Marcos 
Gragera, presented it in Spain on my behalf. 
 The second paper was published in the journal Cancer in August 
(online) and November 2015 (printed version). I presented this study (poster) 
at the European Cancer Congress in Vienna, Austria, in September 2015. 
 The third paper was published in British Journal of Haematology in 
February (online) and April 2016 (printed). This work was presented (poster) in 
two conferences in the United States in December 2015: American Society of 
Haematology (ASH) annual meeting in Orlando-Florida and California 
Association of Regional Cancer Registries Conference (CARCR) in 
Sacramento-California. I presented the poster at ASH and my collaborator, Dr 
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Theresa Keegan, presented it on my behalf at the CARCR. The abstract was 
published in the Supplemental volume of Blood on 03 the December 2015.  
The published versions of papers 1, 2 and 3 are provided in the Appendices 4, 
5 and 6, respectively. 
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Chapter 2 Background 
2.1 Haematopoiesis and leukaemogenesis 
2.1.1 Normal haematopoiesis  
Haematopoiesis relates to the production, proliferation, self-renewal, and 
differentiation of blood cells. In response to growth factors such as stem cell 
factor glycoproteins (Interleukins 1 to 7) and colony-stimulating factors, 
multipotent haematopoietic stem cells generate and maintain all differentiated 
lymphoid and myeloid cells present in the blood, bone marrow, spleen, and 
thymus.26 The haematopoietic stem cells produce two progenitor cells: the 
common myeloid and common lymphoid cells. The common lymphoid 
progenitor cell originates the natural killer, T- and B-cells that are part of the 
immune system and have the key role of controlling infections.  
 The common myeloid progenitor cell generates three lineages of cells: 
erythrocyte, megakaryocyte, and myeloblast. The erythrocyte or red blood cell 
is responsible for carrying and delivering oxygen to the body organs and 
tissues. The megakaryocyte produces the platelets or thrombocytes, 
responsible for blood clotting. The myeloblast cell differentiates into four types 
of cells, which have the capability of defending the body against infection and 
toxins: neutrophils, eosinophils, basophils and monocytes. Figure 2.1 shows a 
schematic representation of human haematopoiesis.  
 
2.1.2 Leukaemogenesis 
Leukaemic transformation of a progenitor haematopoietic cell involves a 
disruption in the course of normal proliferation and differentiation process, 
resistance to apoptotic signals, and increased self-renewal. The prevalent 
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theory of leukaemogenesis is that a single haematopoietic cell suffers 
mutation and goes into an unlimited process of self-renewal resulting in 
malignant, poorly differentiated haematopoietic cells (clonal origin of 
leukaemic cell).27 
 
 
Figure 2.1: Haematopoiesis in humans. Source: Terese Winslow, 2008, US, 
http://www.cirm.ca.gov/files/files/about_stemcells/Unit_4_Appendix_B_0.pdf 
  
 Leukaemia cells behave differently than normal haematopoietic 
precursors, with slower cell division and longer time to produce DNA. Yet, 
these cells accumulate persistently in the bone marrow of leukaemic 
patients and progressively replace haematopoietic cells. Eventually, this 
process results in bone marrow failure, which is characterised by severe 
anaemia, bleeding, and infections.27  
 
 35 
 
2.2 Disease definition  
The word leukaemia derives from two Greek words: “leukos”, which means 
white, and “haima”, which means blood. Leukaemia is a malignancy of the 
blood and bone marrow characterized by uncontrolled proliferation of 
transformed haematopoietic cells, which have altered senescence and 
differentiation behaviour.28 
 Leukaemia can be characterised as acute or chronic. In acute leukaemia, 
the abnormal clonal proliferation contains very immature cells (blasts) that do 
not function properly. The blasts multiply quickly and the disease progresses 
rapidly. In chronic leukaemia, the blasts tend to proliferate more slowly than in 
acute leukaemia, the abnormal cells show various levels of differentiation 
beyond the blast stage, and may even function normally.  
 Acute lymphoblastic (also called lymphocytic or lymphoid) leukaemia is 
a malignant transformation of lymphoid progenitor cells and can be classified 
into B-cell and T-cell neoplasms. If the bone marrow and peripheral blood is 
extensively involved, lymphoblastic leukaemia is the appropriate term.29 The 
term lymphoma is applied when the disease presents as a tumour with no or 
minimal evidence of bone marrow and peripheral blood involvement. Acute 
myeloid (also termed myelocytic, myelogenous, or non-
lymphoblastic/lymphocytic leukaemia) is a very heterogeneous disease caused 
by malignant transformation of myeloid progenitor cells with various subtypes, 
described later in this Chapter and in Chapter 3.  
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2.3 Diagnosis and classification  
2.3.1 Diagnosis of acute leukaemia 
In the past, morphologic analysis was used to classify leukaemia in two 
categories: myeloid or lymphoid. Currently, advanced diagnostic techniques 
such as flow cytometry for immunophenotypic analysis, conventional and 
molecular genetics as well as next-generation sequencing-based multigene 
mutation profiling provide precise diagnosis and classification of leukaemias 
that are fundamental to guiding targeted therapy. Some tests are useful not 
only for diagnosis, but also to evaluate if therapy has been effective or 
modifications of the initial treatment is required. The common tests used to 
determine initial response to therapy include the fluorescence in situ 
hybridization (FISH) test, flow cytometry and polymerase chain reaction 
(PCR).30  
 The diagnosis of leukaemia can often be done by analysis of the 
peripheral blood. However, bone marrow examination is also required because 
up to 20% of patients may not present with blasts in the peripheral blood at the 
time of clinical presentation.31 In addition, the morphology of leukaemia cells in 
the blood may differ from the cells in the bone marrow. The samples are 
commonly obtained by aspiration and, in selected cases, by biopsy of the bone 
marrow if necessary (e.g., when the marrow is extremely hypocellular or there 
is myelofibrosis).32 
 The peripheral blood frequently shows anaemia and thrombocytopenia 
with a decrease or increase of leucocytes and a predominance of blasts. In the 
bone marrow, the normal cells are replaced by variable amounts of blasts or 
abnormal promyelocytes (in the case of acute promyelocytic leukaemia). The 
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lineage of leukaemia (lymphoid or myeloid) is often established by morphologic 
and cytochemical examination and, in selected cases, by immunophenotypic 
analysis. After that, the percentage of blasts in the marrow is evaluated. For 
the diagnosis of acute lymphoblastic leukaemia, a marrow replacement of 
approximately 25% by lymphoblasts is generally used as an arbitrary cut-off. 
For acute myeloid leukaemia, the criteria for diagnosis vary according to the 
classification used. The more recent World Health Organisation (WHO) 
classification29 requires 20% or more marrow replacement by myeloblasts, 
whereas the old French-American-British (FAB)33 classification required 30% 
or more myeloblasts in the bone marrow. 
 
Clinical features 
The clinical features of acute leukaemia are secondary to the accumulation of 
malignant cells with consequent bone marrow failure. Symptoms may precede 
the clinical diagnosis by weeks or months and they are often non-specific. 
They include lethargy, pallor, easy or spontaneous bruising, fever, and 
infection. Bone pain and/or limping are very common symptoms. Physical 
examination may show lymphadenopathy, hepatomegaly and/or splenomegaly 
as well as weight loss.27  
 
2.3.2 Classification of acute leukaemia 
In addition to morphology, immunophenotypic, cytogenetic and molecular 
analyses are needed to better classify leukaemias into different subtypes, 
many of which require specific treatment approaches and have different 
prognostic implications. The WHO Classification of Tumours of Haematopoietic 
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and Lymphoid Tissues,29 4th edition, published in 2008, incorporates 
information on cell lineage, morphology, immunophenotype, and clinical and 
genetic characteristics. This manual has been recognised as the international 
standard classification system for leukaemia and other haematological 
diseases. The Haematopoietic and Lymphoid Neoplasm Coding Manual34 of 
the Surveillance Epidemiology and End Results (SEER) Programme used in 
this thesis, is based on the 2008 WHO Classification.  
 
2.3.2.1 Acute lymphoblastic leukaemia 
Over the past 50 years, various classifications of diseases of lymphoid tissues 
and haematopoietic system have been recommended. Lymphoblastic 
leukaemias and lymphomas were believed to be distinct diseases and were 
classified separately. The WHO Classification of Tumours of Haematopoietic 
and Lymphoid Tissues, 3rd Edition, published in 2001, classified malignant 
neoplasms into broad groups of haematologic lineage such as myeloid and 
lymphoid. In these broad groups, lymphoid tumours were called lymphomas 
when presented in their solid phase and leukaemias when presented in the 
circulating phase. The 2008 WHO Classification of Tumours of Haematopoietic 
and Lymphoid Tissues 4th edition recognises that the difference between them 
is artificial and that lymphoblastic leukaemia and lymphoblastic lymphoma are, 
in fact, spectrum of the same disease. The leukaemic cells circulating in the 
peripheral blood can originate in lymph nodes or in the bone marrow. 
Lymphomas are solid masses in lymph nodes or organs containing lymphoid 
tissue (e.g. spleen or liver) and may, occasionally, have circulating tumour 
cells. Table 2.1 shows the SEER classification for Lymphoid Neoplasms. 
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Table 2.1: SEER classification of Lymphoid Neoplasms. Source: Hematopoietic and 
Lymphoid Neoplasm Coding Manual, 2015.
34
 
ICD-O-3  WHO Preferred Histologic Term 
9727/3 Blastic plasmacytoid dendritic cell neoplasm* 
9728/3 Precursor B-cell lymphoblastic lymphoma** 
9729/3 Precursor T-cell lymphoblastic lymphoma, not otherwise specified (NOS)** 
9835/3 Precursor cell lymphoblastic leukaemia, NOS** 
9836/3 Precursor B-cell lymphoblastic leukaemia**  
9837/3 T lymphoblastic leukaemia/lymphoma* 
9811/3 B lymphoblastic leukaemia/lymphoma, NOS*** 
9812/3 B lymphoblastic leukaemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1*** 
9813/3 B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged*** 
9814/3 B lymphoblastic leukaemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1)*** 
9815/3 B lymphoblastic leukaemia/lymphoma with hyperdiploidy*** 
9816/3 B lymphoblastic leukaemia/lymphoma with hypodiploidy*** 
9817/3 B lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32); IL3-IGH*** 
9818/3 B lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)*** 
Based on the WHO 2001 classification: *codes effective from 2001 onwards, **codes valid for 2001–
2009 only. Based on the WHO 2008 classification: ***codes valid from 2010 onwards. 
 
2.3.2.1 Acute myeloid leukaemia 
The WHO classifies the myeloid neoplasms into five major groups including 
acute myeloid leukaemia. Using the tests diagnostics mentioned earlier in this 
section, acute myeloid leukaemia is subclassified according to its lineage into 
granulocytic, monocytic, erythroid or megakaryocytic. Using the 2008 WHO 
classification for Haematopoietic Tumours, acute myeloid leukaemia is also 
defined based on recurrent cytogenetic lesions, concurrent or pre-existing 
multilineage dysplasia, chemotherapy-related myeloid malignancy, and 
whether or not associated with Down syndrome.32 SEER has been using the 
new classification with genetic information since 2010. These data will provide 
relevant information for future studies, but it will require several years until we 
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have sufficient number of patients to conduct robust incidence and survival 
analyses by subtype of acute myeloid leukaemia. Table 2.2 shows the SEER 
classification for Myeloid Neoplasms.  
 
Table 2.2: SEER classification of Myeloid Neoplasms. Source: Hematopoietic and Lymphoid 
Neoplasm Coding Manual, 2015.
34
 
 
ICD-O-3  WHO Preferred Histologic Term 
Acute myeloid leukaemias with recurrent genetic abnormalities  
9911/3 Acute myeloid leukaemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1  
9869/3 Acute myeloid leukaemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1  
9871/3 Acute myeloid leukaemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11  
9865/3 Acute myeloid leukaemia with t(6;9)(p23;q34); DEK-NUP214 
9896/3 Acute myeloid leukaemia with t(8;21)(q22;q22); RUNX1-RUNX1T1 
9897/3 Acute myeloid leukaemia with t(9;11)(p22;q23); MLLT3-MLL 
9866/3 Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA 
9895/3 Acute myeloid leukaemia with myelodysplasia-related changes 
9920/3 Therapy-related myeloid neoplasm 
9861/3 Acute myeloid leukaemia, NOS 
9870/3 Acute basophilic leukaemia 
9840/3: Acute erythroid leukaemia 
9910/3 Acute megakaryoblastic leukaemia 
9891/3 Acute monoblastic and monocytic leukaemia 
9874/3 Acute myeloid leukaemia with maturation 
9872/3 Acute myeloid leukaemia with minimal differentiation 
9873/3 Acute myeloid leukaemia without maturation 
9867/3 Acute myelomonocytic leukaemia 
9931/3: Acute panmyelosis with myelofibrosis 
9898/3 Myeloid leukaemia associated with Down Syndrome  
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2.4 Epidemiology and aetiology 
2.4.1 Incidence 
Childhood cancer is a rare disease accounting for less than 2% of the global 
cancer burden. Yet, every year more than 160,000 children are diagnosed with 
cancer worldwide.35 With current population growth and decrease in childhood 
mortality rates (mostly due to lower mortality from infectious diseases), the 
incidence of childhood cancer is expected to increase by 30% by 2020.36 
About 70% of new cases are predicted to occur in low- and middle-income 
countries, where more than 80% of paediatric cancer deaths currently occur.37 
 Leukaemia is the most common type of childhood malignancy, 
representing a third of all paediatric cancers and about 10% of malignancies in 
adolescents in the developed world. Acute lymphoblastic leukaemia accounts 
for approximately 75%–80% of all childhood leukaemias with an annual 
incidence rate of approximately 4/100,000 persons per year in the United 
States and Europe.24, 35 
There is significant geographical variation in the incidence of childhood 
leukaemia. Childhood acute lymphoblastic leukaemia incidence varies from 1 
to 4.95/100,000 persons per year, with the highest rates reported in Mexico,38 
Costa Rica39 and among whites and Hispanic children living in the United 
States.40, 41 Incidence is also high in Australia and Germany with intermediate 
rates in most European countries. Incidence of acute lymphoblastic leukaemia 
is lower in the Middle East, Sub-Saharan Africa, India, and among black 
children in the United States.32 It is unclear how much geographic variation is 
due to environmental or genetic factors, or under-diagnosis of common acute 
lymphoblastic leukaemia in some countries.42 A previous study measured 
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completeness of cancer registration in Kampala, Uganda among patients aged 
15 years or older. Overall, completeness of ascertainment was 89.6% and 
varied by age (better for younger patients) and tumour site.43  
 The incidence rates of childhood acute lymphoblastic leukaemia have 
increased significantly since 1970s, by 1.4% per year in Europe25, 44 and 
0.5%–0.8% in the United States,6, 23 but have remained stable in the Nordic 
countries.45 Figure 2.2 shows the distribution of acute lymphoblastic leukaemia 
by age group in the United States using SEER data. SEER 18 includes data 
available for all cases of cancer diagnosed from 2000 onwards in the following 
cancer registries: Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, 
San-Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles, San Jose-
Monterey, Rural Georgia, Alaska, Greater California, Kentucky, Louisiana 
(adjustments were needed for cases occurred during July to December in 
2005 due to Hurricanes Katrina and Rita), New Jersey, and Greater Georgia.46  
  Almost universally, the age-adjusted incidence for boys exceeds that 
for girls, with the sex ratio for acute lymphoblastic leukaemia typically between 
1.2 to 1.47 In the developed countries, white patients have moderately higher 
rates of leukaemia than non-white patients.48 For instance, in the United 
States, the annual incidence rates of acute lymphoblastic leukaemia in white 
children are about twice those in black children. Age-specific incidence of 
acute lymphoblastic leukaemia presents a characteristic peak at 2–5 years for 
the common acute lymphoblastic leukaemia in most industrialised countries. 
This early peak is less marked or even absent in economically disadvantaged 
populations (including black patients in the United States and various low- and 
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middle-income countries), and this is precisely the age range with the best 
prognosis for acute lymphoblastic leukaemia.42, 44, 49  
 
 
 Figure 2.2: Percentage of new cases of acute lymphoblastic leukaemia by age groups 
in the United States, SEER18, 2008–2012, all races, and both sexes. Adapted from NCI 
SEER Stat Fact Sheets: Acute Lymphocytic Leukaemia (ALL), 2015. 
http://seer.cancer.gov/statfacts/html/alyl.html
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 Acute myeloid leukaemia comprises about 15%–20% of all paediatric 
leukaemias, with an annual incidence rate of 0.8/100,000 persons per year in 
the United States. Of those diagnosed with this malignancy, approximately 
33% are adolescents and 50% are adults in the developed countries.51 There 
is also substantial geographical variation in the incidence of acute myeloid 
leukaemia, with the highest incidence rates reported in China, Japan and 
among the Maori population in New Zealand. Intermediate rates are reported 
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in Australia, United Kingdom and in the United States. The lowest incidence 
rates of acute myeloid leukaemia are reported in India, Kuwait and Canada.32  
 Although acute myeloid leukaemia is a neoplasm more frequent in older 
people, this disease can occur at any age and remains the leading cause of 
cancer deaths among patients aged ≤ 39 years.3 In contrast to acute 
lymphoblastic leukaemia, there is no evidence of a significant increase of 
incidence of acute myeloid leukaemia among children, adolescents and young 
adults in the United States52 and Europe53 over the last few decades. Figure 
2.3 shows the distribution of acute myeloid leukaemia, by age group in the 
United States using more recent SEER data (2008–2012). Regarding 
race/ethnicity, Hispanic children have the highest incidence rates of acute 
myeloid leukaemia, mostly due to the high incidence of acute promyelocytic 
leukaemia in this population, suggesting genetic predisposition and/or 
exposure to environmental factors.32 
 
2.4.2 Aetiology 
Since its recognition in 1845, the search for an etiologic agent for leukaemia 
has been intense, and numerous factors have been proposed, from infectious, 
chemical or physical agents to genetic factors. To date, the precise pathogenic 
events that contribute to the development of leukaemia remain largely 
unknown, but it does appear that various factors may act together. 
Additionally, variations may exist from individual to individual and between 
different types of leukaemia.54 
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Figure 2.3: Percentage of new cases of acute myeloid leukaemia by age groups in the 
United States, SEER 18, 2008–2012, all races, both sexes. Adapted from NCI SEER Stat 
Fact Sheets: Acute Myeloid Leukaemia (AML), 2015. 
http://seer.cancer.gov/statfacts/html/amyl.html 
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 Most of the environmental exposures that have been suggested lack 
biological or consistent epidemiological evidence. Ionizing radiation is the only 
established causal exposure for paediatric leukaemia.56, 57 Less than 5% of 
incident cases are associated with inherited predisposing genetic disorders, 
such as Down and Li-Fraumeni syndromes, ataxia-telangiectasia, 
neurofibromatosis, polymorphism of xenobiotic metabolizing enzymes, or with 
prenatal exposure to X-rays or chemotherapeutic drugs.58, 59 Children with 
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Down syndrome have a 10–20 fold increased risk of developing acute 
lymphoblastic or myeloid leukaemia than children without Down syndrome.60 
 Biological studies suggest that both prenatal and postnatal events may 
be involved in the development of leukaemia. Most chromosome 
translocations happen in utero, during foetal haemopoiesis, probably as 
initiating events. In most cases, secondary genetic events are also required. 
The most well-known hypotheses for the aetiology of childhood leukaemias are 
Kinlen’s population-mixing61 and Greaves’ delayed infection hypotheses62 
described below and illustrated in Figure 2.4.58  
 
Kinlen’s hypothesis  
Kinlen proposed that clusters of childhood acute lymphoblastic leukaemia 
result from a limited epidemic caused by a common but relatively non-
pathogenic infection occurring in individuals who were susceptible, following 
contact or ‘population mixing’ with individuals who are infected. 61 
 
Greaves’ hypothesis  
Greaves suggested that both acute lymphoblastic and myeloid leukaemias in 
children originate from two spontaneous mutations. One would occur in utero 
through the generation of a pre-leukaemic clone caused by chromosomal 
rearrangements, a second is assumed to occur after birth, following the infant’s 
first contact with a diverse range of antigens leading to secondary genetic 
abnormalities.62 
 Some studies suggest other risk factors for acute lymphoblastic 
leukaemia, but they are still controversial. They include the following: high 
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birthweight,63-65 maternal reproductive history,65 parental use of tobacco66 or 
alcohol,67 maternal diet,68 parental exposure to pesticides69 or paint and 
petroleum solvents,70 and exposure to high levels (>0.3 or 0.4 T) of 
residential power-frequency magnetic fields.71 
 
 Figure 2.4: Infection-based models of leukaemia development. Adapted from Pui et 
al., The Lancet 2008
58
 
 
 Chromosomal translocations are often associated with acute leukaemia 
and it is well established that most of these patients carry multiple genetic 
abnormalities. Disease outcome varies not only among cytogenetic subtypes 
of leukaemia, but also within each subtype of disease. Patients carrying a 
single genetic alteration may have different associated genetic abnormalities54 
Genome-wide analyses of gene expression have helped the understanding of 
leukaemogenesis and prognosis, but little is known about how genetic 
mutations produce overt leukaemia or induce resistance to drugs used to treat 
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this disease. There is evidence that leukaemia with different biologic subtypes 
may not share the same causal associations. For instance, acute 
lymphoblastic leukaemia in infants is commonly associated with MLL gene 
rearrangements and has almost 100% concordance rate in identical twins. 
This suggests that the leukaemogenesis in this subtype of leukaemia is 
basically complete in utero. Distinctively, non-MLL rearrangement B-cell 
lymphoblastic leukaemia, which has a higher incidence in children aged 2–5 
years, has a much lower concordance rate in identical twins (10%–15%).72 
This suggests that after an in-utero initiation process, a post-birth event may 
occur and lead to overt leukaemia.73  
 Figure 2.5 shows the multiple genetic events that can occur in the 
pathogenesis of B-cell lymphoblastic leukaemia at both diagnosis and relapse. 
For example, a haematopoietic stem cell lymphoid progenitor can have an 
initiation mutation that deregulates the normal haematopoiesis and may be 
influenced by inherited variants. This haematopoietic stem cell may progress to 
a mature B-cell (normal cell) or, through cooperative alterations undergo 
lymphoid leukaemogenesis. After chemotherapy, the leukaemic cells are 
destroyed and the patient is cured. However, on some occasions, one single 
resistant cell can be selected, undergo self-renewal and cause disease 
relapse. Genetic alterations that predispose to treatment resistance may be 
acquired or be present since diagnosis. 
 Currently, almost all patients with acute lymphoblastic leukaemia can be 
classified based on a specific genetic lesion. The most frequent genetic 
abnormalities in common acute lymphoblastic leukaemia are hyperdiploidy and 
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TEL-AML1 (ETV6-RUNX1) fusions. The frequency of specific genotypes in 
childhood acute lymphoblastic leukaemia is shown in Figure 2.6.72 
 
 
Figure 2.5: Multiple genetic events in acute lymphoblastic leukaemia at diagnosis and 
relapse. Source: Inaba et al., The Lancet 2013
73
 
 
 Adolescents and young adults with acute lymphoblastic leukaemia often 
have inferior outcomes compared to children with this disease. This fact is 
partially explained by the increased frequency of Philadelphia chromosome 
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positive and T-cell ALL associated with inferior outcome in the older 
population. Moreover, there is a lower incidence of ETV6-RUNX1 fusion and 
hyperdiploidy among adolescents and young adults, alterations that are 
associated with better outcome.58, 72, 74  
 
 
Figure 2.6: Genomic abnormalities in childhood acute lymphoblastic leukaemia. The 
genetic alterations seen exclusively in patients with T-cell ALL are shown in purple. 
Source: Pui et al., J Clin Oncol 2011
72, 75 
 
 Acute myeloid leukaemia is a complex and very heterogeneous 
malignancy. However, there is enough evidence that acute myeloid leukaemia 
subtypes share a few similar pathways that results in leukaemogenesis and 
overt disease.76 The accepted hypothesis is that acute myeloid leukaemia is a 
consequence of two collaborative types of genetic alterations that controls cell 
self-renewal and differentiation.77 Figure 2.7 shows the most frequent genetic 
alterations in children with acute myeloid leukaemia. Approximately 95% of 
children with acute myeloid leukaemia have at least one genetic alteration.  
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Figure 2.7: Genetic abnormalities in childhood acute myeloid leukaemia. Left side: most 
common karyotypic alterations. About 80% of all children with AML have genomic 
structural alterations. Right side: mutation profile in children with AML with normal 
karyotype. Source: Pui et al., J Clin Oncol 2010
72, 75
 
 
2.5 Risk stratification, treatment and prognosis 
The recognition that acute lymphoblastic and myeloid leukaemias are 
heterogeneous disease has guided risk-directed therapy aimed at improving 
survival as well as the quality of life of survivors.58 The identification of patients 
with high risk of relapse allows that very intensive treatment is provided only 
for high-risk patients, hence preventing excessive toxic effects among cases 
with low-risk disease.78 Cytogenetic and molecular characteristics as well as 
assessment of minimal residual disease have been substituting many 
conventional prognostic factors in both acute lymphoblastic and myeloid 
leukaemias. The risk stratification of acute leukaemias and several risk 
adapted-treatments are described in the sections below.72 
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2.5.1 Acute lymphoblastic leukaemia 
Specific treatment approaches for acute lymphoblastic leukaemia may differ 
depending on the disease presentation, but they regularly include remission-
induction, intensification or consolidation treatment, and maintenance therapy 
to eradicate leukaemia cells.27  
 Patients with acute lymphoblastic leukaemia generally need long 
maintenance treatment in order to prevent relapse. During 6 to 12 months, 
intensive multidrug chemotherapy is used, followed by a less intensive regimen 
for 2.5 to 3 years, given daily or weekly. The mechanism by which lower dose 
chemotherapy regimen eradicates the residual leukaemic cells is poorly 
understood. 
 When continuation treatment was given during a shorter period of time 
(18 months or less) for children and adults with acute lymphoblastic leukaemia, 
survival was lower than that of conventional treatment. While approximately 
65% of young patients may be cured with only 12 months of chemotherapy, it 
is not possible to identify these cases with certainty and the current 
recommendation is to treat these patients for two years or more.27 Common 
drugs used for the treatment of acute lymphoblastic leukaemia include 
corticosteroids, asparaginase and vincristine.79  
 Currently, early response to therapy is assessed by most groups via 
measurement of residual disease at specific time points in treatment: at day 8 
in the peripheral blood and day 29 in the bone marrow.25 Minimal residual 
disease, which is the number of residual leukaemia cells expressed in 
percentage of normal nucleated cells in the bone marrow, has been 
recognised as the most important prognostic factor for survival in patients with 
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acute lymphoblastic leukaemia and can be detected by polymerase chain 
reaction or by flow cytometry. One study lead by the Children’s Oncology 
Group,30 revealed that the presence of minimal residual disease in the blood at 
day-8 and in the bone marrow at day-29 was associated with lower event-free 
survival (length of time after cancer treatment that the patient remains free of 
disease or complications). This occurred in all patients diagnosed with B-ALL 
regardless risk group stratification. Even children with as little minimal residual 
disease as 0.01% to 0.1% leukaemia cells at day 29 had worse event-free 
survival than patients negative for minimal residual disease (5-year EFS was 
59% vs. 88%, respectively). This suggests that continuous minimal residual 
disease monitoring may be useful to identify patients with high or intermediate 
risk of relapse (those with a somewhat slow early response to therapy) and 
guide therapy. However, clinicians should be aware that some patients with 
persistent minimal residual disease may be cured, while some patients with 
minimal residual disease negative (undetectable) at remission can still present 
leukaemia recurrence.80, 81 This emphasises the fundamental role of 
maintenance treatment for patients with acute lymphoblastic leukaemia. 
 Treatment directed at the central nervous system is of key importance 
and should be initiated early in the course of treatment. Several factors are 
taken into account when selecting the intensity of therapy, such as risk of 
relapse and the quantity of leukaemic cells in the cerebral spinal fluid.82 It has 
been established that cranial irradiation can cause various acute and late 
adverse effects such as secondary malignancies, neurocognitive disorders and 
endocrinopathies. Consequently, in many centres, cranial irradiation has been 
replaced by intrathecal and systemic chemotherapy.83, 84 82 
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 Induction failure is rare in children, and can be defined as the presence 
of leukaemic cells in the peripheral blood, bone marrow or extra medullary 
location after 4–6 weeks of induction therapy. All children with acute 
lymphoblastic leukaemia who have induction failure are considered very high-
risk patients and haematopoietic stem-cell transplantation is recommended.85 
In a previous study, children who had T-cell leukaemia appeared to have 
higher survival with transplantation than with chemotherapy, while children 
who had precursor B-cell leukaemia without other unfavourable characteristics 
appeared to have higher survival with chemotherapy alone.86  
 Detailed information on adolescents and young adults is comparatively 
scarce because of the smaller number of incident cases in this age group, as 
well as lower enrolment of these patients in clinical trials compared with 
children and older adults.87 Consequently, adolescents are commonly 
examined together with children aged 10–15 years in paediatric trials or with 
patients aged 20–30 years in adult trials.74 There is evidence that substantial 
decline in survival is observed beyond 15 years of age at diagnosis.88  
One study examined patients aged 16–20 years with acute 
lymphoblastic leukaemia enrolled in the Children’s Cancer Group (CCG) and 
Cancer and Leukaemia Group B (CALGB) clinical trials, and compared 
outcomes from the distinct protocols used by these groups. Sever-year event-
free survival and overall survival were 63% and 67% respectively for patients 
treated on CCG protocols vs. 34% and 46% for those treated on CALBG 
protocols. The main differences between both treatment approaches were 
earlier and more intensive central nervous system prophylaxis and higher 
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cumulative doses of nonmyelosuppressive drugs used by CCG compared to 
CALBG protocols.74 
 At present, evidence suggests that intensified treatment protocols may 
reduce or eliminate the influence of some prognostic factors, such as male 
sex, black race and Down syndrome, on survival.89, 90 One study in the United 
States showed that when intensified treatment is provided, black and white 
children of both sexes have the same chance of attaining high survival and 
cure.90  However, these results need to be interpreted with caution because, to 
date, they have only been observed in a single institution. Moreover, although 
children with Down syndrome have an increased risk of developing acute 
lymphoblastic leukaemia and lower survival, outcomes are comparable in 
children with and without Down syndrome after adjustment for favourable and 
unfavourable cytogenetic lesions.91 
Clinical trials have identified several factors predictive of outcomes after 
acute lymphoblastic leukaemia, as summarised in Table 2.3.92 The few 
particular subgroups of high-risk patients with acute lymphoblastic leukaemia 
that should be treated with a risk-adapted protocol are described below.72  
 
Philadelphia Chromosome-Positive ALL  
Due to the extremely poor prognosis in the past, children Philadelphia 
Chromosome-Positive ALL are currently treated with intensive chemotherapy 
plus imatininb or desatinib, tyrosine kinase inhibitors. Haematopoietic stem cell 
transplantation may be recommended in case of relapse. 
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High-Risk T-cell ALL  
The management of patients with high-risk T-cell ALL requires intensive 
treatment with asparaginase and dexamethasone. A subtype of T-cell ALL 
called early T-cell precursor ALL has a dismal prognosis even when they 
undergo haematopoietic stem cell transplantation. Clinicians and researchers 
continue to explore new treatment strategies aimed at improving outcomes of 
patients with this entity. 
 
Infant acute lymphoblastic leukaemia 
Infants with acute lymphoblastic leukaemia continue to fare poorly even with 
intensive therapeutic regimens. The role of haematopoietic stem cell 
transplantation in first remission has been investigated in very high-risk 
patients (age <6 months, WBC > 300 X 109, and MLL rearrangement).72 
 
Table 2.3: Predictors of outcome and treatment response for children with acute 
lymphoblastic leukaemia. Adapted from Hunger et al., Pediatr Blood Cancer 2013.
92
 
 Good prognosis Poor prognosis 
Age at diagnosis > 1 and < 10 years <1 or ≥ 10 years 
WBC count at 
diagnosis 
< 50,000/L  ≥ 50,000/L 
Immunophenotype B-precursor ALL T-precursor ALL 
CNS or testicular 
leukaemia 
Absent Present  
Presence of genetic 
lesions 
ETV6-RUNX1 fusion 
Hyperdiploidy with 
favourable 
chromosome trisomies 
MLL-rearrangements (MLL-R) 
Hypodiploidy (<44 chromosomes) 
Intrachromosomal amplification of chromosome     
21 (iAMP21) 
Philadelphia chromosome positive: t(9;22) 
BCR/ABL 
Early treatment 
response 
Yes No 
MRD after induction <0.01% ≥ 1% 
Abbreviations: ALL, acute lymphoblastic leukaemia; CNS, central nervous system; WBC, white 
blood cell 
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Adolescent and young adult acute lymphoblastic leukaemia 
As mentioned in section 2.5.1, adolescent and young adults with acute 
lymphoblastic leukaemia have poorer outcomes compared with children. In the 
mid-2000s, collaborative trials began to treat these patients with paediatric 
protocols and several studies have shown excellent results.93-95 Between 2007 
and 2012, a large prospective adult intergroup trial (C10403)96 in the United 
States, investigated the adoption of a successful protocol used by the 
Children’s Oncology Group (COG ALL0232) for treatment of patients aged 16–
39 years with acute lymphoblastic leukaemia.97 A total of 296 patients with B- 
or T-cell ALL were treated with paediatric protocols by adult 
haematologists/oncologists. The significant improvement in outcomes (event-
free survival and overall survival) supports the use of paediatric protocols by 
adult haematologists to treat adolescents and young adults with this neoplasm. 
However, despite of improvement, there is evidence that these patients 
continue to be treated with low-intensity chemotherapy regimens in many 
centres.98 An explanation may be that some clinicians are not yet convinced 
about the paediatric approach superiority compared to the conventional 
treatment and may await more evidence from a randomized Phase III study.98 
Another possibility is that adult haematologists might not feel as familiar as 
paediatricians in managing the treatment-related toxicity secondary to the 
intensive paediatric protocol. Some complications of treatment such as 
pancreatitis, osteonecrosis, hyperglycemia, and infection seem to occur more 
often in older patients (> 10 years old). This may cause adult clinicians to 
change prescribed drug dosage and schedule.99, 100 Lastly, while most 
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academic centres in the United States have adopted the paediatric regimens 
this may not be the same in community hospitals.98  
 In spite of the dramatic improvement in survival, an appreciable risk of 
death remains for many years after diagnosis of acute lymphoblastic 
leukaemia, and significant numbers of children and adolescents still die of 
relapsed or refractory disease. The main determinants of survival are time to 
relapse, site of relapse, leukaemia immunophenotype, and more recently, 
minimal residual disease. Patients who present relapse within 36 months of 
diagnosis have a dismal 5-year overall survival of approximately 15%.92, 101  
 Salvage chemotherapy or even haematopoietic stem cell 
transplantation for both adults and children with relapsed or refractory acute 
lymphoblastic leukaemia have not improved outcome, and intensive research 
continues to be done in order to find new therapeutic agents able to improve 
survival in these patients. New monoclonal antibodies such as cluster of 
differentiation (CD) 19, CD20, CD22, and CD52 have been developed. The 
rationale for the use of monoclonal antibodies is that lymphoblasts express 
various cell-surface antigens that may be favourable targets for this therapy. 
For instance, over 95% of B-cell ALL and more than 90% of lymphoblasts 
express CD19 and CD22, respectively.102 Monoclonal antibody therapy has 
been recently used in clinical trials to treat children and adults with relapsed or 
refractory acute lymphoblastic leukaemia. The initial results have been 
favourable with good tolerability and high levels of negative minimal residual 
disease. However, longer follow-up time is necessary to assess toxicity and 
long-term outcome. 102 
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2.5.2 Acute myeloid leukaemia  
Similar to acute lymphoblastic leukaemia, risk-adapted therapy has become 
critical for acute myeloid leukaemia. Acute myeloid leukaemia has been risk 
stratified in two major groups. The low risk group (about 25% of the cases) 
includes patients with CBF AML (t[8;21], inv16, t[15;17]), infant AML, AML with 
Down syndrome, AML with CEBPA and NPM1 mutations (non-FLT3-ITD) or  
megakaryoblastic AML with the t(1;22) abnormality, and minimal residual 
disease negative. The high-risk group (about 25% of the cases) includes 
patients with unfavourable cytogenetic alterations (monosomies 5 and 7), 
FLT3-ITD and TP53 mutations, secondary AML, AML associated with 
myelodisplastic syndrome, and minimal residual disease positive.72 In 
approximately 40%–50% of cases there is not a good genetic or molecular 
marker to determine the disease prognosis and clinicians use minimal residual 
disease assessment to guide treatment.103  
 In general, the treatment of acute myeloid leukaemia is performed using 
four to five intensive courses of cytarabine and anthracyclines chemotherapy. 
Maintenance therapy appears not to have any advantage in acute myeloid 
leukaemia as it occurs for acute lymphoblastic leukaemia. Central nervous 
system directed therapy with triple agents is also recommended for acute 
myeloid leukaemia. Haematopoietic stem cell transplantation is performed 
more often among young patients with acute myeloid leukaemia than for acute 
lymphoblastic leukaemia (about 30% vs. 5%).72 
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Core-binding factor AML  
Core-binding factor AML (CBF AML) is associated with chromosomal 
rearrangements between chromosomes 8 and 21 (t8;21) and within 
chromosome 16 (inv [16]). This subtype accounts for about 25% of all 
childhood acute myeloid leukaemia cases and its prevalence decreases with 
advancing age. CBF AML prevalence is approximately 10%–15% in adults 
aged 60 years or younger and 5% in patients older than 60 years.104 With 
intensive chemotherapy regimens with three to four drugs, CBF AML has 
become a group of good prognosis with 3-year overall survival of 
approximately 90% in children and adolescents105 and about 69% for young 
adults.8 Patients with t(8;21) AML may have a higher incidence of relapse than 
those with inv(16). However with the receipt of haematopoietic stem cell 
transplantation, they have a high possibility of cure.72 
 Children and young adults with acute promyelocytic leukaemia have 
also a favourable prognosis with 3-year overall survival of approximately 75%–
90% when all-trans retinoic acid or arsenic trioxide is associated to 
conventional chemotherapy.106 Haematopoietic stem cell transplantation is not 
recommended for children in complete remission, but may be indicated for 
those who relapse.72  
 
Down syndrome and acute myeloid leukaemia 
In contrast to acute lymphoblastic leukaemia, patients with acute myeloid 
leukaemia and Down syndrome have a better prognosis than non-Down 
syndrome patients with acute myeloid leukaemia. Therefore, the current 
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treatment approach is to reduce chemotherapy agents in order to avoid 
complications of treatment, particularly cardiotoxicity. 
 
Neonatal and infant acute myeloid leukaemia 
Because neonates with acute myeloid leukaemia may have spontaneous 
remission, some clinicians may choose to observe them rather than begin 
chemotherapy immediately. When chemotherapy is necessary, careful dose 
adjustments should be done in order to avoid toxicity. Neonates tend to have 
worse clinical course due to complications of treatment and disease resistance 
than children. On the contrary, infants with acute myeloid leukaemia often 
have similar prognosis as older children provided that they receive intensive 
chemotherapy regimen. Haematopoietic stem cell transplantation seems not to 
improve outcome in these patients and can cause serious adverse effects. 
 
Acute myeloid leukaemia with altered genes (FLT3-ITD, NPM and CEBPA 
mutations) 
FLT3-ITD mutations are associated with poor prognosis in children (5-year 
overall survival < 35%).107 The use of haematopoietic stem cell transplantation 
is still controversial, being usually reserved for high-risk patients. In contrast, 
patients with FTL3 point mutation have a better outcome and are often treated 
with chemotherapy only. Patients with NPM and CEBPA mutations have a 
favourable prognosis; therefore haematopoietic stem cell transplantation is not 
usually recommended for these patients. 
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AML with MLL-rearrangements 
AML with MLL-rearrangements is a heterogeneous disease and prognosis 
may vary from 22% for patients with t(6;11) to 100% for those with t(1;11). The 
role of haematopoietic stem cell transplantation remains controversial in this 
subtype of disease.108  
 
 In summary, the prognosis of acute leukaemia has improved 
substantially in the last few decades, mainly for acute lymphoblastic leukaemia 
and some subtypes of acute myeloid leukaemia. This improvement was 
possible due to national and international collaborative clinical trials that 
investigate the association of various factors on outcome. Risk-adapted 
therapy based on patient’ clinical and genetic features and minimal residual 
disease assessment have largely contributed to treatment success in both 
acute lymphoblastic and myeloid leukaemia treatments. However, for specific 
types of disease, prognosis is still poor and new treatment approaches are 
warranted.  
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Chapter 3: Literature review 
This literature review was divided in two sections. The first section contains the 
literature review on acute lymphoblastic leukaemia (ALL) and the second 
section provides the literature review on acute myeloid leukaemia (AML). The 
second section was subdivided in order to study acute promyelocytic 
leukaemia (APL) and acute myeloid leukaemia (non-APL) separately.  
 
3.1 Acute lymphoblastic leukaemia  
3.1.1 Aims 
The main aim of this literature review was to identify how survival from 
childhood acute lymphoblastic leukaemia varied over time in different 
populations, and to document the main advances in the diagnosis and 
treatment of this malignancy. I have also investigated, as a secondary aim, 
worldwide trends in incidence of acute lymphoblastic leukaemia.  
 
3.1.2 Search strategy and eligibility criteria 
I searched the databases Medline, Embase, Global Health and LILACS to 
identify studies reporting incidence of and survival after acute lymphoblastic 
leukaemia in children and adolescents. Databases were searched for 
publications from the last 5 years (from 2008 onwards) but also included 
relevant studies cited in these publications. I used the following approach: 1) 
Study population: “Child*” OR “paediatric” OR “pediatric” OR “boys” OR “girls” 
OR “infant*” OR “baby” OR “babies” OR adolescent*” AND 2) Acute 
lymphoblastic leukaemia terms: (“acute” OR “precursor”) AND (“lymphoblastic” 
OR “lymphoid” OR “lymphocytic”) AND “leukaemia” OR “leukemia” AND 3) 
 64 
 
Disease outcome terms: “survival” OR “incidence”. I searched for articles 
published in English, Portuguese or Spanish due to my language proficiency. 
After duplicates had been removed, all titles and abstracts of publications 
identified in the course of my primary search were reviewed for relevance and 
eligibility criteria.  
 Eligibility criteria were: 1) original studies that report any length of 
survival from or incidence of acute lymphoblastic leukaemia in children and 
adolescents, 2) studies types were: cohort studies, clinical trials, reviews, 
systematic reviews and meta-analyses and cross-sectional studies. 
Conferences abstracts were excluded. Articles titles and abstracts were 
screened to select papers for full text screening.  
 
3.1.3 Search results 
My primary search identified 5,710 references. A total of 3,138 duplicates were 
removed using Endnote X6 and by hand searching, resulting in 2,572 
references. From the remaining 2,572 references, 161 articles that appeared 
relevant from the abstract were reviewed in full and 26 were selected for 
inclusion in this literature review. The process of selection of the studies for 
this literature review is presented in Figure 3.1. 
 The 26 selected articles were published between 1998 and 2014, most 
in the last five years, and covered the period from 1962–2014. The study 
designs included population-based cohort, clinical trial, case-control and cross-
sectional studies. Systematic reviews and one meta-analysis (on 
abandonment of treatment) were also included. The studies covered many 
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geographical areas, but most originated from Europe and the United States. 
The population age range varied from 0–19 years.  
 The main outcome of interest was survival to a specified time post-
diagnosis. Data on disease biology, incidence, abandonment of treatment, 
relapse and treatment toxicity were also captured in some of the studies. 
Abandonment of treatment refers to children who either refused to begin 
potentially curative therapy at diagnosis or who interrupt therapy during active 
treatment. It does not include loss to follow-up after relapse or completion of 
therapy. The 26 studies identified from the literature search are summarised in 
Table 3.1. 
 In this Chapter, I report the main results from this literature review under 
a number of sub-headings as follows: biology and survival of ALL, incidence, 
improvement of survival over time, racial and ethnic differences in survival, 
survival among children with acute lymphoblastic leukaemia and Down 
syndrome, the survival gap between high income and low- and middle-income 
countries, abandonment of treatment, and the twinning programmes. 
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Full-text articles excluded 
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1. Survival or incidence were not 
the focus of the studies (n = 129) 
 
2. Results included in more 
recent studies or reviews (n = 3) 
 
3- Reported on outcome for a 
different disease subtype (n = 3) 
Studies included in the 
literature review  
(n = 26) 
Figure 3.1: Process of selection of the studies for literature review on acute lymphoblastic 
leukaemia 
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Table 3.1: Characteristics of included studies and results of the literature review on acute lymphoblastic leukaemia 
First author,  
year, setting 
Study design Period Age  
(Y) 
Number of cases 
(neoplasm) 
Outcomes 
01. Stiller CA, 1989, UK 
109
 Population-based 
cohort 
1971–1982 0–14  4,070 (ALL) 5–year-survival increased significantly from 37% during 1971–73 to 66% during 1980–82 and was 
significantly higher for children included in clinical trials than for those who were not.  
02. Foucar K, 1991, US
110
  Hospital-based cohort 1969–1986 0–19  196 (ALL) Median overall survival (ALL): 37 months in American Indian girls but 140 months in non-Hispanic 
white girls 
03. Hesseling PB, 1995, 
South Africa
111
 
Hospital-based cohort 1983–1993 0–14  112 (leukaemias) 5-year ALL survival: 63% for whites vs. 17% for blacks. 
Median survival time: 52 months for blacks vs. 9 months for whites 
04. Dordelmann M, 1998, 
Europe (BFM)
112
 
Clinical trials 1981–1995 0–14  61 (ALL DS)  
4,049 (ALL NDS) 
EFS: ALL DS = 58%, ALL NDS = 70%. When DS children received treatment similar to that for 
NDS children, survival improved (65% vs. 70%, respectively). For children under 6 years, EFS 
was similar among DS and NDS children (73 % vs. 74%) regardless protocol modification. 
05. Chessells JM, 2001, 
UK
113
 
Clinical trials 1971–1986 0–14  55(ALL DS) 
3,596 (ALL NDS) 
5-year survival: ALL DS = 73%, ALL NDS =82%. 
EFS: ALL DS = 53%, ALL NDS = 63%. 
06. Kadan-Lottick NS, 2003, 
US
114
 
Population-based 
cohort 
1973–1999 0–19  4,952 (ALL) 5-year survival was worse among blacks, Hispanics and Native Americans than among whites: 
84% for whites, 81% for Asians/Pacific Islanders, 75% for blacks, and 72% for American 
Indian/Alaskans and Hispanics. 
07. Howard SC, 2004, 
Brazil
115
 
Hospital-based cohort 1980–2002 0–17  375 (ALL) 5-year EFS increased progressively: 32% during 1980–89, 47% during 1990–94, and 63% during 
1997–2002. Level of abandonment of treatment decreased from 16% to 0.5% over 22 years 
period. 
08. Šteliarová-Foucher, 
2004, Europe
24
 
Population-based 
cohort 
1970–1999  0–19  113,243 (multiple 
cancers); 35,570 
(leukaemias)  
Leukaemias: ASAIR =44.8 per million person-years, AAPC~1.4% per year over 30 years.  
5-year survival for children increased from 44% in 1970s to 75% in 1990s), higher in the west 
than in the east. 
09. Shah A & Coleman MP, 
2007, England & Wales
25
 
Population-based 
cohort 
1911–2000  0–14  N/A (leukaemias) Incidence rates increased from 38.3 in 1971–1975) to 46.1 in 1996–2000. MR decreased from 
26.4 to 10.3 per 100,000.  Average quinquennial change =1.5. 
10. Arora RS, 2007, Asia, 
Africa, America 
Central/South
116
  
Review 1980–2005 0–14  N/A (multiple 
cancers, including 
ALL) 
For acute leukaemias: Level of abandonment of treatment varied from 16% in Brazil to 50% in 
India. Recently, level of abandonment of treatment reduced to <1% in Mexico under the public 
medical insurance and in Recife (Brazil) after the start of “twining programme”. 
11. Ribeiro RC, 2008, Africa, 
Asia, Europe and America 
South
117
 
Cross-sectional  2005–2006 0–14  25,863 (9,747 ALL) 5-year survival: 5%-10% in Bangladesh, the Philippines, Senegal, Tanzania and Vietnam, 30% in 
Morocco, and 40%–60% in Egypt, Honduras, Ukraine, and Venezuela.  
12. Coustan-Smith E, 
2009, US & Italy
118
 
Clinical trials  1992–2006 5–19  139 (T-ALL)  St. Jude: 10-year survival  = 19% ETP ALL vs. 84% non-ETP ALL 
AEIOP: 2-year survival = 45% ETP ALL vs. 90% non-ETP ALL 
13. Smith MA, 2010, US
6
 Population-based 
cohort 
1975–2006 0–19  N/A (multiple 
cancers, including 
ALL) 
ALL incidence rates increased from 1975 to 2006 (0.8% per year). 5-year relative survival rose 
from 61% (1975–1978) to 88.5% (1999–2002). Relative survival for infants remained poor 
compared to that for older children, but it increased significantly from 22% (1975–1978) to 62% 
(1999–2000).  
14. Shah A, 2010, UK
119
 Population-based 
cohort 
1971–2000 0–14  321 (DS) 
12,310 (NDS) 
5-years survival: ANLL DS: <1% (1970s) to ≥ 80% (1990s); ANLL NDS vs. DS= 84% vs. 64% 
(1996–2000). ALL DS: 7% (1970s) to 59% (1990s); ALL NDS= 83 % (1996–2000). 
15. Perez-Saldivar ML, 2011, 
Mexico
38
 
Hospital based cohort 2006–2007 0–14  228 (leukaemias) ALL: ASAIR = 49.5 per million, highest for children aged 1–4 years (77.7 per million). AML ASAIR 
= 6.9 per million.  
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First author,  
year, setting 
Study design Period Age  
(Y) 
Number of cases 
(neoplasm) 
Outcomes 
16 Lightfoot TJ, 2012, UK
120
 Population-based 
cohort 
1990–1997 0–14 1,559 (ALL) HR of death =1.29 for children living in deprived areas (quintiles 4-5) compared to those living in 
affluent areas (quintiles 1-3). HR of death = 1.12 for children with father in the lowest vs. highest 
social class. 
17. Kroll ME, 2012, UK
121
 Population-based 
cohort 
1966–2005  0–15  54,650 (multiple 
cancers) 
ASAIR increased by 0.7% per year, with step model increases in 1971, 1990 and 2002.  
18. Pui CH, 2012, US
90
 Population-based & 
clinical trials 
1992–2007 0–14  749 blacks, 5,381 
whites (ALL) 
SEER data: ALL 5-year survival: 73% for blacks vs. 86% for whites during 1992–2000; and 82% 
for blacks vs. 89% for whites during 2001–2007. St. Jude: survival did not differ significantly 
between black and white children  
19. Pui CH, 2013, US
122
 Review (report on 15 
clinical trials) 
1962–2007 0–18  2,852 (ALL) 10-year survival improved from 11% (1962–1966) to 91% (2000–07) in the US during the last 5 
decades. 5-year survival = 93.5% during 2000–2007. 
20. Kersten E, 2013, 
Tanzania
123
 
Hospital-based cohort 2008–2010 0–18  106 (81 ALL and 25 
AML) 
2-year EFS: ALL = 33%, AML = 0%. 10 children died before start of treatment; 19 died of toxicity.  
Abandonment of treatment=8%. 
21. Gatta G, 2013, Europe
5
 Population-based 
cohort 
1999–2007 0–14  59,579 (19,097 
ALL) 
5-year survival (all cancers) in eastern Europe rose from 65.2% (1999–2001) to 70.2% (2005–
07). For ALL, 5-year survival increased from 82.2% (1999–2001) to 87.6% (2005-2007) with 
disparities among regions. 
22. Gupta S, 2013, Asia, 
America Central/South
124
 
Systematic review & 
meta–analysis 
2010–2011 0–18  10,494 
(leukaemias) 
Level of abandonment of treatment ranged from 0–74%. For ALL, level of abandonment of 
treatment was 29% I n lower-MICs and 2% in upper-MICs, but highly heterogeneous in lower-
MICs. 
23. Rivera-Luna R, 2013, 
Mexico
125
 
Hospital-based cohort 2007–2010 0–18  8,963 (3,748 ALL) Abandonment of treatment = 27% (2000) vs. 4.1% (2011), stable since 2007. For leukaemias 
alone, IR= 75.3 per million per year (year 2010). MR declined from 5.93 to 5.4 per 100,000 during 
the study period. 
24. Perez-Cuevas R, 2013, 
Mexico
126
 
Hospital based cohort 2006–2009 0–14  3,821 (1,774 ALL) 3-year survival: 50.0% for ALL and 30.5% for AML. Wide ALL survival variation within the five 
Mexican regions: from 21.3% in the south-southwest to 64.6% in northwest. 
25. Valery P, 2014, North 
America, Oceania and 
Africa
127
 
Review (population- 
and hospital-based) 
1980–2013 0–14  N/A (multiple 
cancers, including 
ALL) 
ALL 5-year survival: significantly lower in IP than non-IP in the US, as well as in New Zealand and 
Pacific Island Polynesians. South Africa: survival much lower in blacks compared to whites.  
26. Buitenkamp T, 2014, 
Europe
128
 
Report on 16 clinical 
trials (BMF and Dutch 
group) 
1995–2004 0–18  653 (DS ALL)  
4445 (NDS ALL) 
8-year EFS and OS = 64% and 74% (DS) and 81% and 89% (NDS). Relapse was the main 
prognostic factor for lower survival.in DS-ALL. 2-year TRM was 7% DS vs. 1% NDS [patients 
 
Abbreviations: AAPC, annual average percentage change; AEIOP, Italian Paediatric Haematology-Oncology Association; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; ANLL, acute 
non-lymphoblastic leukaemia; ASAIR, age-standardised annual incidence rates; BFM, Berlin-Frankfurt-Münster Study Group; DS, Down syndrome; EFS, event-free survival; ETP, early T-cell precursor; 
HR=hazard ratio of death; IP, indigenous populations; MICs, middle income countries; MR, mortality rates; NDS, non-Down syndrome; SEER, Surveillance, Epidemiology and End Results; St. Jude, St. Jude 
Children’s Research Hospital; US, United States; UK, United Kingdom. 
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3.1.4 Main findings 
The biology and survival of acute lymphoblastic leukaemia  
Genetic studies have been essential to better understand the characteristics, 
behaviours and prognosis of malignancies. Childhood acute leukaemias have 
been thoroughly studied and are, to date, the most understood neoplasm from a 
genetic perspective.7 This has allowed the development of new therapies that 
have substantially improved survival after acute myeloid leukaemia and, even 
more so after acute lymphoblastic leukaemia. Milestones in biologic research of 
acute lymphoblastic leukaemia mostly predate 2000. They are summarised in 
Table 3.2. 
 
Table 3.2: Landmarks in understanding the biology of acute lymphoblastic leukaemia.  
Source: Pui et al., Semin Hematol 2013
7
 
Year Biologic advance 
1958 First cytogenetic study in ALL129   
1970 First report of Philadelphia chromosome-positive ALL130 
1973 First identification of T-cell by spontaneous rosette formation with sheep 
erythrocytes131 
1978 Classification of ALL by chromosome number > 50 (hyperdiploidy) is associated 
with prolonged remission duration132 
1981 Immunologic monitoring of residual leukaemia133 
1984 First identification of immunophenotype-specific chromosome translocations: 
t(11;14) in T-cell ALL and t(1;19) in pre-B ALL134 
2002 First genomic-wide profiling of gene expression135 
2007 First genomic-wide study of changes in DNA copy number106 
2009 Germline genetic variants associated with the development of ALL136, 137 
2012 First whole-genome sequencing study to identify driver mutations in early T-cell 
precursor ALL138 
 
 According to the WHO classification29 reviewed in section 2.3.2, acute 
lymphoblastic leukaemia is divided into two major immunophenotypic subtypes: 
precursor B-cell (B-ALL) and precursor T-cell (T-ALL). B-ALL is the most 
common subtype, accounting for about 85% of all cases of acute lymphoblastic 
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leukaemia. Nearly all B-ALL cases can now be classified genetically, which 
facilitates risk-directed therapy.7 By contrast, the T-ALL subtype corresponds to 
15% of all cases acute lymphoblastic leukaemia, often presents with poor 
prognostic factors (e.g. older age) and is usually treated with a standard protocol 
rather than targeted therapies. With intensive chemotherapy, the prognosis of 
children with T-ALL has increased considerably and is currently fairly similar to 
that of B-ALL. However, among T-ALL cases, there is a very high-risk subgroup 
called early T-cell precursor ALL (ETP ALL).  
 Coustan-Smith et al.118 analysed data from 239 children with T-ALL 
enrolled in clinical trials at St. Jude Children’s Research Hospital in the United 
States and in the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) 
ALL 2000 trial. At St. Jude, 12% of these children had ETP-ALL, and overall 10-
year survival was much lower than that of children with non-ETP ALL (19% vs. 
84%, respectively). In children enrolled in the AIEOP ALL-2000 trial, the 
prognosis of children with ETP ALL was also dismal (2-year overall survival was 
45% vs. 90% for those with non-ETP ALL).  
 In populations with higher incidence of childhood acute lymphoblastic 
leukaemia (e.g. whites in developed countries) common ALL (early precursor B-
cell) accounts for about 70% of acute lymphoblastic leukaemia cases. In low 
incidence populations such as India and Nigeria, early precursor B-cell ALL 
corresponds to only 30% of the cases, and T-ALL has a higher relative incidence. 
The higher incidence of common ALL among affluent populations suggests that 
environmental factors associated with high socioeconomic status may play an 
important role in the aetiology of acute lymphoblastic leukaemia.139  
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Incidence of acute lymphoblastic leukaemia: increasing trends  
Several studies reported that the incidence of childhood acute lymphoblastic 
leukaemia has been increasing since the 1970s, at least in Europe (except 
Nordic countries) and in the United States. In Europe, age-standardised 
incidence rates (ASIR) increased on average, by 1.4% per year over 30 years.25, 
44 In the United States, ASIR increased by 0.5%–0.8% over 25–31 years.6, 23 This 
increase was observed in both sexes, in all age groups examined (<1y, 1–4 y, 5–
9y and 10–14y) and, in the United States where data were available, in both 
blacks and whites.  
 Some controversy exists regarding whether this reported increase of acute 
lymphoblastic leukaemia incidence is artefactual (e.g., due to better diagnosis) or 
real. Kroll et al.121 examined the trends of childhood cancer incidence, including 
leukaemias, observed in Great Britain from 1966 to 2005, and compared it with 
changes in registration procedures. For leukaemias, incidence rates increased by 
0.7% per year during this period. The step model showing increased incidence in 
1971, 1990, and 2002 coincided with improvement in general cancer registration. 
For instance, a reviewed recording process was introduced on 1 January 1971, 
the responsibility for cancer registration was transferred from area of treatment to 
area of residence on 1 July 1978, and in 2001, the Department of Health 
developed a plan to improve the effectiveness of cancer registries. In another 
study, Kroll et al.140 reported that among children from poor communities in Great 
Britain, there was clinical evidence for an under-diagnosis of acute lymphoblastic 
leukaemia during the 1980s and 1990s among children who died due to severe 
infections. These suggested that, at least in part, the increased incidence was 
secondary to improved registration.  
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 Adamson et al.141 also suggested that the increase in acute lymphoblastic 
leukaemia incidence in Europe was largely due to improvement in cancer 
registration, and this was a result of the enrolment of most children with cancer in 
clinical trials. The fact that increased rates occurred in almost all malignancies is 
consistent with better cancer registration. Despite these reports, there is strong 
evidence to support the increased incidence rates of acute lymphoblastic 
leukaemia being real. 
 Firstly, studies that showed an increasing incidence of childhood 
leukaemia used large populations and relied on standardised high-quality data 
collected over 25–40 years. Therefore, the possibility of bias is unlikely. For 
example, Šteliarová-Foucher et al.16 compared data from 63 European 
population-based registries containing records of 131,243 children and 
adolescents (0–19 years), including 35,570 leukaemias. Age-standardised 
incidence rates were calculated and compared. Lymphoid leukaemias rates 
increased by ~1.4% per year over 30 years in this cohort. 
 Secondly, improvements in diagnostic methods observed in the last 3 
decades are likely to explain only a small part of the reported increase in acute 
lymphoblastic leukaemia incidence. In the Kroll et al.121 study cited above, for 
acute lymphoblastic leukaemia the improvement in diagnostic approach that 
occurred in 1985 was restricted to immunohistochemistry. This is used to identify 
subtypes of leukaemias, but not to make the initial leukaemia diagnosis. The 
same is valid for other diagnostic techniques developed later that helped to 
stratify risk and guide therapy. 
 Thirdly, according to one study based on a high-quality population-based 
registry in Britain, during 1980–1996, the average annual percentage change in 
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incidence rates of acute lymphoblastic leukaemia was 1.4%. It was suggested 
that this was due to an increase of the precursor B-cell sub-type. This increase 
was not followed by an increase of other subtypes of acute lymphoblastic 
leukaemia or acute myeloid leukaemia, making it unlikely that the acute 
lymphoblastic leukaemia increased incidence is simply secondary to an 
improvement in completeness of registration.142 
 Finally, another study analysed data on childhood leukaemia over most of 
the twentieth century, and examined incidence and mortality trends by age, sex 
and 5-year calendar periods, in England and Wales.25 Incidence increased 4% 
every 5 years from the early 1971 to 2000, mainly in infants (<1 year old) and 
children aged 1–4 years. The assumption that a lethal infection could have 
“masked” a diagnosis of leukaemia in the beginning of the century leading to 
leukaemia under-diagnosis,143  does not explain the increase in leukaemia 
incidence during 1971–2000. The authors showed that considering the decrease 
in infant mortality in this period, children that survived up to 5 years would need to 
have had a 20-fold higher incidence of leukaemia than the rest of the population, 
to account for the incidence growth. The mortality rates declined considerably 
during this period, reflecting the extraordinary improvement in survival during the 
last 50 years. However, the incidence rates continued to increase, supporting the 
hypothesis that the rise in acute lymphoblastic leukaemia incidence was real 
(Figure 3.2). 
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Figure 3.2: Trends in leukaemia incidence, survival and mortality in children, England  
and Wales, 1971–2000. Source: Shah and Coleman, Br J Cancer 2007
25 
 
Remarkable improvement in survival from acute lymphoblastic leukaemia 
in the last 50 years 
Acute lymphoblastic leukaemia was consistently fatal during the 1960s. Today, 5-
year survival in the developed countries is, at the population-based level,5, 7, 19 
approximately 80%–90% and up to 93.5% in clinical trials.7 
 This outstanding achievement was driven by a multidisciplinary treatment 
approach, novel chemotherapeutic agents, a better understanding of the biology 
of acute lymphoblastic leukaemia, the development of new diagnostic methods 
and more precise risk stratification. Because acute lymphoblastic leukaemia is a 
complex disease, responses to treatment may vary considerably even among 
children with the same disease phenotype. Precise risk stratification is key for the 
provision of individualised treatment to children with acute lymphoblastic 
leukaemia: more intensive and prolonged regimens should be given to high-risk 
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patients (10%–30% of patients), whilst a less intensive protocol should be applied 
for favourable-risk patients, preventing under- or over-treatment, respectively. 
 In high-income countries, collaborative clinical trials and standardised 
protocols have led to a rapid increase in survival. Stiller and Draper109 compared 
the survival trends of 4,070 children with acute lymphoblastic leukaemia treated 
in the United Kingdom Medical Research Council trials (UKALL) during 1971–
1982. Five-year survival increased substantially from 37% during 1971–1973 to 
66% during 1980–1982. The impact of the inclusion of children with acute 
lymphoblastic leukaemia in clinical trials was evident: survival was significantly 
higher for these children than for those not included in the UKALL trials. 
Moreover, for these children, there was no survival difference based on treatment 
at centres of different sizes. However, for children not included in clinical trials, 
survival was higher among those treated at larger centres with high volumes of 
patients (average of six new children per year) than for those treated at smaller 
centres (less than a patient per year).  
 The most significant therapeutic advances resulting from clinical trials are 
summarised in Table 3.3. Importantly, these improvements associated with the 
use of risk-directed therapy led to a reduction or elimination of some adverse 
prognostic factors, such as high initial white blood cell count, Philadelphia 
chromosome-positive ALL, a subgroup of children with Down syndrome, black 
race, and male gender. For example, blacks and male children now have similar 
survival as white and female children, at least in some centres in developed 
countries (section 2.5.1).90, 144 
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Table 3.3: Landmark advances in the development of therapy for childhood acute 
lymphoblastic leukaemia. Source: Pui et al., Semin Hematol 2013
7
 
Year Therapeutic advance 
1948 “Transient remissions” induced by aminopterin145 
1971 Combination chemotherapy and effective central nervous system (CNS)-directed therapy 
cure approximately 50% of patients146 
1981 Re-induction treatment improves outcome147 
1982 Triple intrathecal therapy with methotrexate, hydrocortisone, and cytarabine may 
effectively substitute prophylactic cranial irradiation in some patients148 
1983 Post-remission weekly high-dose asparaginase improves outcome149 
1983 Intermediate-dose methotrexate with leucovorin rescue decreases systemic and 
testicular relapses150 
1991 Dexamethasone is more effective than prednisone in preventing CNS relapse151 
1995 Inherent genetic polymorphisms in gene encoding thiopurine methyltransferase influence 
mercaptopurine toxicity152 
1998 Individualised methotrexate dose improves outcome153 
2009 Effective systemic and intrathecal chemotherapy can eliminate the need for prophylactic 
cranial irradiation in all patients144 
2009 Imatinib improves early treatment outcome in Philadelphia chromosome-positive ALL154 
 
Racial and ethnic differences in survival from acute lymphoblastic 
leukaemia 
Cancer survival inequalities between blacks and whites in the United States have 
been well documented for different types of cancer in adults and children.155, 156 
Survival disparities between black and white children with acute leukaemia have 
been also reported in Africa.111, 157 For example, in a paediatric oncology unit at 
Tygerberg Children’s Hospital in South Africa, 77 children (0–14 years) 
diagnosed with acute lymphoblastic leukaemia during 1983–1993, were treated 
with the Berlin-Frankfurt-Münster Study Group (BFM) ALL 1983 protocol. Among 
these children, 38% were white, 46% so-called coloured, and 16% were blacks. 
Five-year survival was 63% among whites, 38% among coloured and a dismal 
17% among blacks (P value < 0.01). The median survival time (the length of time 
from the date of diagnosis of leukaemia in which half of patients are alive) was 
52.5 months for whites but only 9 months for blacks. The number of children with 
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acute lymphoblastic leukaemia was small, but the data from this hospital-based 
registry were considered reliable by the authors (less than 3% of loss to follow-up 
and accurate information on disease presentation and outcome). The differences 
in survival between the three groups could not be explained by differences in 
prognostic factors or treatment compliance.111 
 Several factors have been suggested to explain the racial survival gap, 
such as socioeconomic status, biologic or cultural factors, treatment responses 
and patients’ unique genetic characteristics. Recently, Pui et al.90 have 
demonstrated that when black children receive intensive risk-based therapy and 
comprehensive supportive care, they can achieve similar survival as white 
children, thereby reducing the impact of some adverse factors, such as high 
leukocyte count, T-cell immunophenotype, chromosome translocation t(1,19), 
and ancestry-related relapse hazard. They compared survival from childhood 
cancer between children treated at St. Jude Children’s Research Hospital and 
children registered in one of the cancer registries of the National Cancer 
Institute’s SEER programme during two periods (1992–2000 and 2001–2007). 
For acute lymphoblastic leukaemia, 5,222 children (0–14 years) were analysed 
using data from the SEER programme, and 908 children from St. Jude. Survival 
was lower, in both periods, for black children registered in the SEER programme. 
At St. Jude, however, survival did not differ significantly between races in either 
period (Table 3.4). Type of health insurance coverage was used as a proxy for 
financial status of those children at St. Jude. Black children were more likely to 
have public insurance than private insurance, suggesting lower socioeconomic 
status. In the SEER programme, there was no information on socioeconomic 
status, disease clinical feature, the proportion of children treated in specialised 
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centres or on the proportion treated by protocol-directed therapy, precluding 
some specific comparisons with data from St. Jude. This is a tertiary referral 
hospital and is expected to treat a greater proportion of high-risk children. Despite 
the less favourable prognostic factors, black children had similar survival as white 
children. This study suggests that equivalent treatment can reduce or eliminate 
racial disparities among children with acute lymphoblastic leukaemia as 
discussed earlier in section 2.5. 
 
Table 3.4: Comparison of 5-year survival between black and white children with acute 
lymphoblastic leukaemia. Data from St. Jude and SEER programme, 1992–2007. Adapted 
from Pui CH et al., J Clin Oncol 2012
90
 
 1992–2000 2001–2007 
 Blacks Whites  Blacks Whites  
Dataset N 5-y OS N 5-y OS P-value N 5-y OS N 5-y OS P-value 
SEER 233 72.8% 1,931 85.9% < 0.01 358 82.1% 2,700 89% < 0.01 
St. Jude 82 81.6% 370 85.7% 0.58 76 89.4% 380 93.2% 0.41 
Abbreviations: OS, overall survival; SEER, Surveillance, Epidemiology and End Results; St. Jude, St. Jude 
Children’s, Research Hospital. The P-values for testing differences in survival between black and white patients. 
 
 A recent systematic review by Valery et al.127 assessed the international 
burden of childhood cancer in indigenous populations. Although information 
about ethnicity is scarce in most countries and the available data may lack 
accuracy and quality, significant differences were reported. Most of the studies 
showed that survival from leukaemias was usually lower for indigenous children 
than for non-indigenous children. For example, a hospital-based study evaluated 
196 children aged 0–19 years when diagnosed with acute lymphoblastic 
leukaemia, at the University of New Mexico affiliated institutions in the United 
States.  Survival was compared among three ethnic groups (Hispanic and non-
Hispanic whites, and American Indians) during 1969–1986. Median overall 
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survival for children with acute lymphoblastic leukaemia was considerably lower 
in indigenous populations than non-indigenous populations: only 8 months for 
American Indian boys and 37 months for American Indian girls, but 36 months for 
non-Hispanic white boys and 140 months for non-Hispanic white girls.110  
 In a population-based study114 of 4,952 children and adolescents (0–19 
years) diagnosed with acute lymphoblastic leukaemia and registered in the SEER 
programme between 1973 and 1999, survival was compared among five ethnic 
groups: white, black, Hispanic, Asian/Pacific Islander, and American 
Indian/Alaskan Native. After adjusting for age, sex and treatment era, 5-year 
survival was lower among blacks, Hispanics and Native Americans than among 
whites and Asians: 84% for whites, 81% for Asians/Pacific Islanders, 75% for 
blacks, and 72% for American Indian/Alaskans and Hispanics.  
 The authors of the systematic review above127 suggested that the most 
likely causes of worse prognosis among indigenous children were: lack of cancer 
awareness among this population, lack of availability of treatment different from 
traditional indigenous medicine, cultural factors, treatment refusal, and 
abandonment of treatment. In paediatric oncology, treatment adherence has 
been reported to vary from 41% to 98%158-160 and abandonment of treatment is 
considered the major cause of treatment failure in low-income countries. 
 Moore et al.161 conducted a systematic review of cancer aetiology and 
patterns among indigenous population in South American countries. They 
obtained information on indigenous adults, but there was no information on 
indigenous children. The authors pointed out the need for improvement of cancer 
registration in low- and middle- income countries in general, as well as among 
indigenous populations in these countries. In fact, data collected by the 
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International Agency for Research on Cancer (IARC) contain information on 
indigenous population from only two countries: the United States and New 
Zealand. 
 
Survival from acute lymphoblastic leukaemia among children with Down 
syndrome  
Most researchers have found that children with Down syndrome have a 10–20 
fold increased risk of developing acute lymphoblastic and myeloid leukaemias 
over children without Down syndrome.60 In general, acute lymphoblastic 
leukaemia in children with Down syndrome has inferior outcome than in other 
children.162 This has mostly been attributed to treatment toxicity, particularly 
infectious complications, including bacterial, viral and fungal infections. 
Consequently, these children tend to receive less intensive chemotherapy 
prompting them to a higher risk of relapse.52  
 A population-based study by Shah et al.,162 evaluated trends in 5-year 
survival in children (0–14 years) with and without Down syndrome, diagnosed 
with leukaemia  from 1971 to 2000 in Great Britain. This study showed that for 
acute non-lymphoblastic leukaemia (ANLL), including acute myeloid leukaemia, 
5-year survival increased significantly from less than 1% in the early 1970s to 
80% or over in the 1990s. This improvement was even higher for Down 
syndrome children than for non-Down syndrome children (84% vs. 64%) during 
1996–2000. However, for acute lymphoblastic leukaemia, survival for children 
with Down syndrome increased from 7% to 72% during 1991–1995, but 
decreased later, and remained lower than that for non-Down syndrome children 
(59% vs. 83%) during 1996–2000.  
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 The authors suggested that the poor prognosis observed in children with 
Down syndrome and leukaemias in the 1970s and early 1980s were associated 
with lack of appropriate treatment and less recruitment to clinical trials. About 
38% of children with Down syndrome and acute leukaemias received minimal 
treatment or were advised not to receive any treatment, and died. During 1971–
2000, recruitment of children with Down syndrome and leukaemias into clinical 
trials was lower than that of children without Down syndrome: for acute 
lymphoblastic leukaemia, the difference was 40% vs. 70%, and for acute myeloid 
leukaemia it was 23% vs. 50%, respectively.  
 During the mid-1980s, it became more common to treat Down syndrome 
children on standard leukaemia protocol. Several clinical trials112 have shown that 
when intensive treatment, comprehensive supportive care and rigorous control of 
infections are provided, outcomes in children with Down syndrome tend to be 
similar to that of children without Down syndrome.  
 In Europe, four consecutive clinical trials conducted by the BFM group,112 
from 1981 to 1995, compared treatment outcome of 61 children aged less than 
15 years with acute lymphoblastic leukaemia and Down syndrome, to 4,049 
children with acute lymphoblastic leukaemia without Down syndrome. Six-year 
event-free survival was lower among children with Down syndrome than those 
without Down syndrome (58% vs. 70%, P value = 0.14). However, event-free 
survival was similar when intensive chemotherapy was administered and optimal 
supportive care was provided (65% vs. 70%, P value = 0.66). For children under 
6 years, event-free survival was similar between the two groups regardless of 
protocol differences (73 % vs. 74%, P value = 0.7). These findings suggest that, 
given intensive treatment, children with acute lymphoblastic leukaemia and Down 
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syndrome can achieve the same survival than that of children with acute 
lymphoblastic leukaemia without Down syndrome, but these results did not reach 
statistical significance. 
 Two clinical trials conducted by the UK Medical Research Council113 from 
1985 to 1997 showed worse event-free survival and overall survival in 55 children 
aged 15 years or less with acute lymphoblastic leukaemia and Down syndrome, 
compared to 3,596 children with acute lymphoblastic leukaemia without Down 
syndrome: 5-year survival was 73% vs. 82%, and 5-year event-free survival was 
53% vs. 63% respectively. 
 Recently, Buitenkamp et al.128 conducted a retrospective analysis 
including a large sample of 653 children (0–18 years) with Down syndrome and 
acute lymphoblastic leukaemia enrolled in 16 international trials, from 1995 to 
2004. They identified a sub-group of children with Down syndrome with more 
favourable prognosis: children aged under 6 years, with white blood cell count 
<10X109/L, and with the cytogenetic abnormalities ETV6-RUNX1 and 
hyperdiploidy. Children with these cytogenetic aberrations comprised 12% of 
children with Down syndrome and acute lymphoblastic leukaemia, and are 
probably eligible for future treatment reduction in order to avoid toxicity, the major 
cause of mortality in this study cohort. Except for this specific sub-group, less 
intensive treatment has not been recommended for the remaining children with 
Down syndrome and acute lymphoblastic leukaemia due to the high potential risk 
of relapse. 
 
 
 83 
 
The survival gap between high income and low- and middle-income 
countries 
About 80% of children with cancer live in low- and middle-income countries and 
approximately 94% of all childhood cancer deaths occur in these countries.163 
Despite the extraordinary increase in survival from acute lymphoblastic 
leukaemia in the last half century, many children still die from this treatable 
disease, mainly in resource-poor areas. Survival from childhood acute 
lymphoblastic leukaemia varies widely worldwide as demonstrated below. 
 
High-income countries 
Important survival variations exist even among high-income countries. Gatta et 
al.5 estimated 5-year survival from childhood cancers in 59,579 European 
children (19,097 acute lymphoblastic leukaemia cases), aged 0–14 years, during 
2000–2007. This population-based study collected data from 74 registries in 29 
European countries. Survival improved in all regions studied, but the greatest 
improvement was in Eastern Europe: 5-year survival for multiple cancers 
increased from 65.2% (1999–2001) to 70.2% (2005–2007). However, wide 
disparities within European areas persisted despite major improvements in 
diagnosis and treatment seen in the last few decades. Five-year survival for 
acute lymphoblastic leukaemia was 80.3% in Eastern Europe but it ranged from 
86.7% to 90.1% in other European regions during 2005–2007. The authors 
suggested that the poorer survival in Eastern Europe might be due to the lack of 
government funding for cancer control, absence of national cancer plans, and 
inadequate access to optimal treatment.  
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Another European study conducted by Lightfoot et al,120 investigated the 
association between SES and survival among children (0–14 years) diagnosed 
with ALL during 1990–1997. An area-based deprivation index and father’s 
occupation information were used as surrogates of SES. Overall survival was 
significantly lower for children living in deprived areas (quintiles 4 and 5) than in 
affluent areas (quintiles 1–3) (HR = 1.29, 1.05–1.57). Similarly, survival was 
somewhat inferior for children with a father from the lowest social class than the 
highest social class (HR = 1.12, 0.97–1.29) (Figure 3.3). The authors highlighted 
that these findings are of particular importance considering that in the UK all 
children have access to the same treatment guaranteed by the National Health 
Service (NHS), thus modifiable factors such as adherence to treatment may play 
a role in the survival differences observed.
 
Figure 3.3 :Overall survival of children (0–14 years) with ALL in the UK, by area-based 
deprivation quintiles at diagnosis (left) and father’s employment status, (right), 1990–1997. 
Source: Lightfoot et al., Eur J Cancer  2012
120
  
 
In the United States, Smith et al.6 analysed data from the SEER 
programme and estimated 5-year relative survival after acute lymphoblastic 
leukaemia and other cancers, in children and adolescents (0–19 years), during 
1975–2006. Relative survival increased from 61% (1975–1978) to 89% (1999–
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2002). For infants (<1 year) with ALL, relative survival increased substantially 
from 22% (1975–1978) to 62% (1999–2002), but remained lower than that of 
older children.  
 In a recent review, Pui et al.7 reported the results of 15 clinical trials 
conducted at St. Jude Children’s Research Hospital, which included 2,852 
children (1–18 years) with acute lymphoblastic leukaemia, during 1962–2007. 
Ten-year survival improved from 11.1% (1962–1966) to 91.1% (2000–2007) in 
the United States over these four decades. During 2000–2007, 5-year survival 
was as high as 93.5%. The author discusses that protocol-directed therapy with 
children enrolled in clinical trials is essential for optimal outcomes. Moreover, 
genome-wide studies as well as minimal residual disease measurements are 
important for risk stratification and target therapy. To date, cranial irradiation has 
been reserved for those children who have high-risk of central nervous system 
relapse, and has been even abandoned at St. Jude.144 
 Although in the United States survival in children with acute lymphoblastic 
leukaemia is one of the highest in the world, several studies have documented 
survival disparities among children with cancer and different races and ethnicities 
(described above). Similarly to Europe, most children with cancer in the United 
States are enrolled in clinical trials as soon as they are diagnosed with 
leukaemia, and are referred for treatment at specialised paediatric centres. This 
has long been considered the “gold-standard” practice for children with cancer, 
including acute lymphoblastic leukaemia. 
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Low- and middle-income countries  
Survival varies widely between and within low- and middle-income countries. A 
few examples are described as follows. In Tanzania, as in most countries in 
Africa, there is no cancer registry, and hospital records are of poor quality. In 
2004, in order to provide free cancer care to all children in the country, the 
Tanzanian government opened a paediatric ward with 17 beds at the Ocean 
Road National Cancer Institute in Dar es Salaam. A recent retrospective study123 
examined data on 106 children aged 0–18 years diagnosed with acute leukaemia 
(81 acute lymphoblastic leukaemia and 25 acute myeloid leukaemia) during 
2008–2010. Two-year event-free survival for acute lymphoblastic leukaemia was 
still low (33%), but much better than in 2005, when only 1 out of 20 children 
survived one year. For acute myeloid leukaemia, 2-year event-free survival was a 
0%. In this study, ten children died before the start of treatment, 19 died of 
treatment toxicity and 8 children abandoned treatment.  
 The authors suggested that the main reasons for the poor outcomes were 
related to delays in seeking and receiving treatment, limited access to 
chemotherapy drugs and diagnostic supplies, insufficient beds for paediatric 
oncology, abandonment of treatment, and lack of health personnel. In Tanzania, 
there was only one paediatric oncologist for the entire country, located at Dar es 
Salaam. In addition, one third of children with leukaemias were malnourished, 
and one third had concomitant malaria, both factors that might have contributed 
to the poor leukaemia prognosis. 
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Asia, Africa, Latin America and Europe (Ukraine)  
Ribeiro et al.164 performed a cross-sectional study aimed to assess the paediatric 
oncology services in ten low- and middle-income countries, and estimate survival 
from childhood cancers. Population-based and hospital based-registries were 
scarce in these countries. A field survey of clinicians, health officials and health 
care managers was conducted during 2005–2006. The more relevant findings in 
this study were: (1) 5-year “postulated” survival for children under 15 years with 
all cancers combined, was much lower than survival in high-income countries: 
5%–10% in Bangladesh, the Philippines, Senegal, Tanzania and Vietnam; 30% in 
Morocco; and 40% in Egypt, Honduras, Ukraine and Venezuela; (2) the number 
of children cared for by individual paediatric oncologists varied from 1:10 to 1:75; 
(3) annual government expenditure on health was the best predictor of survival; 
(4) diagnostic testing and treatment supplies were often lacking or in short 
supply.  
 
Mexico 
Mexico has one of the highest incidence rates of childhood leukaemia globally. 
The Mexico National Registry for Childhood Cancer started in 2006. During the 
period 2006–2007, the average annual incidence rate of acute lymphoblastic 
leukaemia was 49.5 per million in Mexico City, among the highest in the world.38 
An effective treatment of acute leukaemia takes, on average, 2 to 3 years, and it 
is complex and expensive. This prevents many children from developing 
countries from receiving appropriate treatment. In 2006, a public medical 
insurance programme was created in Mexico, aimed at providing optimal 
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standardised treatment for children with cancer: the Fund for Protection against 
Catastrophic Expenditures (FPGC). 
 Rivera-Luna et al.125 evaluated the impact of the FPGC on children with 
cancer aged 18 years or less, enrolled in one of the 47 accredited Mexican 
institutions during 2007–2010. They reported that 8,963 children enrolled in this 
public medical insurance programme were diagnosed with cancer (3,748 with 
acute lymphoblastic leukaemia). Across Mexico, the incidence rate of acute 
leukaemia alone was 75.3 per million per year (year 2010). Several improvement 
in outcomes were observed after the implementation of the programme: (1) 
although still elevated, standardised mortality rates declined from 5.93 to 5.4 (per 
100,000) during the study period; (2) level of abandonment of treatment 
decreased from about 27% (2000) to 4.1% (2011), and it has remained stable 
since 2007; (3) adherence to treatment (including following the prescription, using 
drugs regularly and as recommended, as well as accuracy of administration159) 
increased from 48% before the FPGC to 95% in 2011. In conclusion, the FPGC 
had a positive impact during the first years of implementation, allowing uninsured 
children to receive cancer treatment. The authors emphasised that further 
improvements are needed in order to decrease the burden of paediatric cancer in 
this population. 
 In another study, Perez-Cuevas et al.126 estimated 3-year survival of 3,821 
children (0–14 years) with cancer treated under the FPGC during 2006–2009. 
The proportion of children covered increased from 3.3% in 2006 to 55.3% in 
2009, without evidence of further increase of children assisted. Acute 
lymphoblastic leukaemia accounted for 46.4% of the cases and acute myeloid 
leukaemia for 7.4%. Three-year survival was far lower than that of developed 
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nations: 50.0% for acute lymphoblastic leukaemia and 30.5% for acute myeloid 
leukaemia. Moreover, childhood leukaemia survival varied dramatically among 
geographic areas of Mexico: from 64.6% in northwest to 21.3% in the south-
southwest. 
 Ribeiro, RC165 argues that the south-southeast region of Mexico has the 
highest estimated incidence of children with cancer, but less than 40% of these 
children were registered in the FPGC. He highlighted that this region has the 
lowest Human Development Index (HDI, an index that combines three indicators 
of human development: life expectancy, educational attainment and income) 
compared to other geographic areas of Mexico, suggesting that the FPGC has 
not been as effective and equally distributed in the more deprived areas of 
Mexico as it has been in the more affluent areas of the country. 
  Finally, the recent published CONCORD-2 study,19 a global surveillance of 
cancer survival, reported 5-year net survival after acute lymphoblastic leukaemia 
on 74,343 children aged 0–14 years from about 215 registries in 53 countries. 
Five-year net survival was as high as 90% in Canada, Austria, Germany, Norway 
and Belgium, and about 80%–89% in the United Sates and various other 
developed countries on different continents. Strikingly, survival was less than 
60% in most low-and middle-income countries, including Indonesia, Lesotho, and 
Mongolia. 
 
The problem of abandonment of treatment in low- and middle-income 
countries 
Abandonment of treatment is an established cause of treatment failure among 
children with cancer in low- and middle-income countries.166 Arora et al.116 
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reviewed the literature to evaluate the level of abandonment of treatment, 
possible causes and potential opportunities for improvement in these 
disadvantaged populations. Their findings showed that abandonment of 
treatment is widespread in the developing world, involves all childhood cancers 
and is more evident in Asia (e.g. India and Turkey), Africa (e.g. Morocco), and 
many countries in Central and South America. For acute leukaemias, level of 
abandonment of treatment varied from 16% in Brazil to 50% in India. More 
recently, level of abandonment of treatment was reported as less than 1% in 
Mexico under the FPGC, and also in Recife, Brazil due to the impact of twinning 
programmes (described below). 
 In high-income countries, abandonment of treatment is rare. When this 
happens, the authors suggested that it might result from the child’s physical 
discomfort, parents’ poor understanding about the disease and its treatment, and 
parents’ fear and uncertainty regarding treatment benefits. 
 By contrast, in low- and middle-income countries, a greater number of 
reasons were suggested to explain abandonment of treatment, including (1) lack 
of financial resources, hospital facilities and trained health professionals; (2) lack 
of parental education and cancer awareness; (3) long distances from home to 
treatment centre; and (4) religious beliefs. 
 Gupta et al.124 performed a systematic review and meta-analysis to 
examine the problem of abandonment of treatment in children with cancer from 
low- and middle-income countries. Level of abandonment of treatment among 
children with cancer ranged from 0% to 74.5%.166 For acute lymphoblastic 
leukaemia, level of abandonment of treatment was greater in low-income 
countries (29%) than in upper-middle-income countries (2%), with wide 
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heterogeneity. They argued that prevention of abandonment of treatment is a 
priority and is as important as prevention of cancer treatment-related deaths or 
relapse in poor-resource settings. Abandonment of treatment was consistently 
under-reported and data were obtained only directly from authors. 
 In China, Shanghai is the only city that provides insurance for catastrophic 
diseases. At Shanghai Children’s Medical Centre, during 1998–2003, out of 234 
children diagnosed with acute lymphoblastic leukaemia, 66 abandoned treatment 
(mostly of them did not live in Shanghai), and 52 died due to treatment toxicity. 
According to one of the physicians of the Shanghai Medical Centre, the situation 
is much worse in other areas of the country, particularly in rural areas where only 
around 10% of Chinese children with acute lymphoblastic leukaemia receive 
protocol-based treatment.167  
 
Twinning programmes: a real possibility for survival improvement among 
children with cancer in resource-poor countries  
Twinning programmes are partnerships between public hospitals in developing 
countries and specialised cancer centres in the developed nations. By integrating 
education, capacity building and research, these programmes have been proved 
to be effective in decreasing deaths of children with cancer with long-term results. 
Successful established programmes include My Child Matters Initiative,168 La 
Mascota programme,169 the International Network for Cancer Treatment and 
Research,170 and the International Outreach Programme (IOP).171 
 Howard et al.115 described an example of the effectiveness of a twinning 
programme. They reviewed the outcomes of 375 children with acute 
lymphoblastic leukaemia treated in Recife, Brazil during 1980–2002, when a 
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partnership was developed through the International Outreach Programme. 
During 1980–1989 (early period), patients were treated at a public general 
hospital without a paediatric oncology unit, standardised treatment protocols, 
trained nurses or 24h physician coverage. Moreover, the availability of health 
supplies was limited. During 1990–1994 (middle period), children with acute 
lymphoblastic leukaemia were treated at a different hospital, with a protocol from 
the St. Jude Children’s Research Hospital, but still without an oncology unit or 
specialised oncology nurses. During 1997–2002 (recent period), children with 
acute lymphoblastic leukaemia were treated with St. Jude protocol in a dedicated 
paediatric oncology unit, with trained health professionals and access to an 
Intensive Care Unit. Five-year event-free survival increased steadily: from 32% in 
the early period, to 47% in the middle period and 63% in the recent period. 
Abandonment of treatment decreased from 16% to 0.5%. 
 There is an enormous inequity in the distribution of resources allocated 
between countries for cancer care and control. Even though an estimated 80% of 
the disability-adjusted life-years (DALYs, i.e., a measure of overall disease 
burden expressed as the number of years lost due to ill-health, disability or early 
death) lost to cancer occur in low- and middle-income countries, only about 5% of 
the global resources for cancer are distributed to these countries. In Africa, this 
situation is even worse: Sub-Saharan African regions receive only 0.2% of global 
cancer spending.172, 173 In paediatric oncology, survival is dreadful in those 
countries where the annual government expenditure on health is below US$200 
per capita.164 
 In summary, in high-income countries, most children with cancer have 
access to care, and the main causes of treatment failure are relapse, drug 
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resistance and treatment toxicity. By contrast, in the low- and middle-income 
countries where 80% of children with cancer reside, access to care ranges from 
less than 10% to 70%, and the leading causes of therapy failure are 
abandonment of treatment and advanced disease at diagnosis, in addition to 
treatment-related toxicity and relapse. Currently, the main focus of leukaemia 
treatment in high-income countries is to find new therapeutic approaches to 
achieve cure, decrease toxicity and improve the quality of life of survivors. In 
contrast, in the low- and middle-income countries, the main focus of treatment is 
on improving access to optimal care and increasing the low outcomes. Table 3.5 
summarizes these differences.  
 
Table 3.5: Main differences in paediatric cancer care between high- and low- and middle-income 
countries. Adapted from a seminar by Ribeiro, RC; May 2013; www.cure4kids.org/ums/org. 
Feature High-income countries Low- and middle-income countries 
Access to care Virtually 100%  <10% to 70% 
Causes of 
failure 
Disease relapse, drug resistance, 
treatment-related toxicity 
Abandonment of treatment, advanced 
disease, treatment-related toxicity, relapse 
Major focus on Finding cures and improving quality of 
life of survivors 
Improving access to care and increasing 
survival 
Activities Disease mechanisms (genomic 
medicine), risk-adapted therapy and 
prevent long-term complications 
Understand the causes of abandonment of 
treatment, community education and adapt 
curative therapy with local resources 
 
 Survival is a measure of the cancer burden and the effectiveness of health 
systems, and plays a key role in the development of health policies. Long-term 
surveillance of cancer incidence has been essential to providing information on 
cancer aetiology and to help guiding cancer prevention policies. Surveillance of 
cancer survival is expected to be similarly valuable, allowing comparisons 
between and within countries and stimulating debate on strategies aimed at 
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reducing geographic and racial/ethnic survival inequalities, particularly in low- and 
middle-income countries.174 
 Along with data on incidence and mortality from cancer registries, survival 
trends provide a fundamental resource to help to interpret the influences of 
different risk factors, early diagnosis and treatment approach in different 
populations. Policy-makers paid little attention to population-based survival 
estimations until the publication of the EUROCARE studies.175, 176 These studies 
compared survival from different types of cancer, in adults and children, across 
many countries in Europe, and focused on the reasons for the reported survival 
disparities. The findings of EUROCARE studies had a significant impact on 
cancer control policies in some countries such as United Kingdom and Denmark.  
 Moreover, the survival inequalities identified by the CONCORD study20 
have guide important political actions. For example, the very poor cancer survival 
observed in Algeria suggests deficiencies in the healthcare system and 
inappropriate cancer registration in the country. In the near future, cancer 
registries will be established in Algeria in order to improve monitoring of cancer 
incidence and survival. 
 In another report, Pritchard-Jones et al.163 argued that, to improve access 
to care for children with cancer in low- and middle-income countries, each 
country should develop a national cancer control plan, taking into account 
socioeconomic, cultural and geographical factors. In addition, the authors 
emphasised the fundamental need for collaboration between national and 
international institutions in order to achieve sufficient recruitment of patients for 
clinical trials. This, eventually, can help further treatment developments. 
 In conclusion, the results of this literature review reinforce the need for 
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continuous global surveillance of paediatric and young adult cancer survival. 
Population-based comparisons of survival among children, adolescents and 
young adults with acute leukaemia can provide invaluable information to 
physicians, researches, policy-makers and governments. To effectively deliver 
health care to the population, it is necessary: (1) to assess the burden of disease 
in this population (e.g., cancer incidence and survival), (2) determine health care 
priorities, (3) implement health services, (4) monitor outcomes closely. 
 
3.2 Acute myeloid leukaemia  
3.2.1 Aims 
The main aims of this literature review were to identify worldwide trends of 
survival and early death after childhood and young adult acute myeloid leukaemia 
and to investigate the main predictors of outcome.  
 
3.2.2 Search strategy and eligibility criteria 
In my previous literature review (section 3.1.2), I found that all relevant articles 
published in the LILACs and Global Health databases, were also published in 
English in Medline/PubMed. Therefore, I have not searched these databases for 
my second literature review. I searched PubMed and Scopus databases to 
identify studies reporting survival and early death after acute myeloid leukaemia 
in children, adolescents and young adults.  
 I initially searched for publications from the last 5 years (from 2009 
onwards) but also included relevant studies cited in these publications. I used the 
following approach: 1) Study population: “Child*” OR “paediatric” OR “pediatric” 
OR “boys” OR “girls” OR “infant*” OR “baby” OR “babies” OR “adolescent*” OR 
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“young adult*” OR "AYA*” AND 2) Acute myeloid leukaemia terms: “acute” AND 
(“myeloid” OR “myeloblastic” OR “myelogenous” OR “promyelocytic” OR “non-
lymphocytic” OR “non-lymphoblastic” OR “nonlymphocytic” OR 
“nonlymphoblastic”) AND “leukaemia” OR “leukemia” AND 3) Disease outcome 
terms: “survival” OR “early death” OR “treatment-related mortality” OR "early 
mortality” OR “premature death” OR “premature mortality” OR “induction death". 
No language restrictions were applied. After duplicates have been removed, all 
titles and abstracts of publications identified in the course of primary search were 
reviewed for relevance and eligibility criteria (full electronic search strategy is 
presented in Figure 3.4). 
 Eligibility criteria were: 1) original studies that report early death and any 
length of survival from acute myeloid leukaemia in children, adolescents and 
young adults 2) studies types were: cohort studies, clinical trials, reviews, 
systematic reviews and cross sectional studies. Conferences abstracts were 
excluded. Articles titles and abstracts were screened to select papers for full text 
screening.  
 
3.2.3 Search results 
My primary search identified 1,592 references. A total of 154 duplicates were 
removed using Endnote X6 and by hand searching, resulting in 1,438 references. 
From the remaining 1,438 references, 177 articles that appeared relevant from 
the abstract were reviewed in full and 39 were selected for inclusion in this 
literature review. Similar to the acute lymphoblastic leukaemia literature review, 
the studies covered many geographical areas, but most originated from Europe 
and the United States. These studies were further separated into two parts: 23 
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studies selected for the literature review on acute promyelocytic leukaemia (Table 
3.8) and 16 studies for the literature review on non-APL acute myeloid leukaemia 
(Table 3.10).  
 The majority of these studies were clinical trials, but there were also 
several population-based studies. Some articles reported the results from all 
acute myeloid leukaemia subtypes combined, some studies report APL and non-
APL AML findings separately and other studies excluded patients with acute 
promyelocytic leukaemia.  
My search for early death after acute promyelocytic leukaemia was later 
expanded to report trends over a longer period of time (1990 onwards), following 
a suggestion made to me by a reviewer from Cancer, the peer-reviewed journal 
that accepted my paper for publication. Because the majority of these studies 
were clinical trials and used different eligibility criteria and definitions of early 
death, it was challenging to clearly compare population-level changes in early 
death over time, supporting the need for population-based studies to examine 
this question more closely.
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Full-text articles assessed 
for eligibility  
(n = 177) 
Studies included in the 
literature review  
(n = 39) 
APL = 23 
AML (non-APL) = 16 
Figure 3.4: Process of selection of the studies for literature review on acute myeloid leukaemia 
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3.2.4 Main findings 
3.2.4.1 Acute promyelocytic leukaemia  
Acute promyelocytic leukaemia is a relatively rare haematologic neoplasm, 
characterised by an interruption of the myeloid differentiation at the 
promyelocytic stage. Even though its precise incidence is unknown, it is 
estimated that approximately 600 to 800 new cases per year occur in the 
United States,177, 178 and accounts for about 4% to 8% of all acute myeloid 
leukaemias in children and adults.179 Interestingly, the incidence of acute 
promyelocytic leukaemia is strongly associated with age. It is rare in children 
younger than 10 years, the incidence then increases continuously from 10 
years until young adulthood, and remains constant up to 60 years when it 
starts to decline.180, 181  
 Intriguingly, the incidence of acute promyelocytic leukaemia is higher 
among Hispanics than non-Hispanic patients, with reports from Venezuela, 
Peru, Nicaragua, Spain, Brazil, and Mexico (Mexican Mestizos) confirming 
these findings.178, 182-185 To date, no environmental or work-related factors 
have been associated with the incidence of this disease. Interestingly, the 
incidence of acute promyelocytic leukaemia is fairly similar in males and 
females, which differs from the gender distribution observed in other acute 
leukaemias (ALL and non-APL AML). However, one European study reported 
an unusually higher proportion of incident cases among females than males 
aged less than 40 years.186  
 In the mid-1970s, Rowley et al. discovered that a translocation 
between chromosomes 15 and 17 was associated with acute promyelocytic 
leukaemia.187 This chromosome abnormality occurs in more than 90% of 
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acute promyelocytic leukaemia and is found exclusively in this malignancy.178 
This disease is genetically characterised by the presence of PML-RAR 
fusion protein, generated as a consequence of the specific reciprocal 
translocation of these chromosomes.188 The PML-RAR fusion protein holds 
most of the functional domains of the PML and RARα proteins.189 This 
discovery was fundamental in guiding molecular therapy for acute 
promyelocytic leukaemia. All-trans retinoic acid and arsenic trioxide have the 
potential to induce promyelocyte differentiation rather than their obliteration. 
These drugs have become the first example of differentiation induction 
treatment of human cancer.28 
 Hyperleukocytosis (100 X 109/L or greater) and coagulopathy are 
common features of acute promyelocytic leukaemia, often leading to early 
death, mainly due to intracranial haemorrhage.190 Early death definition 
varies, according to different studies, as death occurring between 7 to 45 days 
after the diagnosis of acute leukaemia (Table 3.8). Most studies, however, 
define early death as death occurring within 30 days after leukaemia 
diagnosis, and this is the definition used in this thesis. 
 A characteristic of acute promyelocytic leukaemia is its exceptional 
responsiveness to all-trans retinoic acid (ATRA) or arsenic trioxide (ATO). 
Due to the severity of this disease with higher risk of bleeding, these drugs 
should be initiated as soon as acute promyelocytic leukaemia is suspected. 
No delay should occur waiting for laboratory confirmation.191 The successful 
history of treatment for acute promyelocytic leukaemia is summarised in Table 
3.6 and described below. 
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Table 3.6: The history of acute promyelocytic leukaemia: a paradigm of success in 
translational medicine. Adapted from Lo-Coco presentation at the Association des 
Médecins Hématologues et Oncologues du Québec (AMHOQ) Annual Meeting, 2013
192
 
Year Therapeutic advance 
1957 First description of acute promyelocytic leukaemia (APL) 
1973 APL is highly responsive to treatment with single anthracycline chemotherapy 
1977 Specific chromosome translocation t(15;17) is identified 
1987 APL is responsive to all-trans retinoic acid (ATRA) 
1990 The altered genes are identified  
1993 Clinical trials (AIDA study) show high cure rates with ATRA plus chemotherapy 
1995 ATRA is approved by the US Food and Drug Administration in November 
1996 APL is also responsive to arsenic trioxide (ATO) 
2001 Registration and licensing of ATO for treatment of patients with relapsed APL 
2004–06 High cure rates with ATRA plus chemotherapy 
2006–12 It is possible to treat APL with ATRA + ATO (chemotherapy-free)  
 
Survival and early death after acute promyelocytic leukaemia: results 
from clinical trials 
Acute promyelocytic leukaemia was once a virtually fatal disease. In a 
retrospective study, 57 patients diagnosed with acute promyelocytic 
leukaemia during 1949–1964 were examined. Only 7% patients (n = 5) 
survived more than 4 months. The majority of patients died from 
haemorrhagic events.193, 194  
 During the 1970s and 1980s, several studies were performed that 
aimed at finding the best anti-haemorrhagic treatment for acute promyelocytic 
leukaemia, but no preventive or therapeutic regimen was found satisfactory. 
One retrospective study evaluated 268 consecutive patients aged 7 to 78 
years from 29 Italian institutions during 1984–1987.195 The goal of this study 
was to investigate the incidence of early haemorrhagic death and the 
effectiveness of different treatment approaches (heparin, anti-fibrinolytics or 
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supportive care alone). Overall, early haemorrhagic death was 9.4% and 
median survival was 12.5 months. The authors found no difference between 
the three treatment strategies and suggested that prospective randomized 
trials were urgently needed in order to identify better treatment for acute 
promyelocytic leukaemia and prevent haemorrhagic deaths.  
 In the 1990s and 2000s, several multi-collaborative clinical trials in 
Europe and the United States investigated the use of ATRA in newly 
diagnosed patients with acute promyelocytic leukaemia.196-208 These studies 
have uniformly revealed that the introduction of ATRA alone or with 
chemotherapy decreased bleeding and, consequently, early death, improving 
overall survival. For instance, one study in the United States analysed 346 
patients aged 1–81 years at diagnosis of acute promyelocytic leukaemia 
during 1992–1995. About half of patients received chemotherapy (control 
group) and half received ATRA. Overall, early death was 12.4%, with 11% 
occurring in the ATRA group and 14% in the chemotherapy group. Although 
the difference was not statistically significant (P = 0.52), the probability of 
relapse decreased in the ATRA group. Moreover, survival was significantly 
better in the ATRA group.198  
 Another study in Europe analysed 44 children aged 1–16 years when 
diagnosed with acute promyelocytic leukaemia during 1992–1997. Half of 
children received chemotherapy alone and the other half of children were 
treated with ATRA. Death within 6 weeks of diagnosis was 4.5% in the ATRA 
group vs. 32% in the chemotherapy group (P value = 0.04). Furthermore, 
overall survival was 87% in the ATRA group vs. 45% in the chemotherapy 
group (P value = 0.003). 
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Survival and early death after acute promyelocytic leukaemia: results 
from population-based studies  
The outcomes reported from population-based studies are usually inferior to 
those described in clinical trials or single institutions in the developed 
countries. The main reason for this is that population-based studies provide 
data on virtually all patients diagnosed with leukaemia (or other type of 
cancer) in the population. Differently, clinical trials include selected groups of 
patients, usually excluding those who are very sick and may not tolerate 
intensive treatment protocols. Therefore, while in developed countries early 
death has been reported to be around 3% to 8% in clinical trials,9, 209 results 
from population-based studies in Europe (Sweden Cancer Registry) and in 
the US (SEER data) has varied from 17%–29%.22, 186, 210 These findings 
caused some controversy in the literature, on whether early death after acute 
promyelocytic leukaemia has decreased after the introduction of ATRA. Some 
examples are described below. 
 Derolf et al.210 estimated survival and early death of 111 patients with 
acute promyelocytic leukaemia (corresponding to 2.5% of all cases of acute 
myeloid leukaemia) aged 0 to > 80 years, during 1993–2005, using data from 
the nationwide Swedish Cancer Registry. Early death (30-day mortality) 
decrease from 27% in 1993–1999 to 18% in 2000–2005 and 3-year relative 
survival was 53% vs. 69% respectively. The authors suggested that the 
introduction of ATRA in the treatment of this leukaemia might have 
contributed to the better outcomes in the more recent calendar period.  
 Lehmann et al.186 studied 105 patients aged 16 years or older, with 
acute promyelocytic leukaemia (3.2% of all acute myeloid leukaemia cases) 
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during 1997–2006, using data from the Swedish Adult Acute Leukaemia 
Registry. This Registry works in collaboration with the Regional Tumour 
Registry in the six Swedish health care regions, reporting 98% of coverage of 
all acute leukaemia patients. In contrast to the previous study, the authors 
have not observed improvement in early death and reported early death as 
high as 29%. Strikingly, they found that 35% of patients had not received 
ATRA and about 41% of early death was secondary to haemorrhage. In 
addition, the authors observed that early death increased with age at 
diagnosis, and was strongly associated with poor performance status (PS 
classification is described in Table 3.7). They concluded that, at a population 
level (unselected patients), early death is still remarkably high in Sweden and 
suggested that lack of adherence to treatment guidelines may have 
contributed to this unfavourable outcome. 
 
Table 3.7: Performance Status Classification. Source: The World Health Organisation / 
Eastern Cooperative Oncology Group Performance Status
211, 212
  
Grade Explanation of activity 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. 
Up and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking 
hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 Dead 
 
 In the United States, Park et al.22 examined 1,400 children and adults 
with acute promyelocytic leukaemia during 1992–2007 using SEER data. 
Overall early death was 17.3%, with only a slight change over time (from 
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22.3% in 1992–1995 to 14.7% in 1996–2001 and 17.5% in 2002–2007, P 
value = 0.068). The authors concluded that early death remains high in the 
United States and highlighted that health care providers should be educated 
to recognise acute promyelocytic leukaemia as an emergency and promptly 
initiate ATRA. 
 Finally, a recent study in the United States213 reported the results from 
a population-based study using SEER data from 1977–2007 and a hospital-
based study conducted during 1997–2009 that examined early death after 
promyelocytic leukaemia in patients aged 15 years or older. The authors 
found high 30-day mortality in both studies (26% and 20% respectively). 
Seven-day mortality was also examined in the hospital data and was found as 
high as 19%. Ten out of 13 patients who died within 30-days in the later study 
received ATRA. This study emphasised that early death is currently the 
greatest contributor to overall mortality in patients with acute promyelocytic 
leukaemia despite the use of ATRA. They argue that further understanding of 
the pathogenesis of haemorrhagic complications in acute promyelocytic 
leukaemia and use of more aggressive supportive care are warranted.  
 
Differentiation syndrome 
Although bleeding is the major cause of early death in children and adults with 
acute promyelocytic leukaemia, other relevant causes of death are infections 
and differentiation syndrome, complications that often occur in the first 3 
weeks of treatment.214 Differentiation syndrome is a relatively common and 
serious complication secondary to the use of ATRA and/or arsenic trioxide for 
the treatment of acute promyelocytic leukaemia. This syndrome is estimated 
  106 
to occur in 2 to 31% patients during induction treatment and is characterised 
by fever and pulmonary, cardiovascular, and/or renal dysfunction. Its 
pathogenesis is not entirely clear but it seems to be secondary to an 
inflammatory systemic response caused by ATRA (or arsenic) use. Due to the 
severity of this syndrome, several collaborative groups have incorporated the 
use of corticosteroids as preventive and therapeutic measures. Treatment is 
essentially supportive and may include vasopressors, mechanical ventilation 
and dialysis. In critical patients, ATRA and arsenic should be temporarily 
discontinued and the patients admitted to an Intensive Care Unit.215, 216  
  
Acute promyelocytic leukaemia in developing countries 
Despite the excellent prognosis of acute promyelocytic leukaemia among 
children and adults, the success of new contemporaneous therapeutic 
regimens has not been equally shared in low- and middle-income countries. In 
Brazil, a retrospective study217 with 134 patients aged 5–79 years during 
2003–2006, revealed that only 68% of patients treated with anthracyclines 
and ATRA reached complete remission. Thirty-two percent of patients died 
during induction therapy and about 10% died during the consolidation phase, 
numbers significantly higher than those reported in high-income countries 
(5%–10% during induction and less that 5% during consolidation).9, 218, 219 
Early death (defined in this study as death within 14 days of diagnosis) was 
very high (26.4%) and haemorrhage was the main cause of death (22%). The 
authors concluded that the highest priority to improve outcome in developing 
countries might be intensive treatment and supportive care during the 
induction phase, when the majority of haemorrhagic deaths occur. They 
  107 
highlighted that no patient was excluded from the study based on their age or 
unfavourable performance status (differently than what usually occurs in 
clinical trials). This study also suggests that the availability of ATRA and 
anthracyclines itself is not enough to decrease the gap in outcome between 
developed and developing countries. 
 
The International Consortium on Acute Promyelocytic Leukaemia  
Over a decade ago, a group comprised of international members of the 
American Society of Haematology developed an initiative to help developing 
countries to improve outcomes from acute promyelocytic leukaemia through 
medical education programmes.220 The International Consortium on Acute 
Promyelocytic Leukaemia was created in 2005 and received support from 
collaborative groups in the United States and Europe. The goal of this 
consortium is to develop treatment guidelines based on successful trials 
conducted in the developed countries, but adapted to local conditions. This 
Consortium offers online meetings with experts (usually twice a month), helps 
in the development of therapeutic protocols, and monitors the supportive care 
provided and treatment response. This initiative has allowed some patients 
with acute promyelocytic leukaemia in countries such as Brazil, Mexico, Chile 
and Uruguay to achieve outcomes similar to those in high-income 
countries.220  
 In summary, acute promyelocytic leukaemia is currently a highly 
curable disease. With modern treatment that includes chemotherapy with 
anthracyclines-based agents and ATRA (or arsenic trioxide), many large 
collaborative trials in Europe, the United States and Japan have reported 
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complete remission rates up to 95%, and cure in 80% or more patients treated 
with these regimens.9, 186, 196, 197, 199, 200, 209 Nevertheless, there is evidence 
from both population-based studies and also from clinical trials that early 
death remains high in some centres in developed and especially in the 
developing countries. Further evaluation of early death trends at the 
population level and examination of predictors of early death are needed. 
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Table 3.8: Consecutive reports on early death and survival in patients diagnosed with acute promyelocytic leukaemia, 1990–2014 
First author, year, 
setting 
Study design N Period Age 
(Years) 
Early death Survival 
 Definition Percentage  
1.Rodeghiero F, 
1990, Italy
195
 
Clinical trials 268 1984–1987 7–78 Death occurring in the first 10 days 
after starting chemotherapy 
9.4% died due to 
haemorrhagic events and 
3.2% due to other causes 
(pre-ATRA era) 
Median survival: 12.5 months for all 
patients (pre-ATRA era) 
2. Fenaux P, 1993, 
Europe
196
 
Clinical trials 101 1991–1992 6–67 Death during chemotherapy or 
ATRA, or during the period of 
aplasia after chemotherapy, without 
evidence of resistant leukaemia 
9.0% in the ATRA group 
and 8.0% in the 
chemotherapy group 
 
1-y overall survival: 
91% (ATRA group) 
80% (chemotherapy only) 
3. Estey E, 1997, 
US
197
 
Clinical trial ATRA: 43 
Control: 57 
1991–1995 
1979–1991 
13–72 
17–80 
Death during induction therapy 19.0% 
30.0% 
1-y disease-free survival: 
87% (ATRA group) 
67% (control group) 
4. Tallman MS, 
1997, US
198
 
Clinical trials 346 1992–1995 1–81 Death within 28 days of diagnosis  12.4% (overall) 
11.0% (ATRA group) 
14.0% (control group) 
1-, 2- and 3-y overall survival 
respectively: 
84%, 74% and 71% (ATRA group) 
75%, 57% and 50% (control group) 
5. Mandelli F, 1997, 
Europe
199
 
Clinical trials 240   1993–1996 2–73 Death during induction therapy 5.0% 1- and 2-y overall survival respectively 
90% and 87% (ATRA + chemotherapy) 
6. Fenaux P, 1999, 
Europe
200
 
Clinical trials 439 1993–1996 ≤ 77 Death occurring during induction 
treatment with ATRA, without 
evidence of resistant leukaemia 
7.0% 2-y overall survival: 
84% (ATRA followed by chemotherapy) 
81% (ATRA + chemotherapy) 
7. Sanz MA, 1999, 
Spain
201
 
Clinical trials 123 1996–1998 1–74 Death occurring during induction 
therapy or during the period of 
aplasia after chemotherapy 
9.8% 2-y overall survival: 
82% (ATRA + chemotherapy) 
8. Di Bona E, 2000, 
Italy
202
 
Clinical trials 622 1989–1997 1–74 Early haemorrhagic deaths 
occurring in the first 10 days after 
starting treatment  
3.8% in study w/ idarubicin 
+ ATRA, 7.3% w/ 
idarubicin alone 
N/A 
9. Lengfelder E, 
2000, Europe
203
 
Clinical trials 51 1994–1999 16–60 Death during induction therapy 
before recovery from therapy 
immunosuppression 
8.0% 2-y overall survival: 
88% (ATRA + chemotherapy) 
10. Mann G, 2001, 
Austria
204
 
Clinical trials 44 1993–2002 1–16 Death within 6 weeks of diagnosis 4.5% (ATRA group)  
32.0% (control group)  
5-y overall survival: 
87% (ATRA + chemotherapy) 
45% (chemotherapy only) 
11. Asou N, 2001, 
Japan
205
 
Clinical trials 369 1992–1997 15–86 Death within 28 days of start of 
chemotherapy 
8.0% 6-y overall survival: 
65% (ATRA alone or with chemotherapy) 
12. Testi AM, 2005, 
Italy
206
 
Clinical trials 107 1993–2000 1–17 Death occurring within 34 days of 
diagnosis  
3.7%  10-y overall survival: 
89% (ATRA + chemotherapy) 
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First author, year, 
setting 
Study design N Period Age 
(Years) 
Early death Survival 
 Definition Percentage  
13. Schlenk RF, 
2005, Europe
221
 
Clinical trials 82 1995–2003 16–60 Death <7 days after completion of 
the first induction therapy or death 
during double induction therapy 
12% Overall survival at 46 months: 
82% (ATRA + chemotherapy) 
14. Yanada M, 
2007, Japan
208
 
Clinical trial 279 1997–2002     15–70  Early haemorrhagic death 3.2% (ATRA for all 
patients) 
5-y event-free survival 
68% in patients without haemorrhage 
event  
31% in patients with haemorrhage event 
15. Jacomo RH, 
2007, Brazil
217
 
Hospital-based (12 
institutions) 
134 2003–2006 5–79 Early mortality: death within 14 days 
of diagnosis. 
Death during induction 
Death during consolidation. 
26.4%  
 
32.1% 
10.5% 
Mean survival time = 707 days (583–
820). 
3-year overall survival <60% 
(Anthracyclines + ATRA) 
16. Derolf AG, 
2009, Sweden
210
  
Population-based  
 
111 1993–2005 All ages 
included 
Death occurring within 30 days of 
diagnosis. 
Induction mortality 
27% during 1993–1999 
18% during 2000–2005 
3-y relative survival: 
61% during 1993–1999 
69% during 2000–2005 
17. Lo-Coco F, 
2010, Italy
9
 
Clinical trials 642           
453 
1993–2000
 
2000–2006 
18–≤ 61 Induction death – death within 45 
days of treatment using ATRA and 
idarubicin  
5.5% for AIDA-0493
1
 
5.6% for AIDA-2000
2
 
6-y overall survival  
78.1% for AIDA-0493
1
 
87.4% for AIDA-2000
2
 
18. Lehmann S, 
2011, Sweden
186
 
Population-based  105 1997–2006 ≥16 Death within 30 days of diagnosis 29.0% (35.0% of patients 
did not receive ATRA) 
5-y overall survival: >16y and <40y = 
82%; 40y–59y = 75%; ≥ 60y = 25% 
19. Park JH, 2011, 
US (SEER)
22
 
Population-based  1,400 1992–2007 All ages Death within 30 days of diagnosis  17.3%  3-y overall survival: 70% 
20. Iland HJ, 2012, 
Australia and New 
Zealand
209
 
Clinical trials 124 2004–2009 >1 Induction death within 36 days of 
ATRA exposure 
3.2% 2-y overall survival: 93% 
21. McClellan JS, 
2012, US (Stanford 
and SEER)
213
 
Hospital-based & 
population-base  
70 
N/A 
1997–2009 
1977–2007 
 
≥15 Death within 7 or 30 days from the 
start of chemotherapy 
18.6% (7 days) and 26.0% 
(30 days) 
20.0%  (30 days) 
3-y overall survival of high-, intermediate- 
and low-risk patients were 56%, 70% and 
83%, respectively (Stanford) 
22. Altman JK, 
2013, Israel and 
US
222
 
Hospital-based  204 1992–2009 1–85 Death occurring within 30 days of 
presentation to medical care 
11.0%, 61% due to 
haemorrhage (only in 31% 
of cases ATRA was 
ordered the day PL was 
suspected) 
N/A 
23. Fisher BT, 
2014, US
21
 
Hospital-based  163  1999–2009 All ages 
Included 
Induction death within 7 and 30 
days of admission 
4.3% (7 days) 
6.1% (30 days) 
N/A 
Abbreviations: ATRA, all-trans retinoic acid; N/A, not applicable; SEER, Surveillance Epidemiology and End Results; US, United States; AIDA, Amsterdam Investigator-initiate D Absorb trials 
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3.2.4.2 Acute myeloid leukaemia  
Acute myeloid leukaemia is the most common type of acute leukaemia and its 
incidence increases with advanced age. It accounts for about 15%–20% of all 
leukaemias in children, approximately 33% of leukaemia in adolescents and 
50% of leukaemia in adults.51  
 Similarly to acute lymphoblastic leukaemia, the incidence of non-APL 
acute myeloid leukaemia is higher among males than females with a ratio of 
1.5:1. The aetiology of acute myeloid leukaemia remains largely unknown. 
The most recognised cause of this malignancy is previous treatment with 
chemotherapy or radiation, leading to 10%–20% of cases of acute myeloid 
leukaemia cases.178, 223 
 Patients with non-APL acute myeloid leukaemia continue to have a 
much lower long-term survival compared to those with acute lymphoblastic or 
promyelocytic leukaemia. Biologic and non-biologic factors predictive of 
outcome after acute myeloid leukaemia are described below. 
 
Survival trends and the effect of age at diagnosis on the outcome of 
acute myeloid leukaemia in children, adolescents and young adults. 
Several studies have shown improvement in survival after acute myeloid 
leukaemia over time, but to a lesser degree when comparing with the survival 
from acute lymphoblastic and promyelocytic leukaemias. Pulte et al.224 
investigated 5- and 10-year survival of 560 children aged 0–14 years with 
acute non-lymphoblastic leukaemia and also 2,855 children with acute 
lymphoblastic leukaemia during 1990–2004. This study showed that 5-year 
relative survival improved from 41.9% in 1990–1994 to 59.9% over 2000–
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2004 among patients with non-lymphoblastic leukaemia, while 5-year survival 
for acute lymphoblastic leukaemia increased from 80.2% to 87.5% in the 
same period. 
 In another study, Pulte et al.10 examined 5- and 10-year survival of 
adolescents and young adults with haematologic malignancies. The authors 
examined 709 patients aged 15–24 years with acute myeloid leukaemia 
during 1985–2005. Survival improved considerably but it was lower than that 
of the younger paediatric cohort. Five-year relative survival improved from 
20.0% in 1981–85 to 47.2% in 2001–2005, while 10-year survival increased 
from 15.2% to 45.1%. The authors hypothesized that the lower survival in 
these older patients may be due to the lack of insurance, inferior enrolment in 
clinical trials and lower adherence to treatment. 
 In Sweden, a large study210 (n = 9,729) was conducted to examine the 
survival trends after acute myeloid leukaemia in all patients registered in the 
Swedish Cancer Registry, during a long period of time (1975–2005). Although 
this study has included patients with a previous malignancy (which may result 
in worse outcomes), survival after acute myeloid leukaemia was found higher 
than that observed by Pulte et al. in the two studies mentioned above. Five-
year relative survival in the more recent era of treatment (1997–2005) was 
65% for patients aged 0–18 years and 58% for those aged 19–40 years. The 
authors suggested that the superior survival of patients with acute myeloid 
leukaemia in Sweden compared with that in the United States might be to the 
public health system that guarantees equal access to health service for all 
citizens. In Sweden, virtually all patients are treated at non-private hospitals 
with haematologic units and therefore have access to optimal treatment, 
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including haematopoietic stem cell transplantation, without financial burden for 
their families.  
 Other researchers have also investigated the association of age at 
diagnosis with outcome after acute myeloid leukaemia. Razzouk et al.225 
analysed 424 patients aged 0–21 years from two American institutions during 
1983–2002. Patients with Down syndrome and acute promyelocytic 
leukaemias were excluded due to their distinctive (better) prognosis compared 
with other subtypes of acute myeloid leukaemia. This study revealed that, 
after adjusting for cytogenetic characteristics and white blood cell count, 
patients aged less than 10 years of age at diagnosis had higher 5-year overall 
survival (49.4%) than those aged 10 years or older (34.8%). The authors 
found that the hazard of death increased substantially with each year of age in 
both calendar periods examined (1983–1989 and 1990–2002). They 
concluded that older patients (≥ 10 years) do not benefit, to the same extent 
younger patients do, from the use of modern intensive treatment, including 
haematopoietic stem cell transplantation. They suggested that further 
research is required to evaluate if pharmacokinetic differences play a role on 
the higher rate of treatment-related mortality among patients aged 10 years or 
older. 
 An European study51 evaluated 891 children aged under 18 years 
during 1993–1998 treated in the AML BMF trials and 290 adolescents and 
young adults aged 17 to 29 years in the AML Cooperative Group (AMLCG) 
and AML Study Group (AMLSG) trials during 1992–1999. Five-year event-free 
survival was higher for younger than older patients: 54%, 46% and 28% for 
patients aged 2–12 years (children), 13–20 years (adolescents) and 21–29 
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years (young adults), respectively. When patients with favourable karyotypes 
were excluded, 5-year event-free survival was similar for infants (< 2years) 
and children (44% and 46% respectively) and lower for adolescents and 
young adults (35% and 23%, respectively). The authors concluded that the 
prognosis of acute myeloid leukaemia decreases after childhood regardless of 
other risk factors such as karyotype.  
 Walter et al.226 investigated early death during induction therapy (death 
occurring within 28 days after initiation of treatment) in 3,365 older patients 
(aged 17–89 years) enrolled in clinical trials in the United States during 1986–
2009. Overall early death was 10.3% (11.1% at Southwest Oncology Group 
and 9.9% at MD Anderson Cancer Center clinical trials). The authors 
examined the association between early death and age and other covariates. 
These covariates were: platelets, white blood cell count, albumin, creatinine, 
bilirubin, percentage of blasts in the peripheral blood and bone marrow, 
haemoglobin, fibrinogen, lactate dehydrogenase, blood neutrophils, as well as 
sex, race, performance status and secondary AML. Performance status was 
the strongest single predictor of early death (or treatment-related mortality). 
The authors concluded that, even though age does increase the risk of 
treatment-related complications and death, it should not be used as a single 
predictor of outcome to guide therapy (usually set to an arbitrary cut-off of 55-
60 years that separates younger and older patients). 
 More recently, Rubnitz et al.227 evaluated the effect of age on outcome 
for children and young adults with acute myeloid leukaemia treated with 
different protocols. They examined 351 patients aged 0–21 years treated in 3 
consecutive clinical trials at St. Jude during 1991–2008. Using the most 
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recent protocol (AML02: 2002–2008), the authors found a substantial increase 
in survival for older patients (10–21 years), with 3-year overall survival 
currently similar to that for younger patients (0–9 years): 69% vs. 75%, 
respectively (P value = 0.36). This result differs from those of previous 
population-based studies6 and clinical trials (including one in the same 
institution225) performed between 1980s and 1990s. The authors suggested 
that the survival improvement observed for all ages is secondary to the use of 
target therapy, aggressive supportive care and monitoring of minimal residual 
disease. Nonetheless, the cumulative incidence of treatment-related mortality 
was significantly higher for patients aged 10–21 years than that for younger 
children. They concluded that treatment toxicity remains an important problem 
for adolescents and young adults with acute myeloid leukaemia and re-
emphasised the prognostic significance of age on outcome. 
 
The association of race and ethnicity on outcome of children and young 
adults with acute myeloid leukaemia 
There is evidence that race/ethnicity is also associated with the outcome of 
children, adolescents and young adults with acute myeloid leukaemia. A 
population-based study228 evaluated the effect of race and insurance in the 
outcome of 523 patients aged 21–64 years with acute myeloid leukaemia 
diagnosed during 1999–2006 in the State of Virginia, United States. The 
results of this study revealed that the hazard of death for black patients was 
increased by 43% relative to that for white patients (HR = 1.43). Moreover, 
uninsured and publicly insured patients also had a higher hazard of death 
compared to privately insured patients (HR = 1.29 and 1.39, respectively), 
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suggesting the need for better insurance coverage of minority and 
disadvantage group of patients. The authors also highlighted the results of 
previous studies showing that black patients are more likely to be diagnosed 
with disease in more advanced stages and receive sub-optimal treatment.  
 A more recent study229 using SEER data from 1992–2006, examined 
the association of race/ethnicity on outcome of patients aged ≥ 15 years with 
acute leukaemia and other types of cancer. This study demonstrated that 5-
year survival has improved over time for all types of malignancies. For acute 
leukaemia, survival increased substantially for non-Hispanic white and 
younger (less than 65 years) Hispanic patients, but here was no survival 
improvement for black and older Hispanic patients. In fact, there was 
evidence that survival inequalities increased between non-Hispanic white and 
black patients during the two calendar periods examined. Five-year survival 
for patients aged 15–64 years, diagnosed with acute leukaemia during 1992–
1996 and 2002–2006 was respectively: 28% and 39% for non-Hispanic white, 
29% and 38% for Hispanic and 26% and 27% for black patients. 
 Rubnitz et al.230 studied 229 white and 58 black patients aged 21 years 
or younger diagnosed with acute myeloid leukaemia during 1980–2002 and 
enrolled in five consecutive clinical trials at St. Jude Children’s Research 
Hospital. Although the authors did not find a difference in survival between 
white and black children over the entire study period, they did observe worse 
survival for black children in the more recent trial: 5-year overall survival for 
black children was 27% vs. 56% for white children. However, these results did 
not reach statistical significance, possibly due to the inferior power to detect 
differences when data from an individual trial were examined separately 
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compared to data from the combined trials. The authors argued that the trend 
toward worse outcome for black children might be due to pharmacogenetic 
differences that may influence their response to targeted therapy. In addition, 
Hispanic children treated at St Jude (n = 34) seemed to have a good 
outcome: 5-year overall survival was 67% for all trials combined and 75% 
during the most recent trial (1997–2002). The authors suggest that these 
results reflect the favourable leukaemia characteristics of these patients: the 
majority was younger than 10 years and had approximately 43% of favourable 
cytogenetic abnormalities.  
 
Non-biological factors associated with survival of children, adolescents 
and young adults with acute myeloid leukaemia 
Borate et al.231 studied the association between non-biological factors (i.e. 
health insurance status, marital status and income) and survival among 
patients aged 19–64 years when diagnosed with acute myeloid leukaemia. 
They examined 5,541 patients during 2007–2011 using SEER 18 data. The 
results of this study showed worse survival for single or divorced patients, 
those with no insurance or public health insurance, and among patients who 
live in a county within the lower quintiles of median household income, 
compared with married, privately insured patients and those living within the 
higher two quintiles of median household income.  
 Another European study232 investigated the association between 
socioeconomic status and outcome after acute myeloid leukaemia and 
multiple myeloma. A total of 5,541 patients of all ages, diagnosed with acute 
myeloid leukaemia during a 33-year period (1973–2003) were examined. The 
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authors used occupation as a surrogate for socioeconomic status and found 
that patients with higher than lower socioeconomic status had better survival. 
The overall mortality was higher among blue-collar workers compared with 
white-collar workers in the three calendar periods examined: HR of death was 
1.26, 1.23 and 1.45 during 1980–1989, 1990–1999 and 2000–2005, 
respectively. 
 
Cytogenetic alterations effect on outcome after acute myeloid leukaemia 
Cytogenetic alterations are considered one of the most relevant prognostic 
factors in acute myeloid leukaemia. Grimwade et al.233 studied 1,612 patients 
aged 0–55 years with de novo and secondary acute myeloid leukaemia during 
1988–1995 in the United Kingdom. The main aim of this study was to evaluate 
the significance of pre-treatment diagnostic cytogenetics on outcome of 
patients with acute myeloid leukaemia. The authors identified groups of 
children and young adults that present different responses to treatment and 
relapse risk, allowing for targeted therapy. In addition, the cytogenetic risk 
groups were found to have significant predictive value for the outcome of 
haematopoietic stem cell transplantation. Nonetheless, cytogenetic analysis 
was not able to precisely predict outcomes for individual patients, mainly for 
those within the heterogeneous intermediate risk group. The authors 
highlighted the need of further identification of independent prognostic factors, 
including molecular features, to better guide therapy and improve outcome 
after acute myeloid leukaemia. The survival of children and young adults in 
this cohort varied widely according to the cytogenetic risk: 5-year overall 
survival was 65%, 41% and 14% for favourable, intermediate and adverse risk 
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groups, respectively. Table 3.9 shows the cytogenetic risk groups for acute 
myeloid leukaemia. 
 
Table 3.9: Cytogenetic Risk Group. Source: Grimwade et al., Blood 1989
233
 
Risk Group Cytogenetic abnormality Additional comments 
Favourable  t(8;21) 
t(15;17) 
inv(16) 
Alone or in conjunction of 
other abnormalities 
Intermediate Normal 
+8 
+21 
+22 
del(7q) 
Del(9q) 
Abnormal 11q23 
All other structural/numerical 
abnormalities 
Cytogenetic abnormalities 
not classified as favourable 
or adverse 
 
Lack of additional favourable 
or adverse cytogenetic 
changes  
Adverse –5 
–7 
del(5q) 
Abnormal 3q 
Complex 
Alone or in conjunction with 
intermediate-risk or other 
adverse-risk abnormalities 
 
The impact of molecular alterations on survival after acute myeloid 
leukaemia 
In the last two decades, various studies have been conducted in order to 
identify potential molecular targets to guide new therapeutic approaches and 
increase survival after acute myeloid leukaemia in children and adults. Ho et 
al.234 evaluated a total of 847 patients aged 1 month to 20 years, who were 
enrolled in the Children’s Oncology Group collaborative clinical trials during 
1995–2005. Thirty-eight (4.5%) patients had CEBPA mutation, which is 
recognised to be associated with leukaemia outcome. There were two types 
of CEBPA mutations more often associated with older patients and those with 
normal karyotype. The CEBPA mutations have occurred exclusively in 
intermediate risk patients and were considered an independent predictive 
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factor of outcome after acute myeloid leukaemia. Patients with single or 
double CEBPA mutations have favourable outcomes with lower incidence of 
relapse (13% vs. 44%) and higher survival (83% vs. 51%) than those without 
CEBPA mutations. The authors concluded that patients with CEBPA 
mutations may not benefit from haematopoietic stem cell transplantation in 
first remission and should be treated with chemotherapy alone. 
 One European study235 analysed the prognostic significance of 
cytogenetic abnormalities in 729 children aged 0–16 years enrolled in the UK 
Medical Research Council trials (AML 10 and 12), during 1988–2002. The 
most common alteration was rearrangements of 11q23 found in about 16% of 
patients with acute myeloid leukaemia (half of them were infants). This study 
confirmed the favourable prognosis of the cytogenetic abnormalities t(8;21) 
and inv(16) with 10-year survival equal to 80% and 81%, respectively. The 
poor prognosis abnormalities with correspondent 10-year overall survival (OS) 
were: abnormality of 12q, 35%; t(6;9), 50%; abnormality of 5q, 27%; 
monosomy 7, 32%; and t(9;22), survival not estimated due to small number of 
cases. The 10-year overall survival for children with normal karyotype was 
58%. The authors highlighted that the predictive significance of these 
alterations may be different in the future, and further studies should be done 
to identify new genetic alterations that may guide novel risk stratification for 
acute myeloid leukaemia.  
 In summary, in order to improve survival, there is a need to integrate 
basic sciences with clinical sciences (translational medicine), which includes 
genome-wide analysis for every patient with acute myeloid leukaemia in order 
to identify novels molecular markers that have prognostic implications.  
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The importance of population-based studies for acute myeloid 
leukaemia 
A study in Sweden236 discussed the significance of population-based data on 
the advance of acute myeloid leukaemia. The nationwide Swedish Cancer 
Registry is a well-recognised registry for its high-quality and comprehensive 
source of information on individual cancer patients. Reporting is compulsory in 
Sweden, thus the registry collects information on essentially all patients with 
cancer in the country. In addition to the routinely collected data, there is 
information on patients' eligibility for chemotherapy, performance status 
(available for approximately 97% of cases) and nearly complete follow-up of 
patients. Furthermore, because all Swedish citizens have a unique personal 
identification code, all their information, including level of education, medical 
history and cause of death can be tracked after migration within its territory 
and upon return from overseas. It is also possible to evaluate socioeconomic 
status based on national registries. The authors of this study assert that 
population-based data are important not only to provide incidence and 
mortality trends, but also relevant supplementary information for clinicians to 
guide therapeutic decisions. Using data from the Swedish Acute Leukaemia 
Registry during 1997–2007, more than 3,000 patients aged 16 years or older 
with acute myeloid leukaemia were examined. The authors investigated the 
effect of selecting patients with acute myeloid leukaemia and better 
performance status on survival. Early death (30-day mortality) after acute 
promyelocytic leukaemia was also investigated. The main findings are 
described as follows:  
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1. Five-year overall survival for non-APL AML patients was 60% for patients 
aged less than 30 years, 49% for those aged 30–44 years and, for patients 
older than 54 years no more than 23%. When only patients with performance 
status 0–II were included in the analysis, survival increased substantially, 
mainly for patients aged 55 years or more (about a 50% increase).  
 
2. Overall early death after acute promyelocytic leukaemia was 42% during 
the late 1990s. For patients younger than 60 years, early death declined from 
25% in the late 1990s to 10% from 2001 onwards. The authors concluded 
clinical trials continue to be the best study design to investigate specific 
therapeutic approaches for acute leukaemias. However, important limitations 
exist due to small number of patients with specific subtypes of disease, and 
selection of patients. The authors emphasized the importance of linking high-
quality cancer registry data with patient information from medical records for 
the improvement of cancer outcome. 
 
Haematopoietic stem cell transplantation and acute myeloid leukaemia 
Haematopoietic stem cell transplantation (HSCT) is an established curative 
therapeutic possibility for a minority of high-risk patients with acute myeloid 
leukaemia. In the last 10 years, the use of HSCT has increased in the 
developed countries. This is, in part, due to an increase in the use of 
unrelated donor, better supportive care and the availability of less toxic pre-
treatment regimes.237-239 However, the indication of HSCT remains somewhat 
controversial. The major causes of HSCT failure are relapse and treatment-
related toxicity, including graft-versus-host disease, chemotherapy and 
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radiation toxicity, and severe infections. Therefore, a key strategy is to focus 
on strategies to prevent post-transplant relapse. 
 Various factors should be accounted for when using genetic data to 
recommend HSCT to a patient with acute myeloid leukaemia. For instance, 
although the presence of NPM1 gene mutation has been considered to have 
a "protective" effect for patients with AML, this may not be true for patients 
older than 65 years according to the results of a recent clinical trial.240 A better 
understanding of the biology of acute myeloid leukaemia has allowed an 
improved pre-, peri- and post-transplant management. This has been enabled 
by the use of less toxic drugs. The combination of monoclonal antibodies with 
classical drugs are promising and may allow intensive treatment without 
increasing treatment related-toxicity.237 
 In conclusion, acute myeloid leukaemia is a very complex malignancy 
characterised by phenotypic, cytogenetic, and genetic heterogeneity. Its 
aetiology is largely unknown, but may occur due to a preceding 
haematological disorder or exposure to toxic agents such as chemotherapy 
drugs. It is accepted that nearly all patients with acute myeloid leukaemia 
have multiple malignant clones. Each subclone comprises a unique 
combination of genetic and epigenetic alterations and may have different 
responses to treatment.241 
 Biological and non-biological factors such as socioeconomic status, 
race/ethnicity, marital status, and genetic and epigenetic characteristics have 
been implicated in outcomes from acute myeloid leukaemia. Age at diagnosis 
remains one of the most relevant prognostic factors for acute myeloid 
leukaemia along with performance status.  
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 As documented in this literature review, improvement in survival from 
acute myeloid leukaemia has been modest, particularly when compared with 
other types of acute leukaemias. Treatment relies mostly on chemotherapy, 
appropriate use of bone marrow transplant and aggressive supportive care. 
The current consensus is that the better approach to treat these patients will 
rely on individualised treatment strategies (precision medicine), but additional 
research is needed to identify the best treatment for each patient. 
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Table 3.10: Characteristics of included studies and results of the literature review on acute myeloid leukaemia  
First Author,  
Year, setting 
Study design Period Age at 
diagnosis  
Number of cases Early death Survival or hazard of death 
   (Years)  Definition Percentage  
1. Grimwade D, 
1998, UK
233
 
Clinical trials 
(MRC AML 
10) 
1988–1995 0–55 1,612 with de novo or 
secondary AML 
N/A N/A 5-y OS by cytogenetic risk: 65%, 41%, 14% for 
favourable, intermediate and adverse risk, respectively 
2. Razzouk BI, 
2006, US
225
 
Clinical trials 
(2 institutions) 
1983–2002 < 21 St. Jude: 288 
MDA: 136 
N/A N/A Children w/AML (non-APL, non-DS) aged <10y has 
better outcome w/ the more recent intensive treatment: 
5-y OS = 49.4% (<10y) and 34.8% (age ≥ 10y) 
3. Rubnitz JE, 
2007, US
230
 
Clinical trials 
 
1980–2002 ≤ 21 White: 229 
Black: 58 
N/A N/A 5-y OS was 39% for whites and 34% for blacks. 
Trial AML97: 56% whites and 27% blacks  
4. Creutzig U, 
2008, Europe
51
 
Clinical trials 1993–1998 
1992–1999 
1993–1998 
<18  
17–29 
                 AML BMF: 891    
AMLCG  
and AMLSG: 290  
N/A N/A 5-y EFS: 54% (2 to 12y), 46% (13 to 20y) and 28% (21 
to 29y). Excluding patients w/ favourable karyotype: 
same results for children (44%) and infants (46%), and 
inferior for adolescents (35%) and young adults (23%) 
5. Pulte D, 2008, 
US (SEER)
224
 
Population-
based  
1990–2004 0–14 NALL: 560 N/A N/A 5- and 10-y relative survival improved from 1990–94 to 
2000–04 from 41.9% to 59.9% and from 38.7% to 
59.1%, respectively 
6. Pulte D, 2009, 
US, SEER
10
 
Population-
based  
1985–2005 15–24 AML: 709 N/A N/A 5- and 10-y survival improved from 1981–85 to 2001–
05 from 20.0% to 47.2% and from15.2% to 45.1%, 
respectively 
7. Derolf AR, 
2009, Sweden
210
 
Population-
based 
1973–2005 All age  
included 
9,729  N/A N/A 5-y RS in 1997–05 was 65 % for patients aged 0–18y 
and 58% for 19–40y. Excess mortality when MDS 
preceded AML (HR=1.51)  
8. HO PA, 2009, 
US
234
 
Clinical trials         1995–2005 1mo to <21y 847 N/A N/A CEBPA mutations in 4.5% of patients (mostly older 
and w/ normal karyotype), exclusively in intermediate 
cytogenetic risk. 5-y OS for patients w/ vs. without 
CEBPA = 83% and 51%  
9. Kristinsson, 
2009, Sweden
232
 
Population-
based 
1973–2005 All aged  
included 
9,165 N/A N/A Occupation was a proxy for SES. Patients with higher 
than lower SES had better survival. Overall mortality 
was higher among blue-collar workers compared with 
white-collar workers in the 3 calendar periods: HR= 
1.26, 1.23 and 1.45 during 1980–1989, 1990–1999 
and 2000–2005, respectively). 
10. Harrison CJ, 
2010, UK
235
 
Clinical trials AML10: 1988–95 
AML12: 1994–02 
0–16 729 (non-APL) N/A N/A 10-y OS for children w/ normal karyotype = 58% vs. w/ 
t(8;21) = 80%; w/ inv(16) = 81% w/ 12q abnormalities 
= 35%; w/ t(6;9) = 50%; w/ 5q loss = 27% monosomy 
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First Author,  
Year, setting 
Study design Period Age at 
diagnosis  
Number of cases Early death Survival or hazard of death 
7 = 32% 
11. Walter RB, 
2011, US
226
  
Clinical trials SWOG: 1986–09 
MDA   : 1995–08 
SWOG: 17–88 
MDA: 14–89 
SWOG: 1,127 (non-APL) 
MDA   : 2,238 (non-APL) 
Death within 28 days 
of initiation of therapy  
SWOG: 11.1% 
MDA   : 9.9% 
Not described 
12. Bradley CJ, 
2011, US
228
  
Population-
based  
1999–2006 21–64 523 N/A N/A HR for black vs. white patients = 1.43 
HR of uninsured and publicly vs. privately insured 
patients = 1.29 and 1.39 
13. Pulte D, 
2012, US 
(SEER)
229
 
Population-
based 
1992–1996 
 2002–2006 
≥ 15 N/A N/A N/A 5-y RS for acute leukaemias, 1992–96 and 2002–06, 
respectively: 15–64y = 28% and 39% (nHw), 26% and 
27% (b) and 29% and 38% (H); ≥ 64 = 5% and 6,5% 
(nHw), 5% and 7% (b) and 7% and 11% (H)* 
14. Rubnitz JE, 
2012, US (St. 
Jude)
227
 
Clinical trials  AML91: 1991–96 
AML97: 1997–02 
AML02: 2002–08 
≤ 21 351 N/A N/A 3-y OS AML91/97 and AML02 protocols, respectively: 
0–9 y = 60% and 75%, 10–21y = 48% and 69%. TRM 
was higher for patients aged 10–21y 
15. Juliusson G, 
2012, US 
(SEER) and 
Sweden
236
 
Population-
based 
1997–2006          0–84 <30y: 65 
30–44y: 171 
 
N/A N/A 5-y OS for AML unselected patients aged <30y and 
30–44y, respectively = 60% and 49%  
16. Borate UM, 
2015, US
231
 
Population-
based  
2007–2011 19–64 5,541 N/A N/A Median OS = 16mo, worse for uninsured or Medicaid, 
single or divorced, and lower county-level income 
patients  
Abbreviations: ALL, acute lymphoblastic leukaemia; APL, acute promyelocytic leukaemia; AML, acute myeloid leukaemia; b, black; BFM, Berlin-Frankfurt-Münster; DS, Down syndrome; EFS, event-free 
survival; HR, hazard ratio; MDA, MD Anderson Cancer Center; MRC, Medical Research Council; mo, months; MDS, myelodysplastic syndrome; N/A, not applicable; nHw, non-Hispanic white; OS, overall 
survival; RS, relative survival; SEER, Surveillance Epidemiology and End Results; TRM, treatment-related mortality; UK, United Kingdom; US, United States; NALL (non ALL); St. Jude, St. Jude Children’s 
Research Hospital; SWOG, Southwest Oncology Group; y, years;  w, white. *Survival for Hispanic may be over-estimated because of the lack of specific life tables for this group. 
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Chapter 4: Materials and Methods 
This chapter is divided in four sections. In the first section (study design), I 
give an overview of the main data used in survival analysis with their pros and 
cons. In the second section, I specify the source of data and variables I have 
used. In the third section, I explain the methods I have deployed in my 
studies. In the fourth section, I describe the main biases that can occur when 
using population-based studies. 
 
4.1 Study design 
Survival can be estimated using data from population-based or hospital-based 
cancer registries. The studies in this thesis are all population-based cohort 
studies. 
The main characteristics, advantages and pitfalls of both registries data are 
summarised in Table 4.1. Hospital-based registries can provide detailed data 
on individual patient such as diagnostic methods, treatment protocol, and 
level of abandonment of treatment. These are very useful for the estimation of 
survival of patients according to treatment protocols, stage of disease, risk 
stratification, among others. However, these data may not be representative 
of the entire population and may provide inaccurate demographic data. 
Population-based studies are therefore important for assessing the burden of 
cancer in the general population, providing more accurate estimates of 
incidence, mortality and survival. These measures allow for epidemiological 
research that investigates the aetiology of the disease (e.g., cancer) and the 
effect of preventive and therapeutic strategies, as well as guidance of health-
care planning. 
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Table 4.1: Main differences between hospital-based and population-based cancer registries. 
Adapted from Valsecchi and Steliarova-Foucher, Lancet Oncol 2008
242
 
 Hospital-based cancer 
registry 
Population-based cancer registry 
Aims To provide data for: 
- hospital’s cancer 
programme 
- individual patient 
- hospital administration 
To provide data on general population for:  
- assessment of cancer burden 
- assessment of preventive measures 
- health-care planning 
- patient-care assessment 
- causal research 
Background 
population 
Proportion of population 
living in referral area  
General population, defined by residence 
area and enumerated in population census 
Data 
sources 
- Hospital departments 
- Autopsy reports (in same 
hospital) 
- Outpatient records 
- Hospital departments 
- Autopsy reports 
- Outpatient clinics 
- Death certificates 
- General practitioners 
- Screening programmes 
- Health insurance companies 
- Population registries 
- Hospices 
Registration 
sources 
On-site search - Notification 
- Active search in referral hospitals 
- Linkage with other data sources 
Output - Frequencies of cancer 
types 
- Statistics on treatment 
abandonment 
- Survival of patients, 
according to    stage, 
treatment protocols, and 
other criteria 
- Incidence 
- Mortality (if full access to regional or national data) 
- Prevalence 
- Population-based survival 
Pitfalls - Incidence of cancer in 
general population cannot 
be derived, 
- Imprecise demographical 
data, 
- Incomplete long-term 
follow-up data, 
- Patients characteristics 
and survival not 
necessarily representative 
of patient population 
- Erroneous diagnostic data 
- Missing or incomplete 
information on treatment 
- Missing or incomplete 
follow-up for late effects of 
treatment (apart from 
multiple cancers) 
 
  Hospital based data can be used for observational studies or 
interventional studies (clinical trials). Clinical trials are essential to evaluate 
the effect of cancer treatment on a selected population. They are recognised 
as the “gold standard” practice in the unprecedented success of increasing 
childhood leukaemia survival, as well as other types of cancer. However, 
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these studies are subject to selection bias because they reflect the experience 
of those patients who were able to get to the hospital and be admitted, but 
they are not representative of the entire population. Moreover, clinical trials 
usually exclude patients with advanced disease or comorbidities. Clinical trials 
determine the efficacy of treatment in a selected group of cancer patients, 
whereas population-based studies provide information on the effectiveness of 
cancer services in unselected populations.243 
 
4.2 Data source 
4.2.1 The California population and health system 
According to the US Census Bureau (http://www.census.gov), in July 2015 the 
estimated population of California was 39,144,818. Currently, the proportion 
of Hispanics has slightly surpassed the white, non-Hispanic proportion (Figure 
4.1). In California, the health systems differ according to age as described 
below. 
 
Health Systems in California 
The California Children’s Services  
The California Children’s Services (CCS, www.dhcs.ca.gov/services/ccs) is a 
statewide program operated by the State Department of Health Care, which 
provides treatment for children and adolescents with certain conditions such 
as cancer, congenital heart disease and physical disabilities, among others. 
Eligibility criteria include age less than 21 years, being resident in California, a 
family income of less than USD 40,000 and a medical condition covered by 
the CCS. Under these criteria, all children and adolescents with cancer in 
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California are entitled to state coverage of the costs of treatment, regardless 
of their family’s ability to pay. The majority of children’s hospitals in California 
that treat patients with cancer are also specialised cancer centres (see 
Chapter 5). 
 
 
California’s Medicaid program  
Unemployed patients and those with low resources who are aged 21 years or 
older are eligible to apply for the California’s Medicaid program (also called 
Medi-Cal) and to receive coverage for cancer and most other conditions. 
Patients aged 65 years or older are entitled to Medicare coverage, and they 
may also be eligible for supplemental insurance through Medi-Cal (“dual 
eligibility”). The Medicare and Medicaid are different programs established by 
the United States federal government in the mid-1960s. While Medicare’ rules 
are the same all over the country, Medicaid programs in each State have 
different rules and allowances. 
 Figure 4.1: California population by race/ethnicity. Adapted from the 
US Census Bureau, 2014 (www.census.gov). 
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 One recent study244 estimated that 7%–10% of Medi-Cal expenditure is 
spent on cancer care. The authors used California Cancer Registry data, and 
found wide disparities in survival, quality of care and stage of cancer 
diagnosis in relation to health insurance coverage. Overall, Medi-Cal, dual 
eligible Medicare-Medi-Cal or uninsured patients had cancer diagnosed at a 
more advanced stages, with worse prognosis, and poorer quality of care than 
those with private insurance, Medicare alone or other types of government 
coverage (such as military and government employees). These disparities 
varied by type of cancer examined. 
 
The Patient Protection and Affordable Care Act (ACA or “Obamacare”) 
Several studies have shown that cancer survival is worse among young adults 
without health insurance. For instance, Aizer et al245 used SEER data to 
examine the association between health insurance status and outcomes 
among patients aged 20–40 years with specific types of cancer. Patients with 
health insurance were more likely to have received definitive cancer therapy, 
less likely to have metastatic disease at initial presentation, and had lower all-
cause mortality than uninsured patients. Another study246 revealed that, 
compared to young adults without cancer history, cancer survivors, 
particularly those aged 20–39 years, may forgo cancer treatment due to high 
medical costs.  
  The Patient Protection and Affordable Care Act (ACA or “Obamacare”) 
is a US federal statute signed into law by President Barack Obama on 23 
March 2010 that aims to expand insurance coverage for many uninsured 
patients, including young adults (http://www.dpc.senate.gov/healthreformbill). 
  132 
This program allows patients up to 26 years to remain on their parents’ health 
insurance plan, prevents insurance companies from refusing coverage for 
patients with pre-existing conditions and expands Medicaid coverage, among 
other measures. 
 
4.2.2 The Surveillance, Epidemiology and End Results (SEER) Program 
and the California Cancer Registry (CCR) 
For this thesis, I used data from the California Cancer Registry (CCR), which 
participates in the Surveillance Epidemiology and End Results (SEER) 
Program (http://seer.cancer.gov/about/overview.html) of the National Cancer 
Institute (NCI). SEER is a coordinated system of population-based cancer 
registries across the United States, which has been collecting and publishing 
cancer incidence and survival data since 1973. Initially covering 9 geographic 
areas in the US, SEER has grown to cover 18 areas, corresponding to 
approximately 30% of the US population, based on the 2013 population.  
 The racial/ethnic proportion of population covered by SEER 
corresponds to approximately to 25% of whites, 26% of African Americans, 
38% of Hispanics, 44% of American Indians and Alaska Natives, 50% of 
Asians, and 67% of Hawaiian/Pacific Islanders 
(http://seer.cancer.gov/registries/data.html). 
 SEER collects data on patient demographics (including age, sex and 
race/ethnicity) and tumour information (primary tumour site, morphology, 
stage at diagnosis, first course of treatment, and follow-up for vital status). 
Some variables are derived, such as subsequent tumour, which is based on 
the fact that the same patient has another tumour in the database with a 
  133 
higher sequence number. The characteristics of the SEER population are very 
close to those of the total US population in terms of poverty level and 
education. SEER registries tend to have more foreign-born inhabitants and 
urban areas than the rest of the United States. The population information 
used for cancer rates estimation is regularly obtained from the Census Bureau 
Statistics (http://www.census.gov) and the mortality data reported by SEER 
are extracted by the National Centre for Health Statistics 
(http://www.cdc.gov/nchs/). 
 The CCR was established in 1985 and is recognized as one of the 
leading cancer registries in the world. Cancer reporting became a statutory 
requirement in California in 1988. To date, the CCR has collected detailed 
information on more than 3.4 million cases of cancer diagnosed from January 
1988 onwards, and an estimated 162,000 new cases of cancer are reported 
annually.247 The CCR standard for completeness of ascertainment, estimated 
using time series methods, is at least 98%. All data reported by CCR are 
extracted by trained tumour registrars, directly from the medical records of 
each patient. Table 4.2 shows the history of cancer registration in California.  
 
Follow-up information in CCR 
The CCR, as well as other SEER registries, routinely conducts exhaustive 
active and passive follow-up activities in order to capture the date of last 
known vital status, which is available for all cases. Active follow-up includes 
contact with the patients, their relatives and/or physicians. The passive follow-
up is done via linkage to other data sources, including the following: State 
Vital Statistics, National Death Index (NDI), Social Security Administration, 
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Office of Statewide Health Planning and Development (OSHPD, hospital 
discharge data), centres for Medicare and Medicaid Services (CMS), State 
birth certificates, State motor vehicles, State voter registration, religious 
groups, labour unions, welfare agencies, pathology and doctors records, and 
hospital cancer registries information. In the CCR, the majority of patients 
have full dates of last follow-up (day, month and year). There may be a small 
number of missing day and/or month of last known vital status as discussed 
later in this chapter in section 4.3.4. The year of last vital status is never 
missing in the CCR. 
Current follow-up information in the CCR is defined as “contact with the 
patient within 15 months of the date of last reported follow-up”. Each registry 
in California should report the date of last contact and known vital status 
within 18–22 months of SEER annual data submission. Even though current 
follow-up is preferred, any information should be submitted, whether current 
or not.248 The calculation of follow-up percentage done by SEER/CCR is 
provided in Appendix 2. 
 Survival analyses conducted by SEER/CCR are based on the reported 
date of death or on the documented date of last contact when the patient is 
alive (“reported alive” method). This method has been considered more 
accurate than the “presumed alive” method used by the National Program for 
Cancer Registries (NPCR).249 The NPCR uses passive follow-up to ascertain 
the last vital status and if dead, the date of death, through linkage with the 
National Death Index. Therefore, if an individual is not reported to be dead in 
the National Death Index, she/he is assumed to be alive. A recent study 
conducted by Pinheiro et al.,249 compared survival estimates for certain types 
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of cancer and by race/ethnicity using the “reported alive“ (SEER) and 
“presumed alive” (NPCR) methods. The authors found that, compared to the 
“reported alive”, the “presumed alive” method overestimated survival by 
0.9%–6.2% depending on the type of cancer and race/ethnic group (higher 
survival overestimation among Hispanics). 
Because all the registries in the CCR also participate in SEER, they are 
bound by the SEER data quality standards. The SEER minimal acceptable 
standard for follow-up is 80% for children and 90% for adults, although the 
contractual standards are ≥ 90% and ≥ 95% respectively.250  
 Loss to follow-up may be more significant for young patients (20 years 
or younger) because they often move (e.g., to attend college) and tend to 
have less contact with sources that would generate passive follow-up vital 
status for the cancer registry (social security, Medicaid and hospital 
admissions). Unless they experience disease relapse, young people tend not 
to go to hospitals. In addition, in the United States, when children grow up to 
the age of 26 years or older (the age limit has been expanded since 
implementation of the ACA), they are no longer under their parents’ health 
insurance plan, and may have a new doctor, be treated at a new hospital and 
even neglect to tell their new physician about a previous cancer diagnosis. 
Therefore, a supplementary source of information may be lost.  
Immigrants such as Hispanics and Asians are more likely to have 
incomplete follow-up than whites and blacks.249 Immigrants who are severely 
sick may return to their countries due to financial burden and/or to be close to 
their relatives. The deaths of these patients would then not be captured in the 
National Death Index US statistics. However, as discussed in a previous 
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study, it is unlikely that the small number of Hispanics patients who migrate-
out of the US would bias survival estimates significantly.251 California annual 
interstate migration is about 1.2%, considered the lowest in the US.252  
 
Table 4.2: History of cancer registration in California. Adapted from the California 
Cancer Registry at  https://www.cdph.ca.gov/programs/ccr/Pages/AboutUs.aspx. 
Year  Landmark 
1947 California Tumour Registry established in selected large hospitals 
1960 Alameda County Cancer Registry established as the first population-based cancer 
registry in California 
1969 San Francisco – Oakland Registry included in NCI Third National Cancer Survey 
1972  Cancer Surveillance Program of Los Angeles County established 
1973  San Francisco – Oakland Registry included in NCI’s SEER Program 
1983  Cancer Surveillance Program of Orange County established 
1985  California Cancer Reporting Law signed into effect (CCR established) 
1988 Population-based cancer reporting initiated statewide 
1992 Cancer Surveillance Program of Los Angeles County included in SEER Program 
San Jose-Monterey Registry included in SEER Program 
1997 Fifty years of cancer reporting in California 
2000 Published ten years of complete statewide cancer reporting 
2001   Greater California Registry included in SEER Program 
2007 Twenty years of statewide population-based cancer reporting 
2009 Published 20 years of complete statewide cancer reporting 
 
 The California Cancer Registry works in collaboration with 10 cancer 
registries regions, which are described below: 
Regions 1 & 8: Cancer Prevention Institute of California (Region 1 covers 
Santa Clara Region and Region 8 covers the Bay Area Region) 
Region 2: Cancer Registry of Central California  
Region 3: Sacramento and Sierra Cancer Registry 
Region 4: Central Coast Cancer Registry 
Region 5: Desert Sierra Cancer Surveillance Program 
Region 6: Cancer Registry of Northern California 
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Region 7: Cancer Registry for San Diego and Imperial Counties 
Region 9: Cancer Surveillance Programme (Los Angeles county) 
Region 10: Orange County Cancer Registry. 
 
4.2.3 Variables available in the California Cancer Registry 
The California Cancer Registry makes several variables available to 
researchers that are not, or have only recently become, available in the SEER 
public use data. These include information on health insurance status, 
systemic treatment (chemotherapy, hormone therapy), facility that first report 
the cancer, and an index of socioeconomic status based on census block 
group of residence at time of cancer diagnosis. Most of variables used in this 
thesis have been available in the California Cancer Registry from 1988 
onwards. Health insurance has been routinely collected since 1996 and 
haematopoietic stem cell transplantation since 2003, although in some cases 
this information is available before this year. These variables are specified 
below, based on the California Cancer Registry Data Dictionary.253 
 
Patient’s sociodemographic variables 
Age at diagnosis: Age, in complete years, when the patient was first 
diagnosed with this tumour. In the study of acute lymphoblastic leukaemia, 
age was categorized in 5 groups: <1, 1–4, 5–9, 10–14 and 15–19 years 
because the survival of infant with this disease is significantly worse than that 
of older children. In the acute myeloid leukaemia studies, the age groups I 
used were: 0–9, 10–19, 20–29, 30–39 years. Young adults (20–39 years) 
were included because acute myeloid leukaemia is essentially a disease of 
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older patients and this age group has a worse prognosis than younger 
patients with acute myeloid leukaemia. 
 
Sex: Sex of the patient was categorised as male or female. 
 
Patient identification: It is a unique statewide identification number assigned 
by the California Cancer Registry to identify each registered patient. It is a 
numeric code. This code is also used to identify patients with more than one 
primary tumour and allows for identification of all tumours for a given patient  
 
Date of birth: day, month and year of birth. 
 
Race/ethnicity: SEER race codes reflect the values the cancer registries 
report to it, which are usually obtained from medical records. For California 
Cancer Registry, race is obtained from various sources, including medical 
records, which can be based on self-reported data. Self-reported information 
takes priority over other documentation in medical records and is considered 
the “gold-standard” for race classification.254 According to the California 
Cancer Reporting System Standards Volume I,248 when the patient’s race is 
reported differently by two or more sources within the medical record, race 
should be coded using the following sources in the succeeding priority order: 
1) the patient’s self-declared identification, 2) documentation in the medical 
record, 3) dictated reports, 4) nurses’ notes, and 5) death certificate. 
Ethnicity is not a collected information, but derived from other variables 
based on the North American Association of Central Cancer Registries 
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(NAACCR) algorithms. The NAACCR Hispanic Identification Algorithm (NHIA) 
algorithm is used to identify Hispanic ethnicity and the NAACCR Asian Pacific 
Islander Identification Algorithm (NAPIIA) to identify more specific Asian 
subgroups (http://www.naaccr.org/). Both algorithms are described in the 
Appendix 3. 
In the California Cancer Registry, race/ethnicity is categorised in the 
following groups: non-Hispanic white, non-Hispanic black, Hispanic, 
Asian/Pacific Islander, non-Hispanic American Indian, and other/unknown. 
Hispanic ethnicity is recorded independently of race; therefore, Hispanic 
people may be of any race. It has been shown that the majority of people of 
Hispanic ethnicity are of white race.254  
 
Health insurance status (available from 1996 onwards): Health insurance 
status at time of initial treatment began to be routinely collected by the 
California Cancer Registry in 1996, therefore in all of my studies, this variable 
will be analysed from 1996–2011. Heath insurance has been divided in 4 
categories as follow: 1) Private insurance, which includes health maintenance 
organizations, preferred provider organisations, managed care, and fee-for 
service, 2) Public insurance includes Medicaid, Medicare, military*, Veterans 
Affairs, Indian/Public Health Service and county funded, and other 
government-assisted programs, 3) Uninsured refers to patients with no 
insurance, self-pay, and 4) Insurance unknown or not otherwise specified. 
 
                                            
*
Some researchers considered military under private insurance. In this dissertation, it was 
included under public insurance and accounted for <=1% of cases. 
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Neighbourhood socioeconomic status (SES) has been available in the 
registry from 1988 onwards. Individual information on SES is not routinely 
collected by population-based cancer registries. The California Cancer 
Registry uses an aggregate-level SES index as a surrogate measure at the 
census block group level. This index was created by Yost et al.255 in 2001 and 
has been successfully used by the California Cancer Registry in 
epidemiological studies of incidence256 and survival.257 Census block groups 
contain approximately 1,000 individuals and are considered relatively 
homogenous regarding SES factors. There are three criteria for census block 
groups. The first criterion involves a total population larger than zero, 
excluding census block groups without patients; therefore all census block 
groups are included in the analysis. The second criterion is median income 
greater than zero, excluding non-residential areas such as penitentiaries and 
dormitories. Finally, the third criterion implicates population aged 25 years or 
older bigger than zero, because this is the group of individuals included in the 
education index. 
 In 1990, there were 21,519 census block groups in California, and this 
number has increased to 23,212 in 2010 census.255, 258 The neighbourhood 
SES variable combines seven indicator variables into one single measure 
using a principal component analysis. These indicators are surrogate for 
occupation, poverty, income and education. The occupation variables are the 
proportion of individuals with a blue-collar job and proportion of people older 
than 16 years in the workforce without a job. The poverty measure refers to 
the proportion below 200% of the poverty level. The education index was 
developed by Liu et al.,259 and takes into account the proportion of people in a 
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census block group with certain level of education and the number of years 
taken to obtain that level of education. The income indicators are median 
household income, median home value, and median house rent. The 
correlation of each of the seven indicators with the neighbourhood SES is 
described as follows: education index = 0.87, proportion with a blue-collar job 
= –0.70, proportion of individuals aged 16 years or older without a job = –0.68, 
median household income = 0.85, proportion of the poverty level = –0.87, 
median house rent = 0.63, and median house value = 0.78. Each block group 
received a score and then all the block group level SES scores were divided 
into quintiles based on the statewide distribution. Each patient was assigned a 
neighbourhood SES level based on the census block level he/she lived at the 
time of leukaemia diagnosis. 
 
Tumour variables 
Tumour behaviour: This variable corresponds to the fifth digit of the ICD-O-2 
or ICD-O-3 morphology code that indicates the malignancy or behaviour of 
this tumour. Only tumours with fifth digit equal “3” (malignant/invasive) were 
included in my studies. 
 
Tumour identification: It is unique statewide identification number assigned 
by the California Cancer Registry to identify each tumour. It is a numeric code. 
This variable with the patient identification allows for the identification of 
patients with more than one primary tumour. 
 
Date of diagnosis: day, month and year of leukaemia diagnosis 
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ICD-O-3 Morphology code: The first four digits of the ICD-O-3 morphology 
code, indicates the histology/cell type of this tumour. Coded directly for cases 
diagnosed 2001 and forward. Cases coded prior to 2001 were converted to 
ICD-O-3.  
 
Immunophenotype: For acute lymphoblastic leukaemia, immunophenotype 
was derived from the ICD-O-3 morphology codes and subdivided in B-cell, T-
cell or NOS acute lymphoblastic leukaemia. 
 
Sequence number: The California Cancer Registry provides a variable that 
indicates the sequence of all reportable neoplasms during the patient’s 
lifetime as determined by the central registry. When two or more tumours are 
diagnosed simultaneously, the tumour with the worse prognosis is assigned 
the lowest sequence number. In this thesis, I used the first, primary 
malignancy of each patient. For the acute lymphoblastic leukaemia study, I 
have also examined subsequent (secondary) tumour. 
 
Diagnostic confirmation: Indicates whether, at any time during the patient’s 
medical history, there was microscopic confirmation of this cancer. In my 
studies, microscopic confirmation was 99.8% for acute lymphoblastic 
leukaemia, 99.9% for acute promyelocytic leukaemia and 99.5% for non-APL 
acute myeloid leukaemia 
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Treatment variables 
Chemotherapy: Identifies the type of chemotherapy given as first course of 
treatment at any facility. If chemotherapy was not given, codes are provided to 
record that reason, e.g. chemotherapy was contraindicated, recommended 
but not given, refused, or the patient died before start of treatment. In my 
studies, this covariate was treated as a binary variable: chemotherapy “yes” 
(Y) or “no” (N). There is no information on the type of drugs, dosage or length 
of treatment. 
 
Radiotherapy: This covariate identifies the modality of radiation therapy given 
as first course of treatment. It was used in the acute lymphoblastic leukaemia 
study as binary: radiotherapy performed Y or N. 
 
Haematopoietic stem cell transplantation: This variable has been routinely 
collected for cases diagnosed from 2003 onwards, but has also been reported 
for many patients diagnosed during 1996–2002 and it was used in this thesis 
in the study of acute myeloid leukaemia (Chapter7). 
 
Treatment facilities (HOSPNO): The California Cancer Registry records the 
hospital or other facility with the earliest admission date for each tumour. I 
further classified these hospitals as children hospital Y/N (acute lymphoblastic 
leukaemia study) and hospital affiliated with NCI-designated cancer centres, 
Y/N (acute myeloid leukaemia studies). 
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Follow-up variables 
Date of last known vital status: date of last known vital status available for the 
patient, or date of death if patient deceased. 
 
Vital Status: patient’s vital status as of the date of last contact categorised as 
“dead or “alive”. 
 
Cause of death: The underlying cause of death is coded by the National 
Centre for Health Statistics and the California Department of Public Health 
based on causes of death reported in the death certificate. 
 
4.3 Methods 
4.3.1 Introduction to survival analysis and early death 
4.3.1.1 Survival 
In this thesis, I use the term cancer survival to mean the probability that a 
patient is still alive at a given time since cancer diagnosis. The event of 
interest (failure) is death and the survival time is measured from the date of 
cancer diagnosis (time origin) until death (end-point). Figure 4.2 shows the 
survival time since clinical diagnosis. The survival time can be recorded in 
days, weeks, months or years, whichever is more appropriate to the study 
design and subject matter. For my studies in this thesis, I used survival time in 
years.  
 Some types of cancer, such as breast or colorectal cancer may be 
diagnosed by screening, before the symptoms occur. This situation may 
cause the “lead time bias”, which means that survival time increases, but the 
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death date remains the same, therefore, there is not real survival 
improvement. For acute leukaemias, diagnosis is usually made after 
symptoms presentation. 
 
 
Figure 4.2: The natural history of cancer and estimation of survival time for a patient 
diagnosed clinically. Adapted from Dickman et al., J Intern Med 2006260 
 
 A frequent feature in the analysis of survival data is censoring, which 
occurs when the event of interest (death) is not observed during the course of 
entire follow-up, leading to an incomplete observation of the survival time. The 
reason for censoring is that, in general, it is not possible to follow up all cancer 
patients until death. Some patients will emigrate, some will experience a 
“competing” event and others will not experience the event before the end of 
the study. It is important to incorporate information on censoring into the 
analysis of survival data. 
 Survival is described using two terms: the survival function and the 
hazard function. The survival function S(t) gives the probability of surviving 
beyond some specific time t: S(t) = Pr (T > t), where T, a random variable, is 
the survival time (T ≥ 0 ) and t is the specific value for T. Therefore, S(t) is the 
Disease onset Symptoms Death 
Clinical 
diagnosis 
Survival 
time 
 
Time 
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probability of a patient still being alive (have not had the event) at time (t), and 
varies from 0 to 1. A survival curve plots the survival function over time (t). 
 The hazard function h(t) or hazard rate gives the instantaneous hazard 
at time t for the failure event (death) to occur provided that the individual has 
survived up to just before time t.261 The range for the hazard varies from 0 to 
infinity and depends on the measure of time used (days, weeks, months, 
years, etc.). The hazard function is advantageous in survival analysis because 
it considers the immediate risk attached to a patient known to be alive at time 
t and has proved to be particularly useful in comparing the survival of different 
groups of individuals. While the survival curve can only stay the same (e.g. 
nobody dies during a study to test a new drug) or decrease over time (patients 
die over time), the hazard can oscillate up and down over time. 
 For the analysis of survival data, special methods are required because 
survival time is never negative and survival times are often censored. A major 
assumption in most survival analyses, including those used in this thesis, is 
that censoring is non-informative, i.e., time to death from cancer is 
independent of time to censoring (alive or death due to other causes). This 
means that the patients who have not been censored by a given time are a 
random sample of the patients still at risk. Non-informative censoring does not 
introduce bias to survival estimation, whereas informative censoring does. In 
my studies, it is reasonable to assume that informative censoring was not a 
concern due to two main reasons: firstly, because there was not a large 
amount of loss to follow-up, and secondly, there are not significant competing 
causes of death among the young population studied. In addition, I have also 
provided a descriptive analysis of the causes of death in each study, and my 
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findings showed that > 90% of deaths occurred due to acute leukaemia. 
Some other causes reported in death certificates (e.g., infection and 
haemorrhage), may also be caused by leukaemia. 
 
4.3.1.2 Early death 
Because of the severity of acute myeloid leukaemia, this malignancy requires 
initiation of treatment as soon as possible. This is specifically relevant for 
acute promyelocytic leukaemia, a subtype of acute myeloid leukaemia, 
because the patients often present bleeding, thrombosis and/or severe 
infection in the first days and weeks after diagnosis. Thus, treatment with 
chemotherapy and ATRA should be initiated as soon the disease is 
suspected. Failure to do so can lead to early death.  
 In this thesis, in addition to survival, I examined early death as an event 
of interest in acute promyelocytic and acute myeloid leukaemias studies 
(Chapters 6 and 7). In my studies, early death was defined as death within 30 
days of leukaemia diagnosis, and was estimated as the proportion of 
individuals who died in this period. This definition varies slightly according to 
different studies (Supplementary Table in Chapter 6). In addition to 30-day 
mortality, I have also investigated 7-day mortality for patients with acute 
promyelocytic leukaemia because they have a greater risk of death in the first 
days after diagnosis. The Pearson’s chi-squared test (χ2) was used to test the 
null-hypothesis that the frequency distribution of early death was equal within 
strata for each covariate. 
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4.3.2 Estimation of cancer survival 
A variety of methods can be used to estimate survival. The main methods are 
summarised in Table 4.3. Cause-specific survival estimates the probability of 
dying due to a given disease, e.g. cancer. In this case, the event of interest is 
death due to cancer. Cause-specific survival is not often used in population-
based studies because a reliable and accurate cause of death is not usually 
available in cancer registries, especially in poor-resource countries.262 
  Most often, the estimation of cancer survival in children, adolescents 
and young adults (< 45 years) is performed using overall survival because, at 
least in the developed countries, the competing causes of death are rare. The 
event of interest is all deaths and it does not take into account the cause of 
death. When we have individual data, overall survival can be estimated using 
the Kaplan-Meier (or product limit) method, which I have used in this thesis.263  
 
Table 4.3: Measures of cancer survival. Adapted from Dickman and Hakulinen, 2006
260
 
 Advantages Issues 
Observed, overall, 
absolute or crude 
survival 
Reflects total mortality. May 
be more relevant to the 
patient and/or clinician 
Comparisons may be confounded by age  
Cause-specific 
survival 
Reflects mortality due to 
cancer 
Requires certification of coding the 
underlying cause of death  
Relative / net survival Reflects mortality due to 
cancer, capturing both direct 
and indirect mortality 
Requires estimates of expected survival 
of the cancer patients, which is derived 
from mortality in the general population 
(“background” mortality) 
 
The Kaplan-Meier method 
The Kaplan-Meier method is a non-parametric or “distribution-free” estimate of 
the survival function, which allows us to estimate survival probabilities in the 
presence of censoring. A major assumption of the Kaplan-Meier method is 
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that censoring is non-informative, as described in section 4.3.1.1. In the 
Kaplan-Meier method, the follow-up time period is divided into intervals so 
that each interval contains one survival time t. Each death starts one interval, 
which ends just before another death occurs. We estimate the probability of 
occurrence of death at each death time, which is calculated as the number of 
deaths at that time divided by the number of individuals at risk at that time (i.e. 
not dead and not censored).264 We then subtract these probabilities from one. 
These new consecutive probabilities are multiplied cumulatively across all 
failure times to obtain the estimated survival probabilities. The estimated 
survival probabilities are constant between consecutive survival times and 
decrease at each death time, leading to the characteristic “stair step” Kaplan-
Meier survival curves. This is illustrated in Figure 4.3, which used a sample of 
data from one of my studies presented later in the thesis. The Kaplan-Meier 
survival curves can be estimated separately for different groups of individuals.  
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Figure 4.3: The characteristic “stair step” Kaplan-Meier survival curve 
 
 The main reasons to use nonparametric methods such as Kaplan-
Meier include their relative simplicity, the fact that survival data can be nicely 
displayed in graphs, including when there is censoring, and the possibility to 
easily compare patterns of survival among two or more groups of patients. 
Additionally, this method can be used to inform more complex modelling of 
survival data.  
 The log-rank test is a non-parametric test that can be used to compare 
the survival curves of two or more groups of individuals across various time 
points. When a large enough sample is used, the log-rank test is a valid and 
powerful test of hypothesis that the survive curves (S) of two or more groups 
are different:265  
Null hypothesis: S1(t) = S2(t) for all times t 
Alternative hypothesis: S1(t) ≠ S2(t) at any time t 
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The log-rank test gives a P-value for the hypothesis test, which represents the 
strength of the evidence against the null hypothesis of no difference between 
one or more groups. The smaller the P-value, the stronger the evidence 
against the null hypothesis. However, the log-rank test does not provide an 
overall measure of the association between survival and the explanatory 
variables. Therefore, it does not estimate the magnitude of the difference in 
survival for different groups of individuals being compared.  
 
The cohort and period approaches 
In the acute lymphoblastic leukaemia study, the 5-year survival in the 3 
calendar periods examined and the 10-year survival in 1988–1995 and 1996–
2003 were estimated using the classical cohort-based approach because 
most patients had been followed for at least 5 or 10 years, respectively, during 
these time periods. The traditional cohort-based approach provides survival 
estimates using all the observed follow-up data. There was not follow-up 
information to estimate 10-year survival for patients diagnosed during 
calendar period 2004–2011 using this approach.  
 For the acute promyelocytic and non-APL acute myeloid leukaemia 
studies, I chose to use the period approach266 for the calendar period 2004–
2011 when patients had less than 5 (or 10) years of follow-up. The period 
approach provides a short-term prediction of their survival up to 5 (or 10) 
years after diagnosis on the assumption that their probabilities of survival will 
be the same as those observed during the most recent years for which follow-
up data were available. The period approach deploys exactly the same data 
on patients and their follow-up as are deployed in the cohort-based 
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approaches; it just combines the probabilities vertically (calendar period) 
instead of horizontally (year or period of diagnosis) (Figure 4.4).267 Estimates 
of long-term survival using the period approach are usually higher than the 
long-term survival estimated by cohort-based analysis given improvement in 
survival over time. The estimates from the cohort-based and period 
approaches will be the same when there is no change in the disease outcome 
over time. 
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Figure 4.4 Data used for period and cohort approaches. The pink frame shows the data used to estimate 10-year survival for the 2004–2011 
period using the period approach. The traditional cohort approach was used to estimate 10-year survival during 1988–1995 and 1996–2003 (white 
frame) and 5-year survival in all calendar periods. The numbers within the cells represent the years of follow-up since acute leukaemia diagnosis.
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4.3.3 Measuring association: Cox models and logistic regression 
Although one may be interested in the distribution of survival time in one 
particular population, often researchers and clinicians are interested in 
comparing survival distributions between two or more groups of people. In 
addition, when explanatory variables are available, their influence on survival 
(or another event such as early death) is often assessed. This can simply be 
done by looking at Kaplan-Meier plots within groups or, in the case of early 
death, by tabular comparisons between death/no death and the exposure 
variable. In my three studies, I aimed at investigating the association between 
survival and early death, and sociodemographic and selected clinical factors. I 
used univariable and multivariable models as described below. 
 
The Cox proportional hazards model: hazard ratios for death 
In order to measure the association between survival and the explanatory 
variables, I used the Cox proportional hazards model, the most frequently 
used model in survival analysis, developed by David Cox in 1972.268 The Cox 
model allows for the estimation of the magnitude of an association between 
survival and each explanatory variable (univariable analysis) and can also 
account for multiple independent variables simultaneously (multivariable 
analysis).  
 An important feature of the Cox model is that it assumes that the 
individual and the baseline hazard rates may vary over time, but their ratio, 
called the hazard ratio, is assumed to be constant at all times t across groups. 
This assumption is known as the proportional hazards assumption, 
characteristic of this model. This model also accounts for censoring. 
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Formulation of the Cox model 
Under the Cox proportional hazards model, the hazard function at time t for 
individual with values x1, x2..., xk for the explanatory variables X1, X2... Xk is 
formulated as: 
 
h(t|x1, x2..., xk ) = h0 (t) exp (β1X1 + β2X2.... + βkXk) 
 
where h0 (t) is the baseline hazard and β1,2,K are the regression coefficients to 
be estimated from the model; these are the log hazard ratios. 
A hazard ratio equal to 1 reveals no association between the hazard of death 
and the explanatory variable. A hazard ratio different than 1 indicates that 
there is an association between the hazard of death and the explanatory 
variable. We incorporate sampling error into these estimates using a 
confidence interval (CI) and a P-value test. The CI gives a range of plausible 
values for the true hazard ratio. I used 95% CIs, meaning that there is a 95% 
chance that the true population hazard ratio is included in this interval. If the 
confidence interval contains 1, it means that there is no evidence for a 
statistically significant difference between the groups of individuals being 
compared in a test of the null hypothesis at the 5% level. 
 The P-value for the hypothesis test demonstrates the strength of the 
evidence against the null hypothesis. Two statistical tests are commonly used 
to test the null hypothesis: the Wald statistic and the likelihood ratio test.  
 
 
 
  156 
Testing the proportional hazards assumption 
To test the proportional-hazards assumption in my three studies, I examined 
the log-log survival plots and used the Schoenfeld residuals269 to confirm the 
results. 
If an explanatory variable satisfies the proportional-hazard assumption, the 
graph of the log-log survival function versus the survival times in two or more 
groups should be approximately parallel. If the proportional-hazard 
assumption is not met, the curves will not be parallel and can even cross each 
other.270 However, this approach does not extend well to incorporate 
adjustment for confounders. In this situation, the approach using Schoenfeld 
residuals is more is more suitable for general use when there are several 
explanatory variables. 
 In the study of acute lymphoblastic leukaemia (Chapter 5), there was 
evidence that three variables (age at diagnosis, immunophenotype and 
secondary malignancy) did not meet the proportional hazard assumption and I 
needed to use an alternative method to the Cox model. I used the stratified 
Cox proportional hazards model, which is a direct extension to the Cox model. 
In the stratified model, I assume that the proportional hazards model holds 
within groups of patients defined by the strata, instead of overall. This method 
does not provide an estimate of the effect of the explanatory variable used in 
the stratification on survival. 
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Formulation of the stratified Cox model 
Under the stratified Cox proportional hazards model, the hazard function at 
time t for an individual with explanatory variables X1, X2... xk that are in the 
stratum i, is formulated as: 
hi (t) = h0i (t) exp (β1x1 + β2x2.... + βkxk) 
where i denotes the level of the categorical variable which defines the strata. 
The hazard ratios are assumed to be the same regardless of stratum, but the 
baseline hazard can be stratum specific.  
 
Time-dependent variable 
In the analyses presented in the acute lymphoblastic study (Chapter 5), I 
investigated the occurrence of a second primary malignancy after the 
diagnosis of acute lymphoblastic leukaemia, called secondary malignancy. 
Because this is a variable that changes over time, it needs to be handled 
accordingly. 
 The Cox model can be used when time-dependent variables are 
present in the model, in which case the explanatory variables in the hazard 
model are replaced by time-dependent versions, x (t), which represent the 
value of the variable at time t. To perform analyses using time-dependent 
variables, the data need to be arranged appropriately. Individuals who had the 
event (i.e., secondary neoplasm) will have a row of data pre-event and one 
row of data post-event. This can be done using the stsplit command in Stata. 
Patients who did not have the event will have only one row of data. 
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Logistic regression: the odds ratios for early death 
In order to examine the association between early death and various 
sociodemographic and clinical factors, I used logistic regression. Logistic 
regression models the log odds of binary outcomes for a single or multiple 
exposures (binary, categorical or continuous explanatory variables). 
 
A. Formulation of the logistic regression for early death 
 
Log odds of early death =  + 1 x1 + 2 x2 + .... k xk 
 
where  = intercept and  is a vector of parameters which represent the 
associations between the explanatory variables and early death (i.e., ‘age 
group’  is a vector of indicators of being in different age groups). The intercept 
() is the log odds when all explanatory variables are at their baseline level. 
The  parameters are the log odds ratios, which are the increases in the log 
odds that are associated with a unit increase in exposure.  
 This model also gives the 95% CI for the odds ratio (OR) and one can 
perform tests of the null hypothesis that an OR = 1 (log OR = 0), indicating no 
association between the explanatory variable and the outcome. In the 
alternative hypothesis, an OR  1, indicates an association between early 
death and the explanatory variables. Similarly to the Cox models, the 
hypothesis tests are performed using the Wald test or the likelihood ratio test.  
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Handling explanatory variable observed for part of the studies  
The majority of the variables used in this thesis were available from 1988 to 
2011. However, one of the explanatory variables, health insurance status 
(insurance), was available only from 1996 onwards, when it started to be 
routinely collected by the California Cancer Registry. To measure the 
association of insurance and the hazard of death or odds of early death, using 
Cox regression and logistic regressions respectively, I created 2 extra models 
using data from 1996 onwards: one containing all explanatory variables but 
health insurance and another with the explanatory variables including health 
insurance. 
 
Handling missing dates 
Three dates are required to estimate survival: date of birth, date of diagnosis 
and date of last known vital status (date of death or censoring). Date of birth is 
not included in the definition of survival time, but is relevant to allocate 
patients for the estimation of survival by age groups.  
  It is feasible to impute some missing elements assuming that a 
possible error will not potentially bias the survival estimates. When there were 
missing dates in my data, I used an algorithm developed by the CONCORD 
Working Group19 to perform imputation. The following dates are considered 
imputable: day and month of birth, day of diagnosis, and day and month of 
last vital status (date of death or censoring).  
 The first step of the imputation process requires the identification of the 
lower and upper bounds of the period in which the date to be imputed can 
potentially lie (the imputation period). It is important to pay attention to the 
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month length (28, 30, 31 days), and, in the case of February, whether it falls in 
a leap year (29 days). The second step is to identify the middle day of the 
imputation period as the imputed date. The rational for this is based on the 
actuarial assumption (uniform distribution of the date during the imputation 
period), therefore the expected date for the occurrence of an event is the 
middle day. In the imputation process, day and month of birth and last vital 
status are imputed first followed by imputation of day of diagnosis. 
 In the California Cancer Registry, most of the dates were complete 
(day, month and year). In the datasets I used in this thesis, there was not 
missing year, missing months of diagnosis and vital status varied from 
0.25%–0.60% and 0.01–0.13%, respectively; and missing days of diagnosis 
and vital status varied from 2.9%–5.1% and 0.40%–0.71%. Therefore, I 
assume that the imputation of dates performed in my analyses was not 
sufficient to lead to bias in survival estimates. 
 Follow-up information is vital for accurate estimation of cancer survival. 
As discussed in section 4.2.2, the California Cancer Registry conducts 
intensive active and passive follow-up to provide the more precise follow-up 
information. Inevitably, during a long-term observation, some patients will 
have emigrated to another State or country and will be lost to follow-up. 
However, the proportion of patients who emigrate is usually small and may 
not influence survival significantly.249 
 Pinheiro et al.249 investigated the impact of follow-up type and missed 
deaths on the estimation of cancer survival using SEER data. They found that 
Hispanics and Asians are more likely to be loss to follow-up than white and 
black patients. Therefore, survival estimates may be significantly 
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overestimated in these patients. Considering that the CCR / SEER standard 
of follow-up information were met and missing last vital status dates were 
minimal in my datasets, I assume that there were not significant bias due to 
loss to follow-up in my studies. Moreover, if the survival of Hispanics were 
overestimated, I would then have an even wider survival gap between white 
and Hispanic patients. 
 
4.3.4 Methods for adjusting for confounders 
In any observational study it is important to adjust for variables that could 
confound the association between an explanatory variable and the outcome of 
interest. For a variable to be considered a confounder, it needs to: 1) be 
associated with the exposure 2) be associated with the outcome or disease of 
interest, 3) should not be in the causal pathway between exposure and 
outcome.271 
 The Kaplan-Meier estimator does not directly enable adjustment for 
confounders. However, this can be done by making the Kaplan-Meier plots for 
an explanatory variable within categories of a confounder. When there is more 
than one confounder this approach becomes more complicated and may not 
be efficient due to a small number of individuals in each subgroup. Thus, use 
of multivariable modelling is usually the best approach to control for 
confounders. To investigate the extent to which the variables confound each 
other, I fitted univariable models for each explanatory variable and 
multivariable models including all the explanatory variables of interest. 
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4.3.5 Statistical interaction or effect-measure modification 
In Epidemiology, the term interaction refers to a condition in which "two or 
more risk factors modify the effect of each other with regard to the occurrence 
or level of a given outcome". Interaction is also known as "effect modification" 
and needs to be differentiated from confounding (described above in section 
4.3.2).
271
  
 For binary variables, interaction means that the association of the 
exposure X on the outcome Y differs depending on whether or not another 
variable Z (the effect modifier) is present. For ordinal or categorical variables, 
interaction means that the association between the exposure X and the 
outcome Y varies across levels (stratum) of a third variable Z (the effect 
modifier).  
 When more than one predictor is included in the model, it is 
appropriate to test for interactions between variables. In Stata, the 
investigation of interaction can be done by adding an interaction term between 
the categorical variables of interest in the model. We can then compare the 
models with and without the interaction term using a likelihood ratio test since 
the models are nested. In this thesis, I tested for interactions between several 
variables as it is shown in the studies, and found no interactions between the 
variables tested. 
 
4.3.6 Stata commands 
All analyses in this thesis were performed using the statistical software Stata 
13.1.  
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In Stata, the stset command informs that time-to-event data have been used 
and this command is used to estimate survival using the Kaplan-Meier 
approach. Then, many built commands can be employed, including the stcox 
command for the survival analysis. 
The logistic command was used to report the odds ratios for early death.  
The stsplit command was used to deal with time-dependent variables.  
The likelihood ratio test was performed using the lrtest command. 
 
4.4 Potential bias in population-based studies 
Many factors may affect survival estimates from population-based studies. 
These factors may be related to the patient or tumour, as well as to data 
quality or heath care system characteristics. Study of the distribution of these 
factors can help to explain differences in survival between different subgroups 
of cancer patients. However, the magnitude of these factors may be 
estimated, but they cannot always be controlled for in the survival analysis. 
Table 4.4 summarises the main factors that influence population-based 
survival estimates.  
 
4.4.1 Biases due to data quality 
The main biases that can occur when estimating survival from population-
based studies are secondary to data quality. The principal elements that affect 
data quality include time since registry’s inception, the experience of registry 
personnel and the availability and quality of different data sources. It is 
necessary to consider four dimensions of data quality: comparability, 
completeness, validity and timeliness:272 
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Comparability: in order to compare incidence and survival between registries, 
regions and countries over time, standardisation of classification, coding and 
definition of new cases are required.  
 
Completeness: is the “extent to which all incident cancers occurring in the 
population are included in the registry database”. Completeness of 
ascertainment (or registration) should be as close to 100% as possible, in 
order to provide incidence rates and survival estimates near to the true value. 
 
Table 4.4: Factors that influence population-based survival estimates. Adapted from Black 
et al., IARC Sci Publ 1998
243
 
Data quality (sources of potential bias) 
Completeness of ascertainment 
Accuracy of recording of the key variables (e.g. date of diagnosis and date of death) 
Completeness of follow-up 
Timeliness 
Death certificate only (DCO) registrations 
Host factors 
Age 
Sex 
Race/Ethnicity 
Comorbidity 
Socio-economic status (SES) 
Behaviour (including awareness of cancer symptoms and compliance with treatment) 
Tumour-related factors 
Extent of disease 
Site of tumour (not applicable for leukaemias) 
Morphology of tumour 
Tumour biology 
Health care-related factors 
Screening (not applicable for leukaemias) 
Diagnostic facilities 
Treatment facilities 
Quality of treatment 
Follow-up care 
  165 
Validity or accuracy: “the proportion of cases in the dataset with a given 
characteristic (e.g. morphology code and age) that truly have the attribute.” It 
depends on the reliability of the sources of information and on the experience 
of cancer registry personnel to collect code and recode the data. 
 
Timeliness: timeliness of reporting cancer data refers to the “promptness at 
which a registry can abstract, process and report reliable and complete data”. 
Some users of cancer data require timely data whenever it is possible. 
However, the early release of these data from registries can affect the 
completeness and accuracy of the data. 
 
Bias due to under-ascertainment of incident cases in different 
populations 
I have used standardised high-quality data from the California Cancer 
Registry. But data quality is expected to vary widely between and within 
developing and developed countries.  
  Differential under-ascertainment of incident cases is a main concern. If 
a substantial number of patients are not recorded in a certain registry area or 
country, it can artificially increase cancer survival estimates for this area or 
country. This is particularly true in resource-poor countries since the 
probability of being registered tends to be correlated to risk factors and the 
accuracy of diagnostic information.243 In developing countries incorrect 
diagnosis of leukaemia is not infrequent since leukaemia symptoms are non-
specific and can be mistaken for infectious diseases such as malaria, 
HIV/AIDS or tuberculosis. Leukaemias can also co-exist with infection and 
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malnutrition in these children, who may be particularly sick. Acute leukaemia 
is a disease that generally leads to death in a few weeks or months without 
treatment. Children living in rural areas of poor countries may die without a 
diagnosis of acute leukaemia having been made. Consequently, under-
reporting of these cases will lead to an over-estimation of survival in this 
particular population. 
  On the other hand, if only a random sample of cases of children with 
acute leukaemia is under-reported (non-differential ascertainment of incident 
cases), there will not be significant bias in survival estimates. This is, 
however, unlikely to happen in low- and middle-income countries due to the 
factors mentioned above. 
 
Bias due to misclassification 
Classification of haematologic malignancies has undergone major changes 
with the publication of the third edition of the International Classification of 
Diseases for Oncology (ICD-O-3) in 2000.273 This has led to a revision of the 
International Classification of Childhood Cancer (ICCC-3).274 As explained 
earlier in this thesis (section 2.3.2), ICD-O-3 codes eliminate the artificial 
difference between lymphoblastic leukaemias and lymphoblastic lymphomas. 
 A particular concern for international comparisons is that registries may 
code differently the neoplasms under study. For example, among the non-
Hodgkin lymphomas (NHL), precursor T-cell lymphoblastic lymphoma is 
relatively frequent in children, and is coded 9729/3 in ICD-O-3. However, in 
the past it was often referred as T-cell NHL without the word “lymphoblastic” 
or “precursor”. This means that some registries might have coded these cases 
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as 9591/3 (NHL not otherwise specified) or 9702/3 (mature T-cell NHL). Thus, 
children with T-cell lymphoblastic lymphoma would be excluded from the 
survival analyses. In this situation, survival estimates for the respective 
registry may be over-estimated, since T-cell cases tend to have a worse 
prognosis than B-cell cases (section 2.5.1).  
 
Potential effect of loss to follow-up and "immortal” cases 
An essential requirement for survival analysis is the ascertainment of the vital 
status of the cancer patients. At the end of the study, each patient should be 
classified as dead, alive or lost to follow-up.  
 Complete follow-up can be very difficult to obtain, especially in low- and 
middle-income countries where death registration may be incomplete, and 
there is a lack of accuracy, efficacy and timeliness in the process of linkage of 
incidence and mortality registrations. Matching the incident cases with 
mortality records in these registries can lead to “immortals”: cancer patients 
who have died but are still recorded as alive in the registry. “Immortal” cases 
in the data of a registry can lead to over-estimation of survival. 
  The direction of bias in the estimation of survival due to loss to follow-
up is unpredictable. In low- and middle-income countries, many of the patients 
lost to follow-up will have died (e.g. due to abandonment of treatment), so 
data from registries with a high proportion of cases lost to follow-up may be 
subject to bias with unduly high survival estimates. On the other hand, some 
patients with a more favourable prognosis might move to another area to 
receive treatment. If those patients are in fact lost to follow-up but are not 
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censored from analysis because the fact of their emigration is unknown, 
survival in the original registry population may be under-estimated. 
 The impact of loss to follow-up will depend on the proportion of this 
indicator in each registry. According to the experience of EUROCARE studies, 
misreporting of vital status up to 4%–5% at 7 or 8 years is likely to occur, but 
will generally lead to a relatively small impact (less than 1%) on five-year 
survival estimates,275 mainly for cancer with relatively high survival,276 such as 
for childhood leukaemia. 
 
Death certificate only (DCO) cases 
Death certificates are a valuable source of information, providing reports on 
cancer cases that were not registered when patients were alive. Registries 
usually trace these cases back in order to confirm whether cancer diagnosis 
was correct, and to obtain the date of cancer diagnosis. In low- and middle-
income countries, death certificates can be absent or of poor quality, with 
incomplete and/or incorrect information. In these countries, registries can face 
great difficulties in getting accurate information from doctors and hospitals.  
 Incident cases that are first identified by the register through death 
certificates are known as death certificate notification (DCN) cases. When 
these cases are traced-back and there is no other source of information 
mentioning cancer rather than death certificates, they are reported as death 
certificate only (DCO) cases. DCO is then considered the “residuum” of cases 
after all trace-back procedures have failed to obtain further information on 
cancer patients. Death certificate initiated (DCI) cases are cancer cases 
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registered after the trace-back procedures are performed by the registries 
(Figure 4.5).277  
 Low DCO proportions may be due to the efficiency of case-finding 
and/or efficiency of track-back procedures, whereas high DCO proportions 
suggest consistent under-reporting of incident cases. By convention, DCO 
cases are excluded from survival analysis: since the date of cancer diagnosis 
is unknown, survival cannot be estimated. This is a potential source of bias. 
  The proportion of DCO cases in cancer registries acceptable for 
inclusion in studies that compare survival internationally is subject of debate. 
The main reason is that DCO proportion is influenced by the availability and 
quality of death certificates, as well as effectiveness of the registry’s matching 
procedures and its capability to trace-back DCN cases. 
 In the United States and Canada, only cancer registries with less than 
5% of DCO cases are included in Cancer in North America.278 Cancer 
Incidence in Five Continents excludes cancer registries with more than 20% 
of DCO cases.272, 277 Thus, registries with more than 20% of DCO cases are 
usually not eligible for inclusion in survival studies. 
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Figure 4.5: The use of death certificates to identify new cases of cancer. Adapted from 
Bray & Parkin, Eur J Cancer 2009
272
 
 
In low- and middle-income countries, in addition to the factors 
mentioned above, parents of children with leukaemia might be constrained in 
seeking treatment for their children due to lack of financial resources, lack of 
education, stigma as well as unavailability of diagnosis or treatment facilities 
close to their homes. Moreover, children in those settings can be severely ill 
due to other comorbidities such as malnutrition and co-infection. These 
children may not be admitted to the hospital for treatment and are less likely 
to be registered. Cancer registries might receive information on their death but 
not on the diagnosis or date of diagnosis of leukaemia.  
  If the proportion of DCO cases is low (<10%), the exclusion of DCOs 
from survival analysis should not bias survival estimation substantially. 
However, if the proportion of DCO cases is high, this is likely to introduce a 
degree of bias. Since the survival of cancer patients registered by DCO is 
DCN cases: 
no other source of 
information rather than 
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DCI cases surely DCN 
NOT-TRACED: 
register as DCO 
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usually inferior to that of all registered cancer patients,279 a high proportion of 
DCO cases will tend to lead to over-estimation of survival.  
  Berrino et al.280 examined the impact of DCO cases on survival of 
patients diagnosed with lung, breast (women) and colorectal cancers, 
registered in the South Thames Cancer Registry during 1986–1987. They first 
estimated 5-year overall (crude) survival (%), excluding DCO cases in the 
usual way. A new data stream became accessible later, allowing the date of 
diagnosis to be ascertained for many cases that, until that point, had been 
DCO registrations. The survival estimates were then repeated after inclusion 
of these cases. When the proportion of DCO cases was higher than 10%, 5-
year crude survival was significantly over-estimated. For breast cancer, the 
inclusion of 11.8% cases in the survival analysis that had previously been 
DCO cases, reduced the overall survival by 10%. For lung and colon cancers, 
DCO proportions were 26% and 22%, and their inclusion in the analysis after 
the date of diagnosis have been obtained, reduced survival estimates by 25% 
and 20% respectively (Table 4.5). Conversely, if the cases that are under-
reported are long-term survivors, survival may then be under-estimated.  
  Beral and Peto281 criticised the results of EUROCARE studies,280, 282-284 
arguing that the consistent lower survival observed in the United Kingdom and 
Denmark compared to other Nordic countries, could be secondary to a 
mistaken date of diagnosis after tracing-back DCO cases, and an under-
reporting of long-term survivors (five years or more). In response, Woods et 
al.276 performed a simulation study to estimate the impact of both factors on 
survival of patients with colon, breast (women) and lung cancers, registered in 
the National Cancer Registry of England and Wales during 1995–2007. 
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Failure to report long-term survivors as high as 40% could explain less than 
half the difference in 1-year survival for breast, lung and colorectal cancers.  
 
Table 4.5: Effect of death certificate only registrations on survival, South Thames 
Cancer Registry, 1986–1987. Adapted from Berrino et al., Sci Publ No 132 1995
280
 
 
Robinson et al.285 examined the impact of DCO cases and incomplete 
registration on survival for 12 anatomic tumour sites, using data from Finnish 
and Thames (UK) registries. First, they estimated 5-year relative survival 
excluding DCO cases as usual. Then, adjustment for DCO cases was made, 
assuming that DCO cases had the same median survival as DCI cases (DCN 
cases successfully traced) matched by sex, age and tumour sites. Adjustment 
for incompleteness was also performed. The proportion of DCO cases varied 
from 1% to 6% in the Finnish registry and was much higher in the Thames 
registry (between 6% and 32%). After adjustments, considerable changes 
were observed to survival estimates for tumours sites with a high proportion of 
DCO cases and/or high percentage of missing cases: adjustment for DCO 
cases led to substantially lower survival, whereas adjustment for 
 Tumour type 
 Lung Breast Colon 
Cancer incidence 1986–1987    
    DCO cases 2,670 906 997 
    Non-DCO cases 7,802 6743 3535 
    DCO (% of total incidence) 25.5 11.8 22.0 
Overall survival (%) at 5 years    
    Conventional (without DCO) 6.4 60.1 33.3 
    Corrected (including DCI) 4.8 54.1 26.6 
    Reduction in survival (%) 25 10 20 
Abbreviations: DCO, death certificate only; DCI, death-certificate-initiated; DCN, death 
certificate notification. 
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incompleteness of registration led to substantial over-estimation of survival in 
the Thames registry. However, the two adjustments resulted in a small effect 
on 5-year relative survival, even with DCO proportions between 10%–20%, 
because the increases in survival secondary to adjustment for incompleteness 
were counteracted by the decrease due to adjustment for DCO cases. 
 Registries from low- and middle-income countries tend to have higher 
proportion of DCO cases and incomplete registration, and both can have an 
important effect on survival estimates. In order to retain data from these 
countries, it is advisable to limit use of data from registries with up to 20% of 
DCO cases. Registries with more than 20% of DCO cases should be then 
excluded. This should be taken into consideration when survival is compared 
between countries, especially between high-income and low- and middle-
income countries. One strategy is to use a sensitivity analysis to examine the 
changes in survival estimation resulting from varying DCO proportions over a 
reasonable range. Sensitivity analysis aims to measure the impact of errors – 
random or systematic – on the estimate’s validity.286 
 In the first CONCORD study,20 DCO proportions were less than 1% in 
the United States, Canada and Australia, and 0%–5% in most European 
countries. In Cuba National Cancer Registry, DCO proportions varied from 
28% to 60%. Not surprisingly, survival estimates in Cuba were likely to be 
over-estimated (Cuba had the highest survival estimates for breast and colon 
cancers comparing to all countries, including the United States, Canada, 
Japan, European countries and Australia).  
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4.4.2 Effect of host variables on survival  
Age: age at diagnosis is an independent risk factor for outcome for most 
types of malignancy, and has a strong prognostic effect in survival after 
childhood and young adult acute lymphoblastic and acute myeloid 
leukaemias. 
 
Sex: Sex has less marked impact on acute leukaemia survival than age at 
diagnosis, but most studies show a better prognosis for females compared to 
males.  
 
Race/ethnicity: Race and ethnicity might influence acute lymphoblastic and 
acute myeloid leukaemias survival as shown in previous studies. 
 
Comorbidities: Comorbidities such as malnutrition, infections, respiratory and 
cardiovascular diseases may affect leukaemia survival by increasing the risk 
of death. Cancer registries, in general, do not provide data on comorbidities. 
However these factors are less relevant when we analyse survival in the 
young population in the developed countries. An interesting population-based 
study recently published in Europe287 examined the effect of comorbidity and 
performance status on mortality and complete remission in patients with acute 
myeloid leukaemia. The authors examine 2,792 patients aged 15–99 years at 
diagnosis over a 12-year period (2000–2012). Among these patients, the 
majority did not have any comorbidity (76%), 19% had one comorbidity and 
only 6% had 2 or more comorbid diseases. Surprisingly, the authors found no 
evidence of an association between comorbidity and short-term mortality 
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(death within 90 days of diagnosis) and, if any, just a not statistically 
significant association with long-term mortality (>90 days to 3 years). The 
strongest factor associated with both short-and long-term mortality was poor 
performance status. 
 
Socioeconomic status (SES): Population-base registries commonly do not 
have individual data on socioeconomic status, and researchers use surrogate 
measures of socioeconomic status at aggregated level.  
 
Patient behaviour: In paediatric oncology, treatment adherence is a process 
that occurs over a long period of time. Non-adherence to oral agents has 
been reported to vary from 10%–50%,288, 289 and it might range from never 
following the prescription to using drugs irregularly, or using more than was 
recommended, as well as errors of administration. In the case of acute 
lymphoblastic leukaemia, it is routine to use oral antineoplastic agents on a 
daily basis for 2–3 years. This can be particularly challenging in low-resource 
areas, especially if free treatment is not available for these children.159 Low 
adherence to treatment can lead to a worse prognosis and lower survival. 
This is less significant for acute myeloid leukaemia because treatment is 
mostly given intravenously. 
 As discussed in my literature review, abandonment of treatment is 
considered the major cause of treatment failure amongst children with cancer 
in developing countries. This is often caused by treatment toxicity, socio-
cultural and economic factors.124, 290 Most of these children who abandon 
treatment will die because acute leukaemia is a fatal disease when not 
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appropriately treated. If abandonment of treatment happens after most of 
treatment is completed, children may be cured or have long-term survival. 
However, this is unlikely to occur in low-resource areas. High loss to follow-up 
can be secondary to high level of abandonment of treatment, and this can 
lead to an over-estimation of survival. The variables level of abandonment of 
treatment and non-adherence to treatment were not available for my studies. 
 
4.4.3 Influence of tumour-related factors on survival 
Acute lymphoblastic leukaemia survival varies according to leukaemia 
immunophenotype (B- or T-cell), genetic lesions, whether or not central 
nervous system or testis is involved, or others diseases are associated such 
as Down syndrome. Likewise, genetic and molecular alteration have 
prognosis factor for acute myeloid leukaemia, but cannot be accounted for in 
this thesis. 
 
4.4.4 Impact of health-related factors on survival 
Sankaranarayanan et al.291 estimated survival from a variety of cancer types 
in 5 developing countries, and compared survival to that of developed 
countries. The most remarkable differences in survival were found for 
leukaemias, lymphomas and tumours of testis, malignancies that can be 
cured or have long-term survival when appropriate treatment is provided  
  Inequalities in access to care, quality of care and diagnostic limitations 
result in an enormous survival gap between developing and developed 
countries. In this thesis, health insurance status and type of hospital were 
used as a surrogate for access to care.  
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 Acute leukaemia, as well as other types of malignancies, causes 
considerable morbidity and mortality among children, especially in low- and 
middle-income countries. Despite its relevance for national and international 
cancer control strategies, cancer surveillance has been often under-used. In 
the United Sates, Glaser et al.292 attributed this fact to an “under-appreciation 
of the scope of the resources, and a professional mind-set that descriptive 
epidemiology is simplistic and limited”.  
 Lately, this scenario has been changing: international collaborative 
programmes such as EUROCARE176 and CONCORD293 have been effectively 
using cancer surveillance research to produce critical information on cancer 
survival and thus influence health policy. EUROCARE and CONCORD high-
resolution studies aim to provide more specific information such as cancer 
stage at diagnosis, diagnosis procedures used for staging, and treatment; in 
order to interpret survival differences in comparative international studies.294 
As noted by Hiatt and Himer,295 “cancer surveillance research must not only 
describe the cancer burden and track changes in cancer rates; it also must 
explain the reasons for observed disparities and trends in cancer burden”. 
This is the main goal of my thesis.  
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Chapter 5 Racial/Ethnic and Socioeconomic 
Disparities in Survival Among Children With Acute 
Lymphoblastic Leukaemia in California, 1988–2011: A 
Population-Based Observational Study 
 
5.1 Preamble to research paper 1 
In the background chapter and in the literature review, I acknowledged that 
acute lymphoblastic leukaemia is the most frequent cancer in children and 
adolescents in the United States, Europe and other developed countries, for 
which cancer registration data have been standardised, allowing accurate 
estimates of incidence and survival. 
 Acute lymphoblastic leukaemia is a severe disease that leads to death 
within a few months after diagnosis if intensive chemotherapy regimens and 
adequate supportive care are not provided. Treatment is of long duration 
(2.5–3 years), expensive and carries a massive burden to patients and their 
families. If treatment is not appropriate, the patient has a high chance of 
disease relapse and consequent death. 
 Despite the dramatic improvement in survival in the last five decades, 
from universally fatal to potentially curable disease, survival from this 
malignancy varies widely between and within countries, indicating a need for 
further investigation of the main factors associated with disease outcome at a 
population-level. 
 Due to the high-quality data available from the California Cancer 
Registry and a large sample of an ethnically and racially diverse population, I 
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had the opportunity to analyse survival of virtually all patients aged 0–19 
years diagnosed with acute lymphoblastic leukaemia (nearly 10,000) during 
almost 25 years study period (1988–2011), allowing for examination of trends 
in outcome. 
 In this population-based study, I simultaneously investigated the 
influences of neighbourhood socioeconomic status, type of health insurance 
at time of initial therapy, type of treating facility, and race/ethnicity on survival. 
My study extends the work of prior studies by considering these factors in 
addition to those examined previously (age at diagnosis, gender, leukaemia 
immunophenotype, and calendar period). 
 In the literature, there is little information on the occurrence of 
secondary neoplasms in children and adolescents treated for acute 
lymphoblastic leukaemia.296-299 Utilizing data from the California Cancer 
Registry, I was able to provide information on this relevant adverse effect of 
treatment. I also provided descriptive information on chemotherapy and 
central nervous system radiation. 
 My findings identified subgroups with poor survival and highlighted the 
value of specific information to better understand the causes of lower survival 
in some groups of children and adolescents with acute lymphoblastic 
leukaemia, facilitating the eventual development of strategies to decrease 
survival inequalities. 
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Summary 
Background Despite advances in treatment, survival from acute 
lymphoblastic leukemia (ALL) remains lower among non-White children than 
White children in the US. We investigated the association of race/ethnicity and 
socioeconomic status (SES) with survival. 
Procedures We analyzed 9,295 Californian children (3,251 Whites, 4,890 
Hispanics, 796 Asians, and 358 Blacks) aged ≤19 years diagnosed with a first 
primary ALL during 1988–2011. We used the Kaplan-Meier method to 
estimate survival at 1, 5 and 10 years after diagnosis for three calendar 
periods. Hazard ratios of death for race/ethnicity, SES, and clinical factors 
were estimated by Cox regression models. 
Results Median follow-up time was 7.4 years (range 0–25 years). Over time, 
survival after ALL improved steadily, but inequalities persisted across 
races/ethnicities. Five-year survival (95% confidence interval) was 85.0% 
(83.6–86.2) for White, 81.4% (78.3–84.0) for Asian, 79.0% (77.8–80.2) for 
Hispanic, and 74.4% (69.4–78.8) for Black children. In multivariable-adjusted 
models, the hazard of death was increased by 57% among Black, 38% 
among Hispanic, and 33% among Asian children compared with White 
children. Patients residing in the lowest SES neighborhoods at diagnosis had 
a 39% increased risk of death than those living in higher SES neighborhoods. 
Conclusion Despite significant improvements in survival, non-White children 
and children residing in low SES neighborhoods experienced worse survival 
even after adjusting for potential confounders. Our findings highlight the need 
to capture specific information on disease biology, treatment and treatment 
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compliance to better understand the predictors of lower survival in minority 
and low SES groups. 
 
Introduction 
Acute lymphoblastic leukemia (ALL) is the most common pediatric neoplasm 
and the leading cause of death due to disease in children and adolescents 
aged 1–19 years in the United States (US).6 Several studies have reported an 
increase in the incidence of childhood ALL in Europe 24 and the US.23 
Evidence suggests that there may be an inherited genetic predisposition to 
this disease among different races/ethnicities.300 Strikingly, genetic factors 
that increase the susceptibility to ALL appear also to be associated with drug-
resistant ALL phenotypes and might, in part, explain the poor survival in 
certain ethnic groups.301 
Survival from childhood ALL represents one of the most successful 
advances in the history of science and medicine. ALL was consistently fatal 
until the 1950s; however, currently approximately 90% of children can be 
cured in developed countries.7 This progress has been attributed largely to 
the use of effective chemotherapy regimens of variable intensities that are 
adapted to precise risk stratification and assessment of early treatment 
response.7 
Despite the dramatic improvement in the survival of children with ALL 
in the last four decades, survival has varied widely by race/ethnicity in 
developed 302 and developing nations.157 Nonadherence to treatment, lack of 
access to care, cultural influences, socioeconomic status (SES), and biologic 
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features have been implicated in these variations.303 However, the extent to 
which these factors contribute to survival inequalities remain unclear. 
 California has the largest and most racially and ethnically diverse 
population in the US,304 and it has maintained a statewide high-quality, 
population-based cancer surveillance system since 1988. In this study, we 
examined how survival after ALL varied by race/ethnicity, SES and clinical 
factors in Californian children over a 24-year period. Our population-based 
study on childhood ALL simultaneously investigates the association of 
race/ethnicity, neighborhood SES, health insurance, type of treating facility, 
treatment, and secondary neoplasms as well as factors examined previously 
(e.g., age, gender, immunophenotype, and calendar period). 
 
Methods 
Patients and study design 
For this population-based observational study, data were retrieved for children 
and adolescents aged 0–19 years residing in California when diagnosed with 
a first, primary ALL from January 1, 1988 through December 31, 2011, and 
followed for vital status through December 31, 2012. Data were obtained from 
the California Cancer Registry (CCR), to which all new cases of cancer 
diagnoses must be reported by State law. The CCR contributes to 
approximately half of the data in the Surveillance, Epidemiology, and End 
Results (SEER) program of the National Cancer Institute (NCI) and is 
estimated to include more than 99% of all invasive cancers diagnosed in 
California. We included the following morphology codes from the International 
Classification of Diseases for Oncology, third edition (ICD-O-3):305 9727, 
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9728, 9729, 9811, 9812, 9813, 9814, 9815, 9816, 9817, 9818, 9835, 9836, 
and 9837. Among 9,429 eligible patients, 9,295 were included for survival 
analysis. The following patients were excluded from analysis: 7 reported by 
death certificate only (DCO), 5 reported by autopsy only, 51 for whom 
race/ethnicity was unknown, 60 of Non–Hispanic American Indian (NHAI) 
race/ethnicity for whom the small sample size precluded analysis, and 11 with 
inconsistent dates of diagnosis or follow-up and/or leukemia classification. 
ALL was morphologically verified in 99.8% of patients, and the percentage of 
cases with verified vital status on December 31, 2012, was 87.1%. 
 Institutional review board (IRB) approval – Ethics approval for human 
subjects research was obtained from the California Prevention Institute of 
California Institutional Review Board. As the analysis was based on state-
mandated cancer registry data, the study was conducted in accordance with 
the waivers of individual informed consent and HIPPA authorization.  
 
Covariates 
Covariates included in the analysis were age at diagnosis (<1, 1–4, 5–9, 10–
14, and 15–19 years); gender (male, female); race/ethnicity [Non–Hispanic 
White (White), Non–Hispanic Black (Black), Hispanic, and Non–Hispanic 
Asian/Pacific Islander (Asian)]; immunophenotype [categorized as B-cell, T-
cell, or not otherwise specified (NOS) according to the morphology codes]; 
secondary neoplasms; and neighborhood SES. Secondary neoplasm was 
defined as a new malignancy registered in the CCR after the diagnosis of 
ALL, following the SEER’s multiple primaries rules for hematopoietic 
diseases.34 Some types of malignant neoplasms have been associated with 
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worse prognosis298 and we have controlled for their occurrence in our 
analyses. Because information on SES at the individual level is not collected 
by the CCR, a previously developed neighborhood SES measure255 was 
used. It is derived from principal components analysis of seven census 
indicator variables of SES (education level, proportion unemployed and with a 
blue collar job, proportion below 200% of federal poverty level, and median 
household income, rent, and home value). This index is based on data at the 
level of the census block groups and is considered adequate as a surrogate to 
SES at individual level,306 and can capture neighborhood-level factors that 
may affect cancer incidence and outcomes.257 SES was divided into quintiles 
based on the statewide distribution and assigned to patients on the basis of 
their residence at time of diagnosis. Other covariates included type of 
insurance at time of initial treatment (private, public, no insurance, or 
unknown) collected from 1996 onwards; calendar period (1988–1995, 1996–
2003, 2004–2011); and type of treating hospital. Because the care provided 
by specialized pediatric oncologic centers may be different from that provided 
in general hospitals, we identified children’s hospitals and pediatric cancer 
centers in California by using listings from the Children’s Hospital 
Association307 and the Children’s Oncology Group (COG).308 These hospitals 
offer clinical trials sponsored by the COG, which is supported by NCI. On the 
basis of the cancer reporting facility, patients were classified by whether they 
had received care at a pediatric cancer center (yes, no). Chemotherapy, 
radiotherapy and time to chemotherapy were evaluated in descriptive 
analyses of treatment. They were not included in the statistical model 
because of changes in the use of central nervous system (CNS) radiation 
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over time144 and the widespread use of chemotherapy protocols. Inclusion of 
treatment in the model did not change the associations observed among 
race/ethnicity, SES, and survival.  
 
Statistical analyses 
We used the chi-square test to compare frequency distributions of 
sociodemographic and clinical characteristics by race/ethnicity.  Follow-up 
time was defined as the date of diagnosis to the date of death from any 
cause, or censoring at the end of the study period (December 31, 2012) or 
last known date of follow-up, whichever came first. 
We estimated overall survival at 1, 5, and 10 years for each covariate 
(except chemotherapy and radiation) and calendar period by the Kaplan-
Meier method. The log-rank test was used to compare differences in survival 
across strata. We used unadjusted and multivariable-adjusted Cox regression 
models to estimate the hazard ratios (HRs) of death with associated 95% 
confidence interval (CI).  
We tested the proportional-hazards assumption by examining log-log 
survival plots and confirmed the results by using Schoenfeld residuals. There 
was evidence that age, immunophenotype, and secondary neoplasms 
violated the proportional hazard assumption, and these were therefore 
included as stratification variables in the models. Secondary neoplasm was 
analysed as a time-dependent variable. 
Because information on type of insurance was not routinely collected 
prior to 1996, we ran three Cox regression models: a model without insurance 
with all patients, a model without insurance but limited to patients diagnosed 
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from 1996 onwards, and another model including insurance but limited to 
patients diagnosed from 1996 onwards. We investigated interactions between 
racial/ethnic groups and other covariates. Statistical analyses were performed 
by using the Stata 13 software and a two-sided P value<0.05 was considered 
statistically significant. 
 
Results 
Sociodemographic and clinical characteristics  
Table 5.1 shows patients and disease characteristics by race/ethnicity. In the 
9,295 patients in our cohort, there was a higher percentage of males (58%) 
than females (42%). More than half the patients (52%) were Hispanic, 
followed by White (35%), Asian (9%), and Black (4%). The median age at 
diagnosis was 4 years for Asian, 5 years for White and Hispanic, and 7 years 
for Black children. By immunophenotype, 60% of patients had B-cell, 12% had 
T-cell, and approximately 28% had NOS ALL. The proportion of T-cell ALL 
was significantly higher in Black (23%) than in White (15%), Asian (13%), and 
Hispanic (10%) children. White and Asian children were more likely to have 
private insurance (80% and 74%, respectively) than Black and Hispanic 
children (53% and 40% respectively). Approximately 1.4% of children were 
diagnosed with secondary neoplasms, of which 58% were solid and 46% 
were hematopoietic. The use of CNS radiation decreased progressively from 
24% in the first time period to 12% in the last period. Chemotherapy was 
administered to more than 98% of children, of whom at least 95% received 
chemotherapy within 2 weeks of diagnosis.  
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Survival  
Table 5.2 displays survival probabilities at 1, 5 and 10 years, by 
sociodemographic and clinical characteristics. Figures 5.1 and 5.2 show 
survival by race/ethnicity and SES, respectively. The median follow-up time 
was 7.4 years (range 0–25 years). By the end of the study period, 1,955 study 
patients died. Survival improved steadily over calendar time but was 
persistently lower for Black, Hispanic, and Asian children than for White 
children. Differences in survival were most striking between Black and White 
children.  
 
Unadjusted and multivariable analyses  
In the unadjusted model all variables were associated with significant 
increased hazard of death. After multivariable adjustment, our analysis 
revealed that the HRs of death were still significant for race/ethnicity and SES 
(Table 5.3). The hazard of death was increased by 57% [HR=1.57 (1.26–
1.96)] among Black, 38% [HR=1.38 (1.23–1.55)] among Hispanic, and 33% 
[HR=1.33 (1.12–1.59)] among Asian children compared with White children. 
Patients residing in the lowest SES neighborhoods were at 39% [HR=1.39 
(1.18–1.64)] increased risk of death than those in the higher SES 
neighborhoods. After controlling for other covariates, the hazard of death was 
not associated with the type of hospital in which children were treated or with 
type of insurance for patients diagnosed from 1996 onwards. Insurance 
minimally attenuated the HRs for race/ethnicity and SES among patients 
diagnosed from 1996 onwards (Table 5.3). In addition, the inclusion of SES in 
our model did not substantially change the racial/ethnic differences in survival 
  190 
that we observed. There were no significant interactions between 
race/ethnicity, SES, calendar period and other study covariates. 
 
Discussion 
In our large population-based study of nearly 10,000 children with ALL, 
survival for Black, Hispanic, and Asian children was lower than that for White 
children. The survival differences we observed in our cohort persisted over 
time and were most marked between Black and White children. In contrast to 
previous studies reporting that survival of Asian children was similar to114 or 
better155 than for White, Hispanic, and Black children, our study showed that 
Asian children in California had lower survival than White children with ALL. 
Our results are consistent with a previous study302 that also used US 
population-based data, but we extended their findings by additionally 
investigating neighborhood SES, secondary neoplasms, type of insurance, 
treatment and treating facility.  
Genetic and non-genetic factors help to explain disparities in cancer 
survival. Our population-based study allowed the investigation of non-genetic 
factors and found that neighborhood SES had a significant, independent 
association with survival, particularly when comparing children residing in the 
highest and lowest SES neighborhoods. The inclusion of SES in our statistical 
model did not substantially change the racial/ethnic differences in survival that 
we observed, suggesting that other factors underlie these survival disparities. 
Our SES finding is consistent with previous studies of poorer survival among 
financially deprived populations.309 
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White and Asian children were more likely than Hispanic and Black 
children to have private insurance, but the type of insurance did not 
significantly affect survival after ALL after adjustment for other variables. 
Insurance may have not been associated with survival because, in California, 
patients younger than 21 years are eligible for California Children’s Services 
(CCS), a State program that offers insurance for chronic and complex 
diseases and covers all children with cancer with or without insurance. 
Although the CCS program ensures that all children with ALL have access to 
care, this may not be sufficient in the long-term for children with low SES. 
Differences in relapse rates among children from different racial/ethnic groups 
have been observed. In a study on adherence to oral 6-mercaptopurine during 
the maintenance phase of ALL treatment, nonadherence was significantly 
higher among non-White children than White children and it considerably 
increased relapse rates. Sociodemographic characteristics also played a 
significant role in adherence to treatment.309 
Although past evidence suggests that children with ALL treated at 
specialized pediatric cancer centers had better survival than those at general 
hospitals,310 our study did not find survival differences by treating facility. 
Because the treating facility typically refers to the hospital that initially 
diagnosed and/or treated the patient, it is possible that some children 
admitted in nonspecialized pediatric hospitals were later referred to pediatric 
cancer centers where standardized COG protocols were used, thus 
confounding our results.  
ALL is a lethal disease if treatment is not started promptly. Although the 
lack of appropriate chemotherapy agents might contribute to the lower 
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survival in Eastern Europe,311 our examination of the proportion of children 
treated with chemotherapy and time from diagnosis to the start of treatment 
showed that the majority of study patients were treated within the first 2 weeks 
of diagnosis. However, late diagnosis might have had an adverse effect on 
outcome. Parents who are undocumented immigrants or of lower SES may 
wait longer to seek medical care for their children or may do so when the child 
is already severely sick. Late diagnosis may increase the risk of (early) 
death312-314 because patients may develop severe infectious and/or metabolic 
complications prior to referral to a specialized cancer center.190 However, we 
did not have sufficient information to evaluate this possibility. 
Our data indicate that the use of prophylactic cranial irradiation has 
decreased markedly over time, suggesting protocol adherence to the new 
recommendations for using systemic and intrathecal therapy instead of 
radiation for children with high-risk CNS relapse. This recommendation aims 
to prevent late radiation-related complications such as second neoplasms.299 
Infants and older children had significant lower survival than did children aged 
1–9 years, supporting findings in previous studies in Europe5 in the US.6 
The treatment of childhood leukemia is complex, expensive, and lengthy (2.5–
3 years). With modern supportive care, fewer than 10% of deaths among 
children with ALL are due to therapy-associated toxicity,315 and disease 
relapse remains the leading cause of death.316 Although relapsed ALL is 
treated with curative intent in the US, the long-term survival of children who 
relapse is only approximately 25%, even when bone marrow transplant is 
available.316 Multiple factors might affect the survival of children with ALL, and 
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this can be a complex construct involving socioeconomic and cultural 
variables.309 
Differences in disease biology may explain, in part, the persistent gap 
in survival by race/ethnicity. For example, in our study, survival differences 
were more marked between Black and White children (Figure 5.1; Table 5.3). 
Intrinsic biologic features may partially explain this observation. Previous 
studies reported that compared to White children, Black children with ALL had 
a higher incidence of unfavourable features, including high leukocyte count, 
higher proportion of T-cell leukemia, chromosome translocations [e.g. t(1,19)], 
and molecular abnormalities associated with an increased risk of relapse.317 
In contrast, approximately 50% of White children have ALL with favorable 
genetic features (B-cell ALL), which translate to excellent prognosis.300 Pui et 
al.90 reported that survival rate of Black children receiving intensive risk-based 
therapy and comprehensive supportive care can be similar to that of White 
children, thereby reducing the impact of these adverse factors. However, to 
our knowledge, these results found at a single institution, have not been 
replicated. 
 Intrinsic biologic differences may also play an important role in the poor 
prognosis of ALL among Hispanic children. A recent review303 of the genomic 
profiling of ALL associated with susceptibility and outcome among Hispanic 
children identified a novel subtype of ALL called Philadelphia chromosome-
like (Ph–like) ALL among these children. The incidence of Ph-like ALL in 
Hispanic children is significantly higher (35%) than in non-Hispanic children 
(7%). Approximately 50% of children with this subtype overexpress the 
somatic cytokine receptor-like factor 2 (CRLF2).317 Furthermore, Perez-
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Andreu et al.318 demonstrated that inherited GATA binding protein 3 (GATA3) 
variants are also overrepresented among Hispanics and increase the 
susceptibility to Ph-like ALL. The presence of both these variants is 
associated with a higher risk of relapse among Hispanic children with ALL and 
may in part explain their poor response to treatment. 
 Our study has some limitations. Data on specific genetic abnormalities 
have only been collected by the CCR since 2010. Because of the small size of 
this group, we could not compare the survival of children on the basis of 
genetic characteristics. However, this will be of interest in future studies. Most 
children and adolescents with ALL in California are treated at pediatric cancer 
centers that use COG protocols, but we do not have information about which 
patients are treated with these protocols and the intensity of treatment 
administered. We lacked data on relapse rates, as disease recurrence is not 
routinely collected by population-based cancer registries. 
 The strengths of our study include the use of a high-quality population-
based dataset, a large sample of an ethnically and racially diverse population, 
and long period of post-diagnostic observation that allowed us to examine 
trends in outcome. Our study covered nearly the entire population of children 
and adolescents diagnosed with ALL in California and provided information on 
numerous factors such as neighborhood SES, insurance, treatment, treating 
facility, secondary neoplasm, and immunophenotype as well as age, gender 
and calendar period. 
In summary, despite the remarkable improvement in cure rates after ALL, 
non-White children and children in low SES neighborhoods have been 
disproportionally dying even when access to high-quality care is available and 
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standardized protocols are followed. In the coming years, genomic findings 
will dramatically change the prognostic classification of ALL. In the era of 
precision medicine, the value of population-based cancer registries can be 
improved by collaborating with pediatric oncologists and cancer registries 
from COG-affiliated hospitals. Capturing specific biologic (e.g., ALL genomic 
signature, minimal residual disease, blast chromosomal abnormalities, 
presenting white counts, and NCI risk grouping), and socioeconomic (e.g., 
treatment compliance) information can help to identify predictors of 
racial/ethnic differences in treatment failure and guide the development of 
interventions aimed at improving survival for minority and low SES children 
with ALL. 
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Table 5.1: Sociodemographic and clinical characteristics of children (aged 0–19 years) 
with acute lymphoblastic leukemia diagnosed from 1988 to 2011 and followed up to 2012 
in California, by race/ethnicity 
 
  
Covariates Whites 
N (%) 
Blacks 
N (%) 
Hispanics 
N (%) 
Asians 
N (%) 
Total cohort 
N (%) 
P* 
Total  3251 (35) 358 (4) 4890 (52) 796 (9) 9295 (100)  
Age at diagnosis, years    
<1 69 (2.1) 9 (2.5) 158 (3.2) 29 (3.6) 266 (2.9)  
1–4 1468 (45.2) 117 (32.7) 2023 (41.4) 382 (48.0) 3990 (42.9)  
5–9 868 (26.7) 102 (28.5) 1216 (24.9) 194 (24.4) 2382 (25.6)  
10–14 465 (14.3) 74 (20.7) 807 (16.5) 101 (12.7) 1447 (15.5)  
15–19 381 (11.7) 56 (15.6) 686 (14.0) 90 (11.3) 1213 (13.1) <0.0001 
Median  5 7 5 4 5  
       
Gender       
Male   1911 (58.8) 206 (57.5) 2815 (57.6) 459 (57.7) 5391 (58.0)  
Female 1340 (41.2) 152 (42.5) 2075 (42.4) 337 (42.3) 3904 (42.0) 0.738 
       
Chemotherapy       
No 44 (1.3) 11 (3.1) 79 (1.6) 7 (0.9) 141 (1.5)  
Yes 3207(98.7) 347 (96.9) 4811 (98.4) 789 (99.1) 9154 (98.5) 0.031 
       
CNS radiation       
No 2717 (83.6) 275 (76.8) 4085 (83.5) 687 (86.3) 7764 (83.5)  
Yes 534 (16.4) 83 (23.2) 805 (16.5) 109 (13.7) 1531 (16.5) 0.001 
       
Treatment at a pediatric cancer center  
No 931 (28.6) 131 (36.6) 1571 (32.1) 240 (30.1) 2873 (30.9)  
Yes 2320 (71.4) 227 (63.4) 3319 (67.9) 556 (69.9) 6422 (69.1) 0.001 
       
Leukemia immunophenotype  
T-cell 483 (14.9) 84 (23.4) 464 (9.5) 102 (12.8) 1133 (12.2)  
B-cell 1736 (53.4) 176 (49.2) 3183 (65.1) 490 (61.6) 5585 (60.1)  
NOS 1032 (31.7) 98 (27.4) 1243 (25.4) 204 (25.6) 2581 (27.7) <0.0001 
       
Secondary neoplasms     
No 3209 (98.7) 356 (99.4) 4838 (98.9) 782 (98.2) 9185 (98.8)  
Yes 42 (1.3) 2 (0.6) 52 (1.1) 14 (1.8) 110 (1.2) 0.223 
       
Socioeconomic status  
1. Lowest 20% 247 (7.6) 96 (26.8) 2067(42.2) 102 (12.8) 2513 (27.0)  
2 532 (16.4) 109 (30.5) 1256 (25.7) 120 (15.1) 2020 (21.7)  
3. Middle 20% 683 (21.0) 66 (18.4) 831 (17.0) 139 (17.5) 1723 (18.5)  
4 847 (26.0) 58 (16.2) 479 (9.8) 200 (25.1) 1585 (17.1)  
5. Highest 20% 942 (29.0) 29 (8.1) 257 (5.3) 235 (29.5) 1463 (15.7) <0.0001 
       
Calendar period       
1988–1995 1169 (35.9) 104 (29.0) 1162 (23.8) 222 (27.9) 2657 (28.6)  
1996–2003 1093 (33.6) 127 (35.5) 1670 (34.1) 270 (33.9) 3160 (34.0)  
2004–2011 989 (30.4) 127 (35.5) 2058 (42.1) 304 (38.2) 3478 (37.4) <0.0001 
       
Type of health insurance: limited to cases diagnosed from 1996 onwards (N=6638) 
No insurance 14 (0.7) 9 (3.5) 106 (2.9) 4 (0.7) 133 (2.0)  
Private insurance 1669 (80.1) 135 (53.2) 1493 (40.0) 425 (74.0) 3722 (56.1)  
Public insurance 341 (16.4) 101 (39.8) 1997 (53.6) 128 (22.3) 2567 (38.7)  
Unknown 58 (2.8) 9 (3.5) 132 (3.5) 17 (3.0) 216 (3.2) <0.0001 
       
Abbreviations: CNS, central nervous system; NOS, not otherwise specified. *Chi-squared test P-values. 
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Table 5.2: Overall survival with 95% confidence intervals for acute lymphoblastic 
leukemia at 1, 5, and 10 years after diagnosis in children (0–19 years old) in California 
from 1988 to 2011, by sociodemographic and clinical factors. 
Covariates 1-year survival 
(95% CI) 
5-year survival 
(95% CI) 
10-year survival 
(95% CI) 
All children 94.5 (94.0–95.0) 81.2 (80.3–82.0) 77.1 (76.1–78.0) 
Age at diagnosis    
<1 76.9 (71.3–81.6) 50.2 (43.7–56.2) 45.7 (39.1–52.1) 
1–4 97.9 (97.4–98.3) 89.3 (88.2–90.3) 86.3 (85.1–87.4) 
5–9 96.6 (95.8–97.3) 86.2 (84.7–87.6) 80.7 (78.8–82.4) 
10–14 91.8 (90.2–93.1) 73.5 (71.0–75.7) 69.0 (66.3–71.5) 
15–19 86.3 (84.2–88.1) 60.2 (57.2–63.0) 55.8 (52.6–58.8) 
Log-rank test P-value<0.00001 
    
Race/ethnicity    
White 95.8 (95.0–96.4) 85.0 (83.6–86.2) 81.5 (80.0–82.9) 
Black 91.8 (88.4–94.2) 74.4 (69.4–78.8) 70.7 (6–75.4) 
Hispanic 93.9 (93.2–94.5) 79.0 (77.8–80.2) 74.4 (73.0–75.7) 
Asian 94.4 (92.6–95.8) 81.4 (78.3–84.0) 77.4 (74.0–80.4) 
Log-rank test P-value<0.00001 
    
Gender    
Male   94.3 (93.7–94.9) 79.5 (78.3–80.6) 75.1 (73.8–76.3) 
Female 94.7 (94.0–95.4) 83.5 (82.2–84.7) 79.9 (78.4–81.2) 
Log-rank test P-value<0.00001 
    
Leukemia immunophenotype 
B–cell 95.4 (94.8–95.9) 82.7 (81.6–83.7) 77.8 (76.5–79.0) 
T–cell 90.8 (88.9–92.3) 73.8 (71.0–76.3) 71.0 (68.0–73.7) 
NOS 94.3 (93.3–95.1) 81.1 (79.5–82.6) 77.8 (76.1–79.4) 
Log-rank test P-value<0.00001 
    
Calendar period    
1988–1995 93.0 (91.9–93.9) 76.9 (75.2–78.5) 72.8 (71.1–74.5) 
1996–2003 94.8 (93.9–95.5) 80.7 (79.3–82.1) 76.7 (75.1–78.1) 
2004–2011 95.5 (94.7–96.1) 85.7 (84.3–87.0) N/A 
Log-rank test P-value<0.00001 
    
Socioeconomic status   
1. Lowest 20% 93.5 (92.4–94.4) 77.0 (75.3–78.7) 72.5 (70.5–74.3) 
2 94.5 (93.4–95.5) 81.5 (79.6–83.2) 77.8 (75.6–79.6) 
3. Middle 20% 94.5 (93.3–95.4) 82.3 (80.3–84.1) 78.4 (76.2–80.5) 
4 95.3 (94.1–96.2) 82.2 (80.1–84.1) 78.2 (75.9–80.3) 
5. Highest 20% 95.5 (94.3–96.4) 85.4 (83.3–87.1) 81.3 (78.9–81.6) 
Log-rank test P-value<0.00001 
    
Treatment at a pediatric cancer center  
No  92.9 (91.9–93.8) 77.0 (75.4–78.6) 73.2 (71.4–74.9) 
Yes 95.2 (94.7–95.7) 83.0 (82.0–84.0) 78.9 (77.7–80.0) 
Log-rank test P-value=0.0014 
    
Type of health insurance: limited to cases diagnosed from 1996 onwards (N=6638) 
No insurance 93.3 (88.1–96.9) 77.6 (68.9–84.1) 74.2 (64.4–81.6) 
Private insurance 96.6 (94.9–96.2) 85.2 (83.9–86.4) 81.8 (80.3–83.2) 
Public insurance 94.8 (93.9–96.5) 81.5 (79.9–83.1) 76.3 (74.3–78.3) 
Unknown 91.6 (87.0–94.6) 66.2 (59.3–72.2) 63.0 (55.8–69.3) 
Log-rank test P-value<0.00001 
    
Abbreviations: CI, confidence interval; NOS, not otherwise specified; N/A, not applicable. 
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Table 5.3: Unadjusted and multivariable-adjusted hazard ratios and 95% confidence intervals 
for overall survival in children (0–19 years old) with acute lymphoblastic leukemia in California 
Covariates Death 
 N(%) 
Unadjusted HR1 
(95% CI) 
(1988–2011) 
Adjusted HR2 
(95% CI) 
(1988–2011) 
Adjusted HR3 
(95% CI) 
(1996–2011) 
Adjusted HR4 
(95% CI) 
(1996–2011) 
Race/ethnicity      
White 568 (29.1) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
Black 100 (5.1) 1.78 (1.44–2.20) 1.57 (1.26–1.96) 1.74 (1.31–2.31) 1.72 (1.29–2.28) 
Hispanic 1123 (57.4) 1.47 (1.33–1.62) 1.38 (1.23–1.55) 1.43 (1.22–1.68) 1.37 (1.17–1.62) 
Asian 164 (8.4) 1.26 (1.06–1.50) 1.33 (1.12–1.59) 1.42 (1.13–1.79) 1.40 (1.11–1.76) 
      
Gender      
Male   1237 (63.3) 1.27 (1.16–1.39) 1.19 (1.09–1.31) 1.20 (1.06–1.35) 1.19 (1.06–1.35) 
Female 718 (36.7) 1.0 (Reference) 1.0 (Reference) 1.00 (Reference) 1.00 (Reference) 
      
Socioeconomic status     
1.Lowest 20% 623 (32.3) 1.61 (1.39–1.87)    1.39 (1.18–1.64) 1.40 (1.12–1.75) 1.30 (1.04–2.27) 
2. 414 (21.2) 1.29 (1.10–1.51)    1.15 (0.97–1.35) 1.20 (0.95–1.51) 1.15 (0.91–1.44) 
3. Middle 20% 339 (17.3) 1.20 (1.02–1.41)    1.13 (0.95–1.33) 1.10 (0.87–1.38) 1.06 (0.84–1.34) 
4. 324 (16.6) 1.23 (1.04–1.45)    1.17 (0.99–1.39) 1.22 (0.97–1.54) 1.20 (0.95–1.51) 
5. Highest 20% 246 (12.6) 1.00 (Reference)   1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
      
Calendar period      
1988–1995 781 (39.9) 1.66 (1.47–1.87) 1.97 (1.74–2.24) N/A N/A 
1996–2003 744 (38.1) 1.38 (1.22–1.56) 1.50 (1.33–1.70) 1.52 (1.34–1.73) 1.50 (1.33–1.71) 
2004–2011 430 (22.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
      
Treatment at a pediatric cancer center 
No 724 (37.0) 1.35 (1.23–1.48) 1.06 (0.96–1.16) 1.05 (0.92–1.19) 1.05 (0.92–1.19) 
Yes 1231 (63.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
      
Type of health insurance: model limited to cases diagnosed from 1996 onwards (N=6638) 
No insurance 29 (2.5) 1.54 (1.06–2.23) N/A N/A 1.22 (0.83–1.89) 
Private insurance 583 (49.6) 1.00 (Reference) N/A  N/A 1.00 (Reference) 
Public insurance 487 (41.5) 1.31 (1.16–1.47) N/A N/A 1.15 (1.01–1.32) 
Unknown 75 (6.4) 2.31 (1.82–2.94) N/A N/A 1.77 (1.38–2.26) 
      
Abbreviations: HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified. The multivariable models were 
adjusted for all variables presented in the table and stratified by age, immunophenotype and secondary neoplasm. HR1: 
unadjusted model, HR2: adjusted model without insurance, 1988–2011; HR3: adjusted model without insurance, 1996-2011; 
HR4: adjusted model with insurance, 1996–2011. 
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Figure 5.1: Overall survival by race/ethnicity among children (0–19 years old) 
diagnosed with acute lymphoblastic leukemia in California, 1988–2011 
 
 
Figure 5.2: Overall survival by socioeconomic status among children (0–19 years 
 old) diagnosed with acute lymphoblastic leukemia in California, 1988–2011 
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5.3 The incidence of acute lymphoblastic leukaemia in children and 
adolescents in California 
For acute lymphoblastic leukaemia, there is statistical evidence of an increase in 
annual incidence rates for blacks since 1998 (annual percentage change, APC = 
1.8%, 95% CI = 0.6%–3.0%) and Hispanics (APC = 1.1%, 95% CI = 0.6%–1.6%), 
and borderline evidence of an increase for whites (APC = 0.6%, 95% CI = 0.0%–
1.2%). There is not statistical evidence of an increase in incidence for Asian patients 
(Table 5.4, Figure 5.3).  
The incidence rates and APC were calculated using SEER*Stat v.8.3.1 
(http://seer.cancer.gov/seerstat/). 
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Table 5.4: Age-adjusted incidence rates (IR) (per 1,000,000) and annual percentage change of 
acute lymphoblastic leukaemia, by race/ethnicity in children aged 0–19 years, California, 1988–
2011. 
  White Black Hispanic Asian 
 
IR (95% CI) IR (95% CI)  IR (95% CI) IR (95% CI) 
Total 36.3 (35.0–37.6) 19.8 (17.8–21.9) 46.3 (45.1–47.7) 31.1 (29.0–33.4) 
1988 37.7 (32.0–44.1) 15.8 (7.9–28.3)  37.4 (30.7–45.2) 40.0 (27.4–56.5) 
1989 30.5 (25.4–36.3) 13.0 (5.9–24.5) 40.3 (33.4–48.2) 30.5 (20.1–44.5) 
1990 33.6 (28.3–39.6) 16.8 (8.6–29.2) 33.5 (27.5–40.4) 35.7 (24.6–50.2) 
1991 41.8 (35.9–48.4) 13.7 (6.8–24.7) 45.0 (38.1–52.8) 14.9 (8.1–25.0) 
1992 31.0 (25.9–36.8) 21.2 (12.3–34.1) 45.1 (38.3–52.7) 31.8 (21.7–44.9) 
1993 37.3 (31.7–43.5) 18.4 (10.3–30.6) 39.9 (33.8–46.9) 30.0 (20.2–42.2) 
1994 32.4 (27.2–38.4) 21.4 (12.4–34.4) 46.2 (39.7–53.6) 29.6 (20.1–42.2) 
1995 32.3 (27.1–38.2) 14.4 (7.4–25.4) 42.4 (36.3–49.3) 24.2 (15.8–35.5) 
1996 33.9 (28.6–40.1) 20.5 (11.9–33.1) 50.4 (43.8–57.8) 36.1 (25.7–49.4) 
1997 36.7 (31.1–43.1) 24.9 (15.2–38.6) 46.8 (40.5–53.7) 28.7 (19.5–40.8) 
1998 37.4 (31.6–44.0) 24.1 (14.5–37.7) 43.0 (37.0–49.6) 33.5 (23.4–464) 
1999 37.3 (31.4–43.9) 15.4 (7.9–26.9) 41.7 (35.9–48.1) 23.4 (15.1–34.5) 
2000 38.0 (32.0–44.8) 19.9 (11.4–32.4) 47.8 (41.8–54.6) 26.0 (17.3–37.6) 
2001 38.6 (32.5–45.6) 25.8 (15.7–39.8) 42.9 (37.2–49.3) 33.7 (23.7–46.4) 
2002 34.1 (28.3–40.7) 16.3 (8.7–28.1) 49.1 (43.0–55.8) 34.4 (24.3–47.2) 
2003 33.2 (27.4–39.8) 13.7 (6.6–25.2) 44.9 (39.2–51.3) 34.0 (24.1–46.6) 
2004 44.3 (37.5–52.0) 18.7(10.2–31.5) 48.3 (42.3–54.8) 30.6 (21.3–42.5) 
2005 35.5 (29.4–42.5) 21.0 (11.7–34.7) 45.4 (39.7–51.7) 35.4 (25.5–47.9) 
2006 35.9 (29.7–43.0) 26.2 (15.7–41.0) 50.3 (44.3–56.9) 31.6 (22.2–43.5) 
2007 44.0 (37.0–51.9) 25.4 (14.8–40.5) 51.0 (45.0–57.5) 29.2 (20.3–40.6) 
2008 36.6 (30.2–43.9) 22.6 (12.9–36.7) 54.2 (48.1–60.9) 36.4 (26.5–48.9) 
2009 39.0 (32.3–46.6) 19.9 (10.6–34.0) 52.0 (46.0–58.5) 32.9 (23.5–44.8) 
2010 36.3 (29.8–43.7) 28.4 (17.1–44.3) 53.0 (47.0–59.5) 31.8 (22.6–43.4) 
2011 40.2 (33.3–48.1) 23.4 (13.4–38.1) 46.1 (40.6–52.3) 31.7 (22.5–43.3) 
APC (%) (95% CI) 
p–value  
0.6 (0.0–1.2) 
0.05 
1.8 (0.6–3.0) 
0.01 
1.1 (0.6–1.6) 
<0.001 
0.3 (–0.7–1.3) 
0.56 
Abbreviations: APC, annual percentage change; CI, confidence interval; IR, incidence rates. 
Patients of American Indian (small numbers) or unknown race/ethnicity were excluded. 
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Figure 5.3: Age-specific incidence rates of acute lymphoblastic leukaemia (per 100,000), by 
race/ethnicity, for patients aged 0–19 years, California, 1988–2011. 
  
0
1
2
3
4
5
6
In
c
id
e
n
c
e
 r
a
te
s
 o
f 
A
L
L
 (
p
e
r 
1
0
0
,0
0
0
) 
Year after diagnosis 
White Black Hispanic Asian
  205 
Chapter 6 Disparities in Early Death and Survival in 
Children, Adolescents and Young Adults with Acute 
Promyelocytic Leukaemia in California 
 
6.1 Preamble to research paper 2 
In my literature review, I learned that acute promyelocytic leukaemia was a subtype 
of acute myeloid leukaemia with a favourable prognosis, and it is currently considered 
one of the most curable leukaemia subtypes. However, this malignancy is 
characterised by severe coagulopathy that leads to death within a few days after 
diagnosis (early death) if treatment including all-trans retinoic acid (ATRA) is not 
promptly initiated as soon as diagnosis of the disease is suspected.  
 From the results of clinical trials and population-based studies, I observed that 
there was controversy regarding whether mortality within 30 days of diagnosis of 
acute promyelocytic leukemia had decreased because of the introduction of ATRA 
and other factors such as advances in supportive care measures and prompt access 
to medical care. ATRA was approved by the US Food and Drug Administration in the 
end of 1995. Using the high-quality data from the California Cancer Registry, I 
evaluated early death and survival trends before and after the introduction of ATRA. 
 To my knowledge, this is the first population-based study that examines the 
association of early death in children, adolescents and young adults with acute 
promyelocytic leukemia and simultaneously investigates the potential association of 
health insurance status, race/ethnicity, hospital type, socioeconomic status, as well 
as age and sex, with disease outcomes. Because recent studies have examined 
early death in patients aged ≥ 15 years and there is a lack of population-based 
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studies in young patients with acute promyelocytic leukemia, I investigated early 
death and survival in patients aged 0–39 years in California over a 25-year period.  
 Unlike many clinical trials and even some population-based studies, I did not 
exclude who were not eligible for chemotherapy or those who died within 7 days of 
diagnosis, increasing the generalizability of my findings. The results of my study 
highlight the need for strategies aimed to improve access to effective treatment for 
young patients with acute promyelocytic leukemia, mainly in disadvantaged 
populations. 
 
6.2 Research paper 2 
 
Disparities in early death and survival in children, adolescents and young 
adults with acute promyelocytic leukemia in California 
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Précis  
 During the ATRA era, 30-day mortality and survival improved among children 
and AYAs with APL, while 7-day mortality remained constant. 
 Higher risk of 30-day mortality and worse survival were associated with lack of 
health insurance (1996–2011) and Hispanic race/ethnicity. 
 
ABSTRACT 
Background Findings from clinical trials and population-based studies have differed 
as to whether mortality within 30 days of diagnosis (early death) of acute 
promyelocytic leukemia has decreased in the era of all-trans retinoic acid (ATRA) and 
anthracycline-based chemotherapy.  
Methods We investigated 7- and 30-day mortality and survival in 772 patients aged 
0–39 years when diagnosed with APL during 1988–2011, using data from the 
California Cancer Registry. We used logistic regression and Cox proportional models 
to examine the association of early death and survival, respectively, with 
sociodemographic and clinical factors.  
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Results Overall 30-day mortality decreased significantly over time, from 26% (1988–
1995) to 14% (2004–2011) (P = 0.004). In multivariable analysis, the odds of 30-day 
mortality were 3 times as high during 1988–1995 than 2004–2011 (P = 0.001). 
However, 7-day mortality did not improve over time (P = 0.229). When patients who 
died within 7 days of diagnosis were excluded, 30-day mortality during 1996–2011 
was 3%–8%, similar to levels reported in clinical trials. Higher early death and lower 
survival were associated with lack of health insurance (1996–2011) (early death OR 
= 2.67, P = 0.031) and Hispanic race/ethnicity (early death OR = 2.13, P = 0.014). 
Early death was not associated with age, sex, socioeconomic status or hospital type. 
Black patients also experienced worse survival.  
Conclusions Our findings revealed a decreased 30-day mortality during the ATRA 
era, but 7-day mortality remained high. Efforts to achieve equal outcomes in young 
patients with APL should focus on improving access to effective treatment, mainly 
among uninsured patients and those of Hispanic and Black race/ethnicity. 
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INTRODUCTION 
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) 
that carries the PML/RAR-α fusion in more than 90% of cases. Bleeding and 
thrombosis are frequent and can be aggravated by cytotoxic chemotherapy, resulting 
in early death due mainly to intracranial hemorrhage.319  
 An estimated 600 to 800 new cases of APL (4%–13% of AML cases) occur 
annually in the U.S., most frequently in adults.177, 180 While APL was once highly fatal, 
the addition of all-trans retinoic acid (ATRA) to anthracycline-based chemotherapy 
and the introduction of arsenic trioxide (arsenic) have dramatically improved 
outcomes; currently, 95%–100% of patients with APL gain complete remission.209, 220  
Moreover, arsenic has become the treatment of choice for relapsed APL after 
frontline treatment with ATRA and chemotherapy.320 
 ATRA and arsenic rapidly reduce the risk of hemorrhage and should be 
initiated as soon as APL is suspected.321 ATRA was approved by the U.S. Food and 
Drug Administration (FDA) in November, 1995 and arsenic in September, 2000. 
During the ATRA era, early death has decreased overall, from approximately 20%193, 
195 to 5%–10%.202 However, early death remains high in the U.S.22, 213 and Europe,186 
implicating factors other than ATRA. 
Because recent studies have examined early death and survival in patients aged ≥15 
years186, 213, 322 and there are few reports of population-based studies in young 
patients with APL (Supplementary Table S1), we investigated early death and 
survival in patients in California, diagnosed at ages 0–39 years over a 25-year period, 
and assessed the association of sociodemographic and clinical factors with these 
outcomes. 
PATIENTS AND METHODS  
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Patient selection 
Data were obtained from the California Cancer Registry, to which reporting is 
mandatory and completeness of cases is at least 98%.323 We identified all patients 
with a first, primary APL diagnosed at age 0 to 39 years during 1988–2011 and 
followed until December 31, 2012. APL was diagnosed as histology code 9866 in the 
International Classification of Diseases for Oncology, third edition.305 Of 784 patients 
identified, 4 were excluded due to missing date of diagnosis and 8 due to unknown or 
Native American (small subgroup) race/ethnicity. Our study included 772 patients. 
 
Variables 
The variables examined for association with APL outcomes were age at diagnosis, 
categorized as four groups based on progressive decrements in survival324 (0–9, 10–
19, 20–29 and 30–39 years); sex; era of diagnosis according to ATRA approval by 
the U.S. FDA (pre-ATRA era, 1988–1995; earlier ATRA era, 1996–2003; and later 
ATRA era, 2004–2011); race/ethnicity (non–Hispanic white [white], non-Hispanic 
black [black], Hispanic, and Non-Hispanic Asian/Pacific Islander [Asian]); initial care 
at hospitals affiliated with National Cancer Institute (NCI)-designated cancer centers; 
type of health insurance at admission (routinely documented starting in 1996) (none, 
public, private or unknown/not otherwise specified); and neighborhood 
socioeconomic status (SES) based on block-level census data. Neighborhood SES 
quintiles based on statewide distribution have been utilized extensively in 
California.255   
 Information on hospital designation was from the initial reporting facility. There 
were no data on intensity of treatment or drugs used (conventional genotoxic 
chemotherapy, ATRA and/or arsenic).  
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Statistical analysis 
We used univariable and multivariable logistic regression to investigate the 
association of the sociodemographic and clinical factors with 7- and 30-day mortality, 
through estimation of the odds ratios (ORs) and associated 95% confidence intervals 
(CIs). We analyzed 30-day mortality with and without patients who died within 7 days. 
We estimated overall survival (all-cause survival) at 1 and 5 years by using the 
Kaplan-Meier method, and compared differences in survival across strata for each 
variable using the log-rank test. We used univariable and multivariable Cox 
regression models to examine the association of sociodemographic and clinical 
factors with the risk of death, through estimation of the hazard ratios (HRs) and 
associated 95% CIs. Schoenfeld residuals were used to assess the proportional 
hazard assumptions. We tested for interactions between calendar periods, age 
groups, neighborhood SES and race/ethnicity. All statistical analyses we performed 
by using the Stata 13 software. A two-sided P<0.05 was considered statistically 
significant. 
 
RESULTS 
Approximately 16% of all AML cases in the registry were APL, most of which (79%) 
were diagnosed during the ATRA era (after 1995).  According to death certificates, 
most patients died of leukemia (n = 228, 90%); a much smaller percentage of 
patients died of other (n = 17, 7%) or unknown (n = 7, 3%) causes. Fewer than 2% of 
patients died of complications of APL treatment, such as infection (n = 2), renal 
dysfunction (n = 1) or heart failure (n = 1). Table 6.1 summarizes patient 
characteristics.  
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Early death  
Among patients who experienced early death, median age at diagnosis was 29 years; 
82 of these patients (11%) died within 7 days and 133 (17%) died within 30 days of 
diagnosis. Thirty-day mortality decreased significantly over the 3 eras from 26% in 
1988–1995 (pre-ATRA) to 16% in 1996–2003 (earlier ATRA era) to 14% in 2004–
2011 (later ATRA era) (P=0.004, Table 6.1) (Figure 6.1). However, 7-day mortality 
showed no evidence of a significant decrease. In a multivariable analysis (Table 6.2), 
the odds of 30-day mortality differed significantly between 1988–1995 and later eras 
(P=0.001), but not between the 1996–2003 and 2004–2011 eras. Hispanic patients 
had a risk of 30-day mortality approximately twice that of white patients. After 1995, 
type of health insurance was significantly associated with both 7-day and 30-day 
mortality; the risk of 30-day mortality was approximately 3 times as high in uninsured 
as in privately insured patients [OR=2.67 (95% CI: 1.10–6.52)]. Early death was not 
found to differ significantly between patients with private vs. public insurance (P = 
0.243). 
When patients with 7-day mortality (n = 82) were excluded from analysis, 30-day 
mortality decreased from 15% during 1988–1995 to 8% during 1996–2003 and 3% 
during 2004-2011 (P < 0.0001; data not shown). There was no evidence of 
interactions between any variables.  
 
 
Survival 
During 0 to 25 years of follow-up (median in entire cohort, 4.4 years), 33% of patients 
(n = 252) died. Five-year survival increased from 46.7% during 1988–1995 to 70.1% 
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during 1996–2003 and 77.3% during 2004–2011 (P < 0.0001, Table 6.1). Based on 
the log-rank test, a lower survival estimate was significantly associated with earlier 
period of diagnosis, male sex, older age at diagnosis, and lack of health insurance 
(Table 6.1). In univariable analyses, survival was lower in Hispanic and black vs. 
white patients and uninsured vs. insured patients. In multivariable models, the 1988–
1995 era, black/Hispanic race/ethnicity and lack of health insurance remained 
significantly associated with the hazard of death (Table 6.3). There was no evidence 
of a difference in HR between patients with private vs. public insurance (P = 0.999). 
There was no evidence of violation of the Cox proportional hazard assumptions or of 
interactions between any variables.  
When we excluded patients who died within 30 days of diagnosis in 1996–2011, 5-
year survival increased from 77.8% (95% CI: 70.7%–83.3%) to 88.8% (95% CI: 
82.4%–93.0%) among patients aged 0–19 years, and from 72.5% (95% CI: 67.8%–
76.6%) to 86.3% (95% CI: 81.9%–89.7%) among patients aged 20–39 years (data 
not shown). 
 
DISCUSSION 
In our population-based study spanning 25 years, 30-day mortality decreased 
significantly after 1995, coinciding with the introduction of ATRA and guidelines 
recommending aggressive blood product support and intensive infection prophylaxis 
and treatment for suspected APL. Nevertheless, 30-day mortality remained higher 
than that observed in non-APL subtypes of AML,325 and 7-day mortality did not 
improve over time. Our findings suggest that factors other than ATRA contributed to 
early death; these may include the timing of diagnosis or chemotherapy, hospital 
availability of ATRA/arsenic during the critical 2–3 days after diagnosis, adequate 
  215 
blood products and infection prophylaxis and treatment. A recent study of randomly 
selected hospitals in the U.S. found that less than half had ATRA, and one of the 
main barriers to availability was the absence of ATRA on their formularies.326 
 Patients who suffered early death probably lacked early access to effective 
treatment and/or were too ill when admitted; ten patients in this study died on the day 
of diagnosis. The FDA’s approval of ATRA (and later, arsenic) may not have resulted 
in the wide or timely availability of these drugs across all California hospitals.  
 Moreover, despite the great effectiveness of ATRA and arsenic, treatment may 
cause severe complications that should be recognized and treated promptly, such as 
differentiation syndrome. Differentiation syndrome occurs in about 2%–31% of 
patients receiving induction therapy and can mimic other severe complications, such 
as pulmonary hemorrhage, renal dysfunction and heart failure.215 Because of the 
abrupt presentation and potential gravity of differentiation syndrome, preemptive use 
of corticosteroids has been proposed.216 The syndrome may be promoted by delaying 
chemotherapy after ATRA,327 and delaying ATRA itself for more than 2 days may 
increase the risk of fatal hemorrhage.222 These findings confirm the importance of 
early diagnosis, rapid intensive treatment and adequate supportive care.  
 Importantly, we found that uninsured patients had a higher risk of early death 
and lower survival estimates than those with private and public insurance, suggesting 
lack of adequate access to care. Our results are consistent with a previous report of 
worse survival in uninsured vs. insured AYAs.245 Wider insurance coverage is likely to 
provide better outcomes for these patients. Additionally, early death was higher 
among Hispanic patients, and survival was lower among black and Hispanic patients, 
than those among white patients. Similar findings have been reported in children with 
acute lymphoblastic leukemia (ALL),155, 328 children with AML (excluding APL)329 and 
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adults with AML (including APL).322 To provide effective and sustainable treatment to 
patients with APL – a severe but highly curable disease – efforts should also address 
the social contributors to health inequity,330 such as poverty, inadequate access to 
transportation, and lack of education resources. 
 In general, population-based studies,22, 213 such as ours, show a greater 
proportion of early death than do multi-institutional protocols. The differing findings 
may reflect the exclusion of patients who died during the first week or were too ill for 
chemotherapy in prior studies.331 In our study, when we excluded deaths within 7 
days, we found 30-day mortality during the ATRA era to approximate that in clinical 
trials.202, 208 Similarly, when we excluded patients who died within 30 days of 
diagnosis, 5-year survival was close to that reported in multi-institutional trials in 
children and AYAs.206, 332 These observations suggest that selection bias may 
contribute to the differences in reported survival and early death between most 
clinical trials and population-based studies.  
 Our study had several limitations. Hospital designation was limited to the 
location of initial care at the reporting facility, so it is possible that some patients 
diagnosed at one type of facility were subsequently treated at another. However, 92% 
of our patients received at least part of their treatment at this hospital, suggesting that 
our findings were not substantially influenced by this factor. We also lacked data on 
patients’ risk classification at diagnosis, laboratory data, and blood products 
administered. Although this information would likely have contributed additional 
important findings, disease outcomes such as early death and survival are of 
paramount concern.  
 Survival is a measure of the cancer burden and the health system 
effectiveness and plays a key role in the development of health policies.19 Our large 
  217 
California APL cohort allowed us to compare early death and survival across 
treatment eras and investigate sociodemographic factors associated with outcome. 
To our knowledge, this is the first population-based study to investigate the 
association of race/ethnicity with early death and survival in children with APL and to 
consider the association of outcome with health insurance, hospital type, age, sex, 
treatment era and neighborhood SES. Further, unlike previous population-based 
studies,22, 213, 325 we were able to assess 7-day mortality.  
 In conclusion, our findings indicate a true reduction of 30-day mortality among 
children and AYAs with APL in California, suggesting adherence to modern 
therapeutic strategies. However, 7-day mortality remained high, suggesting that 
factors other than ATRA played a role in early death. We identified subgroups of 
patients vulnerable to early death and reduced survival, including the uninsured and 
Hispanic patients. Black patients also experienced worse survival. To improve 
outcomes among young patients with APL, efforts should focus on improving access 
to effective treatment, mainly among uninsured patients and those of Hispanic and 
Black race/ethnicity.  
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Table 6.1 Patient characteristics, early mortality, and overall survival 
Characteristic 
 
N (%) 7-day 
 mortality (%) 
Pa 
 
30-day 
mortality (%) 
Pa 
 
1-year OS 
(%) 
5-year OS 
(%) 
Pb 
 
Total 772 (100) 82 (11.0)  133 (17.2)  78.0 (74.9-80.8) 68.1 (64.6-71.4)  
Calendar period         
1988–1995 (pre-ATRA) 163 (21.1) 22 (13.5)  42 (25.8)  61.7 (53.7-68.7) 46.7 (38.9-54.2)  
1996–2003 (earlier ATRA era) 266 (34.5) 22 (8.3)  43 (16.2)  78.9 (73.5-83.4) 70.1 (64.2-75.2)  
2004–2011 (later ATRA era) 343 (44.4) 38 (11.1) 0.229 48 (14.0) 0.004 85.1 (80.9-88.5) 77.3 (72.1-81.9) <0.0001 
Age at diagnosis, years ( Median=27 y)        
0–9 50 (6.5) 2 (4.0)  4 (8.0)  84.0 (70.5-91.2) 71.8 (57.1-82.3)   
10–19 172 (22.3) 17 (9.9)  26 (15.1)  81.4 (74.7-86.5)  69.8 (62.1-76.2)   
20–29 225 (29.1) 27 (12.1)  38 (16.9)  79.9 (74.0-84.6)  73.2 (66.7-78.6)   
30–39 325 (42.1) 36 (11.1) 0.396 65 (20.0) 0.152 74.0 (68.9-78.5)  63.1 (57.4-68.3)  0.023 
Race/ethnicity         
White 256 (33.2) 20 (7.8)  32 (12.5)  82.8 (77.6-86.9)  72.2 (66.1-77.4)   
Black 45 (5.8) 7 (15.6)  9 (20.0)  73.3 (57.9-83.9)  56.6 (40.6-69.9)   
Hispanic 388 (50.3) 46 (12.4)  79 (20.4)  74.9 (70.2-87.6) 66.5 (61.4-71.1)  
Asian 83 (10.7) 9 (12.1) 0.266 13 (15.7) 0.070 80.6 (70.2-87.6) 69.2 (57.5-78.3)  0.068 
Sex         
Male   391 (50.7) 51 (13.3)  77 (19.7)  75.0  (70.4-79.0) 63.1 (57.8-67.8)  
Female 381 (49.3) 31 (8.7) 0.028 56 (14.7) 0.066 81.1 (76.8-84.7)  73.2 (68.3-77.4)  0.005 
Initial care at hospitals affiliated with NCI-designated cancer centers      
Yes 155 (20.1) 11 (7.1)  20 (12.9)  81.2 (74.0-86.5) 73.1 (65.2-79.6)  
No 617 (79.9) 71 (11.4) 0.120 113 (18.3) 0.111 77.2 (73.7-80.3) 66.8 (62.8-70.5)  0.078 
Neighborhood socioeconomic status (quintile)       
1. Lowest 20% 216 (28.0) 26 (12.2)  42 (19.4)  75.3 (69.0-80.5) 66.3 (59.4-72.3)   
2. 168 (21.8) 24 (14.0)  35 (20.8)  74.9 (67.5-80.8) 66.5 (58.6-73.3)   
3. Middle 20% 151 (19.6) 12 (7.8)  24 (15.9)  78.8 (71.3-84.5) 66.9 (58.5-74.0)  
4. 128 (16.6) 13 (10.2)  19 (14.8)  81.2 (73.3-87.0) 73.1 (64.2-80.1)   
5. Highest 20% 109 (14.1) 7 (6.4) 0.187 13 (11.9) 0.275 83.5 (75.1-89.2) 70.0 (59.9-77.9) 0.425 
Health insurance (only patients diagnosed in 1996–2011; n = 609)     
None 45 (7.4) 14 (31.8)  19 (42.2)  53.1 (37.6-66.4)  50.6 (35.2-64.2)  
Public 212 (34.8) 16 (7.4)  23 (10.9)  86.8 (81.4-90.7)  77.2 (70.6-82.5)   
Private 294 (48.3) 27 (9.2)  45 (15.3)  82.0 (77.1-85.9) 74.4 (68.8-79.1)   
Unknown/Not otherwise specified  58 (9.5) 3 (5.1) <0.0001 4 (6.9) <0.0001 91.2 (80.2-96.3)  79.2 (65.5-88.0)  0.0001 
Abbreviation: ATRA, all-trans retinoic acid.  aChi-squared P-value for testing whether early death differs among groups for each covariate. b Log-rank P-value comparing 
differences in survival across strata for each variable. ‡ Three patients were excluded due to missing day of diagnosis. 
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Table 6.2 Relation of sociodemographic and clinical factors to 30-day mortality 
 
Factor 
Unadjusted OR1  
(95%CI) 
 (1988–2011) 
Adjusted OR2  
(95% CI) 
(1988–2011) 
Adjusted OR3  
(95%CI)  
(1996–2011) 
Adjusted OR4  
(95% CI) 
 (1996–2011) 
Calendar period     
1988–1995 (pre-ATRA) 2.18 (1.37–3.46) 3.01 (1.66–5.46) N/A N/A 
1996–2003 (earlier ATRA era) 1.20 (0.77–1.87) 1.39 (0.80–2.43) 1.41(0.81–2.46) 1.30 (0.74–2.30) 
2004–2011 (later ATRA era) 1 (base) 1 (base) 1 (base) 1 (base) 
     
Sex     
Male 1.42 (0.97–2.07) 1.21 (0.76–1.96) 1.22 (0.70–2.13) 1.18 (0.67–2.08) 
Female 1 (base) 1 (base) 1 (base) 1 (base) 
     
Age at diagnosis (years)   
0–9  1 (base) 1 (base) 1 (base) 1 (base) 
10–19  2.06 (0.69–6.22) 1.90 (0.54–6.74) 1.78 (0.40–7.95) 2.01 (0.44–9.18) 
20–29  2.36 (0.80–6.95) 1.83 (0.52–6.42) 1.67 (0.38–7.38) 1.72 (0.38–7.78) 
30–39  2.90 (1.01–8.35) 2.48 (0.73–8.45) 2.61 (0.61–11.1) 2.61 (0.60–11.4) 
     
Race/ethnicity     
White 1 (base) 1 (base) 1 (base) 1 (base) 
Black 1.75 (0.77–3.97) 1.82 (0.63–5.20) 2.48 (0.72–8.51) 2.37 (0.68–8.31) 
Hispanic 1.79 (1.14–2.79) 2.13 (1.16–3.89) 2.20 (1.04–4.63) 2.23 (1.01–4.92) 
Asian 1.3 (0.65–2.61) 1.35 (0.56–3.26) 1.11 (0.36–3.51) 1.24 (0.39–3.87) 
     
Neighborhood socioeconomic status (quintiles)  
1. Lowest 20% 1.80 (0.92–3.52) 1.03 (0.44–2.44) 0.83 (0.28–2.52) 0.87 (0.27–2.80) 
2.  1.91 (0.96–3.79) 1.08 (0.46–2.53) 0.99 (0.33–2.92) 1.03 (0.33–3.20) 
3. Middle 20% 1.38 (0.67–2.84) 0.93 (0.39–2.23) 0.88 (0.29–2.72) 0.93 (0.29–3.01) 
4. 1.30 (0.61–2.77) 0.81 (0.32–2.02) 0.79 (0.25–2.53) 0.83 (0.25–2.72) 
5. Highest 20% 1 (base) 1 (base) 1 (base) 1 (base) 
     
Initial care at hospitals affiliated with NCI-designated cancer centers  
Yes 1 (base) 1 (base) 1 (base) 1 (base) 
No 1.53 (0.92–2.55) 1.07 (0.57–2.00) 1.30 (0.62–2.72) 1.19 (0.55–2.56) 
     
Health insurance (limited to patients diagnosed in 1996–2011; n=609) 
None 3.91 (2.01–7.62) N/A N/A 2.67 (1.10–6.52) 
Public 0.66 (0.39–1.13) N/A N/A 0.66 (0.32–1.33) 
Private 1 (base) N/A N/A 1 (base) 
Unknown/NOS 0.40 (0.14–1.17) N/A N/A 0.22 (0.06–0.79) 
Abbreviations: OR, odds ratio; CI, confidence interval; NCI, National Cancer Institute. 
All multivariable comparisons were adjusted for chemotherapy (Y/N) and all variables in the table unless 
otherwise noted. OR1: unadjusted model (1988–2011), OR2: adjusted model without insurance (1988–2011), 
OR3: adjusted model without insurance (1996–2011), OR4: adjusted model with insurance (1996–2011) 
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Table 6.3 Relation of sociodemographic and clinical factors to the hazard of death 
Factor Death 
n (%) 
 
Unadjusted HR1  
 (95% CI) 
(1988–2011) 
Adjusted HR2 
(95% CI) 
(1988–2011) 
Adjusted HR3 
(95% CI) 
(1996–2011) 
Adjusted HR4 
(95% CI) 
(1996–2011) 
Calendar period      
1988–1995 (pre-ATRA) 94 (37.3) 2.79 (2.04–3.80) 2.84 (2.06–3.91) N/A N/A 
1996–2003 (earlier ATRA era) 86 (34.1) 1.39 (1.01–1.90) 1.39 (1.01–1.91) 1.43 (1.04–1.98) 1.40 (1.01–1.94) 
2004–2011 (later ATRA era) 72 (28.6) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base) 
      
Age at diagnosis, years      
0–9 14 (5.6) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base) 
10–19 52 (20.6) 1.14 (0.63–2.05) 1.07 (0.58–1.96) 1.13 (0.51–2.52) 1.20 (0.54–2.67) 
20–29 60 (23.8) 1.03 (0.58–1.85) 0.99 (0.54–1.81) 0.98 (0.44–2.16) 0.96 (0.43–2.14) 
30–39 126 (50.0) 1.56 (0.90–2.72) 1.43 (0.80–2.53) 1.82 (0.85–3.88) 1.83 (0.85–3.93) 
      
Race/ethnicity      
White 73 (29.0) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base) 
Black 20 (7.9) 1.79 (1.09–2.93) 1.81 (1.08–3.03) 1.97 (0.98–3.96) 1.80 (0.89–3.62) 
Hispanic 134 (53.2) 1.33 (1.00–1.77) 1.48 (1.08–2.02) 1.38 (0.90–2.12) 1.31 (0.84–2.03) 
Asian 25 (9.09) 1.11 (0.70–1.75) 1.21 (0.76–1.91) 1.11 (0.58–2.12) 1.12 (0.58–2.15) 
      
Sex      
Male   145 (57.5) 1.42 (1.11–1.83) 1.27 (0.98–1.64) 1.52 (1.10–2.11) 1.50 (1.08–2.07) 
Female 107 (42.5) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base) 
      
Neighborhood socioeconomic status (quintile)    
1. Lowest 20% 75 (29.8) 1.24 (0.82–1.86) 0.90 (0.57–1.41) 1.02 (0.54–1.94) 0.98 (0.51–1.89) 
2. 58 (23.0) 1.20 (0.79–1.83) 0.94 (0.60–1.46) 1.01 (0.53–1.90) 1.00 (0.53–1.90) 
3. Middle 20% 52 (20.6) 1.15 (0.75–1.77) 0.93 (0.60–1.46) 0.95 (0.50–1.82) 0.94 (0.49–1.80) 
4. 33 (13.1) 0.86 (0.53–1.39) 0.72 (0.44–1.18) 0.76 (0.38–1.51) 0.75 (0.37–1.49) 
5. Highest 20% 34 (13.5) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base) 
      
Initial care at hospitals affiliated with NCI-designated cancer centers  
Yes 41 (16.3) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base) 
No 211 (83.7) 1.35 (0.97–1.88) 1.07 (0.75–1.52) 1.31 (0.83–2.06) 1.26 (0.79–1.99) 
      
Health insurance (only patients diagnosed 1996–2011; n=609)   
None 22 (13.9) 2.57 (1.59–4.14) N/A N/A 2.00 (1.20–3.31) 
Public 49 (31.0) 0.91 (0.63–1.31) N/A N/A 1.00 (0.67–1.48) 
Private 74 (46.) 1.0 (base) N/A N/A 1.0 (base) 
Unknown/NOS 13 (8.2) 0.82 (0.46–1.48) N/A N/A 0.64 (0.35–1.17) 
Abbreviations: HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified; NCI, National Cancer Institute. 
All multivariable comparisons were adjusted for chemotherapy (Y/N), and all variables in the table unless otherwise noted.  
HR1: unadjusted model (1988–2011), HR2: adjusted model without insurance (1988–2011), HR3: adjusted model without 
insurance (1996–2011); HR4: adjusted model with insurance (1996–2011). 
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Table S 6.1 Consecutive reports of early death after diagnosis of acute promyelocytic leukemia, 1990–2014 
First Author N Period Age, y 
Early death 
Definition Percentage 
Rodeguiero, F195 268 1984–1987 7–78 Death within 10 days after starting chemotherapy 9.4% died of hemorrhagic events and 3.2% of other 
causes (pre-ATRA era) 
Fenaux, P196 101 1991–1992 6–67 Death during chemotherapy or ATRA, or during post-
chemotherapy aplasia, without evidence of resistant leukemia 
9.0% in the ATRA group , 8.0% in the 
chemotherapy group, (ATRA increased event-free 
survival) 
Estey, E197 43 1991–1995 13–80 Death during induction therapy 18.6% 
Tallman, MS198 346 1992–1995 1–81 Death within 28 days of diagnosis  12.4% 
Mandelli, F199 240  1993–1996 2–73 Death during induction therapy 5% 
Di Bona, E202 622 1989–1997 1–74 Hemorrhagic death during the first 10 days of treatment  3.8% in study A (idarubicin + ATRA) 
7.3% in study B (idarubicin alone) 
Fenaux, P200 439 1993–1996 ≤ 77 Death during induction with ATRA, without evidence of 
resistant leukemia 
7.0% 
Sanz, MA201 123 1996–1998 1–74 Death during induction therapy or post-chemotherapy aplasia  9.8% 
Lengfelder, E203 51 1994–1999 16–60 Death during induction phase before recovery from 
chemotherapy-related myelosuppression 
8.0% 
Mann, G204 44 1993–2002 1–16 Death within 6 weeks of diagnosis 4.5% (ATRA group), 32% (control group)  
Asou, N205 369 1992–1997 15–86 Death within 28 days after start of chemotherapy 8.0% 
Testi, AM206 107 1993–2000 1–17 Death within 34 days of diagnosis  3.7%  
Schlenk, RF221 82 1995–2003 16–60 Death <7 days after completion of the first induction therapy 
or death during double induction therapy 
12% 
Yanada, M208 279 1997–2002 15–70 Early hemorrhagic death 3.2% (ATRA for all patients) 
Derolf, AG210 111 1993–2005 All ages Death within 30 days of diagnosis  25% during 1993–1999, 18% during 2000–2005 
Lo-Coco, F9 642           
453 
1993–2000 
2000–2006 
18–≤ 61 Death within 45 days of induction treatment with ATRA and 
idarubicin (AIDA) 
5.5% in AIDA-04931, 5.6% in AIDA-20002 
Lehman, S186 105 1997–2006 ≥16 Death within 30 days of diagnosis 29.0% (35.0% of patients received no ATRA) 
Park, JH22 1,400 1992–2007 All ages Death within 30 days of diagnosis  17.3%  
Iland, HJ209 124 2004–2009 >1 Death within 36 days of ATRA induction therapy 3.2% 
McClellan, JS213 70 
 
1997–2009 
1977–2007 
≥15 
19–93 
Death within 7 or 30 days from the start of chemotherapy 
Death within 30 days of diagnosis 
18.6% (7 days) and 26.0% (30 days)  
20.0% 
Altman, JK222 204 1992–2009 1–85 Death within 30 days of presentation to medical care 11.0% 
Fisher, BT21 163  1999–2009 All ages Death during induction, within 7 and 30 days of admission 4.3% (7 days), 6.1% (30 days) 
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Figure 6.1: Early death from acute promyelocytic leukemia in California, after diagnosis 
at age 0–39 years.  A. Entire study period (1988–2011), B. Pre-ATRA era (1998–1995), C. 
Earlier ATRA era (1996–2003), D. Later ATRA era (2004–2011). Ten patients who died 
on the day of diagnosis were considered to have a survival time of 1 day. 
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6.3 The incidence of acute promyelocytic leukaemia in 
children, adolescents and young adults in California 
For acute promyelocytic leukaemia, there is statistical evidence of annual 
increase in incidence rates since 1988 for whites (annual percentage change, 
APC = 4.3%, 95% CI = 2.9%–5.7%) and Hispanics (APC = 4.0%, 95% CI = 
1.9%–6.1%). There is no statistical evidence of an increase in incidence for 
Asian patients (APC = 0.8%, 95% CI = -2.3%–4.1%). It was not possible to 
estimate the APC for blacks due to the small number of cases (Table 6.4). 
The incidence rates and APC were calculated using SEER*Stat v.8.3.1 
(http://seer.cancer.gov/seerstat/). 
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Table 6.4: Age-adjusted incidence rates (per 1,000,000) and annual percentage change 
of acute promyelocytic leukaemia, by race/ethnicity in children aged 0–39 years, 
California, 1988–2011. 
 
  
 White Black Hispanic Asian 
 IR (95% CI) IR (95% CI) IR (95% CI) IR (95% CI) 
Total 1.3  (1.1–1.4) 1.3 (1.0–1.8) 2.1 (1.9–2.3) 1.4 (1.1–1.8) 
1988 0.8 (0.4–1.6) 0.6 (0.0–3.7) 0.6 (0.1–1.8) 0.6 (0.0–3.4) 
1989 0.9 (0.4–1.8) 1.5 (0.2–5.2) 0.8 (0.2–1.8) 0.5 (0.0–2.9) 
1990 0.6 (0.2–1.4) 0.5 (0.0–3.3) 0.8 (0.3–1.9) 0.6 (0.0–3.0) 
1991 0.7 (0.3–1.5) 1.5 (0.2–5.1) 1.2 (0.5–2.4) 2 (0.5–5.1) 
1992 1.0 (0.5–1.9) 0.8 (0.0–3.9) 0.8 (0.2–1.9) 1 (0.1–3.5) 
1993 1.0 (0.5–1.9) 1.9 (0.4–5.5) 2.0 (1.0–3.4) 2 (0.5–5.0) 
1994 1.2 (0.6–2.1) 0.7 (0.0–3.8) 1.2 (0.5–2.4) 2.4 (0.8–5.5) 
1995 1.5 (0.8–2.5) 0.0 (0.0–2.5) 1.8 (0.9–3.1) 0.4 (0.0–2.4) 
1996 0.9 (0.4–1.8) 0.7 (0.0–3.9) 2.0 (1.1–3.4) 2.2 (0.7–5.2) 
1997 1.5 (0.8–2.6) 1.4 (0.2–5.0) 1.2 (0.6–2.3) 1.3 (0.3–3.9) 
1998 1.0 (0.4–2.0) 0.0 (0.0–2.5) 2.7 (1.7–4.1) 0.3 (0.0–2.2) 
1999 1.4 (0.7–2.4) 2.1 (0.4–6.0) 3.0 (2.0–4.5) 2.1 (0.7–4.9) 
2000 1.2 (0.6–2.2) 0.7 (0.0–3.8) 2.3 (1.3–3.6) 1.2 (0.2–3.6) 
2001 1.1 (0.5–2.0) 2.6 (0.7–6.8) 2.6 (1.6–4.0) 0.7 (0.1–2.6) 
2002 1.4 (0.7–2.5) 2.1 (0.4–6.1) 2.2 (1.3–3.5) 2.8 (1.1–5.8) 
2003 1.6 (0.9–2.8) 1.3 (0.2–4.9) 2.4 (1.4–3.7) 1.2 (1.1–3.5) 
2004 1.1 (0.5–2.1) 1.3 (0.2–4.8) 2.3 (1.4–3.5) 0.7 (0.1–2.7) 
2005 0.9 (0.4–1.9) 1.3 (0.2–4.9) 1.7 (0.9–2.7) 1.3 (0.4–3.5) 
2006 1.9 (1.0–3.2) 3.1 (0.9–7,9) 3.4 (2.3–4.8) 1.6 (0.4–4.0) 
2007 2.1 (1.2–3.5) 0.6 (0.0–3.7) 3.3 (2.2–4.6) 2.4 (1.0–5.0) 
2008 2.1 (1.2–3.5) 2.0 (0.4–6.0) 3.1 (2.1–4.4) 1.9 (0.7–4.2) 
2009 1.5 (0.8–2.8) 0.8 (0.0–4.4) 2.3 (1.4–3.5) 1.7 (0.5–4.0) 
2010 1.6 (0.8–2.9) 2.1 (0.4–6.3) 2 (1.2–3.1) 1.0 (0.2–2.9) 
2011 2.7 (1.6–4.2) 2.2 (0.4–6.4) 2.9 (1.9–4.2) 1.5 (0.5-3.7) 
APC (%) (95%) CI 
p-value 
4.3 (2.9–5.7) 
<0.001 
*** 
N/A  
4.0 (1.9–6.1) 
0.001 
0.8(-2.3–4.1)    
0.60 
Abbreviations: APC, annual percentage change; CI, confidence interval; IR, incidence 
rates. Patients of American Indian (small numbers) or unknown race/ethnicity were 
excluded. ***Could not be estimated. 
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Figure 6.2: Age-adjusted incidence rates of acute promyelocytic leukaemia (per 
1,000,000), by race/ethnicity, for patients aged 0–39 years, California, 1988–2011. 
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Chapter 7 Predictors of early death and survival 
among children, adolescents and young adults with 
acute myeloid leukaemia in California, 1988–2011: a 
population-based study 
 
7.1 Preamble to research paper 3 
In the background chapter and literature review, I discussed acute myeloid 
leukaemia as a disease that more often affects older adults, however, it can 
happen at any age at diagnosis, even in newborns. I have also learned that, 
despite improvement in treatment, supportive care and haematopoietic stem 
cell transplantation in the last few decades, survival from this disease is still 
low and acute myeloid leukaemia remains the leading cause of cancer deaths 
among patients  39 years. 
 I recognised that there was a lack of population-based studies focusing 
on children, adolescents, and young adults with this disease. Therefore, I 
aimed at investigating trends in survival and early death (i.e, death occurring 
within 30 days of diagnosis) among this population during 1988–2011 using 
data from the California Cancer Registry. I have examined the association 
between sociodemographic and clinical factors, including neighbourhood 
socioeconomic status, health insurance, race/ethnicity, hospital type, age and 
sex, with survival and early death. I have also provided descriptive information 
on treatment (chemotherapy and haematopoietic stem cell transplantation) 
and on patient’s cause of death. 
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 In the multivariable analyses, I presented the overall findings and also 
the results by age groups because of my a priori hypothesis that 
socioeconomic and demographic factors (race/ethnicity, neighbourhood 
socioeconomic status, treatment facility and health insurance status) would 
have a greater impact on older versus younger patients. 
 My study demonstrated that mortality among young patients with acute 
myeloid leukaemia remains high in California, particularly among those 
patients older than 9 years. My results highlighted the main factors associated 
with worse outcome and suggested possible strategies to improve survival 
from this severe malignancy. 
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ABSTRACT 
A better understanding of factors associated with early death and survival 
among children, adolescents and young adults with acute myeloid leukaemia 
(AML) may guide health policy aimed at improving outcomes in these 
patients. We examined trends in early death and survival among 3935 
patients aged 0 to 39 years with de novo AML in California during 1988–2011 
and investigated the association between sociodemographic and selected 
clinical factors and outcomes. Early death declined from 9.7% in 1988–1995 
to 7.1% in 2004–2011 (P = 0.062), and survival improved substantially over 
time.  However, 5-year survival was still only 50% (95% CI 47%–53%) even in 
the most recent treatment period (2004–2011). Overall, the main factors 
associated with poor outcomes were older age at diagnosis, treatment at 
hospitals not affiliated with National Cancer Institute-designated cancer 
centers, and black race/ethnicity. For patients diagnosed during 1996–2011, 
survival was lower among those who lacked health insurance compared to 
those with public or private insurance. We conclude that mortality after AML 
remained strikingly high in California and increased with age. Possible 
strategies to improve outcomes include wider insurance coverage and 
treatment at specialised cancer centres. 
 
INTRODUCTION  
Acute myeloid leukaemia (AML) is a complex and highly heterogeneous 
disease. Without treatment, most patients die within weeks or months of 
diagnosis333. Survival among patients with AML has increased over the last 3 
decades, mostly among patients younger than 60 years of age, but progress 
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has now reached a plateau163, 334 and acute leukaemias, including AML, 
remain the leading cause of cancer deaths among patients aged 39 years or 
younger2, 3. Although complete remission can be achieved in approximately 
75% to 90% of patients younger than 60 years of age, approximately 35% to 
50% of these patients experience relapse within the following 2 years335, 336. 
Disturbingly, children, adolescents and young adults who survive AML may 
suffer long-term debilitating complications of treatment, such as secondary 
malignancies, cardiovascular and neurocognitive dysfunctions, as well as 
severe psychosocial effects.337-342 
 Given the lack of population-based studies focusing on young patients 
with AML10, we aimed to evaluate trends in survival and early death (i.e., 
death occurring within 30 days of diagnosis) among patients aged 0 to 39 
years with AML in California, and investigate sociodemographic and selected 
clinical factors associated with poor outcomes.  
 
PATIENTS AND METHODS 
Patients  
Our data were obtained from the California Cancer Registry (CCR), which 
participates in the Survival Epidemiology and End Results (SEER) 
Programme of the National Cancer Institute (NCI). Reporting of all malignant 
neoplasms is compulsory in California, and the standard for completeness of 
ascertainment is at least 98%.323 In addition to relevant variables available in 
the SEER datasets, the CCR provides information on hospital designation 
(i.e., whether the initial reporting hospital is affiliated with a NCI-designated 
cancer center), whether the patient has undergone chemotherapy or 
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hematopoietic stem cell transplantation (HSCT), and neighbourhood 
socioeconomic status (SES). 
Ethics approval for human subject research was obtained from the 
Cancer Prevention Institute of California Institutional Review Board. As the 
analysis was based on state-mandated cancer registry data, the study was 
conducted in accordance with the waivers of individual informed consent and 
HIPAA authorization. 
 We identified all patients aged 0 to 39 years who were diagnosed with 
de novo AML between January 1, 1988 and December 31, 2011, and 
excluded those with acute promyelocytic leukaemia, which has a much more 
favourable prognosis than the other subtypes of AML and was the focus of a 
separate study.343 Information on patients with AML associated with Down 
syndrome (who also have a better prognosis) was only available in the CCR 
from 2010 onwards; prior to that, these cases were classified as ‘AML not 
otherwise specified’. Therefore, it was not possible to study these patients 
separately. 
 To identify cases of AML diagnosed during 1988–2011, we used the 
following morphology codes from the International Classification of Diseases 
for Oncology, 3rd edition (ICD-O-3)305: 9840, 9861, 9867, 9870–9874, 9891, 
9895–9898, 9910, 9920, and 9931. We excluded patients diagnosed by 
autopsy or death certificate only (n = 12), patients of non-Hispanic American 
Indian (n = 20) or unknown (n = 18) race/ethnicity, and patients with a missing 
month of diagnosis (n = 22). Patients who died on the day of diagnosis (n = 
28) were included. Of the 4007 patients reviewed, 3935 (98.2%) were 
included in the analyses. All the patients were followed from the date of 
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diagnosis until death, loss to follow-up, or the end of the study (December 31, 
2012), whichever occurred first. 
 
Demographic and clinical variables  
We examined early death and survival with a comprehensive set of variables 
in order to identify the main factors associated with poorer prognosis among 
young patients (≤ 39 years of age). Age is independently associated with 
survival after AML, and a progressive survival decline is observed from 10 
years of age.5, 225, 226, 344, 345 Based on these observations, we categorized age 
in 4 groups (0–9, 10–19, 20–29, and 30–39 years). To evaluate trends in 
outcomes, we used 3 calendar periods of diagnosis (1988–1995, 1996–2003, 
and 2004–2011). Race/ethnicity was classified in 4 groups [non–Hispanic 
white (white), non-Hispanic black (black), Hispanic, and non-Hispanic 
Asian/Pacific Islander (Asian)]. Neighbourhood SES was divided into quintiles 
by using a previous developed index,255 which is based on block-level census 
data, and is considered an adequate surrogate to SES at the individual 
level.257, 346 Patients’ health insurance status was routinely reported by the 
CCR from 1996 onwards and was categorized in 4 groups [uninsured, publicly 
insured, privately insured, or unknown/not otherwise specified (NOS)]. Binary 
variables were sex (male/female) and initial care at hospitals affiliated with 
NCI-designated cancer centers (Y/N).  
 We provided descriptive information on chemotherapy and HSCT, that, 
like all treatment data collected by the CCR, is limited to the first course of 
treatment, with no details on treatment regimens or intensity. Information on 
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HSCT was routinely reported from 2003 onwards; however, it was also 
abstracted for patients diagnosed during 1996–2002, when available.  
 
Statistical analysis 
Our analyses investigated how the following variables representing 
sociodemographic and clinical characteristics were associated with early 
death and overall survival: age at diagnosis, treatment period, sex, 
race/ethnicity, neighbourhood SES, health insurance status, and treatment 
facility. All of the variables considered had a priori hypothesized or previously 
observed18, 226, 228, 325, 347, 348 associations with early death or survival. We also 
hypothesized that sociodemographic factors would have a greater impact on 
survival in older versus younger patients and investigated this hypothesis by 
analysing the hazard of death by age group. 
 
Early death 
Chi-squared tests were used for testing whether early death differs among 
groups for each covariate. The Kruskal-Wallis test was also used for ordinal 
covariates (age group, neighborhoud SES and calendar period). We used 
multivariable logistic regression to obtain the odds ratios (ORs) for early death 
(death within 30 days of diagnosis) and the corresponding 95% confidence 
intervals (95% CIs) associated with sociodemographic and clinical 
characteristics. We used the likelihood ratio test as an overall significance test 
for the association of each independent variable with early death. 
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Survival  
We estimated the overall (all causes) survival at 1, 5, and 10 years by using 
the Kaplan-Meier method and tested differences in survival across strata of 
each variable with the log-rank test (the log-rank test for trend was also 
estimated for ordinal variables). Twenty-eight patients who died on the day of 
diagnosis were considered to have a survival time of 1 day.  
 The 5-year survival in the 3 calendar periods examined and the 10-
year survival in 1988–1995 and 1996–2003 were estimated using the 
traditional cohort-based approach, because most patients had been followed 
for at least 5 or 10 years, respectively, during these time periods. For patients 
who had all been followed up for at least 10 years, the classical cohort 
approach provided survival estimates using all the observed follow-up data. 
For patients with less than 5 (or 10) years of follow-up, we used the period 
approach267 to obtain a short-term prediction of their survival up to 5 (or 10) 
years after diagnosis on the assumption that their partial probabilities of 
survival will be the same as those observed during the most recent years for 
which follow-up data were available. 
We used multivariable Cox regression to obtain the hazard ratios (HRs) 
and corresponding 95% CIs for each variable, and the likelihood ratio test as 
an overall significance test for the association of each independent variable 
with survival. The proportional hazard assumption, assessed by looking at 
Schoenfeld residuals, was met for all variables in the multivariable model. To 
investigate whether the association of survival with sociodemographic and 
clinical factors varied with age, we fitted separate Cox models by age group 
(0–9, 10–19, 20–29 and 30–39 years) and tested for interactions between age 
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group and each variable using the likelihood ratio test. Statistical analyses 
were performed using Stata 13 software (StataCorp, College Station, TX), and 
a 2-sided P value of less than 0.05 was considered statistically significant.  
 
RESULTS 
Sociodemographic and clinical characteristics  
Among 3935 patients, the median age at diagnosis was 23 years (range, 0–
39 years), with a slight predominance of males (53.5%) (Table 7.1). Most 
patients were white (41%) or Hispanic (39%) and were treated at hospitals 
that were not affiliated with NCI-designated cancer centres (74%). For 
patients diagnosed during 1996–2011, 85% had health insurance (46% had 
private insurance and 39% had public insurance), 4% were uninsured, and 
11% had unknown or not otherwise specified health insurance status. 
 Chemotherapy was administered to 93% of patients; it was 
recommended, but not given, to 2% of patients, and refused by 0.2% of 
patients (or their families). A total of 690 patients (26%) received HSCT; 324 
(27%) of those diagnosed during 1996–2003 and 366 (30%) of those 
diagnosed during 2004–2011. Leukaemia was the cause of death in 88% of 
patients; a small percentage died of other (9%) or unknown (3%) causes. Of 
the deaths resulting from other causes, 3% were caused by infections (data 
not shown). 
 
Early death  
In total, 332 patients (8.4%) died within 30 days of diagnosis. There was a 
trend towards a reduction in early death over time, from 9.7% in 1988–1995 to 
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8.6% in 1996–2003 to 7.1% in 2004–2011 (P = 0.062) (Table 7.1). Overall, in 
unadjusted analyses, early death was strongly associated with age, hospital 
designation, neighbourhood SES, and health insurance status (Table 7.1). In 
multivariable analyses in which all variables were mutually adjusted (Table 
7.2), the odds of early death increased progressively with age: the OR for 
older patients (aged 30 to 39 years) was increased by 70% relative to that for 
younger patients (aged 0 to 9 years) (OR = 1.70, 95% CI 1.22–2.38). Patients 
treated at hospitals not affiliated with NCI-designated cancer centres had a 
higher risk of early death compared with those treated at hospitals affiliated 
with such centres (OR = 1.75, 95% CI 1.28–2.39). Uninsured patients 
diagnosed during 1996–2011 had an approximately 3 times greater risk of 
early death than privately insured patients (OR = 2.91, 95% CI 1.65–5.12); 
there was no evidence of such a difference between publicly and privately 
insured patients (P = 0.849). Patients living in the lowest SES 
neighbourhoods had a significantly greater risk of early death than patients 
living in the highest SES neighbourhoods (OR = 1.57, 95% CI 1.05–2.34). 
 
Survival 
Of 3935 patients included in the analysis, 2272 (58%) died over the course of 
follow-up. Approximately 93% of patients had confirmation of vital status 
within 18 months of the study end date. The median time to death for 
deceased patients was 0.9 years, the median follow-up time for surviving 
patients was 8.8 years, and the overall median follow-up time using reverse 
censoring349 was 10.0 years. Overall survival improved substantially over time 
for all ages and racial/ethnic groups. Five-year survival increased from 32.9% 
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(95% CI 30.3–35.5) in 1988–1995 to 50.0% (95% CI 47.0–52.9) in 2004–2011 
(Table 7.1). Based on the log-rank test, there was evidence of an association 
between worse survival and older age at diagnosis (Figure 7.1), black 
race/ethnicity, receipt of initial care in hospitals not affiliated with NCI-
designated cancer centres, and, for patients diagnosed during 1996–2011, 
lack of health insurance. In a multivariable Cox regression analysis in which 
all variables were mutually adjusted (Table 7.3), we found an increased 
hazard of death for older patients compared with younger patients (30 to 39 
vs. 0 to 9 years of age) (HR = 1.55, 95% CI 1.38–1.74), for black patients 
compared with white patients (HR = 1.27, 95% CI 1.08–1.49), and for patients 
who received initial care at hospitals not affiliated with NCI-designated cancer 
centres compared with those initially treated at such facilities (HR = 1.18, 95% 
CI 1.07–1.31). For patients diagnosed during 1996–2011, the hazard of death 
was higher among uninsured patients than among privately insured patients 
(HR = 1.34, 95% CI 1.01–1.78), with no evidence of a difference in hazard 
between privately and publicly insured patients (P = 0.429).  
 When we fitted separate Cox models by age at diagnosis (Tables 7.4 
and 7.5), we observed that the association between the hazard of death and 
sociodemographic and clinical factors varied by age group. Table 7.4 presents 
Cox models for the factors available during 1988–2011 (all variables except 
health insurance status) by age group at diagnosis. Table 7.5 additionally 
includes health insurance status, but is limited to patients diagnosed during 
1996–2011. For patients aged 0 to 9 years, we found no association between 
the risk of death and sociodemographic or clinical factors, whereas 
associations were found with advancing age (Table 7.4). Markedly, for 
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patients aged 30 to 39 years, the hazard of death was substantially higher 
among those who received initial care at hospitals not affiliated with NCI-
designated cancer centres (HR = 1.31, 95% CI 1.08–1.58) (Table 7.4) and, 
during 1996–2011, among uninsured patients (HR = 1.78, 95% CI 1.14–2.76) 
(Table 7.5). We also observed an increased risk of death among black 
patients, particularly those aged 20 to 29 years (HR = 1.70, 95% CI 1.21–
2.39) (Table 7.4). However, despite observed differences in associations 
between the explanatory variables and survival by age group, none of these 
were found to be statistically significant when we tested for interactions 
between age group and each variable, and the results should therefore be 
interpreted with caution.  
 
DISCUSSION 
Our study found evidence of a reduction in early death and an improvement in 
survival after AML over a 25-year period for patients of all age and 
racial/ethnic groups in California. Overall, early death and survival were 
associated with several sociodemographic and clinical factors, including age 
at diagnosis, race/ethnicity, neighbourhood SES, hospital designation, and 
health insurance status. Despite substantial improvements, approximately half 
of the patients died in the most recent treatment period (2004–2011).  
 We found worse survival among black patients than white patients, 
consistent with previous studies of AML and acute lymphoblastic leukaemia 
(ALL).226, 228-230, 322, 329, 340-342, 347 Results from several clinical trials at a single 
institution in the US showed survival in black children with AML to be similar 
to that in white children.230 However, a recent trial at the same institution 
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showed a trend towards worse outcomes in black children compared to those 
in white and Hispanic children230. It is not yet clear what factors accounted for 
the disparities in survival among black patients with AML that were observed 
in our and other studies. Black race/ethnicity has been associated with both 
favourable and unfavourable cytogenetic subtypes. 230, 342 It is possible that 
pharmacogenetic differences between black and white patients contribute to 
different responses to chemotherapy.230, 350 Another possibility is that black 
patients have had less access to chemotherapy and/or HSCT. A recent study 
using CCR data linked to hospital discharge data showed that the odds of 
receipt of HSCT and chemotherapy were lower among black than non-black 
patients.348 
 Interestingly, we found no evidence of differences in survival between 
Hispanic and white patients in any age group. This differs from the results of 2 
consecutive clinical trials of the Children’s Oncology Group (patients aged 0 to 
21 years),329 but is consistent with the population-based study mentioned 
above348 that found survival among Hispanics to be similar to that among 
white patients after adjustment for age (all ages included), and with pediatric 
clinical trials that showed favourable outcomes among Hispanic patients with 
AML.230 These observations contrast with the worse survival observed among 
Hispanic children and adolescents with ALL in the US302, 303, 328, 347 and 
suggest that unfavourable biological characteristics are associated with 
survival after ALL,303 but may not contribute, to the same extent, to the worse 
outcomes after AML. In fact, clinical trials have shown favourable cytogenetic 
characteristics among Hispanic children with AML.230 
 Clinical329 and population-based studies348 that looked at the 
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association of race/ethnicity with survival lacked information on SES. Our 
information on neighbourhood SES found a significant association between 
lower SES and higher early death, but there was no evidence of an 
association between neighbourhood SES and survival. This suggests that 
some patients with lower neighbourhood SES lacked access to optimal 
treatment during the critical initial days after AML diagnosis. 
 Our findings showed that survival was better among patients aged 0 to 
9 years and there was no evidence of increased hazard of death associated 
with sociodemographic and clinical characteristics in this age group. However, 
among older patients, particularly those aged 30 to 39 years, we observed an 
association between increased risk of death and several sociodemographic 
and clinical factors, including treatment at hospitals not affiliated with NCI-
designated cancer centres, lack of health insurance, and black race/ethnicity. 
The diagnosis of AML in older patients may carry a worse prognosis and likely 
requires more intensive chemotherapy and, in some cases, HSCT. 
Consequently, these patients possibly have a higher probability of treatment-
related complications (mainly haemorrhage and infection) requiring more 
aggressive treatment and long-term supportive care.  
 Recent studies have shown that the biology of pediatric AML differs 
from that of adult AML and that structural and numerical chromosome 
alterations have prognostic implications.52, 233, 235 For instance, core-binding 
factor AML [CBF AML: t(8;21) and inv(16)/t(16;16)], which has a favourable 
prognosis, is more frequent in children and adolescents than in adults. In 
contrast, abnormalities of chromosomes 5 and 7 are more common in adults 
and are associated with a dismal prognosis52. Additionally, somatic mutations 
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in selected genes such as FLT3, NPM1, and CEBPA are known to have 
prognostic clinical significance in pediatric and adult AML. Whereas double 
CEBPA and isolated NPM1 mutations are associated with a reduced risk of 
relapse and better survival234, 351 , patients with internal tandem mutations of 
FLT3 (FLT3/ITD mutations) have a higher risk of relapse and worse survival 
and may benefit from receipt of HSCT.207 Adult AML has a higher prevalence 
of FLT3/ITD mutations compared to pediatric AML (27% vs. 12%).52 These 
cytogenetic and genomic differences may, in part, account for the inferior 
outcomes we observed among older patients and explain the association 
between worse survival and sociodemographic and clinical factors. Hence, 
interventions to improve timely access to high-quality complex therapy and 
optimal supportive care for all individuals with AML have the potential to 
reduce mortality and morbidity, particularly among higher-risk and minority 
patients. 
 Other factors that may contribute to the worse outcomes among older 
patients with AML include the lower participation of adolescents and young 
adults in clinical trials or treatment at hospitals that are not affiliated with NCI-
designated cancer centres compared with that of pediatric patients.352 We had 
no information on patients’ clinical trial enrollment, but our observations 
support the results from a previous study18 showing that adolescents and 
young adults with cancer who were treated at hospitals affiliated with NCI-
designated cancer centres had better outcomes than those treated at 
hospitals not affiliated with such centres.  
 Moreover, we found evidence of increased early death and worse 
survival among uninsured patients compared to privately or publicly insured 
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patients. These results agree with recent studies that showed health 
insurance status to be independently associated with the risk of death,228, 353, 
354 and highlight the importance of health systems that provide timely access 
to adequate treatment (chemotherapy and, when recommended, HSCT) and 
optimal supportive care, including prophylaxis and control of invasive fungal 
infection. 
 Intensive chemotherapy regimens, improvements in supportive care, 
development of risk-adapted treatment strategies (through cytogenetic studies 
and early response to treatment as measured by minimal residual disease), 
and provision of HSCT to a greater number of high-risk patients are 
considered the primary causes of better outcomes in AML, rather than novel 
therapeutic agents.355 Although improvements in HSCT have led to a 
significant decrease in transplant-related morbidity and mortality in patients 
with AML,355 the role of HSCT remains controversial. With the progress in the 
use of chemotherapy and the improvement in risk assessment over the last 
25 years, HSCT in first remission is not recommended for patients with AML 
that has a favourable prognosis (CBF AML),356 and the use of HSCT may be 
limited to intermediate-risk patients who experience relapse after undergoing 
initial therapy.357  
 Because AML is a complex disease characterized by morphological 
and cytogenetic heterogeneity, we believe that multiple factors may have 
contributed to the lower survival we observed among older patients and those 
of black race/ethnicity. Further improvements in disease outcomes will also 
require the development of more effective and less toxic agents for each 
subtype of the disease (precision medicine).358 Conventional genetic and, 
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more recently, genomic studies have played a key role in advancing the cure 
for ALL over a period of almost 30 years,359 and the same benefit is expected 
for AML. In the new era of basket trials (clinical trial design based on the 
hypothesis that the presence of a molecular marker predicts response to a 
targeted therapy regardless of tumour histology360 and big data infrastructure 
(including access to electronic medical records and linkage of cancer registry 
data with insurance claims information),16 national and international 
collaborations are fundamental to help to answer questions regarding 
treatment efficacy, toxicity and long-term survival. 
 Our study has several limitations. Hospital designation was limited to 
the location of care at the first reporting facility, so it is possible that some 
patients who were initially treated at one type of facility were subsequently 
treated at another. Nevertheless, the majority of our patients (90%) received 
at least part of their treatment at the reporting hospital. The CCR, like the 
majority of population-based cancer registries, does not collect information on 
patients’ performance status, baseline cytogenetic risk assessment or 
relapse. Without these additional data, it was not possible to clearly 
investigate whether there was an association between the receipt of HSCT 
and survival. Although supplementary clinical information would have 
contributed additional important findings and explained some of the variability 
of our results, our study provided relevant information on survival and early 
death over a 25-year period in the most populous and racial/ethnically diverse 
state of the United States, using high-quality data. We have also provided 
important information on factors that may have influenced AML outcomes. To 
our knowledge, this is the first population-based study to consider the 
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association between neighbourhood SES and outcomes (survival and early 
death) and to identify associations of several sociodemographic and clinical 
factors with survival, both overall and stratified by age group among children, 
adolescents and young adults with AML. Whereas clinical trials are essential 
to develop guidelines for the best therapeutic regimen (better efficacy with 
less toxicity), they provide data in less than 3% of the cancer population 16, 
although this proportion is usually higher among paediatric patients. In 
addition, clinical trials commonly report relatively short outcomes (i.e., event-
free survival and 1 to 5 years overall survival). Our study included up to 10 
years of survival estimates on virtually all patients in California, important 
information to evaluate long-term outcomes and excess mortality after 
treatment. 
 In conclusion, survival after AML increased over time among children, 
adolescents and young adults, but 5-year survival was still only 50% or less in 
the most recent treatment period (2004–2011). We identified subgroups with a 
higher risk of death from the disease, including those aged 10 to 39 years, 
uninsured patients, those who received initial care at hospitals not affiliated 
with NCI-designated cancer centres, and those of black race/ethnicity. At the 
population-based level, strategies to address the high burden of AML, 
especially among adolescents and young adults, may include wider insurance 
coverage and treatment at specialised cancer centrers. 
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Table 7.1 Patient characteristics, early death and overall survival in patients aged 0 to 39 years with acute myeloid leukaemia in California, 1988–2011 
Characteristics Total  
N (%) 
Early death  
N (%) 
P
a
 
 
1-year OS 
(95% CI) 
5-year OS 
(95% CI) 
10-year OS* 
(95% CI) 
P
b
 
 
Total 3935 (100) 332 (8.4)  66.8 (65.3–68.3) 42.8 (41.2–44.4) 39.6 (38.0–41.3)  
Calendar period        
1988–1995  1303 (33.1) 126 (9.7)  59.3 (56.6–62.0) 32.9 (30.3–35.5) 30.7 (28.3–33.3)  
1996–2003  1299 (33.0) 111 (8.6)  68.1 (65.4–70.5) 45.8 (43.0–48.5) 42.4 (39.6–45.1)  
2004–2011  1333 (33.9) 95 (7.1) 0.0620/0.0626 72.8 (70.3–75.1) 50.0 (47.0–52.9) 45.2 (42.5–47.9) <0.0001/<0.0001 
Age at diagnosis, years        
0–9 964 (24.5) 55 (5.7)  73.2 (70.3–75.9) 52.4 (49.1–55.6) 50.0 (46.1–52.9)  
10–19 733 (18.6) 52 (7.1)  69.8 (66.3–73.0) 44.7 (40.9–48.4) 41.4 (37.6–45.2)  
20–29 951 (24.2) 94 (9.9)  64.8 (61.6–67.7) 40.4 (37.2–43.7) 37.9 (34.6–41.1)  
30–39 1287 (32.7) 131 (10.2) <0.0001/0.0003 61.7 (58.9–64.3) 36.2 (33.5–38.9) 32.6 (29.9–35.4) <0.0001/<0.0001 
Median 23 27      
Race/ethnicity        
Non–Hispanic white   1607 (40.8) 131 (8.2)  65.4 (63.0–67.7) 44.3 (41.8–46.7) 40.8 (38.2–43.3)  
Non–Hispanic black 276 (7.0) 27 (9.8)  60.7 (54.6–66.1) 33.1 (27.4–38.8) 31.5 (25.8–37.2)  
Hispanic 1545 (39.3) 147 (9.5)  68.2 (65.8–70.5) 42.8 (40.2–45.4) 39.6 (36.9–42.3)  
Asian/Pacific Islander 507 (12.9) 27 (5.3) 0.0230 70.2 (65.9–74.0) 42.8 (38.3–47.3) 40.3 (35.7–44.8) 0.0087 
Sex        
Male   2106 (53.5) 188 (8.9)  66.8 (64.7–68.8) 41.8 (39.6–44.0) 39.0 (36.8–41.2)  
Female 1829 (46.5) 144 (7.9) 0.2360 66.7 (64.5–68.9) 43.9 (41.6–46.3) 40.4 (38.0–42.8) 0.3151 
Initial care at hospitals affiliated with NCI-designated cancer centres     
Yes 1039 (26.4) 53 (5.1)  72.3 (69.5–75.0) 49.4 (46.2–52.5) 46.8 (43.5–50.0)  
No  2896 (73.6) 279 (9.6) < 0.0001 64.8 (63.0–66.5) 40.4 (38.6–42.3) 37.1 (35.2–39.0) < 0.0001 
Neighbourhood socioeconomic status (quintiles)       
1. Lowest 20% 986 (25.1) 108 (11.0)  65.1 (62.0–68.4) 42.1 (38.9–45.4) 38.8 (35.4–42.1)  
2. 826 (21.0) 61 (7.9)  68.3 (65.0–71.4) 41.0 (37.5–44.5) 37.7 (34.2–41.2)  
3. Middle 20% 783 (19.9) 64 (8.2)  64.8 (61.3–68.0) 40.3 (36.7–43.8) 37.1 (33.5–40.6)  
4. 714 (18.1) 57 (8.0)  68.0 (64.4–71.3) 46.2 (42.4–50.0) 42.9 (39.0–46.7)  
5. Highest 20% 626 (15.9) 42 (6.7) 0.0180/0.0178 68.4 (64.6–71.9) 45.5 (41.4–49.4) 43.1 (39.0–47.1) 0.1446/0.0338 
Health insurance status (limited to patients diagnosed in 1996–2011, N = 2632)   
None 99 (3.8) 21 (21.2)  56.3 (45.7–65.7) 37.9 (27.7–48.0) 37.9 (27.7–48.0)  
Public  1038 (39.4) 78 (7.5)  71.9 (69.0–74.5) 47.6 (44.4–50.9) 43.8 (40.3–47.2)  
Private 1207 (45.9) 86 (7.1)  71.0 (68.3–73.5) 49.9 (47.0–52.8) 46.5 (43.5–49.5)  
Unknown/NOS  288 (10.9) 21 (7.3) < 0.0001 67.9 (62.1–73.0) 42.6 (36.6–48.4) 37.1 (31.1–43.2) 0.0045 
Abbreviations: OS, overall survival; CI, confidence interval; NOS, not otherwise specified; NCI, National Cancer Institute.
a
The chi-squared was used to test whether early death differs 
among groups for each variable. For ordinal variables, the Kruskal-Wallis test also is reported (value on the right). bThe log-rank was used to test differences in survival across strata for 
each variable. The log-rank test for trend also is reported for ordinal variables (value on the right) *Ten-year survival during 2004–2011 was estimated using the period approach.  
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Table 7.2 Relation of sociodemographic and clinical factors to early death in patients aged 0 to 39 years with acute myeloid leukaemia in California, 1988–2011 
Characteristics Adjusted OR1  
1988–2011(95% CI) 
 
P-value* Adjusted OR2  
1996–2011(95% CI)  
 
P-value* Adjusted OR3  
1996–2011 (95% CI) 
 
P-value* 
Calendar period       
1988–1995  1.38 (1.04–1.83)  N/A  N/A  
1996–2003 1.22 (0.92–1.63)  1.23 (0.92–1.64)  1.20 (0.90–1.61)  
2004–2011  1 (reference) 0.0799 1 (reference) 0.1552 1 (reference) 0.2208 
       
Sex       
Male 1.11 (0.88–1.40)  1.21 (0.91–1.62)  1.20 (0.90–1.61)  
Female 1 (reference) 0.3656 1 (reference) 0.1908 1 (reference) 0.2153 
       
Age at diagnosis, years       
0–9  1 (reference)  1 (reference)  1 (reference)  
10–19  1.21 (0.82–1.40)  1.16 (0.90–2.76)  1.13 (0.70–1.81)  
20–29  1.64 (1.16–2.34)  1.58 (1.03–2.42)  1.44 (0.93–2.21)  
30–39  1.70 (1.22–2.38) 0.0049 1.36 (0.89–2.06) 0.1743 1.27 (0.84–1.94) 0.3915 
       
Race/ethnicity       
Non-Hispanic white 1 (reference)  1 (reference)  1 (reference)  
Non-Hispanic black 1.15 (0.74–1.79)  1.07 (0.58–1.97)  1.06 (0.58–1.96)  
Hispanic 1.14 (0.86–1.49)  1.22 (0.86–1.73)  1.12 (0.78–1.61)   
Asian/Pacific Islander 0.65 (0.42–0.99) 0.0599 0.66 (0.38–1.15) 0.1533 0.66 (0.38–1.14) 0.2791 
       
Neighbourhood socioeconomic status (quintiles)      
1. Lowest 20% 1.57 (1.05–2.34)   1.58 (0.90–2.76)  1.54 (0.87–2.72)  
2.  1.04 (0.68–1.57)  1.29 (0.73–2.27)  1.28 (0.72–2.26)  
3. Middle 20% 1.18 (0.78–1.77)  1.51 (0.86–1.73)  1.53 (0.87–2.69)  
4. 1.19 (0.78–1.81)  1.54 (0.87–2.70)  1.58 (0.90–2.80)  
5. Highest 20% 1 (reference) 0.0934 1 (reference) 0.4512 1 (reference) 0.4411 
       
Initial care at hospitals affiliated with NCI-designated cancer centres  
Yes 1 (reference)  1 (reference)  1 (reference)  
No 1.75 (1.28–2.39) 0.0002 1.96 (1.32–2.92) 0.0004 1.99 (1.33–2.97) 0.0004 
       
 Health insurance status (limited to patients diagnosed in 1996–2011, N = 2632)  
Uninsured N/A  N/A  2.91 (1.65–5.12)  
Public N/A  N/A  1.03 (0.73–1.46)  
Private N/A  N/A  1 (reference)  
Unknown/NOS N/A N/A N/A N/A 1.04 (0.01–0.43) 0.0046 
Abbreviations: OR, odds ratio; CI, confidence interval; NOS, not otherwise specified; NCI, National Cancer Institute. OR1: adjusted model without 
insurance (1988–2011); OR2: adjusted model without insurance (1996–2011); OR3: adjusted model with insurance (1996–2011). *Likelihood ratio test. 
  251 
Table 7.3 Relation of sociodemographic and clinical factors to the hazard of death after acute myeloid leukaemia in patients aged 0 to 39 years in 
California, 1988–2011 
Characteristics Adjusted HR1 
1988–2011 (95% CI) 
P-value* Adjusted HR2 
1996–2011 (95% CI) 
P-value* Adjusted HR3 
1996–2011(95% CI) 
P-value* 
Calendar period       
1988–1995  1.58 (1.43–1.76)  N/A  N/A  
1996–2003  1.14 (1.03–1.27)  1.14 (1.02–1.27)  1.12 (1.00–1.25)  
2004–2011  1.0 (reference) <0.0001 1.0 (reference 0.0211 1.0 (reference) 0.0460 
Age at diagnosis, years       
0–9 1.0 (reference)  1.0 (reference)  1.0 (reference)  
10–19 1.23 (1.07–1.40)  1.28 (1.08–1.52)  1.28 (1.07–1.51)  
20–29 1.34 (1.18–1.52)  1.39 (1.18–1.64)  1.38 (1.17–1.62)  
30–39 1.55 (1.38–1.74) <0.0001 1.49 (1.28–1.74) <0.0001 1.49 (1.28–1.74) <0.0001 
Race/ethnicity       
Non-Hispanic white 1.0 (reference)  1.0 (reference)  1.0 (reference)  
Non-Hispanic black 1.27 (1.08–1.49)  1.33 (1.08–1.65)  1.34 (1.08–1.65)  
Hispanic 1.05 (0.95–1.16)  1.10 (0.96–1.25)  1.08 (0.94–1.24)  
Asian/Pacific Islander 0.98 (0.86–1.13) 0.0318 1.00 (0.83–1.18) 0.0505 1.00 (0.84–1.19) 0.0629 
Sex       
Male  1.03 (0.95–1.12)  0.99 (0.89–1.10)  0.99 (0.89–1.10)  
Female 1.0 (reference) 0.4806 1.0 (reference 0.8900 1.0 (reference) 0.8349 
Neighbourhood socioeconomic status (quintiles)  
1. Lowest 20% 1.14 (0.99–1.31)  1.23 (1.01–1.49)  1.22 (1.00–1.48)  
2. 1.10 (0.95–1.27)  1.20 (1.00–1.46)  1.20 (0.99–1.45)  
3. Middle 20% 1.13 (0.98–1.30)  1.30 (1.08–1.58)  1.31 (1.08–1.59)  
4. 1.01 (0.87–1.15)  1.07 (0.88–1.30)  1.07 (0.88–1.31)  
5. Highest 20% 1.0 (reference) 0.1868 1.0 (reference 0.0490 1.0 (reference) 0.0453 
Initial care at hospitals affiliated with NCI-designated cancer centres  
Yes 1.0 (reference)  1.0 (reference)  1.0 (reference)  
No 1.18 (1.07–1.31) 0.0009 1.26 (1.11–1.43) 0.0004 1.27 (1.11–1.45) 0.0002 
Health insurance status (limited to patients diagnosed in 1996–2011, N=2632)  
None N/A  N/A  1.34 (1.01–1.78)  
Public N/A  N/A  1.05 (0.93–1.19)  
Private N/A  N/A  1.0 (reference)  
Unknown/NOS N/A N/A N/A N/A 1.27 (1.07–1.51) 0.0204 
Abbreviations: HR, hazard ratio; CI, confidence interval NOS, not otherwise specified; NCI, National Cancer Institute. HR1: adjusted model without 
insurance, 1988–2011; HR2: adjusted model without insurance, 1996–2011; HR3: adjusted model with insurance, 1996–2011. *Likelihood ratio test. 
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Table 7.4 Relation of sociodemographic and clinical factors to the hazard of death after acute myeloid leukaemia by age group, California, 1988–2011 
Characteristics 
(Total = 3935) 
  HR1 (95% CI) 
0–9 years 
N = 964  
P-value* HR2 (95% CI) 
10–19 years 
N = 733 
P-value* HR3 (95% CI) 
20–29 years 
N = 951 
P-value* HR4 (95% CI) 
30–39 years 
N = 1287 
P-value* 
Calendar period           
1988–1995    1.84 (1.45–2.34)  1.52 (1.19–1.93)  1.29 (1.05–1.59)  1.71 (1.44–2.04)  
1996–2003    1.36 (1.07–1.73)  1.27 (0.99–1.63)  0.95 (0.76–1.18)  1.14 (0.95–1.36)  
2004–2011    1.0 (reference) <0.0001 1.0 (reference) 0.0034 1.0 (reference) 0.0049 1.0 (reference) <0.0001 
           
Race/ethnicity           
Non-Hispanic white   1.0 (reference)  1.0 (reference)  1.0 (reference)  1.0 (reference)  
Non-Hispanic black   1.22 (0.86–1.74)  1.19 (0.81–1.74)  1.70 (1.21–2.39)  1.19 (0.92–1.54)  
Hispanic   1.02 (0.82–1.28)  1.06 (0.83–1.35)  1.05 (0.86–1.30)  1.10 (0.93–1.30)  
Asian/Pacific Islander          0.79 (0.57–1.09) 0.2468 1.16 (0.84–1.60) 0.7294 1.28 (0.99–1.64)       0.0122 0.84 (0.67–1.05) 0.0821 
           
Sex           
Male     0.93 (0.77–1.12)  0.89 (0.73–1.08)  1.17 (0.99–1.38)  1.06 (0.92–1.21)  
Female   1.0 (reference) 0.4455 1.0 (reference) 0.2287 1.0 (reference) 0.0734 1.0 (reference) 0.4152 
           
Neighbourhood socioeconomic status (quintiles)        
1. Lowest 20%   0.88 (0.63–1.22)  1.11 (0.80–1.53)  1.26 (0.94–1.68)  1.19 (0.94–1.51)  
2.   1.07 (0.77–1.47)  0.96 (0.69–1.32)  1.03 (0.77–1.38)  1.21 (0.96–1.53)  
3. Middle 20%   0.86 (0.63–1.20)  0.93 (0.66–1.30)  1.14 (0.86–1.52)  1.31 (1.05–1.53)  
4.   0.83 (0.59–1.17)  0.82 (0.58–1.16)  0.84 (0.62–1.14)  1.31 (1.04–1.64)  
5. Highest 20%   1.0 (reference) 0.4063 1.0 (reference) 0.4579 1.0 (reference) 0.0583 1.0 (reference) 0.1260 
       
Initial care at hospitals affiliated with NCI-designated cancer centres      
Yes   1.0 (reference)  1.0 (reference)  1.0 (reference)  1.0 (reference)  
No   1.10 (0.91–1.32) 0.3314 1.29 (1.03–1.61) 0.0220 1.11 (0.90–1.37) 0.3310 1.31 (1.08–1.58) 0.0042 
           
Abbreviations: HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified; NCI, National Cancer Institute. *Likelihood ratio test.  
  253 
Table 7.5 Relation of sociodemographic and clinical factors to the hazard of death after acute myeloid leukaemia by age group at diagnosis, including health 
insurance status, California, 1996–2011 
Characteristics 
(Total = 2632) 
  HR1 (95% CI) 
0–9 years 
N = 671 
P-value* HR2 (95% CI) 
10–19 years 
N = 510 
P-value* HR3 (95% CI) 
20–29 years 
N = 619 
P-value* HR4 (95% CI) 
30–39 years 
N = 832 
P-value* 
Calendar period           
1996–2003    1.31 (1.02–1.68)  1.28 (0.99–1.64)  0.92 (0.74–1.15)  1.13 (0.94–1.36)  
2004–2011    1.0 (reference) 0.0308 1.0 (reference) 0.0580 1.0 (reference) 0.4640 1.0 (reference) 0.2000 
           
Race/ethnicity           
Non-Hispanic white   1.0 (reference)  1.0 (reference)  1.0 (reference)  1.0 (reference)  
Non-Hispanic black   1.63 (1.04–2.57)  1.23 (0.74–2.05)  1.95 (1.17–3.25)  1.11 (0.78–1.56)  
Hispanic   1.27 (0.93–1.72)  1.05 (0.76–1.44)  1.17 (0.88–1.56)  0.99 (0.79–1.24)  
Asian/Pacific Islander         0.87 (0.55–1.36) 0.0821 1.01 (0.66–1.55) 0.8872 1.40 (1.01–1.92) 0.0392 0.83 (0.62–1.11) 0.4981 
           
Sex           
Male     0.89 (0.70–1.12)  0.84 (0.65–1.08)  1.08 (0.86–1.35)  1.06 (0.88–1.27)  
Female   1.0 (reference) 0.3220 1.0 (reference) 0.1688 1.0 (reference) 0.5054 1.0 (reference) 0.5343 
           
Neighbourhood socioeconomic status (quintiles)        
1. Lowest 20%   0.92 (0.59–1.43)  1.12 (0.71–0.78)  1.37 (0.92–2.04)  1.34 (0.95–1.88)  
2.   1.16 (0.76–1.77)  0.92 (0.59–1.44)  1.03 (0.69–1.53)  1.56 (1.14–2.15)  
3. Middle 20%   1.02 (0.67–1.56)  0.99 (0.64–1.53)  1.21 (0.82–1.78)  1.76 (1.28–2.42)  
4.   0.92 (0.59–1.45)  0.87 (0.54–1.40)  0.77 (0.51–1.16)  1.60 (1.17–2.20)  
5. Highest 20%   1.0 (reference) 0.6758 1.0 (reference) 0.7838 1.0 (reference) 0.0281 1.0 (reference) 0.0035 
       
Initial care at hospitals affiliated with NCI-designated cancer centres      
Yes   1.0 (reference)  1.0 (reference)  1.0 (reference)  1.0 (reference)  
No   1.12 (0.88–1.43) 0.3512 1.44 (1.09–1.90) 0.0078 1.24 (0.93–1.66) 0.1414 1.39 (1.08–1.80) 0.0095 
           
Health insurance status       
None   1.60 (0.63–4.02)  1.78 (0.85–3.75)  0.94 (0.57–1.55)  1.78 (1.14–2.76)  
Public   0.93 (0.69–1.25)  1.21 (0.90–1.64)  0.99 (0.77–1.27)  1.10 (0.90–1.36)  
Private   1.0 (reference)  1.0 (reference)  1.0 (reference)  1.0 (reference)  
Unknown/NOS   1.21 (0.83–1.75) 0.4384 1.35 (0.92–1.99) 0.2399 1.45 (1.02–2.07) 0.1965 1.17 (0.86–1.59) 0.0986 
           
Abbreviations: HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified; NCI, National Cancer Institute. *Likelihood ratio test.  
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Figure 7.1 Overall survival after acute myeloid leukemia by age group at diagnosis, in 
California, 1988–2011 (percentages in the graph correspond to 10-year survival) 
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7.3 The incidence of acute myeloid leukaemia in children, 
adolescents and young adults in California 
For acute myeloid leukaemia (AML non-APL), there is no statistical evidence of an 
annual increase in incidence rates since 1988 for any race (Table 7.6). The 
incidence rates and annual percentage change (APC) were calculated using 
SEER*Stat v.8.3.1 (http://seer.cancer.gov/seerstat/). 
 
Table 7.6: Age-adjusted incidence rates (per 1,000,000) and annual percentage change of acute 
myeloid leukaemia, by race/ethnicity, in children aged 0–39 years, California, 1988–2011. 
 White Black Hispanic Asian 
 
IR (95% CI) IR (95% CI)  IR (95% CI) IR (95% CI) 
Total 8.5 (8.1–9.0) 8.4 (7.4–9.4) 8.6 (8.2–9.0) 9.3 (8.5–10.1) 
1988 9.5 (7.7–11.7) 5.6 (2.4–11.1) 8.1 (5.9–10.9) 9.1 (5.1–14.8) 
1989 8.4 (6.7–10.5) 7.2 (3.7–12.7) 8.5 (6.3–11.2) 9.1 (5.1–14.8) 
1990 7.6 (6.0–9.6) 11.1 (6.3–18.1) 10.5 (8.0–13.4) 9.7 (5.8–15.4) 
1991 6.5 (5.0–8.3) 14.0 (8.5–21.6) 8.1 (6.0–10.7) 12.1 (7.7–18.0) 
1992 8.9 (7.1–11.0) 9.2 (5.1–15.3) 8.4 (6.3–10.9) 8.4 (5.0–13.3) 
1993 7.9 (6.2–10.0) 12.3 (7.3–19.2) 8.5 (6.5–11.1) 11.3 (7.3–16.8) 
1994 9.3 (7.4–11.5) 7.1 (3.5–12.8) 8.0 (6.0–10.4) 10.9 (7.0–16.2) 
1995 9.8 (7.9–12.1) 4.3 (1.7–8.9) 7.4 (5.5–9.7) 5.5 (2.9–9.5) 
1996 6.7 (5.1–8.7) 11.1 (6.5–17.9) 8.3 (6.3–10.6) 12.1 (8.0–17.6) 
1997 8.1 (6.3–10.2) 7.3 (3.6–13.1) 10.7 (8.4–13.3) 8.54 (5.2–13.2) 
1998 9.1 (7.2–11.4) 11.0 (6.4–17.7) 8.9 (6.9–11.3) 7.8 (4.7–12.3) 
1999 11.3 (9.1–13.9) 9.3 (5.1–15.6) 8.2 (6.3–10.4) 10.4 (6.5–15.3) 
2000 7.1 (5.4–9.2) 9.4 (5.2–15.9) 7.9 (6.1–10.1) 7.1 (4.2–11.3) 
2001 8.3 (6.4–10.5) 6.8 (3.3–12.6) 9.0 (7.1–11.2) 7.7 (4.6–12.0) 
2002 9.5 (7.4–11.9) 10.8 (6.2–17.6) 7.2 (5.5–9.2) 7.8 (4.8–12.1) 
2003 7.0 (5.3–9.1) 7.2 (3.5–13.2) 9.7 (7.7–12.0) 8.0 (4.9–12.1) 
2004 6.7 (5.0–8.9) 7.7 (3.8–13.8) 7.7 (6.0–10.0) 9.5 (6.0–14.2) 
2005 8.5 (6.5–10.9) 7.3 (3.6–13.2) 8.2 (6.4–10.2) 7.6 (4.7–11.7) 
2006 8.0 (6.1–10.3) 4.2 (1.5–9.1) 9.1 (7.3–11.3) 9.0 (5.8–13.2) 
2007 10.4 (8.1–13.0) 4.4 (1.6–9.7) 8.5 (6.7–10.6) 9.3 (6.1–13.6) 
2008 11.0 (8.7–13.7) 7.4 (3.5–13.6) 7.6 (5.9–9.6) 8.2 (5.1–12.3) 
2009 8.7 (6.6–11.1) 8.6 (4.4–15.0) 9.7 (7.8–11.9) 8.4 (5.4–12.6) 
2010 9.3 (7.1–11.9) 6.9 (3.1–13.2) 8.2 (6.5–10.2) 12.1 (8.3–16.9) 
2011 8.1 (6.1–10.6) 8.8 (4.2–15.9) 10.0 (8.1–12.2) 9.23 (6.0–13.5) 
APC (%) (95% CI)  
p-value 
0.4 (-0.6–1.3) 
0.44 
-1.5 (-3.3–0.3) 
0.10 
0.1 (-0.5–0.8) 
0.67 
-1.0 (0.1– -2.2) 
0.12 
Abbreviations: APC, annual percentage change; CI, confidence interval; IR, incidence rates. 
Patients of American Indian (small numbers) or unknown race/ethnicity were excluded. 
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Figure 7.2: Age adjusted incidence rates of acute myeloid leukaemia (per  
1,000,000), by race/ethnicity, for patients aged 0–39 years, California, 1988–2011. 
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Chapter 8 Discussion  
 
"Of all the forms of inequality, injustice in health is the 
most shocking and inhumane" 
 
Dr Martin Luther King, Jr. 
(Speech to the Medical Committee for Human Rights, 1966) 
 
8.1 Introduction 
In the last 50 years, national and international clinical trials have allowed dramatic 
improvements in survival after acute leukaemia in children, adolescents and young 
adults. However, the treatment of some high-risk subtypes of acute lymphoblastic 
leukaemia and management of acute myeloid leukaemia (APL and non-APL AML) 
remain challenging, and acute leukaemia is currently the leading cause of cancer 
death among patients aged 39 years or younger in the developed world.2, 3 Strikingly, 
inequalities in outcomes continue to be reported, particularly among patients from 
different socioeconomic, racial/ethnic and age groups.  
Funded by the Children with Cancer UK, this thesis had, initially, the primary 
goal to investigate how survival among children and adolescents with the most 
frequent type of malignancy, acute lymphoblastic leukaemia, has varied over a long 
period of follow-up in California. In addition, I aimed at investigating the predictors of 
survival inequalities in this high-resource State of the United States. 
 During my literature review, I realised that the knowledge about early death 
and survival after acute promyelocytic leukaemia and acute myeloid leukaemia (non-
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APL) is mainly based on clinical trials in the United States10 and Europe,186 with a 
lack of population-based studies for the young adult population. In 2011, Lehmann et 
al.186 reported very high early death after acute promyelocytic leukaemia in a 
population-based study in Sweden that included 105 unselected patients aged 19 
years or older, at 6.4 years median follow-up time. The authors concluded 
“population-based data are needed as a supplement to data from large randomised 
trials for information about the overall APL population”. Therefore, I opted to study 
early death and survival after APL and non-APL AML extending the age range to 
young adults (20–39 years). APL is very rare under 3 years of age, its incidence 
increases until adulthood and remains basically constant up to 60 years, when it 
begins to decline.180, 181 Conversely, non-APL AML increases sharply with age.236 
The study of survival among older adults with APL and non-APL AML is of great 
interest, however this was not the subject of my thesis and may be considered in my 
future studies. Considering these factors, I focused my thesis on the health 
outcomes of patients aged up to 19 years for ALL and up to 39 years for APL and 
non-APL AML. 
 
 The primary goals of this thesis were to evaluate trends in outcomes (survival 
and, when appropriate, early death) in children, adolescents and young adults with 
acute leukaemia in California during nearly 25 years, and to investigate the main 
predictors of outcomes. These overall goals were achieved by focusing on the 
following specific objectives: 
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1. To evaluate survival trends after acute lymphoblastic leukaemia in children and 
adolescents (0–19 years), and examine the association of survival with 
sociodemographic and selected clinical factors. 
2. To investigate early death and survival after acute promyelocytic leukaemia 
among patients aged 0–39 years before and after the approval by the US FDA of all-
trans retinoic acid (November 1995), and to evaluate the association of various 
sociodemographic and clinical factors with these two outcomes. 
3- To evaluate survival and early death trends after acute myeloid leukaemia 
(excluding acute promyelocytic leukaemia) among patients aged 0–39 years, and 
examine the influence of sociodemographic and selected clinical factors on these 
outcomes.  
 In the next sections, I summarise the main results of my thesis providing a 
critical review of these findings (section 8.2), and discuss the main contributions of 
my work to the field of paediatric and young adult haematology, as well as the 
implications for policy makers and researchers (section 8.3). Next, I consider the 
relationship between socioeconomic status, race/ethnicity and survival, and discuss 
an alternative analytical approach apart from those I have chosen for my studies 
(section 8.4). Finally, I consider the limitations of my studies (section 8.5), discuss 
my future research plans (section 8.6) and give the concluding remarks (section 8.7). 
 
8.2 Overall findings of the thesis 
The literature review (Chapter 3) highlighted the need for further studies aimed at 
investigating whether the survival inequalities by age (children, adolescents and 
young adults) observed among patients with acute leukaemia have decreased over 
time.  
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 In addition, it raised a question about the extent to which paediatric protocols 
have been adopted by adult haematologists to treat older patients (15–39 years) with 
acute lymphoblastic leukaemia. 
  This review also emphasised the value of more population-based studies to 
learn whether the improvement in survival and trends in early death after acute 
myeloid leukaemia observed in clinical trials can be generalised to the entire 
population in the United States and elsewhere.  
 Finally, reports of inequalities in survival and early death among different 
racial/ethnic and socioeconomic groups within and between countries revealed the 
need for further studies to identify the main predictors of outcomes. 
  Research paper 1 (Chapter 5) revealed remarkable improvement in survival 
in children and adolescents with acute lymphoblastic leukaemia in California during 
1988–2011. Similar to previous studies, infants (< 1 year) and older children (10–19 
years) fared worse than children aged 1–9 years. However, even after adjustment for 
other covariates, socioeconomic and racial/ethnic survival inequalities existed and 
persisted over time. Non-white patients had worse survival than white patients, with 
the most striking differences observed among blacks and Hispanics. In addition, 
patients living in the lowest socioeconomic neighbourhoods had lower survival than 
those living in the highest socioeconomic neighbourhoods.  
 Moreover, my study revealed the proportion of patients who developed 
secondary neoplasm (1.8%) after treatment of childhood acute lymphoblastic 
leukaemia during a long period of follow-up (nearly 25 years). This finding is 
consistent with previous reports in the literature which showed that the incidence of 
secondary malignancy varied from less than 1% to 10% in this population.299, 361-367 
The variability of these findings has been attributed to differences in therapeutic 
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protocols, accuracy in the reports and completeness of follow-up.298 The majority of 
these reports come from clinical trials in developed countries, emphasizing the 
importance of also collecting this information at the population level, especially in 
low- and middle-income countries. This will require improvement in cancer 
registration in these countries.  
 In this study, access to care measured through health insurance status and 
treatment facility (whether a paediatric cancer centre or not) did not have a 
significant association with survival. This may be explained by the fact that all 
children and adolescents with cancer in California are entitled to health coverage 
through the California Children’s Service and they tend to be referred to hospitals 
where they can get treatment, even if they are undocumented immigrants. 
  The majority of patients (~70%) with ALL received initial care at specialised 
paediatric cancer centres where they are usually enrolled in COG clinical trials and 
receive standardised therapeutic protocols. I did not find an association between 
survival and treatment facility (whether it was a cancer centre or not), but this may be 
because data available in the California Cancer Registry refer to the treatment facility 
where the patient received initial care. Therefore, it is possible that some patients 
diagnosed at a non-specialised cancer centre may later have been transferred to a 
specialised hospital for further investigation or treatment. 
 These findings suggest that the racial/ethnic and socioeconomic inequalities 
observed in my study cannot be solely explained by access to care. In fact, in the 
UK, where all children have access to standard treatment though the National Health 
Service (NHS), socioeconomic inequalities have also been reported. In a national 
population-based study,120 inequalities were worse during the maintenance phase of 
therapy when most treatment is given at home (combination therapy), with a monthly 
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outpatient visit. This suggests that even in developed nations with universal health 
systems, adherence to treatment can be a major issue.  
 Adherence to treatment may have contributed to the survival inequalities 
observed in my study, but there were no data on this to allow an investigation. In the 
US, one study309 demonstrated that when adherence to oral 6-mercaptopurine (a 
medication that should be taken daily during the two-year maintenance phase) was 
below 90% in children and adolescents aged 1–19 years with ALL, the risk of relapse 
was increased 3-fold. Additionally, 31% of relapses were attributable to non-
adherence. Interestingly, the authors found that a higher proportion of non-adherers 
were black and Asian patients compared to non-Hispanic white patients. Among 
blacks and Asians, race-specific sociodemographic factors such as low maternal 
education, single-parent/multiple-children families and low-income families without 
mothers as full-time caregivers, were associated with low adherence to treatment. 
Another study368 revealed that Hispanic patients also had lower compliance to oral 6-
mercaptopurine regimens and a higher risk of relapse than white patients. These 
studies support previous evidence that race/ethnicity and SES in the US are 
intimately related.369, 370  
 
Undocumented immigrants 
California has more than 10 million immigrants, corresponding to about 27% of the 
State population, about twice the US national proportion. Approximately 47% of 
foreign-born residents in California are naturalized US citizens, 26% have a green 
card or another type of visa, and about 26% are undocumented. The majority of 
immigrants are from Latin America (53%), but recently more immigrants have come 
from Asia (37%).371 California immigrants are more likely than US-born families to 
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live in poverty (below 200% of the federal poverty level threshold, Table 8.1). Factors 
such as lower education, lack of awareness about the seriousness of acute 
leukaemia, fear of legal problems among undocumented immigrants and financial 
problems may all lead parents to delay taking their children to the doctor. It is not 
uncommon for patients to miss hospital appointments during the long and complex 
treatment of ALL, for a variety of social, cultural and economic reasons. All these 
factors, together with disease biology, may have contributed to the survival 
inequalities observed in this vulnerable, disadvantaged population of California. The 
data used on my thesis have no information on the legal status of immigrants.  
 
Table 8.1 Children under 18 years living in low-income families (below 200% of 
poverty level threshold) by family nativity in California. Source: Adapted from 
National Kids Count (http://datacenter.kidscount.org/data).
†
 
Children in 
Immigrant 
Families 
Data 
Type 
2010 2011 2012 2013 2014 
Children in 
immigrant 
families 
Number  2.502,000 2,513,000 2,506,000 2.427,000 2,376,000 
Percent 56% 57% 56% 56% 55% 
Children in 
US-born 
families 
Number  1,732,000 1.824,000 1,825,000 1,844,000 1,722,000 
Percent 37% 39% 39% 39% 38% 
 
 Research paper 2 (Chapter 6) showed substantial improvement in early 
death (30-day mortality) and survival after acute promyelocytic leukaemia in patients 
aged 0–39 years after the introduction of all-trans retinoic acid (1996 onwards, the 
ATRA era) compared with patients treated in the pre-ATRA era (1988–1995) in 
California. However, compared with levels reported in clinical trials (3%–8%), early 
death remained high even in the most recent calendar period (14% in 2004–2011).  
                                            
†
 Based on the Population the US Census Bureau, Census 2000 Supplementary Survey, 2001 Supplementary 
Survey, 2002 through 2014 American Community Survey. 
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 The majority of patients who had early death died within the first week of 
diagnosis, and there was no evidence of improvement in 7-day mortality over time. 
When patients who died within 7 days of diagnosis were excluded from the analysis, 
early death results (the proportion who died within 8–30 days of diagnosis) were 
similar to those reported in clinical trials. Likewise, when patients who died within 30 
days were excluded from the analysis, survival after acute promyelocytic leukaemia 
was close to that described in trials. These findings, of similar outcomes only when 
subgroups were excluded, highlight that bias in survival estimates (usually 
overestimation) may occur when evaluating selected patients, because high-risk and 
very ill patients are not usually enrolled in clinical trials. Importantly, this study 
showed that, at the population-base level, many young patients in California still die 
from APL, a highly curable disease. The main predictors of worse survival and early 
death in this study were Hispanic and black race/ethnicity and lack of health 
insurance (for patients diagnosed during 1996–2011). Delay in diagnosis and 
treatment delays of more than 2 days after diagnosis of APL may be the main reason 
7-day and 30-day mortality were persistently high in California during the study 
period. 
 
Lack of insurance for young adults and undocumented immigrants in California 
 California has about 2.7 million undocumented immigrants, mostly from Latin 
America. Of these, approximately 1.5 million are uninsured.372 Some undocumented 
immigrants who have insurance (approximately 30%–40%) may be covered by their 
employers or buy their insurance on the individual market. The remaining 60% to 
70% of young adult documented immigrants who are uninsured, have very few 
health care options. County governments can choose whether to offer health 
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insurance for this population through indigent programs. Of relevance, it has been 
estimated that about 875,000 undocumented immigrants live in counties that do not 
offer health care through the indigent care program.372 Currently, California counties 
that offer health care for the uninsured immigrants are: San Francisco, San Mateo, 
Santa Cruz, Alameda, Santa Clara, Contra Costa, Fresno, Kern, Ventura, Los 
Angeles and Riverside. The safety net providers (mostly community clinics and 
emergency departments) provide care for patients regardless their immigration 
status, however, they do not provide comprehensive health care. 
 According to a new survey, about 68% of California adults who were 
previously uninsured, have obtained health insurance since the implementation of 
the national Affordable Care Act (ACA). Eligible Hispanics and whites gained 
coverage at similar rates. However, despite the health insurance expansion that has 
occurred after the implementation of the ACA in 2014, undocumented immigrants 
were excluded from enrolment. It is estimated that Hispanics still comprise 41% of 
remaining uninsured individuals (Figure 8.1). 
 In June 2015, the California Senate approved a bill that will allow many 
undocumented immigrants to enrol in special healthcare programs aimed to offering 
the same benefits as Medi-Cal (http://www.latimes.com/local/political). This measure 
will allow approximately 240,000 children to enroll to Medi-Cal and some low-income 
adults to enrol to a health plan that provide similar services than Medi-Cal. If this 
measure is effectively implemented, it may significantly improve access to care for 
undocumented immigrants with several diseases, including cancer. Consequently, it 
is expected that the increase in health insurance coverage through the full 
implementation of the Affordable Car Act will improve access to care for young 
adults with cancer and, hopefully, decrease mortality from this disease. 
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Figure 8.1: Demographics of California’s remaining uninsured population by race/ethnicity. 
“Eligible” refers to individuals who are eligible for enrolment in the Affordable Care Act (ACA) based 
on their immigration status (citizen, permanent resident, or legally present immigrant). 
“Undocumented” are those individuals who are not eligible to apply for ACA due to their immigration 
status. Adapted from Wave 3 of the Kaiser Family Foundation California Longitudinal Panel Survey 
(February 18–May 13, 2015) (www.kff.org). 
 
 Research paper 3 (Chapter 7) demonstrated that despite survival 
improvements after acute myeloid leukaemia (non-APL) in children, adolescents and 
young adults (0–39 years) in the last 25 years, 5-year survival has remained at only 
50% or less in the modern era of treatment (2004–2011). There was a trend towards 
a decline in early death over the study period. The main factors associated with 
lower survival were older age (> 9 years), treatment at non-specialised cancer 
centres, black race/ethnicity and lack of health insurance (for patients diagnosed 
during 1996–2011). My findings also suggested that the impact of these factors on 
survival varied by age group, with stronger associations among older patients (10–39 
years).  
 This study on non-APL AML has revealed an association between treatment 
at specialised cancer centres and survival, which was not found in the APL study. 
Whites 
 17% 
Eligible 
 Hispanics  
29% 
Undocumented 
Hispanics 
 41% 
Other  
9% 
Blacks 4% 
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Whereas APL has an established effective treatment with ATRA and/or arsenic 
combined with chemotherapy, non-APL AML is a very heterogeneous disease and 
more effective and less toxic drugs are, hopefully, still to be discovered. 
Haematopoietic stem cell transplantation may be a crucial treatment option in many 
cases. Because of the complexity of this treatment, it requires a multidisciplinary 
team and a specialised cancer centre. The complexity of non-APL AML treatment 
may, in part, explain the worse survival among patients who were not treated in 
these centres. 
 Similarly to the ALL and APL studies, black patients with non-APL AML fared 
worse than whites. In addition to the influence of sociodemographic and economic 
factors on survival inequalities previously discussed, lower availability of matched 
family bone marrow donors may be a possible explanation for the survival gap 
between black and white patients, as reported by a number of studies.373, 374 
 
8.3 Main contributions of the thesis and implications for policy 
makers and researchers 
The work of this thesis provides important information for clinicians, researchers and 
policy makers who aim to improve the long-term survival of children, adolescents 
and young adults with acute leukaemia. The main contributions of my thesis are 
highlighted below. 
 The results of my literature review and research paper 1 (Chapter 5) show 
persistent racial/ethnic and socioeconomic survival inequalities for patients with 
acute lymphoblastic leukaemia. This calls for actions and programmes to decrease 
the survival gap between these subgroups of patients. This may include, but is not 
limited to, prompt access to adequate therapy, better education of parents and 
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patients about the severity and prognosis of the disease, comprehensive 
psychosocial support, and monitoring of treatment compliance. Economic support for 
parents who need to stop working to care for their children may be warranted. 
 Moreover, reports of significantly worse survival among adolescents and 
young adults with acute lymphoblastic leukaemia should be further investigated. 
Have adolescents and young adults with ALL been treated by adult oncologists 
adhering to paediatric protocols, as studies have shown that they are more effective 
and improve survival? A pilot population-based study recently performed in Northern 
California showed that, as recently as 2014, fewer than 25% of adolescents and 
young adults with ALL were treated with paediatric protocols at adult centres. I am a 
co-author of a paper titled "Adoption of Pediatric-Inspired Acute Lymphoblastic 
Leukemia Regimens by Adult Oncologists Treating Adolescents and Young Adults: A 
Population-Based Study", which was recently submitted to a peer-reviewed journal 
and the abstract was accepted for poster presentation at the 2016 American Society 
of Clinical Oncology (ASCO) annual meeting. 
 The findings of my second study on early death after acute promyelocytic 
leukaemia showed that, at the population-based level, early death has decreased, 
but is still high in the more recent era of treatment. My results also revealed worse 
outcomes for patients of Hispanic and black race/ethnicity and those without health 
insurance, pointing to an unmet need to address inequalities among vulnerable 
patients. This may include wider insurance coverage and access to optimal care. 
Moreover, health care providers should be educated to recognise acute 
promyelocytic leukaemia as an emergency that needs immediate initiation of therapy 
with ATRA as soon as this disease is suspected. Of great relevance, hospital 
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administrators and pharmacists should make sure that ATRA is available for prompt 
use when requested by physicians. 
 The results from my third study demonstrated that survival from acute myeloid 
leukaemia, excluding acute promyelocytic leukaemia, remains low in the most recent 
era of treatment. In this high-resource country, young acute myeloid leukaemia 
patients with health insurance (private or public) and those who received initial 
treatment at hospitals affiliated with NCI-designated cancer centres had better 
survival than those without health insurance or treated at non-specialised centres. 
These results support the increasing evidence that young patients with acute 
myeloid leukaemia have better outcomes when treated in academic, tertiary or 
specialised centres than when they receive treatment at community hospitals.18, 310, 
375, 376 This may be explained, in part, by the way university hospitals and specialised 
cancer centres rely on a multidisciplinary team comprised of board-certified 
paediatric haematologists/oncologists, paediatric oncology nurses, radiologists, 
surgeons pathologists as well as paediatric subspecialists.375 This approach also 
includes comprehensive psychosocial support, which is vital due to the heavy burden 
caused by this disease to patients and their families.  
 Furthermore, my findings emphasise the need for further genotypic and 
phenotypic research studies aimed at identifying patients who respond to targeted 
therapies. Risk-adapted therapy (or precision medicine) is expected to lead to more 
effective and less toxic treatment resulting in better survival than that currently 
achieved with conventional chemotherapy.377  
  The majority of population-based cancer registries worldwide do not provide 
data on various important variables such as leukaemia immunophenotype (e.g., B- 
or T-cell ALL), race/ethnicity (particularly on Hispanic and Asian patients), 
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socioeconomic status, health insurance status, cause of death, type of treatment 
facility at diagnosis, secondary tumours, and treatment. In this thesis, I used high-
quality data from one of the world’s largest population-based cancer registries, which 
has all these variables, except detailed information on treatment. Therefore, when I 
investigated survival and early death after leukaemia, I could simultaneously adjust 
for many variables that are recognised to influence outcome (section 4.4). The racial 
and ethnic diversity of the Californian population, along with the long period of 
observation, allowed for comparison of outcomes between different racial/ethnic 
groups of patients. This is especially relevant for acute leukaemia due to a higher 
incidence and often worse prognosis of this disease among Hispanics. Also, data 
from clinical trials are limited by the unequal participation of patients by 
race/ethnicity. Thus, differences in survival observed in clinical trials may be 
influenced by inadequate representation of some patient subgroups.114, 155 
 Moreover, in contrast with most cancer registries worldwide, the California 
Cancer Registry provides information on full dates (day, month and year) of birth, 
diagnosis and last known vital status, with nearly complete data. Therefore, it was 
possible to estimate the specific time points when death occurred within the first 
month after diagnosis. This enabled me to present data on 7-day mortality for acute 
promyelocytic leukaemia and showed that there was no improvement over time, 
identifying an area for improvement. 
 Because of the high-quality data available in the California Cancer Registry, 
the large sample sizes I used, and long-term of observations in my studies, it is 
reasonable to assume that my findings are generalizable to the rest of the US 
population and, probably, to other nations. However, because different countries 
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have diverse racial/ethnic distributions and different healthcare systems, some of the 
relationships I found may differ in different countries. 
 In a very recent national large population-based study378 (not shown in this 
thesis) in which I have collaborated, we investigated survival of children, adolescents 
and young adults (0–39 years) with ALL, AML and Hodgkin lymphoma (HL) by age 
and race/ethnicity during almost four decades (1975–2012) in the US. Using SEER 
data, we found that survival improved significantly for ALL, AML and HL. 
Nonetheless, survival inequalities persisted between white and non-white patients, 
and between children and adolescents and young adults. This recent work has 
shown that same associations found in my thesis also persisted in a larger study and 
for another disease (HL) supporting the generalizability of my thesis work. The 
correspondent paper titled “Racial disparities in the survival of American children, 
adolescents and young adults with acute lymphoblastic leukemia, acute 
myelogenous leukemia and Hodgkin lymphoma” was accepted for publication in 
Cancer in April 2016 and is currently in press.  
 In summary, my main messages for policy makers are that substantial 
survival inequalities persist among patients with acute leukaemia in California 
leading to a considerable number of probably preventable deaths among children, 
adolescents and young adults. My, and various other studies, cited in this thesis 
provide compelling evidence that treatment, treatment adherence, sociodemographic 
and economic factors largely contribute to the survival differences observed among 
vulnerable patients. Therefore, priorities should be set and actions taken. Improving 
health insurance coverage for vulnerable patients – those living in low SES 
neighbourhoods, of black and Hispanic race/ethnicity, and undocumented 
immigrants – are likely to improve access to care and outcomes. However, the 
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quality of care provided for these patients is of extreme relevance because 
leukaemia is a complex disease that needs a multidisciplinary and highly skilled 
team of health professionals to manage potential fatal treatment complications, such 
as sepsis and hemorrhage. Thus, it is advisable that leukaemia patients receive 
treatment at specialised cancer centres with outstanding supportive care.  
 Additionally, all effort should be made to improve enrolment of adolescents 
and young adults in clinical trials, which have long been considered a “gold standard” 
for treatment of leukaemia and other malignancies. Low enrolment in clinical trials 
may partially explain the lower survival among adolescents and young adults 
compared with children with acute leukaemia. Also, the barriers that prevent adult 
haematologists from treating adolescents and young adults with acute lymphoblastic 
leukaemia following more effective paediatric regimens should be urgently 
investigated, so strategies to improve adherence to paediatric protocols can be 
implemented, and would likely save the lives of many young patients. 
 Finally, continuous surveillance is warranted to examine whether survival 
improvements occur in the modern era of treatment (precision medicine) and after 
the implementation of the Affordable Care Act, which is likely to increase insurance 
coverage among less privileged young adults and facilitate access to costly cancer 
treatment.228 The expectation that better access to care will lead to better health 
outcomes is based on the assumption that coverage under the Affordable Care Act 
will be comparable to private insurance or Medicare. The costs of cancer care are 
growing faster than various other areas of medicine.379 Medi-Cal expenditures 
increased from approximately 3 billion in 2011 to more than 6 billion dollars in 
2014.244 Yet, a recent study244 using CCR data showed that patients with cancer who 
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had Medi-Cal or Medi-Cal dual eligibility did not have better outcomes than 
uninsured patients.  
This is concerning and emphasises the need for close assessment of the equality of 
care provided by hospitals and physicians, and monitoring of health outcomes 
among patients covered by Medi-Cal. In this regard, it is crucial to link the data 
obtained by the California Cancer Registry to clinical information and insurance 
claims data. A press released on 18 February 2016 highlights the results of my third 
study on AML and emphasize some of the recommendations mentioned above. A 
copy in PDF of the press release is presented in Appendix 7.  
 
8.4 Further discussions on investigating the relationship between 
socioeconomic, race/ethnicity and survival 
In my studies, I found dramatic survival inequalities by race/ethnicity, with survival 
disadvantage for blacks (also called African Americans) in all three studies. This 
corroborates earlier reports which have shown that, in the US, blacks have higher 
mortality rates than whites in almost all ages and for all major diseases, including 
cancer.370 Compared with whites, survival was also substantially lower among 
Hispanics with ALL and APL, but not among Hispanics with AML.  
Acute leukaemia outcomes also differed substantially by neighbourhoods 
SES. For ALL and AML, survival and early death, respectively, were worse for 
patients living in the lower SES neighbourhoods compared to those living in the 
higher neighbourhoods. These racial/ethnic and SES survival and early death 
differences persisted even after adjustment for all variables in the multivariate Cox 
models including age, sex, health insurance status and treatment facility. All these 
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variables were considered because of a priori hypothesized or previously observed 
associations with early death or survival.18, 226, 228, 324, 346, 347   
 In the United States, it has been well recognized that race is closely related to 
SES and these two factors are related to survival from cancer and other diseases.370, 
380, 381 In my studies, I controlled for race/ethnicity and SES in the same multivariate 
model and observed that the survival differences between patients of different 
race/ethnicity and neighbourhoods SES persisted over time.  
Figure 8.2 is a causal diagram showing the possible relationships between the 
explanatory variables used in my models, and survival. This suggests that SES is on 
the causal pathway between race/ethnicity and survival. Similarly, health insurance 
status and treatment facility are also on the causal pathway between race/ethnicity 
and survival. By including these mediator variables in the multivariable models, the 
adjusted estimated association between race/ethnicity and survival may be 
considered an indirect effect of race/ethnicity on survival. Age, sex and race/ethnicity 
are assumed to be confounders of the associations between SES and survival, and 
between health insurance status and treatment facility and survival.  
The fact that I found an association between race/ethnicity and survival after 
adjustment for the other variables mentioned above suggests that the effect of 
race/ethnicity on survival is not only due to SES, health insurance status and 
treatment facility. There is therefore evidence that other factors related to 
race/ethnicity contributed to the survival inequalities. One possibility is disease 
biology, which was discussed in chapters 3 and 5–7 of this thesis. However, biology 
does not fully explain all survival differences between young patients of different 
race/ethnicity. Differences in quality of care provided to patients with leukaemia are 
likely to explain part of the survival gap. 
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 Similarly, the associations I found between SES and survival after controlling 
for health insurance status and treatment facility (variables that are on the causal 
pathway between SES and survival), suggests that SES is not totally mediated 
through health insurance and treatment centre. 
Several researchers have argued that race/ethnicity is a determinant of social 
class.370, 382 However, differences in health outcomes cannot be solely explained by 
socioeconomic variables such as income, education, etc., because these factors do 
not fully explain causality.381 When race/ethnicity and SES are included together in a 
multivariate model, it may result in an “over-adjustment” and the effect of 
race/ethnicity or SES, respectively, on survival can be, in fact, underestimated.  
 An alternative approach to the multivariate models I used in my studies would 
be to perform a formal mediation analysis383, 384 which takes into account that SES, 
health insurance status and treatment facility are on the causal pathway between 
race/ethnicity and survival. The mediation analysis could disentangle the direct 
effects of race/ethnicity on survival from those that are mediated via SES, health 
insurance status and treatment facility. Similarly such analysis could disentangle the 
direct effects of SES on survival from those mediated via health insurance status and 
treatment facility. 
 
 
 
 
 
 
 
 
 
 
 Age, Sex and  
Race /ethnicity 
 Health insurance status and 
treatment facility 
 Socioeconomic status   Survival 
Figure 8.2: Causal diagram showing measured confounders of the exposure, mediators 
and outcome.  
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8.5 Limitations 
8.5.1 Limitations of the data 
The data used for the investigations presented in this thesis have a few limitations, 
which are mostly due to the lack of clinical data associated with the prognosis of 
acute leukaemia and detailed information on treatment. These data are not routinely 
collected by population-based cancer registries, thus it was not possible to control for 
these factors in the analyses. The relevant variables not available are described 
below. Figure 8.3 illustrates the strengths and weaknesses of cancer registry data, 
such as the California Cancer Registry. 
 
 
 
Figure 8.3: Population-based cancer registries data strengths and weaknesses. Adapted from 
California HealthCare Foundation and Hiatt et al., J Natl Cancer Inst 2015.
385
 Cancer registries 
capture a wealth of information on diagnosis and survival, and some information on the first 
round of treatment, but nothing related to recurrence or to subsequent surgery or other 
treatments.  
 
Information on relapse is relevant because patients who relapse after 
complete treatment for acute leukaemia are known to have a very poor prognosis. 
Therefore, the occurrence of relapse and time to relapse after chemotherapy or 
haematopoietic stem cell transplantation is highly predictive of outcome and is 
commonly used to guide further treatment approaches. Data on relapse demands 
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repetitive active follow-up of a large number of patients, which is challenging for 
population-based cancer registries.109 
 I was able to obtain descriptive information on initial treatment (chemotherapy, 
radiation and/or haematopoietic transplantation). However, there was no information 
available on the therapeutic protocols used, and no detailed data on transplant or 
subsequent treatments. In addition, data on treatment compliance are especially 
relevant for acute lymphoblastic leukaemia due to the requirement of long-term use 
of oral drugs (e.g., 6 mercaptopurine), but this information is not available in 
population-based cancer registries.  
 The cancer registry also lacks more detailed clinical data, such as white 
blood cell count at diagnosis, initial platelet count, cytogenetic or molecular 
characteristics, involvement of central nervous system disease, or minimal residual 
disease assessment, all factors that have been considered associated with 
outcome.175, 201 Consequently, information on group risk stratification, which is 
important to guide personalised therapy, was not available.  
 Likewise, there was no information on performance status, which is highly 
predictive of outcome, mainly for acute myeloid leukaemia.226, 287 However, lacking 
this measure in this young cohort of patients likely impacts the findings less than the 
analyses of older patients, as, in general, young patients are healthier, have better 
performance status (0–II) and fewer secondary malignancies compared with older 
patients. 
 Table 8.2 compares the type of information that can be obtained from 
population-based cancer registries with that which can be obtained through health 
insurance claims and health system electronic medical records. Clearly, the linkage 
of these data can improve our understanding of the disease as well as provide 
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information on the quality of care provided to patients, eventually improving 
treatment outcomes. 
 
Table 8.2: Patient information available in each data source. Adapted from Hiatt et al.,  
J Natl Cancer Inst 2015 
385
 
Data  Population-
based cancer 
registries 
Insurance 
claims data 
Electronic 
medical 
records 
Patient identifiers       
Patient address   NA   
Patient demographics       
Clinical history and comorbidities NA     
Tumour characteristics   NA   
Treatment data  *     
Patient reported data NA NA  * 
Post-acute care treatment NA     
Patient vital status   NA   
Provider identifiers       
* = Incomplete data; NA = data not available in the data source 
 
Other data limitations 
Potential misclassification of race/ethnicity obtained by the CCR, may have 
influenced the association I found in my studies between race/ethnicity and survival 
and/or early death. However, previous studies using cancer registry data (including 
California data), revealed that this variable is of very high quality for self-reported 
race/ethnicity for white and black patients and of moderate quality for Hispanic and 
Asian patients.254, 386 
Another limitation in my studies was the lack of individual-level measures of 
SES to examine along with the measure of neighbourhood SES available in the 
CCR. Therefore, some cultural or deprivation factors associated with survival may 
not have been entirely captured by the neighbourhood SES variable I have used. 
Nonetheless, studies have shown that individual-level and census-based measures 
of SES are closely associated with outcomes,306 and census-based measures of 
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SES may, in fact, uncover risk factors and inequalities in outcome not revealed by 
individual-level measures of SES.387, 388 
 
8.5.2 Limitations of the analysis 
In the analyses presented in this thesis, age was categorised into four (ALL) or five 
(APL and AML) groups. This was based on clinical knowledge and previous reports 
showing survival differences by age.226 Presenting hazard ratios for categories of 
age allows for an easy interpretation of the estimates with age categories. However, 
I also recognise that information is lost when a continuous variable is categorised. 
Further analyses could also consider models in which age is treated as a continuous 
variable. In these models age could be modelled as a linear term, and in this case 
the hazard ratio for age would be that associated with a 1-year increase in age. It is 
likely that the association with age and survival could be non-linear however. 
Therefore, non-linear forms for age could be considered, for example using splines. 
The hazard ratios for age would then be best displayed graphically.  
 As discussed in section 8.4, a formal mediation analysis383, 384 could be 
performed in order to avoid “over-adjustment” with variables that lie on the causal 
pathway between the explanatory variables (SES and race/ethnicity) and survival. 
 
8.6 Areas of further research 
The work presented in this thesis has suggested a number of important areas for 
further research aimed at improving survival of children, adolescents and young 
adults with acute leukaemia and other type of cancers. In this section I give 
background an overview of two planned specific projects I will be leading.  
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8.6.1 Evaluating the burden of childhood and young adult cancer in low- and 
middle-income countries 
In my literature review, it became clear that, in order to improve the poorer survival 
after childhood and young adult leukaemia, as well as other types of cancer, it is 
critical to quantify the incidence and survival of this disease in the population, and 
also investigate factors associated with both incidence and survival. The work of my 
thesis focused on a developed country, and I am now interested in performing similar 
investigations in low- and middle-income countries. A future study will aim at 
examining the childhood cancer incidence and survival in Latin America from 1990 
onwards. 
 Childhood cancer is a rare disease accounting for less than 2% of the global 
cancer burden. Yet, every year more than 160,000 children are diagnosed with 
cancer.35 Missed or late diagnosis, unavailability of treatment and treatment 
abandonment are the main problems affecting children with cancer in low- and 
middle-income countries.389 Children and adolescents living in poor-resource 
countries are exposed to different environmental, biological and socioeconomic 
conditions compared to those children living in high-resource countries. Therefore, 
children in Latin America may have a different incidence, type, presentation, and 
prognosis of cancer than children in developed countries. To decrease mortality and 
morbidity of children with cancer, it is essential to understand the extent to which this 
disease affects the population of interest, as well as age-specific cancer incidence 
and survival patterns. Eventually, priorities can be set with the aim of creating 
regional and national cancer control plans. 
 The main goal of this future project is to generate and provide useful 
information on the burden of childhood cancer in Latin America, by producing an 
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overview of cancer incidence in the young population. A secondary aim is to identify 
cancer registries that collect patients’ follow-up information in order to conduct a 
study of childhood cancer survival, depending on the data availability and quality.  
 This population-based study will build on the results generated by the 
International Incidence of Childhood Cancer monograph, volume 3 (IICC-3, 
http://iicc.iarc.fr/). Around 50 populations aged 0–19 years might be available for 
these analyses. If required, other data sources will also be considered, in order to 
possibly extend the age range up to 39 years, such as the database of the Cancer 
Incidence in Five Continents (http://ci5.iarc.fr/Default.aspx) and the publication 
Cancer in Central and South America, which is close to finalisation in the beginning 
of 2016.  
 
8.6.2 The association of the TP53 R337H mutation with cancer predisposition 
in southern Brazil 
As previously discussed, genetic and molecular information can help to understand 
the aetiology of cancer and guide risk-stratified therapies. Previous studies have 
demonstrated significant correlation between patient genotype and tumour 
phenotype. For example, patients with inherited TP53 mutations and the classic Li-
Fraumeni syndrome have a higher incidence of leukaemia, adrenocortical tumours, 
rhabdomyosarcoma, osteosarcoma, and central nervous system tumours than those 
without this syndrome. In these individuals, cancer tends to develop earlier in life.390-
393 These findings have significant implication for genetic counselling as well as 
clinical management (e.g., annual abdominal ultrasound for children with TP53 
mutation).390, 394, 395  
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A recent study evaluated the involvement of germline predisposition mutations 
in paediatric tumours and revealed that 8.5% of these patients had pathogenic (or 
possibly pathogenic) mutations. The TP53 mutation was one of the most frequent 
cancer predisposing mutations in these children. In addition, the study revealed that 
among patients with available data on family history, only 40% had a positive family 
cancer history.395 
 In the South of Brazil, an inherited mutation – the TP53 R337H – has been 
associated with a higher incidence of adrenocortical tumour and choroid plexus in 
children, but not with other malignancies that characterise the classic Li Fraumeni 
syndrome.394 Preliminary analysis suggests that patients with the R337H mutation 
also have a predisposition to other cancer types, such as breast and gastrointestinal 
cancers. 
 The main aim of this project will be to investigate the family history of children 
with adrenocortical tumour and a germline TP53 mutation using the public TP53 
database created by the International Agency of Research on Cancer (IARC, 
http://www.iarc.fr/p53). My collaborators and I will compare the findings of this study 
with the results from a Brazilian institution. Our hypothesis is that the family history of 
cancer of individuals carrying low-penetrance mutations such as the R337H, is 
different from that of individuals with DNA binding domain TP53 mutations. The 
results of this study may guide genetic counselling of families of children with 
adrenocortical tumour and TP53 mutations. 
 
8.7 Conclusions 
My three studies revealed that outcomes after acute lymphoblastic and myeloid 
leukaemia have substantially improved over time in California. However, long-term 
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survival after acute myeloid leukaemia is still low for all ages, especially for 
adolescent and young adults. 
 Additionally, despite improvement in outcomes, I found that inequalities in 
early death and survival are significant and have persisted in all eras of treatment. In 
particular, worse outcomes were observed in disadvantaged populations, such as 
patients of black and Hispanic race/ethnicity, uninsured patients, and those who live 
in lower socioeconomic neighbourhoods. These highlight the unmet need of 
addressing non-biologic factors that are strongly associated with early death and 
survival after acute leukaemia. 
 Furthermore, with the conclusion of human genomic sequencing and the 
approval by the US Food and Drug Administration of many drugs directed to specific 
molecular targets, we have entered the era of precision medicine. This means that, 
in order to achieve better results for cancer treatments, clinicians need to understand 
the importance of treating subgroups of patients based on molecular signatures. 
Continued research to measure outcomes and adverse effects of new therapy is 
crucial.  
 The new “Cancer MoonShot 2020” Initiative launched by President Barack 
Obama in January 2016 and led by Vice-president Joe Biden, aims “to double the 
rate of progress and make a decade’s worth of advances in five years" 
(http://www.cancermoonshot2020.org/). This initiative has brought much enthusiasm 
and optimism to the medical and research communities. In March 2016, it was 
announced the creation of a ‘National Pediatrics Consortium’, which promises to 
bring “combined immunotherapy as the next-generation standard of care to children 
diagnosed with cancer”. This Consortium has the leadership of the Phoenix 
Children’s Hospital and nine other partners, including the Children’s Hospital of 
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Orange County in California. The focus will be to use whole genomic and proteomic 
analysis to generate comprehensive molecular cancer diagnosis and real-time data 
sharing. 
 While national and international collaborative trials will continue to play a key 
role in the development of new therapeutic approaches for all age groups with acute 
leukaemia, a special focus should be on adolescents and young adults who continue 
to have inferior long-term survival compared with children.  
 Finally, my research highlights the importance of population-based studies to 
better understand the actual burden of disease in the population. Continuous 
improvement in cancer registration and the linkage of population-based data with 
clinical information and laboratory data obtained from patients’ medical records and 
health insurance claims are of paramount importance. The analysis of aggregate 
data can help clinicians, researchers and policy-makers to better understand the 
predictors of outcomes after acute leukaemias, as well as the quality of care 
provided for children, adolescents and young patients with these diseases in 
California. Eventually, priorities can be set in order to improve survival and decrease 
the persistent inequalities in health observed among patients with acute leukaemia in 
California and possibly in other states and nations. 
 
“If we are to preserve civilisation, we must make certain its benefits are 
available to the many, not reserved for the few.” 
Dr Raul Ribeiro, N Engl J Med 2005167 
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Appendix 
Appendix 1. Distribution of acute leukaemia by race/ethnicity in California 
For acute lymphoblastic (ALL) and promyelocytic (APL) leukaemias there was a 
predominance of Hispanic patients. For non-APL acute myeloid leukaemia (AML), 
the proportion of white patients was slightly higher than Hispanic patients (Figure 
1A).  
 
Figure A1: Distribution of patients with acute leukaemias by race/ethnicity in California, 1988–
2011. The age range was 0–19 years for acute lymphoblastic leukaemia (ALL) and 0–39 years for 
acute promyelocytic leukaemia (APL) and non-APL acute myeloid leukaemia (AML). 
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Appendix 2. SEER/CCR Patient Follow-up Calculation 
We assume that Y is the calendar year ending 22 months prior to the due date for 
the November submission, which is November 1st. 396 
For example: For the November 2012 submission – 22 months prior would be the calendar 
year 2010. 
 
Current follow-up percentage (P) is for patients diagnosed during the years prior to Y. 
For example: prior to Y = 2009 & before 
 
If the last reporting year for SEER submission is 2010, the percent of patients diagnosed 
though 2010 who have current follow-up (P) is calculated as follows: 
 
 P = 100 (D+A) / T, where: 
D = the number of cases who died prior to January 1st, Y + 1. D = died prior to 2011 
A = number of cases with follow-up dates on or after Y +1 (dead & alive in 2011 or above) 
T = the total number of patients. This includes A + D + *, where 
 
* = number of cases who were last known alive with follow-up dates prior to January 1st, Y + 
1 (prior to January 1st, 2011 = lost to follow-up) 
 
Appendix 3. Ethnicty algorithms used by the California Cancer Registry 
The North American Association of Central Cancer Registries (NAACCR) Hispanic 
(NHIA) and Asian Pacific Islander Identification Algorithm (NHAPIIA) 
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These algorithms use a combination of NAACCR variables to directly or indirectly 
classify cases as Hispanic or Asian/Pacific Islander for analytical purposes. The best 
approach is to directly obtain complete information from the medical record.  
 The algorithm has been computerized and is available on the NAACCR 
website (http://www.naaccr.org/). It runs as part of a SAS program 
(http://www.sas.com). The CCR generates this variable by examining the primary 
last name, all alias last names, all maiden names, and all death certificate fathers’ 
surnames plus birthplace. 
 
The revised NAACCR Hispanic Identification Algorithm (NHIA) v2.2.1‡  
Direct Identification. Cases reported as Spanish/Hispanic Origin 
 
Appendices 4–7. Research papers 1–3 and press release 
 
                                            
‡
 NAACCR Ethnicity Work Group. NAACCR Guideline for Enhancing Hispano/Latino Identification: 
Revised NAACCR Hispano/Latino Identification Algorithm [NHIA v2.2.1]. Springfield, IL: North 
American Association of Central Cancer Registries; 2009. 
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Racial/Ethnic and Socioeconomic Disparities in Survival Among ChildrenWith Acute
Lymphoblastic Leukemia in California, 1988–2011: A Population-Based
Observational Study
Renata Abrah~ao, MD, MSc,1,2* Daphne Y. Lichtensztajn, MD, MPH,2 Raul C. Ribeiro, MD,3 Neyssa M. Marina, MD,4
Ruth H. Keogh, PhD,5 Rafael Marcos-Gragera, MD, MSc, PhD,6 Sally L. Glaser, PhD,2,7
and Theresa H.M. Keegan, PhD, MSc2,7
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common
pediatric neoplasm and the leading cause of death due to disease in
children and adolescents aged 1–19 years in the United States (US).
[1] Several studies have reported an increase in the incidence of
childhood ALL in Europe [2] and the US.[3] Evidence suggests that
there may be an inherited genetic predisposition to this disease
among different races/ethnicities.[4] Strikingly, genetic factors that
increase the susceptibility to ALL appear also to be associated with
drug-resistant ALL phenotypes and might, in part, explain the poor
survival in certain ethnic groups.[5]
Survival from childhood ALL represents one of the most successful
advances in the history of science and medicine. ALL was
consistently fatal until the 1950s; however, currently approximately
90% of children can be cured in developed countries.[6] This
progress has been attributed largely to the use of effective
chemotherapy regimens of variable intensities that are adapted to
precise risk stratification and assessment of early treatment
response.[6]
Despite the dramatic improvement in the survival of children
with ALL in the last four decades, survival has varied widely by
race/ethnicity in developed [7] and developing nations.[8] Non-
adherence to treatment, lack of access to care, cultural influences,
Background. Despite advances in treatment, survival from acute
lymphoblastic leukemia (ALL) remains lower among non-White
children than White children in the US. We investigated the
association of race/ethnicity and socioeconomic status (SES) with
survival.Procedures.Weanalyzed 9,295Californian children (3,251
Whites, 4,890 Hispanics, 796 Asians, and 358 Blacks) aged 19
years diagnosedwith a first primary ALL during 1988–2011.We used
the Kaplan–Meier method to estimate survival at 1, 5, and 10 years
after diagnosis for three calendar periods. Hazard ratios of death for
race/ethnicity, SES, and clinical factors were estimated by Cox
regression models. Results. Median follow-up time was 7.4 years
(range 0–25 years). Over time, survival after ALL improved steadily,
but inequalities persisted across races/ethnicities. Five-year survival
(95% confidence interval) was 85.0% (83.6–86.2) for White, 81.4%
(78.3–84.0) for Asian, 79.0% (77.8–80.2) for Hispanic, and 74.4%
(69.4–78.8) for Black children. In multivariable-adjusted models, the
hazard of death was increased by 57% among Black, 38% among
Hispanic, and 33% among Asian children compared with White
children. Patients residing in the lowest SES neighborhoods at
diagnosis had a 39% increased risk of death relative to those living in
higher SES neighborhoods. Conclusion.Despite significant improve-
ments in survival, non-White children and children residing in low
SES neighborhoods experienced worse survival even after adjusting
for potential confounders. Our findings highlight the need to capture
specific information on disease biology, treatment, and treatment
adherence to better understand the predictors of lower survival in
minority and low SES groups. Pediatr Blood Cancer
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socioeconomic status (SES), and biologic features have been
implicated in these variations.[9] However, the extent to which
these factors contribute to survival inequalities remain unclear.
California has the largest and most racially and ethnically
diverse population in the US [10] and it has maintained a statewide
high-quality, population-based cancer surveillance system since
1988. In this study, we examined how survival after ALL varied by
race/ethnicity, SES, and clinical factors in Californian children over
a 24-year period. Our population-based study on childhood ALL
simultaneously investigates the association of race/ethnicity,
neighborhood SES, health insurance, type of treating facility,
treatment, and secondary neoplasms as well as factors examined
previously (e.g., age, gender, immunophenotype, and calendar
period).
METHODS
Patients and Study Design
For this population-based observational study, data were
retrieved for children and adolescents aged 0–19 years residing
in California when diagnosed with a first, primary ALL from
January 1, 1988 through December 31, 2011, and followed for vital
status through December 31, 2012. Data were obtained from the
California Cancer Registry (CCR), to which all new cases of cancer
diagnoses must be reported by state law. The CCR contributes to
approximately half of the data in the Surveillance, Epidemiology,
and End Results (SEER) program of the National Cancer Institute
(NCI) and is estimated to include more than 99% of all invasive
cancers diagnosed in California. We included the following
morphology codes from the International Classification of Diseases
for Oncology, third edition (ICD-O-3):[11] 9,727, 9,728, 9,729,
9,811, 9,812, 9,813, 9,814, 9,815, 9,816, 9,817, 9,818, 9,835, 9,836,
and 9,837. Among 9,429 eligible patients, 9,295 were included for
survival analysis. The following patients were excluded from
analysis: 7 reported by death certificate only (DCO), 5 reported by
autopsy only, 51 for whom race/ethnicity was unknown, 60 of Non–
Hispanic American Indian (NHAI) race/ethnicity for whom the
small sample size precluded analysis, and 11with inconsistent dates
of diagnosis or follow-up and/or leukemia classification. ALL was
morphologically verified in 99.8% of patients, and the percentage of
cases with verified vital status on December 31, 2012, was 87.1%.
Institutional review board (IRB) approval—Ethics approval for
human subjects research was obtained from the California
Prevention Institute of California Institutional Review Board. As
the analysis was based on state-mandated cancer registry data, the
study was conducted in accordance with the waivers of individual
informed consent and HIPPA authorization.
Covariates
Covariates included in the analysis were age at diagnosis (<1,
1–4, 5–9, 10–14, and 15–19 years); gender (male, female); race/
ethnicity (Non-Hispanic White [White], Non-Hispanic Black
[Black], Hispanic, and Non-Hispanic Asian/Pacific Islander
[Asian]); immunophenotype (categorized as B-cell, T-cell, or not
otherwise specified [NOS] according to the morphology codes);
secondary neoplasms; and neighborhood SES. Secondary neoplasm
was defined as a new malignancy registered in the CCR after the
diagnosis of ALL, following the SEER’s multiple primaries
rules for hematopoietic diseases.[12] Some types of malignant
neoplasms have been associated with worse prognosis [13] and we
have controlled for their occurrence in our analyses. Because
information on SES at the individual level is not collected by the
CCR, a previously developed neighborhood SES measure [14] was
used. It is derived from principal components analysis of seven
census indicator variables of SES (education level, proportion
unemployed and with a blue collar job, proportion below 200% of
federal poverty level, and median household income, rent, and
home value). This index is based on data at the level of the census
block groups and is considered adequate as a surrogate to SES at
individual level,[15] and can capture neighborhood-level factors
that may affect cancer incidence and outcomes.[16] SES was
divided into quintiles based on the statewide distribution and
assigned to patients on the basis of their residence at time of
diagnosis. Other covariates included type of insurance at time of
initial treatment (private, public, no insurance, or unknown)
collected from 1996 onwards; calendar period (1988–1995,
1996–2003, 2004–2011); and type of treating hospital. Because
the care provided by specialized pediatric oncologic centers may be
different from that provided in general hospitals, we identified
children’s hospitals and pediatric cancer centers in California by
using listings from the Children’s Hospital Association [17] and the
Children’s Oncology Group (COG).[18] These hospitals offer
clinical trials sponsored by the COG, which is supported by the
NCI. On the basis of the cancer reporting facility, patients were
classified by whether they had received care at a pediatric cancer
center (yes, no). Chemotherapy, radiotherapy, and time to
chemotherapy were evaluated in descriptive analyses of treatment.
They were not included in the statistical model because of changes
in the use of central nervous system (CNS) radiation over time [19]
and the widespread use of chemotherapy protocols. Inclusion of
treatment in the model did not change the associations observed
among race/ethnicity, SES, and survival.
Statistical Analyses
We used the x2 test to compare frequency distributions of
sociodemographic and clinical characteristics by race/ethnicity.
Follow-up time was defined as the date of diagnosis to the date of
death from any cause, or censoring at the end of the study period
(December 31, 2012) or last known date of follow-up, whichever
came first.
We estimated overall survival at 1, 5, and 10 years for each
covariate (except chemotherapy and radiation) and calendar period
by the Kaplan–Meier method. The log-rank test was used to
compare differences in survival across strata. We used unadjusted
and multivariable-adjusted Cox regression models to estimate the
hazard ratios (HRs) of death with associated 95% confidence
interval (CI).
We tested the proportional-hazards assumption by examining
log–log survival plots and confirmed the results by using
Schoenfeld residuals. There was evidence that age, immunophe-
notype, and secondary neoplasms violated the proportional hazard
assumption, and these were therefore included as stratification
variables in the models. Secondary neoplasm was analyzed as a
time-dependent variable.
Because information on type of insurance was not routinely
collected prior to 1996, we ran three Cox regression models: a
model without insurance with all patients, a model without
insurance but limited to patients diagnosed from 1996 onwards,
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and another model including insurance but limited to patients
diagnosed from 1996 onwards. We investigated interactions
between racial/ethnic groups and other covariates. Statistical
analyses were performed by using the Stata 13 software and a
two-sided P-value< 0.05 was considered statistically significant.
RESULTS
Sociodemographic and Clinical Characteristics
Table I shows patients and disease characteristics by race/
ethnicity. In the 9,295 patients in our cohort, there was a higher
percentage of males (58%) than females (42%). More than half the
patients (52%) were Hispanic, followed by White (35%), Asian
(9%), and Black (4%). The median age at diagnosis was 4 years for
Asian, 5 years for White and Hispanic, and 7 years for Black
children. By immunophenotype, 60% of patients had B-cell, 12%
had T-cell, and approximately 28% had NOS ALL. The proportion
of T-cell ALLwas significantly higher in Black (23%) than inWhite
(15%), Asian (13%), andHispanic (10%) children.White andAsian
children were more likely to have private insurance (80% and 74%,
respectively) than Black and Hispanic children (53% and 40%
respectively). Approximately 1.4% of childrenwere diagnosedwith
secondary neoplasms, of which 58% were solid and 46% were
hematopoietic. The use of CNS radiation decreased progressively
from 24% in the first time period to 12% in the last period.
TABLE I. Sociodemographic andClinical Characteristics of Children (Aged 0–19Years)WithAcute Lymphoblastic LeukemiaDiagnosed
From 1988 to 2011 and Followed Up to 2012 in California, by Race/Ethnicity
Covariates Whites N (%) Blacks N (%) Hispanics N (%) Asians N (%) Total cohort N (%) Pa
Total 3,251 (35) 358 (4) 4,890 (52) 796 (9) 9,295 (100)
Age at diagnosis, years
<1 69 (2.1) 9 (2.5) 158 (3.2) 29 (3.6) 266 (2.9)
1–4 1,468 (45.2) 117 (32.7) 2,023 (41.4) 382 (48.0) 3,990 (42.9)
5–9 868 (26.7) 102 (28.5) 1,216 (24.9) 194 (24.4) 2,382 (25.6)
10–14 465 (14.3) 74 (20.7) 807 (16.5) 101 (12.7) 1,447 (15.5)
15–19 381 (11.7) 56 (15.6) 686 (14.0) 90 (11.3) 1,213 (13.1) <0.0001
Median 5 7 5 4 5
Gender
Male 1,911 (58.8) 206 (57.5) 2,815 (57.6) 459 (57.7) 5,391 (58.0)
Female 1,340 (41.2) 152 (42.5) 2,075 (42.4) 337 (42.3) 3,904 (42.0) 0.738
Chemotherapy
No 44 (1.3) 11 (3.1) 79 (1.6) 7 (0.9) 141 (1.5)
Yes 3,207(98.7) 347 (96.9) 4,811 (98.4) 789 (99.1) 9,154 (98.5) 0.031
CNS radiation
No 2,717 (83.6) 275 (76.8) 4,085 (83.5) 687 (86.3) 7,764 (83.5)
Yes 534 (16.4) 83 (23.2) 805 (16.5) 109 (13.7) 1,531 (16.5) 0.001
Treatment at a pediatric cancer center
No 931 (28.6) 131 (36.6) 1,571 (32.1) 240 (30.1) 2,873 (30.9)
Yes 2,320 (71.4) 227 (63.4) 3,319 (67.9) 556 (69.9) 6,422 (69.1) 0.001
Leukemia immunophenotype
T-cell 483 (14.9) 84 (23.4) 464 (9.5) 102 (12.8) 1,133 (12.2)
B-cell 1,736 (53.4) 176 (49.2) 3,183 (65.1) 490 (61.6) 5,585 (60.1)
NOS 1,032 (31.7) 98 (27.4) 1,243 (25.4) 204 (25.6) 2,581 (27.7) <0.0001
Secondary neoplasms
No 3,209 (98.7) 356 (99.4) 4,838 (98.9) 782 (98.2) 9,185 (98.8)
Yes 42 (1.3) 2 (0.6) 52 (1.1) 14 (1.8) 110 (1.2) 0.223
Socioeconomic status
1. Lowest 20% 247 (7.6) 96 (26.8) 2,067(42.2) 102 (12.8) 2,513 (27.0)
2 532 (16.4) 109 (30.5) 1,256 (25.7) 120 (15.1) 2,020 (21.7)
3 683 (21.0) 66 (18.4) 831 (17.0) 139 (17.5) 1,723 (18.5)
4 847 (26.0) 58 (16.2) 479 (9.8) 200 (25.1) 1,585 (17.1)
5. Highest 20% 942 (29.0) 29 (8.1) 257 (5.3) 235 (29.5) 1,463 (15.7) <0.0001
Calendar period
1988–1995 1,169 (35.9) 104 (29.0) 1,162 (23.8) 222 (27.9) 2,657 (28.6)
1996–2003 1,093 (33.6) 127 (35.5) 1,670 (34.1) 270 (33.9) 3,160 (34.0)
2004–2011 989 (30.4) 127 (35.5) 2,058 (42.1) 304 (38.2) 3,478 (37.4) <0.0001
Type of health insurance: limited to cases diagnosed from 1996 onwards (N¼ 6638)
No insurance 14 (0.7) 9 (3.5) 106 (2.9) 4 (0.7) 133 (2.0)
Private insurance 1,669 (80.1) 135 (53.2) 1,493 (40.0) 425 (74.0) 3,722 (56.1)
Public insurance 341 (16.4) 101 (39.8) 1,997 (53.6) 128 (22.3) 2,567 (38.7)
Unknown 58 (2.8) 9 (3.5) 132 (3.5) 17 (3.0) 216 (3.2) <0.0001
CNS, central nervous system; NOS, not otherwise specified. ax2 P-value.
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Chemotherapy was administered to more than 98% of children, of
whom at least 95% received chemotherapy within 2 weeks of
diagnosis.
Survival
Table II displays survival probabilities at 1, 5, and 10 years, by
sociodemographic and clinical characteristics. Figures 1 and 2 show
survival by race/ethnicity and SES, respectively. The median
follow-up time was 7.4 years (range 0–25 years). By the end of the
study period, 1,955 study patients died. Survival improved steadily
over calendar time but was persistently lower for Black, Hispanic,
and Asian children than for White children. Differences in survival
were most striking between Black and White children.
Unadjusted and Multivariable Analyses
In the unadjusted model all variables were associated with
significant increased hazard of death. After multivariable adjust-
ment, our analysis revealed that the HRs of death were still
significant for race/ethnicity and SES (Table III). The hazard of
death was increased by 57% (HR¼ 1.57 [1.26–1.96]) amongBlack,
TABLE II. Overall Survival With 95% Confidence Intervals for Acute Lymphoblastic Leukemia at 1, 5, and 10 Years After Diagnosis in
Children (0–19 Years Old) in California From 1988 to 2011, by Sociodemographic and Clinical Factors
Covariates 1-year survival (95%CI) 5-year survival (95%CI) 10-year survival (95%CI)
All children 94.5 (94.0–95.0) 81.2 (80.3–82.0) 77.1 (76.1–78.0)
Age at diagnosis
<1 76.9 (71.3–81.6) 50.2 (43.7–56.2) 45.7 (39.1–52.1)
1–4 97.9 (97.4–98.3) 89.3 (88.2–90.3) 86.3 (85.1–87.4)
5–9 96.6 (95.8–97.3) 86.2 (84.7–87.6) 80.7 (78.8–82.4)
10–14 91.8 (90.2–93.1) 73.5 (71.0–75.7) 69.0 (66.3–71.5)
15–19 86.3 (84.2–88.1) 60.2 (57.2–63.0) 55.8 (52.6–58.8)
Log-rank test P-value<0.00001
Race/ethnicity
White 95.8 (95.0–96.4) 85.0 (83.6–86.2) 81.5 (80.0–82.9)
Black 91.8 (88.4–94.2) 74.4 (69.4–78.8) 70.7 (65.3–75.4)
Hispanic 93.9 (93.2–94.5) 79.0 (77.8–80.2) 74.4 (73.0–75.7)
Asian 94.4 (92.6–95.8) 81.4 (78.3–84.0) 77.4 (74.0–80.4)
Log-rank test P-value<0.00001
Gender
Male 94.3 (93.7–94.9) 79.5 (78.3–80.6) 75.1 (73.8–76.3)
Female 94.7 (94.0–95.4) 83.5 (82.2–84.7) 79.9 (78.4–81.2)
Log-rank test P-value<0.00001
Leukemia immunophenotype
B-cell 95.4 (94.8–95.9) 82.7 (81.6–83.7) 77.8 (76.5–79.0)
T-cell 90.8 (88.9–92.3) 73.8 (71.0–76.3) 71.0 (68.0–73.7)
NOS 94.3 (93.3–95.1) 81.1 (79.5–82.6) 77.8 (76.1–79.4)
Log-rank test P-value<0.00001
Calendar period
1988–1995 93.0 (91.9–93.9) 76.9 (75.2–78.5) 72.8 (71.1–74.5)
1996–2003 94.8 (93.9–95.5) 80.7 (79.3–82.1) 76.7 (75.1–78.1)
2004–2011 95.5 (94.7–96.1) 85.7 (84.3–87.0) N/A
Log-rank test P-value<0.00001
Socioeconomic status
1. Lowest 20% 93.5 (92.4–94.4) 77.0 (75.3–78.7) 72.5 (70.5–74.3)
2 94.5 (93.4–95.5) 81.5 (79.6–83.2) 77.8 (75.6–79.6)
3 94.5 (93.3–95.4) 82.3 (80.3–84.1) 78.4 (76.2–80.5)
4 95.3 (94.1–96.2) 82.2 (80.1–84.1) 78.2 (75.9–80.3)
5. Highest 20% 95.5 (94.3–96.4) 85.4 (83.3–87.1) 81.3 (78.9–81.6)
Log-rank test P-value<0.00001
Treatment at a pediatric cancer center
No 92.9 (91.9–93.8) 77.0 (75.4–78.6) 73.2 (71.4–74.9)
Yes 95.2 (94.7–95.7) 83.0 (82.0–84.0) 78.9 (77.7–80.0)
Log-rank test P-value¼ 0.0014
Type of health insurance: limited to cases diagnosed from 1996 onwards (N¼ 6638)
No insurance 93.3 (88.1–96.9) 77.6 (68.9–84.1) 74.2 (64.4–81.6)
Private insurance 96.6 (94.9–96.2) 85.2 (83.9–86.4) 81.8 (80.3–83.2)
Public insurance 94.8 (93.9–96.5) 81.5 (79.9–83.1) 76.3 (74.3–78.3)
Unknown 91.6 (87.0–94.6) 66.2 (59.3–72.2) 63.0 (55.8–69.3)
Log-rank test P-value<0.00001
CI, confidence interval; NOS, not otherwise specified; N/A, not applicable.
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38% (HR¼ 1.38 [1.23–1.55]) among Hispanic, and 33% (HR
¼ 1.33 [1.12–1.59]) among Asian children compared with White
children. Patients residing in the lowest SES neighborhoods were at
39% (HR¼ 1.39 [1.18–1.64]) increased risk of death than those in
the higher SES neighborhoods. After controlling for other
covariates, the hazard of death was not associated with the type
of hospital in which children were treated or with type of insurance
for patients diagnosed from 1996 onwards. Insurance minimally
attenuated the HRs for race/ethnicity and SES among patients
diagnosed from 1996 onwards (Table III). In addition, the inclusion
of SES in our model did not substantially change the racial/ethnic
differences in survival that we observed. There were no significant
interactions between race/ethnicity, SES, calendar period, and other
study covariates.
DISCUSSION
In our large population-based study of nearly 10,000 children
with ALL, survival for Black, Hispanic, and Asian children was
lower than that for White children. The survival differences we
observed in our cohort persisted over time and were most marked
between Black and White children. In contrast to previous studies
reporting that survival of Asian childrenwas similar to [20] or better
[21] than forWhite, Hispanic, and Black children, our study showed
that Asian children in California had lower survival than White
children with ALL. Our results are consistent with a previous study
[7] that also used US population-based data, but we extended their
findings by additionally investigating neighborhood SES, second-
ary neoplasms, type of insurance, treatment, and treating facility.
Genetic and non-genetic factors help to explain disparities in
cancer survival. Our population-based study allowed the investiga-
tion of non-genetic factors and found that neighborhood SES had a
significant, independent association with survival, particularly
when comparing children residing in the highest and lowest SES
neighborhoods. The inclusion of SES in our statistical model did not
substantially change the racial/ethnic differences in survival that we
observed, suggesting that other factors underlie these survival
disparities. Our SES finding is consistent with previous studies of
poorer survival among financially deprived populations.[22]
White and Asian children were more likely than Hispanic and
Black children to have private insurance, but the type of insurance
did not significantly affect survival after ALL after adjustment for
other variables. Insurance may have not been associated with
survival because, in California, patients younger than 21 years are
eligible for California Children’s Services (CCS), a state program
that offers insurance for chronic and complex diseases and covers
all children with cancer with or without insurance. Although the
CCS program ensures that all children with ALL have access to
care, this may not be sufficient in the long-term for children with
low SES. Differences in relapse rates among children from different
racial/ethnic groups have been observed. In a study on adherence to
oral 6-mercaptopurine during the maintenance phase of ALL
treatment, non-adherence was significantly higher among non-
White children than White children and it considerably increased
relapse rates. Sociodemographic characteristics also played a
significant role in adherence to treatment.[22]
Although past evidence suggests that children with ALL treated
at specialized pediatric cancer centers had better survival than those
at general hospitals,[23] our study did not find survival differences
by treating facility. Because the treating facility typically refers to
the hospital that initially diagnosed and/or treated the patient, it is
possible that some children admitted in non-specialized pediatric
hospitals were later referred to pediatric cancer centers where
standardized COG protocols were used, thus confounding our
results.
ALL is a lethal disease if treatment is not started promptly.
Although the lack of appropriate chemotherapy agents might
contribute to the lower survival in Eastern Europe,[24] our
examination of the proportion of children treated with chemother-
apy and time from diagnosis to the start of treatment showed that the
majority of study patients were treated within the first 2 weeks of
diagnosis. However, late diagnosis might have had an adverse effect
on outcome. Parents who are undocumented immigrants or of lower
SES may wait longer to seek medical care for their children or may
do so when the child is already severely sick. Late diagnosis may
increase the risk of (early) death [25–27] because patients may
develop severe infectious and/or metabolic complications prior to
referral to a specialized cancer center.[28] However, we did not
have sufficient information to evaluate this possibility.
Our data indicate that the use of prophylactic cranial irradiation
has decreased markedly over time, suggesting protocol adherence
to the new recommendations for using systemic and intrathecal
therapy instead of radiation for childrenwith high-risk CNS relapse.
This recommendation aims to prevent late radiation-related
complications such as second neoplasms.[29] Infants and older
Fig 1. Overall survival by race/ethnicity among children (0–19 years
old) diagnosed with acute lymphoblastic leukemia in California, 1988–
2011.
Fig 2. Overall survival by socioeconomic status among children (0–19
years old) diagnosed with acute lymphoblastic leukemia in California,
1988–2011.
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children had significant lower survival than did children aged 1–9
years, supporting findings in previous studies in Europe [30] in the
US.[1]
The treatment of childhood leukemia is complex, expensive, and
lengthy (2.5–3 years). With modern supportive care, fewer than
10% of deaths among children with ALL are due to therapy-
associated toxicity,[31] and disease relapse remains the leading
cause of death.[32] Although relapsed ALL is treated with curative
intent in the US, the long-term survival of children who relapse is
only approximately 25%, even when bone marrow transplant is
available.[32] Multiple factors might affect the survival of children
with ALL, and this can be a complex construct involving
socioeconomic and cultural variables.[22]
Differences in disease biology may explain, in part, the
persistent gap in survival by race/ethnicity. For example, in our
study, survival differences were more marked between Black and
White children (Fig. 1, Table II). Intrinsic biologic features may
partially explain this observation. Previous studies reported that
compared to White children, Black children with ALL had a higher
incidence of unfavorable features, including high leukocyte count,
higher proportion of T-cell leukemia, chromosome translocations
[e.g. t(1,19)], and molecular abnormalities associated with an
increased risk of relapse.[33] In contrast, approximately 50% of
White children have ALL with favorable genetic features (B-cell
ALL), which translate to excellent prognosis.[4] Pui et al.[34]
reported that survival rate of Black children receiving intensive
risk-based therapy and comprehensive supportive care can be
similar to that of White children, thereby reducing the impact of
these adverse factors. However, to our knowledge, these results
found at a single institution, have not been replicated.
Intrinsic biologic differences may also play an important role in
the poor prognosis of ALL among Hispanic children. A recent
review [9] of the genomic profiling of ALL associated with
susceptibility and outcome among Hispanic children identified a
novel subtype of ALL called Philadelphia chromosome-like (Ph-
like) ALL among these children. The incidence of Ph-like ALL in
Hispanic children is significantly higher (35%) than in non-
Hispanic children (7%). Approximately 50% of children with this
subtype overexpress the somatic cytokine receptor-like factor 2
(CRLF2).[33] Furthermore, Perez-Andreu et al.[35] demonstrated
that inherited GATA binding protein 3 (GATA3) variants are also
overrepresented among Hispanics and increase the susceptibility to
Ph-like ALL. The presence of both these variants is associated with
a higher risk of relapse amongHispanic children with ALL andmay
in part explain their poor response to treatment.
Our study has some limitations. Data on specific genetic
abnormalities have only been collected by the CCR since 2010.
Because of the small size of this group, we could not compare the
survival of children on the basis of genetic characteristics. However,
this will be of interest in future studies. Most children and
adolescents with ALL in California are treated at pediatric cancer
centers that use COG protocols, but we do not have information
TABLE III. Unadjusted andMultivariable-AdjustedHazard Ratios and 95%Confidence Intervals for Overall Survival in Children (0–19
Years Old) With Acute Lymphoblastic Leukemia in California.
Covariates Death N (%)
Unadjusted HR1
(1988–2011) (95%CI)
Adjusted HR2
(1988–2011) (95%CI)
Adjusted HR3
(1996–2011) (95%CI)
Adjusted HR4
(1996–2011) (95%CI)
Race/ethnicity
White 568 (29.1) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Black 100 (5.1) 1.78 (1.44–2.20) 1.57 (1.26–1.96) 1.74 (1.31–2.31) 1.72 (1.29–2.28)
Hispanic 1,123 (57.4) 1.47 (1.33–1.62) 1.38 (1.23–1.55) 1.43 (1.22–1.68) 1.37 (1.17–1.62)
Asian 164 (8.4) 1.26 (1.06–1.50) 1.33 (1.12–1.59) 1.42 (1.13–1.79) 1.40 (1.11–1.76)
Gender
Male 1,237 (63.3) 1.27 (1.16–1.39) 1.19 (1.09–1.31) 1.20 (1.06–1.35) 1.19 (1.06–1.35)
Female 718 (36.7) 1.0 (Reference) 1.0 (Reference) 1.00 (Reference) 1.00 (Reference)
Socioeconomic status
1.Lowest 20% 623 (32.3) 1.61 (1.39–1.87) 1.39 (1.18–1.64) 1.40 (1.12–1.75) 1.30 (1.04–2.27)
2. 414 (21.2) 1.29 (1.10–1.51) 1.15 (0.97–1.35) 1.20 (0.95–1.51) 1.15 (0.91–1.44)
3. 339 (17.3) 1.20 (1.02–1.41) 1.13 (0.95–1.33) 1.10 (0.87–1.38) 1.06 (0.84–1.34)
4. 324 (16.6) 1.23 (1.04–1.45) 1.17 (0.99–1.39) 1.22 (0.97–1.54) 1.20 (0.95–1.51)
5. Highest 20% 246 (12.6) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Calendar period
1988–1995 781 (39.9) 1.66 (1.47–1.87) 1.97 (1.74–2.24) N/A N/A
1996–2003 744 (38.1) 1.38 (1.22–1.56) 1.50 (1.33–1.70) 1.52 (1.34–1.73) 1.50 (1.33–1.71)
2004–2011 430 (22.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Treatment at a pediatric cancer center
No 724 (37.0) 1.35 (1.23–1.48) 1.06 (0.96–1.16) 1.05 (0.92–1.19) 1.05 (0.92–1.19)
Yes 1,231 (63.0) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Type of health insurance: model limited to cases diagnosed from 1996 onwards (N¼ 6638)
No insurance 29 (2.5) 1.54 (1.06–2.23) N/A N/A 1.22 (0.83–1.89)
Private insurance 583 (49.6) 1.00 (Reference) N/A N/A 1.00 (Reference)
Public insurance 487 (41.5) 1.31 (1.16–1.47) N/A N/A 1.15 (1.01–1.32)
Unknown 75 (6.4) 2.31 (1.82–2.94) N/A N/A 1.77 (1.38–2.26)
HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified. The multivariable models were adjusted for all variables presented
in the table and stratified by age, immunophenotype and secondary neoplasm. HR1, unadjusted model; Hr2, adjusted model without insurance,
1988–2011; Hr3, adjusted model without insurance, 1996–2011; Hr4, adjusted model with insurance, 1996–2011.
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about which patients are treated with these protocols and the
intensity of treatment administered.We lacked data on relapse rates,
as disease recurrence is not routinely collected by population-based
cancer registries.
The strengths of our study include the use of a high-quality
population-based dataset, a large sample of an ethnically and
racially diverse population, and long period of post-diagnostic
observation that allowed us to examine trends in outcome. Our
study covered nearly the entire population of children and
adolescents diagnosed with ALL in California and provided
information on numerous factors such as neighborhood SES,
insurance, treatment, treating facility, secondary neoplasm, and
immunophenotype as well as age, gender, and calendar period.
In summary, despite the remarkable improvement in cure rates
after ALL, non-White children and children in low SES
neighborhoods have been disproportionally dying even when
access to high-quality care is available and standardized protocols
are followed. In the coming years, genomic findings will
dramatically change the prognostic classification of ALL. In the
era of precision medicine, the value of population-based cancer
registries can be improved by collaborating with pediatric
oncologists and cancer registries from COG-affiliated hospitals.
Capturing specific biologic (e.g., ALL genomic signature, minimal
residual disease, blast chromosomal abnormalities, presenting
white counts, and NCI risk grouping), and socioeconomic (e.g.,
treatment adherence) information can help to identify predictors of
racial/ethnic differences in treatment failure and guide the
development of interventions aimed at improving survival for
minority and low SES children with ALL.
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Disparities in Early Death and Survival in Children,
Adolescents, and Young Adults with Acute Promyelocytic
Leukemia in California
Renata Abrah~ao, MD, MSc1,2; Raul C. Ribeiro, MD3; Bruno C. Medeiros, MD4; Ruth H. Keogh, DPhil5;
and Theresa H.M. Keegan, PhD, MSc2,6
BACKGROUND: Findings from clinical trials and population-based studies have differed with regard to whether mortality within 30
days of diagnosis (early death) of acute promyelocytic leukemia (APL) has decreased in the era of all-trans retinoic acid and
anthracycline-based chemotherapy. METHODS: Using data from the California Cancer Registry, the authors investigated 7-day and
30-day mortality and survival in 772 patients who were aged birth to 39 years when they were diagnosed with APL during 1988 to
2011. Logistic regression and Cox proportional models were used to examine the association of early death and survival, respectively,
with sociodemographic and clinical factors. RESULTS: The overall 30-day mortality decreased significantly over time, from 26% (1988-
1995) to 14% (2004-2011) (P 5.004). On multivariable analysis, the odds of 30-day mortality were 3 times as high during 1988 through
1995 than 2004 through 2011 (P 5.001). However, 7-day mortality did not improve over time (P 5.229). When patients who died within
7 days of diagnosis were excluded, the 30-day mortality during 1996 to 2011 was 3% to 8%, which is similar to levels reported in clini-
cal trials. Higher early death and lower survival were associated with a lack of health insurance (1996-2011) (early death odds ratio,
2.67; P 5.031) and Hispanic race/ethnicity (early death odds ratio, 2.13; P 5.014). Early death was not found to be associated with age,
sex, socioeconomic status, or hospital type. Black patients also experienced worse survival. CONCLUSIONS: The findings of the cur-
rent study revealed a decreased 30-day mortality during the all-trans retinoic acid era, but 7-day mortality remained high. Efforts to
achieve equal outcomes in young patients with APL should focus on improving access to effective treatment, mainly among unin-
sured patients and those of Hispanic and black race/ethnicity. Cancer 2015;121:3990-7. VC 2015 American Cancer Society.
KEYWORDS: acute promyelocytic leukemia, adolescents, all-trans retinoic acid (ATRA), children, early death, health disparities, health
insurance, survival, young adults.
INTRODUCTION
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) that carries the PML/RAR-a fusion
in >90% of cases. Bleeding and thrombosis are frequent and can be aggravated by cytotoxic chemotherapy, resulting in
early death due mainly to intracranial hemorrhage.1
An estimated 600 to 800 new cases of APL (4%-13% of AML cases) occur annually in the United States, most fre-
quently in adults.2,3 Although APL was once highly fatal, the addition of all-trans retinoic acid (ATRA) to anthracycline-
based chemotherapy and the introduction of arsenic trioxide (arsenic) have dramatically improved outcomes; currently,
95% to 100% of patients with APL achieve complete remission.4,5 Moreover, arsenic has become the treatment of choice
for patients with recurrent APL after frontline treatment with ATRA and chemotherapy.6
ATRA and arsenic rapidly reduce the risk of hemorrhage and should be initiated as soon as APL is suspected.7 ATRA
was approved by the US Food and Drug Administration (FDA) in November 1995 and arsenic received FDA approval in
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September 2000. During the ATRA era, early death has
decreased overall, from approximately 20%8,9 to 5% to
10%.10 However, early death remains high in the United
States11,12 and Europe,13 implicating factors other than
ATRA.
Because recent studies have examined early death and
survival in patients aged15 years11,13,14 and there are few
reports of population-based studies in young patients with
APL (see Supporting Information Table S1), we investi-
gated early death and survival in patients in California who
were diagnosed between birth and age 39 years over a 25-
year period, and assessed the association of sociodemo-
graphic and clinical factors with these outcomes.
MATERIALS AND METHODS
Patient Selection
Data were obtained from the California Cancer Registry,
to which reporting is mandatory and completeness of
cases is at least 98%.15 We identified all patients with a
first, primary APL diagnosed between birth and age 39
years during 1988 through 2011 and followed until De-
cember 31, 2012. APL was diagnosed as histology code
9866 in the International Classification of Diseases for On-
cology, 3rd Edition.16 Of 784 patients identified, 4 were
excluded due to a missing date of diagnosis and 8 due to
unknown or Native American (small subgroup) race/eth-
nicity. The current study included 772 patients.
Institutional Review Board Approval
Ethics approval for human subjects research was obtained
from the Institutional Review Board of the Cancer Pre-
vention Institute of California. Because the analysis was
based on state-mandated cancer registry data, the study
was conducted in accordance with the waivers of individ-
ual informed consent and Health Insurance Portability
and Accountability Act (HIPAA) authorization.
Variables
The variables examined for their association with APL
outcomes were age at diagnosis, categorized as 4 groups
based on progressive decrements in survival17 (birth-9
years, 10-19 years, 20-29 years, and 30-39 years); sex; era
of diagnosis according to ATRA approval by the US FDA
(pre-ATRA era [1988-1995], earlier ATRA era [1996-
2003], and later ATRA era [2004-2011]); race/ethnicity
(non-Hispanic white [white], non-Hispanic black [black],
Hispanic, and non-Hispanic Asian/Pacific Islander
[Asian]); initial care at hospitals affiliated with National
Cancer Institute-designated cancer centers; type of health
insurance at the time of admission (routinely documented
starting in 1996) (none, public, private, or unknown/not
otherwise specified); and neighborhood socioeconomic
status (SES) based on block-level census data. Neighbor-
hood SES quintiles based on statewide distribution have
been used extensively in California.18
Information regarding hospital designation was
obtained from the initial reporting facility. There were no
data regarding the intensity of treatment or drugs used
(conventional genotoxic chemotherapy, ATRA and/or
arsenic).
Statistical Analysis
We used univariable and multivariable logistic regression
to investigate the association of the sociodemographic and
clinical factors with 7-day and 30-day mortality through
estimation of the odds ratios (ORs) and associated 95%
confidence intervals (95%CIs). We analyzed 30-day mor-
tality with and without patients who died within 7 days.
We estimated overall survival (all-cause survival) at 1 year
and 5 years using the Kaplan-Meier method, and com-
pared differences in survival across strata for each variable
using the log-rank test. We used univariable and multi-
variable Cox regression models to examine the association
of sociodemographic and clinical factors with the risk of
death through estimation of the hazard ratios and associ-
ated 95%CIs. Schoenfeld residuals were used to assess the
proportional hazard assumptions. We tested for interac-
tions between calendar periods, age groups, neighborhood
SES, and race/ethnicity. All statistical analyses were per-
formed by using Stata 13 statistical software (StataCorp,
College Station, Tex). A 2-sided P<.05 was considered
statistically significant.
RESULTS
Approximately 16% of all AML cases in the registry were
APL, the majority of which (79%) were diagnosed during
the ATRA era (after 1995). According to death certifi-
cates, most patients died of leukemia (228 patients; 90%);
a much smaller percentage of patients died of other (17
patients; 7%) or unknown (7 patients; 3%) causes. Fewer
than 2% of patients died of complications of APL treat-
ment, such as infection (2 patients), renal dysfunction
(1 patient), or heart failure (1 patient). Table 1 summa-
rizes patient characteristics.
Early Death
Among patients who experienced early death, the median
age at diagnosis was 29 years; 82 of these patients (11%)
died within 7 days and 133 (17%) died within 30 days of
diagnosis. Thirty-day mortality decreased significantly
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over the 3 eras from 26% in 1988 to 1995 (pre-ATRA) to
16% in 1996 to 2003 (earlier ATRA era) to 14% in 2004
to 2011 (later ATRA era) (P 5.004) (Table 1) (Fig. 1).
However, 7-day mortality showed no evidence of a signifi-
cant decrease. Onmultivariable analysis (Table 2), the odds
of 30-day mortality differed significantly between 1988 to
1995 and later eras (P5.001), but not between the eras of
1996 to 2003 and 2004 to 2011. Hispanic patients had a
risk of 30-day mortality that was approximately twice that
of white patients. After 1995, type of health insurance was
found to be significantly associated with both 7-day and
30-day mortality; the risk of 30-day mortality was approxi-
mately 3 times as high in uninsured as in privately insured
patients (OR, 2.67; 95% CI, 1.10-6.52). Early death was
not found to differ significantly between patients with pri-
vate versus public insurance (P5.243).
When patients with 7-day mortality (82 patients)
were excluded from analysis, the 30-day mortality
decreased from 15% during 1988 through 1995 to 8%
during 1996 through 2003 and 3% during 2004 through
2011 (P<.0001; data not shown). There was no evidence
of interactions between any variables.
Survival
During 0 to 25 years of follow-up (median in entire
cohort, 4.4 years), approximately 33% of patients (252
patients) died. Five-year survival increased from 46.7%
during 1988 to 1995 to 70.1% during 1996 to 2003 and
77.3% during 2004 to 2011 (P<.0001) (Table 1). Based
on the log-rank test, a lower survival estimate was signifi-
cantly associated with an earlier period of diagnosis, male
sex, older age at diagnosis, and lack of health insurance
(Table 1). On univariable analyses, survival was lower in
Hispanic and black patients versus white patients and
uninsured versus insured patients. In multivariable mod-
els, the era between 1988 and 1995, black and Hispanic
TABLE 1. Patient Characteristics, Early Mortality, and Overall Survival
Characteristic
7-Day
Mortality
(%) Pa
30-Day
Mortality
(%) Pa
1-Year
OS (%)
5-Year
OS (%) Pb
Totalc 772 (100) 82 (11.0) 133 (17.2) 78.0 (74.9–80.8) 68.1 (64.6–71.4)
Calendar period
1988–1995 (pre-ATRA) 163 (21.1) 22 (13.5) 42 (25.8) 61.7 (53.7–68.7) 46.7 (38.9–54.2)
1996–2003 (earlier ATRA era) 266 (34.5) 22 (8.3) 43 (16.2) 78.9 (73.5–83.4) 70.1 (64.2–75.2)
2004–2011 (later ATRA era) 343 (44.4) 38 (11.1) .229 48 (14.0) .004 85.1 (80.9–88.5) 77.3 (72.1–81.9) <.0001
Age at diagnosis, y
Birth to 9 50 (6.5) 2 (4.0) 4 (8.0) 84.0 (70.5–91.2) 71.8 (57.1–82.3)
10–19 172 (22.3) 17 (9.9) 26 (15.1) 81.4 (74.7–86.5) 69.8 (62.1–76.2)
20–29 225 (29.1) 27 (12.1) 38 (16.9) 79.9 (74.0–84.6) 73.2 (66.7–78.6)
30–39 325 (42.1) 36 (11.1) .396 65 (20.0) .152 74.0 (68.9–78.5) 63.1 (57.4–68.3) .023
Median, 27
Race/ethnicity
White 256 (33.2) 20 (7.8) 32 (12.5) 82.8 (77.6–86.9) 72.2 (66.1–77.4)
Black 45 (5.8) 7 (15.6) 9 (20.0) 73.3 (57.9–83.9) 56.6 (40.6–69.9)
Hispanic 388 (50.3) 46 (12.4) 79 (20.4) 74.9 (70.2–87.6) 66.5 (61.4–71.1)
Asian 83 (10.7) 9 (12.1) .266 13 (15.7) .070 80.6 (70.2–87.6) 69.2 (57.5–78.3) .068
Sex
Male 391 (50.7) 51 (13.3) 77 (19.7) 75.0 (70.4–79.0) 63.1 (57.8–67.8)
Female 381 (49.3) 31 (8.7) .028 56 (14.7) .066 81.1 (76.8–84.7) 73.2 (68.3–77.4) .005
Initial care at hospitals affiliated with NCI-designated cancer centers
NCI 155 (20.1) 11 (7.1) 20 (12.9) 81.2 (74.0–86.5) 73.1 (65.2–79.6)
Non-NCI 617 (79.9) 71 (11.4) .120 113 (18.3) .111 77.2 (73.7–80.3) 66.8 (62.8–70.5) .078
Neighborhood SES, quintile
1. Lowest 20% 216 (28.0) 26 (12.2) 42 (19.4) 75.3 (69.0–80.5) 66.3 (59.4–72.3)
2. 168 (21.8) 24 (14.0) 35 (20.8) 74.9 (67.5–80.8) 66.5 (58.6–73.3)
3. Middle 20% 151 (19.6) 12 (7.8) 24 (15.9) 78.8 (71.3–84.5) 66.9 (58.5–74.0)
4. 128 (16.6) 13 (10.2) 19 (14.8) 81.2 (73.3–87.0) 73.1 (64.2–80.1)
5. Highest 20% 109 (14.1) 7 (6.4) .187 13 (11.9) .275 83.5 (75.1–89.2) 70.0 (59.9–77.9) .425
Health insurance (only patients diagnosed in 1996–2011 [n 5 609])
None 45 (7.4) 14 (31.8) 19 (42.2) 53.1 (37.6–66.4) 50.6 (35.2–64.2)
Public 212 (34.8) 16 (7.4) 23 (10.9) 86.8 (81.4–90.7) 77.2 (70.6–82.5)
Private 294 (48.3) 27 (9.2) 45 (15.3) 82.0 (77.1–85.9) 74.4 (68.8–79.1)
Unknown/NOS 58 (9.5) 3 (5.1) <.0001 4 (6.9) <.0001 91.2 (80.2–96.3) 79.2 (65.5–88.0) 0.0001
Abbreviations: ATRA, all-trans retinoic acid; NCI, National Cancer Institute; NOS, not otherwise specified; OS, overall survival; SES, socioeconomic status.
a Chi-square P value for testing whether early death differed among groups for each variable.
b Log-rank P value comparing differences in survival across strata for each variable.
c Three patients were excluded due to missing day of diagnosis.
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race/ethnicity, and lack of health insurance remained sig-
nificantly associated with the hazard of death (Table 3).
There was no evidence of a difference in the hazard ratio
between patients with private versus those with public in-
surance (P5.999). There was no evidence of violation of
the Cox proportional hazard assumptions or of interac-
tions between any variables.
When we excluded patients who died within 30 days
of diagnosis in 1996 through 2011, the 5-year survival
increased from 77.8% (95%CI, 70.7%-83.3%) to 88.8%
(95% CI, 82.4%-93.0%) among patients aged birth to 19
years, and from 72.5% (95% CI, 67.8%-76.6%) to
86.3% (95% CI, 81.9%-89.7%) among patients aged 20
to 39 years (data not shown).
DISCUSSION
In the current population-based study, which spanned 25
years, 30-day mortality decreased significantly after 1995,
coinciding with the introduction of ATRA and guidelines
recommending aggressive blood product support and in-
tensive infection prophylaxis and treatment for suspected
APL. Nevertheless, 30-day mortality remained higher
than that observed in patients with non-APL subtypes of
AML,19 and 7-day mortality did not improve over time.
The findings of the current study suggest that factors
other than ATRA contributed to early death; these may
include the timing of diagnosis or chemotherapy, hospital
availability of ATRA/arsenic during the critical first 2 to 3
days after diagnosis, adequate blood products, and infec-
tion prophylaxis and treatment. A recent study of ran-
domly selected hospitals in the United States found that
<50% had ATRA, and one of the main barriers to avail-
ability was the absence of ATRA on their formularies.20
Patients who experienced an early death most likely
lacked early access to effective treatment and/or were too ill
when admitted; 10 patients in the current study died on the
day of diagnosis. The FDA’s approval of ATRA (and later
arsenic) may not have resulted in the wide or timely avail-
ability of these drugs across all hospitals in California.
Figure 1. Early death from acute promyelocytic leukemia in California after diagnosis between ages birth to 39 years. (A) Entire
study period (1988-2011). (B) Era prior to all-trans retinoic acid (pre-ATRA) (1988-1995). (C) Earlier ATRA era (1996-2003). (D)
Later ATRA era (2004-2011). Ten patients who died on the day of diagnosis were considered to have a survival time of 1 day.
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Moreover, despite the great effectiveness of ATRA
and arsenic, treatment may cause severe complications
that should be recognized and treated promptly, such as
differentiation syndrome. Differentiation syndrome
occurs in approximately 2% to 31% of patients receiving
induction therapy and can mimic other severe complica-
tions, such as pulmonary hemorrhage, renal dysfunction,
and heart failure.21 Because of the abrupt presentation
and potential gravity of differentiation syndrome, the pre-
emptive use of corticosteroids has been proposed.22 The
syndrome may be promoted by delaying chemotherapy
after ATRA,23 and delaying ATRA itself for>2 days may
increase the risk of fatal hemorrhage.24 These findings
confirm the importance of early diagnosis, rapid intensive
treatment, and adequate supportive care.
Importantly, we found that uninsured patients had a
higher risk of early death and lower survival estimates
compared with those with private and public insurance,
suggesting a lack of adequate access to care. The current
study results are consistent with a previous report of worse
survival in uninsured versus insured adolescents and
young adults (AYAs).25 Wider insurance coverage is likely
to provide better outcomes for these patients. In addition,
early death was higher among Hispanic patients, and sur-
vival was lower among black and Hispanic patients com-
pared with white patients. Similar findings have been
reported in children with acute lymphoblastic leuke-
mia,26,27 children with AML (excluding APL),28 and
adults with AML (including APL).14 To provide effective
and sustainable treatment to patients with APL, which is a
severe but highly curable disease, efforts also should
address the social contributors to health inequity29 such as
poverty, inadequate access to transportation, and lack of
educational resources.
TABLE 2. Relation of Sociodemographic and Clinical Factors with 30-Day Mortality
OR for 30-Day Mortality
Factor
Unadjusted OR1
(95% CI)
(1988–2011)
Adjusted OR2
(95% CI)
(1988–2011)
Adjusted OR3
(95% CI)
(1996–2011)
Adjusted OR4
(95% CI)
(1996–2011)
Calendar period
1988–1995 (pre-ATRA) 2.18 (1.37–3.46) 3.01 (1.66–5.46) NA NA
1996–2003 (earlier ATRA era) 1.20 (0.77–1.87) 1.39 (0.80–2.43) 1.41(0.81–2.46) 1.30 (0.74–2.30)
2004–2011 (later ATRA era) 1 (base) 1 (base) 1 (base) 1 (base)
Sex
Male 1.42 (0.97–2.07) 1.21 (0.76–1.96) 1.22 (0.70–2.13) 1.18 (0.67–2.08)
Female 1 (base) 1 (base) 1 (base) 1 (base)
Age at diagnosis, y
Birth to 9 1 (base) 1 (base) 1 (base) 1 (base)
10–19 2.06 (0.69–6.22) 1.90 (0.54–6.74) 1.78 (0.40–7.95) 2.01 (0.44–9.18)
20–29 2.36 (0.80–6.95) 1.83 (0.52–6.42) 1.67 (0.38–7.38) 1.72 (0.38–7.78)
30–39 2.90 (1.01–8.35) 2.48 (0.73–8.45) 2.61 (0.61–11.1) 2.61 (0.60–11.4)
Race/ethnicity
White 1 (base) 1 (base) 1 (base) 1 (base)
Black 1.75 (0.77–3.97) 1.82 (0.63–5.20) 2.48 (0.72–8.51) 2.37 (0.68–8.31)
Hispanic 1.79 (1.14–2.79) 2.13 (1.16–3.89) 2.20 (1.04–4.63) 2.23 (1.01–4.92)
Asian 1.3 (0.65–2.61) 1.35 (0.56–3.26) 1.11 (0.36–3.51) 1.24 (0.39–3.87)
Neighborhood SES, quintiles
1. Lowest 20% 1.80 (0.92–3.52) 1.03 (0.44–2.44) 0/83 (0.28–2.52) 0.87 (0.27–2.80)
2. 1.91 (0.96–3.79) 1.08 (0.46–2.53) 0.99 (0.33–2.92) 1.03 (0.33–3.20)
3. Middle 20% 1.38 (0.67–2.84) 0.93 (0.39–2.23) 0.88 (0.29–2.72) 0.93 (0.29–3.01)
4. 1.30 (0.61–2.77) 0.81 (0.32–2.02) 0.79 (0.25–2.53) 0.83 (0.25–2.72)
5. Highest 20% 1 (base) 1 (base) 1 (base) 1 (base)
Initial care at hospitals affiliated with NCI-designated cancer centers
Yes 1 (base) 1 (base) 1 (base) 1 (base)
No 1.53 (0.92–2.55) 1.07 (0.57–2.00) 1.30 (0.62–2.72) 1.19 (0.55–2.56)
Health insurance (limited to patients diagnosed between 1996–2011 [n 5 609])
None 3.91 (2.01–7.62) NA NA 2.67 (1.10–6.52)
Public 0.66 (0.39–1.13) NA NA 0.66 (0.32–1.33)
Private 1 (base) NA NA 1 (base)
Unknown/NOS 0.40 (0.14–1.17) NA N/A 0.22 (0.06–0.79)
Abbreviations: 95% CI, 95% confidence interval; ATRA, all-trans retinoic acid; NA, not applicable; NCI, National Cancer Institute; NOS, not otherwise specified;
OR, odds ratio; OR1, unadjusted model (1988–2011); OR2, adjusted model without insurance (1988–2011); OR3, adjusted model without insurance (1996–
2011); OR4, adjusted model with insurance (1996–2011); SES, socioeconomic status.
All multivariable comparisons were adjusted for chemotherapy (yes/no) and all variables in the table unless otherwise noted.
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In general, population-based studies,11,12 such as the
current one, demonstrate a greater percentage of cases of
early death compared with multiinstitutional protocols.
The differing findings may reflect the exclusion of patients
who died during the first week or were too ill for chemo-
therapy in prior studies.30 In the current study, when we
excluded deaths that occurred within 7 days, we found
30-day mortality during the ATRA era to approximate
that in clinical trials.10,31 Similarly, when we excluded
patients who died within 30 days of diagnosis, 5-year sur-
vival was close to that reported in multiinstitutional trials
in children and AYAs.32,33 These observations suggest
that selection bias may contribute to the differences in
reported survival and early death between most clinical
trials and population-based studies.
The current study had several limitations. Hospi-
tal designation was limited to the location of initial
care at the reporting facility, and therefore it is possi-
ble that some patients diagnosed at one type of facility
were subsequently treated at another. However, 92%
of the patients in the current study received at least
part of their treatment at the reporting facility, sug-
gesting that the current study findings were not sub-
stantially influenced by this factor. We also lacked
data regarding patients’ risk classification at the time
of diagnosis, laboratory data, and blood products
administered. Although this information would likely
have contributed additional important findings, dis-
ease outcomes such as early death and survival are of
paramount concern. Survival is a measure of the can-
cer burden and the effectiveness of the health system
and plays a key role in the development of health poli-
cies.34 Our large California APL cohort allowed us to
compare early death and survival across treatment eras
and to investigate sociodemographic factors associated
with outcomes. To our knowledge, the current study
is the first population-based study to investigate the
association of race/ethnicity with early death and
TABLE 3. Relation of Sociodemographic and Clinical Factors to the Hazard of Death
Factor
Death
No. (%)
Unadjusted HR1
(95% CI)
(1988–2011)
Adjusted HR2
(95% CI)
(1988–2011)
Adjusted HR3
(95% CI)
(1996–2011)
Adjusted HR4
(95% CI)
(1996–2011)
Calendar period
1988–1995 (pre-ATRA) 94 (37.3) 2.79 (2.04–3.80) 2.84 (2.06–3.91) NA NA
1996–2003 (earlier ATRA era) 86 (34.1) 1.39 (1.01–1.90) 1.39 (1.01–1.91) 1.43 (1.04–1.98) 1.40 (1.01–1.94)
2004–2011 (later ATRA era) 72 (28.6) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base)
Age at diagnosis, y
Birth to 9 14 (5.6) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base)
10–19 52 (20.6) 1.14 (0.63–2.05) 1.07 (0.58–1.96) 1.13 (0.51–2.52) 1.20 (0.54–2.67)
20–29 60 (23.8) 1.03 (0.58–1.85) 0.99 (0.54–1.81) 0.98 (0.44–2.16) 0.96 (0.43–2.14)
30–39 126 (50.0) 1.56 (0.90–2.72) 1.43 (0.80–2.53) 1.82 (0.85–3.88) 1.83 (0.85–3.93)
Race/ethnicity
White 73 (29.0) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base)
Black 20 (7.9) 1.79 (1.09–2.93) 1.81 (1.08–3.03) 1.97 (0.98–3.96) 1.80 (0.89–3.62)
Hispanic 134 (53.2) 1.33 (1.00–1.77) 1.48 (1.08–2.02) 1.38 (0.90–2.12) 1.31 (0.84–2.03)
Asian 25 (9.09) 1.11 (0.70–1.75) 1.21 (0.76–1.91) 1.11 (0.58–2.12) 1.12 (0.58–2.15)
Sex
Male 145 (57.5) 1.42 (1.11–1.83) 1.27 (0.98–1.64) 1.52 (1.10–2.11) 1.50 (1.08–2.07)
Female 107 (42.5) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base)
Neighborhood SES, quintile
1. Lowest 20% 75 (29.8) 1.24 (0.82–1.86) 0.90 (0.57–1.41) 1.02 (0.54–1.94) 0.98 (0.51–1.89)
2. 58 (23.0) 1.20 (0.79–1.83) 0.94 (0.60–1.46) 1.01 (0.53–1.90) 1.00 (0.53–1.90)
3. Middle 20% 52 (20.6) 1.15 (0.75–1.77) 0.93 (0.60–1.46) 0.95 (0.50–1.82) 0.94 (0.49–1.80)
4. 33 (13.1) 0.86 (0.53–1.39) 0.72 (0.44–1.18) 0.76 (0.38–1.51) 0.75 (0.37–1.49)
5. Highest 20% 34 (13.5) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base)
Initial care at hospitals affiliated with NCI-designated cancer centers
Yes 41 (16.3) 1.0 (base) 1.0 (base) 1.0 (base) 1.0 (base)
No 211 (83.7) 1.35 (0.97–1.88) 1.07 (0.75–1.52) 1.31 (0.83–2.06) 1.26 (0.79–1.99)
Health insurance (only patients diagnosed between 1996–2011 [n 5 609])
None 22 (13.9) 2.57 (1.59–4.14) NA NA 2.00 (1.20–3.31)
Public 49 (31.0) 0.91 (0.63–1.31) NA NA 1.00 (0.67–1.48)
Private 74 (46.) 1.0 (base) NA NA 1.0 (base)
Unknown/NOS 13 (8.2) 0.82 (0.46–1.48) NA NA 0.64 (0.35–1.17)
Abbreviations: 95% CI, 95% confidence interval; ATRA, all-trans retinoic acid; HR, hazard ratio; HR1, unadjusted model (1988–2011); HR2, adjusted model
without insurance (1988–2011); HR3, adjusted model without insurance (1996–2011); HR4, adjusted model with insurance (1996–2011); NA, not applicable;
NCI, National Cancer Institute; NOS, not otherwise specified; SES, socioeconomic status.
All multivariable comparisons were adjusted for chemotherapy (yes/no) and all variables in the table unless otherwise noted.
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survival in children with APL and to consider the
association of outcome with health insurance, hospital
type, age, sex, treatment era, and neighborhood SES.
Furthermore, unlike previous population-based stud-
ies,11,12,19 we were able to assess 7-day mortality.
The findings of the current study indicate a true
reduction in 30-day mortality among children and AYAs
with APL in California, suggesting adherence to modern
therapeutic strategies. However, 7-day mortality remained
high, suggesting that factors other than ATRA played a role
in early death. We identified subgroups of patients who
were vulnerable to early death and reduced survival, includ-
ing the uninsured and Hispanic patients. Black patients
also experienced worse survival. To improve outcomes
among young patients with APL, efforts should focus on
improving access to effective treatment, mainly among
uninsured patients and those of Hispanic and black race/
ethnicity.
FUNDING SUPPORT
Supported by Children with Cancer UK (to Dr. Abrah~ao), Cancer
Center Support (CORE) grant P30 CA021765-30 from the
National Institutes of Health (to Dr. Ribeiro), and the American
Lebanese Syrian Associated Charities (to Dr. Ribeiro). Also sup-
ported by the Stanford Cancer Institute (to Dr. Keegan) and the
California Department of Public Health as part of the mandated
statewide cancer reporting program (California Health and Safety
Code Section 103885) and the Surveillance, Epidemiology, and
End Results (SEER) Program of the National Cancer Institute
(NCI) under contracts HHSN261201000140C awarded to the
Cancer Prevention Institute of California, HHSN261201000035C
awarded to the University of Southern California, and HHSN
261201000034C awarded to the Public Health Institute; and the
Centers for Disease Control and Prevention’s National Program of
Cancer Registries, under agreements U55/CCR921930-02
awarded to the Public Health Institute and U58DP003862-01
awarded to the California Department of Public Health. The ideas
and opinions expressed herein are those of the authors, and endorse-
ment by the State of California Department of Public Health, the
National Cancer Institute, and the Centers for Disease Control and
Prevention or their contractors and subcontractors is neither
intended nor should be inferred.
CONFLICT OF INTEREST DISCLOSURES
The authors made no disclosures.
REFERENCES
1. Soignet SL, Frankel SR, Douer D, et al. United States multicenter
study of arsenic trioxide in relapsed acute promyelocytic leukemia.
J Clin Oncol. 2001;19:3852-3860.
2. Ribeiro RC, Rego E. Management of APL in developing countries:
epidemiology, challenges and opportunities for international collabo-
ration. Hematology Am Soc Hematol Educ Program. 2006:162-168.
3. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute
promyelocytic leukemia: recommendations from an expert panel
on behalf of the European LeukemiaNet. Blood. 2009;113:
1875-1891.
4. Iland HJ, Bradstock K, Supple SG, et al; Australasian Leukaemia
and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV
arsenic trioxide as initial therapy in acute promyelocytic leukemia
(APML4). Blood. 2012;120:1570-1580; quiz 1752.
5. Rego EM, Kim HT, Ruiz-Arguelles GJ, et al. Improving acute pro-
myelocytic leukemia (APL) outcome in developing countries through
networking, results of the International Consortium on APL. Blood.
2013;121:1935-1943.
6. Lengfelder E, Lo-Coco F, Ades L, et al; European LeukemiaNet. Ar-
senic trioxide-based therapy of relapsed acute promyelocytic leuke-
mia: registry results from the European LeukemiaNet. Leukemia.
2015;29:1084-1091.
7. Howard SC, Ribeiro RC, Pui CH. Acute complications. In: Pui
CH, ed. Childhood Leukemias (pp. 152, 215, 672), Cambridge,
United Kingdom: University Press; 2012.
8. Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early
deaths and anti-hemorrhagic treatments in acute promyelocytic leu-
kemia. A GIMEMA retrospective study in 268 consecutive patients.
Blood. 1990;75:2112-2117.
9. Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN,
Clarkson BD. Acute promyelocytic leukemia: treatment results dur-
ing a decade at Memorial Hospital. Blood. 1989;73:1116-1122.
10. Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic mor-
bidity and mortality during remission induction with or without all-
trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol.
2000;108:689-695.
11. McClellan JS, Kohrt HE, Coutre S, et al. Treatment advances have
not improved the early death rate in acute promyelocytic leukemia.
Haematologica. 2012;97:133-136.
12. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute pro-
myelocytic leukemia remains high despite all-trans retinoic acid.
Blood. 2011;118:1248-1254.
13. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death
rate in acute promyelocytic leukemia: a population-based report
from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;
25:1128-1134.
14. Patel MI, Ma Y, Mitchell BS, Rhoads KF. Age and genetics: how do
prognostic factors at diagnosis explain disparities in acute myeloid
leukemia? Am J Clin Oncol. 2015;38:159-164.
15. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statis-
tics, trends, and multiple primary cancer analyses from the Surveil-
lance, Epidemiology, and End Results (SEER) Program. Oncologist.
2007;12:20-37.
16. Fritz A, Percy C, Jack A, et al, eds; World Health Organization.
International Classification of Diseases for Oncology. 3rd ed. Ge-
neva, Switzerland: World Health Organization; 2000.
17. Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F. Acute promy-
elocytic leukemia: a population-based study on incidence and survival
in the United States, 1975–2008. Cancer. 2012;118:5811-5818.
18. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic
status and breast cancer incidence in California for different race/eth-
nic groups. Cancer Causes Control. 2001;12:703-711.
19. Percival ME, Tao L, Medeiros BC, Clarke CA. Improvements in the
early death rate among 9380 patients with acute myeloid leukemia
after initial therapy: a SEER database analysis. Cancer. 2015;121:
2004-2012.
20. Mogasala N, Perissinotti A, Bixby D. Clinical availability of all-trans
retinoic acid (ATRA) for patients with suspected acute promyelocytic
leukemia–why national guidelines may not be followed. Poster ses-
sion presented at: 56th ASH Annual Meeting and Exposition; De-
cember 6–9, 2014; San Francisco, CA.
21. Rogers JE, Yang D. Differentiation syndrome in patients with acute
promyelocytic leukemia. J Oncol Pharm Pract. 2012;18:109-114.
22. Sanz MA, Montesinos P. How we prevent and treat differentiation
syndrome in patients with acute promyelocytic leukemia. Blood.
2014;123:2777-2782.
23. Tallman MS, Manji GA. Don’t just stand there, do something: strat-
egies for the prevention of early death in acute promyelocytic leuke-
mia: a commentary. Blood Cells Mol Dis. 2011;46:173-174.
Original Article
3996 Cancer November 15, 2015
24. Altman JK, Rademaker A, Cull E, et al. Administration of ATRA to
newly diagnosed patients with acute promyelocytic leukemia is delayed
contributing to early hemorrhagic death. Leuk Res. 2013;37:1004-1009.
25. Aizer AA, Falit B, Mendu ML, et al. Cancer-specific outcomes
among young adults without health insurance. J Clin Oncol. 2014;
32:2025-2030.
26. Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS,
Robison LL. Racial and ethnic differences in survival of children
with acute lymphoblastic leukemia. Blood. 2002;100:1957-1964.
27. Abrahao R, Lichtensztajn DY, Ribeiro RC, et al. Racial/ethnic and
socioeconomic disparities in survival among children with acute lym-
phoblastic leukemia in California, 1988–2011: a population-based
observational study [published online ahead of print April 20,
2015]. Pediatr Blood Cancer. doi: 10.1002/pbc.25544.
28. Aplenc R, Alonzo TA, Gerbing RB, et al. Ethnicity and survival in
childhood acute myeloid leukemia: a report from the Children’s On-
cology Group. Blood. 2006;108:74-80.
29. Wong WF, LaVeist TA, Sharfstein JM. Achieving health equity by
design. JAMA. 2015;313:1417-1418.
30. Estey EH, Hutchinson F. Newly diagnosed acute promyelocytic leu-
kemia: arsenic moves front and center. J Clin Oncol. 2011;29:2743-
2746.
31. Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic compli-
cations during remission induction therapy for acute promyelocytic
leukemia: incidence, risk factors, and influence on outcome. Eur J
Haematol. 2007;78:213-219.
32. Testi AM, Biondi A, Lo Coco F, et al. GIMEMA-AIEOPAIDA pro-
tocol for the treatment of newly diagnosed acute promyelocytic leu-
kemia (APL) in children. Blood. 2005;106:447-453.
33. Gore SD, Gojo I, Sekeres MA, et al. Single cycle of arsenic trioxide-
based consolidation chemotherapy spares anthracycline exposure in
the primary management of acute promyelocytic leukemia. J Clin
Oncol. 2010;28:1047-1053.
34. Allemani C, Weir HK, Carreira H, et al; CONCORD Working
Group. Global surveillance of cancer survival 1995–2009: analysis of
individual data for 25,676,887 patients from 279 population-based
registries in 67 countries (CONCORD-2). Lancet. 2015;385:977-
1010.
Early Death After APL in Children and AYA/Abrah~ao et al
Cancer November 15, 2015 3997
Predictors of early death and survival among children,
adolescents and young adults with acute myeloid leukaemia
in California, 1988–2011: a population-based study
Renata Abrah~ao,1,2 Ruth H. Keogh,3
Daphne Y. Lichtensztajn,2 Rafael
Marcos-Gragera,4 Bruno C. Medeiros,5
Michel P. Coleman,1 Raul C. Ribeiro6
and Theresa H. M. Keegan2,7
1Department of Non-Communicable Disease
Epidemiology, London School of Hygiene and
Tropical Medicine, London, UK, 2Cancer
Prevention Institute of California, Fremont, CA,
USA, 3Department of Medical Statistics, London
School of Hygiene and Tropical Medicine,
London, UK, 4Epidemiology Unity and Cancer
Registry of Girona, Girona Biomedical Research
Institute, Girona, Spain, 5Division of Hematol-
ogy, Stanford University School of Medicine,
Stanford, CA, 6Leukemia and Lymphoma
Division, Department of Oncology, St. Jude
Children’s Research Hospital, Memphis, TN,
and 7Division of Hematology and Oncology,
Department of Internal Medicine, University of
California Davis School of Medicine,
Sacramento, CA, USA
Received 3 October 2015; accepted for
publication 7 December 2015
Correspondence: Renata Abrah~ao, London
School of Hygiene and Tropical Medicine,
Keppel Street, London WC1E 7HT, UK.
E-mails: renataabrahao8901@gmail.com; renata.
abrahao@lshtm.ac.uk
Summary
A better understanding of factors associated with early death and survival
among children, adolescents and young adults with acute myeloid leukae-
mia (AML) may guide health policy aimed at improving outcomes in these
patients. We examined trends in early death and survival among 3935
patients aged 0–39 years with de novo AML in California during 1988–2011
and investigated the associations between sociodemographic and selected
clinical factors and outcomes. Early death declined from 97% in 1988–
1995 to 71% in 2004–2011 (P = 0062), and survival improved sub-
stantially over time. However, 5-year survival was still only 50% (95%
confidence interval 47–53%) even in the most recent treatment period
(2004–2011). Overall, the main factors associated with poor outcomes were
older age at diagnosis, treatment at hospitals not affiliated with National
Cancer Institute-designated cancer centres, and black race/ethnicity. For
patients diagnosed during 1996–2011, survival was lower among those who
lacked health insurance compared to those with public or private insur-
ance. We conclude that mortality after AML remained strikingly high in
California and increased with age. Possible strategies to improve outcomes
include wider insurance coverage and treatment at specialized cancer
centres.
Keywords: acute myeloid leukaemia, survival, early death,
population-based.
Acute myeloid leukaemia (AML) is a complex and highly
heterogeneous disease. Without treatment, most patients die
within weeks or months of diagnosis (Appelbaum et al,
2006). Survival among patients with AML has increased over
the last 3 decades, mostly among patients younger than
60 years of age, but progress has now reached a plateau
(Pritchard-Jones et al, 2013; Ribeiro, 2014) and acute leukae-
mias, including AML, remain the leading cause of cancer
deaths among patients aged 39 years or younger (Wingo
et al, 2003; Deschler & Lubbert, 2006). Although complete
remission can be achieved in approximately 75–90% of
patients younger than 60 years of age, approximately 35–
50% of these patients experience relapse within the following
2 years (Hann et al, 2004; Burnett, 2005). Disturbingly, chil-
dren, adolescents and young adults who survive AML may
suffer long-term debilitating complications of treatment, such
as secondary malignancies, cardiovascular and neurocognitive
dysfunctions, as well as severe psychosocial effects (Sekeres
et al, 2004; Mulrooney et al, 2008; Byrne et al, 2011; Dores
et al, 2012; Sullivan et al, 2013; Schultz et al, 2014).
Given the lack of population-based studies focusing on
young patients with AML (Pulte et al, 2009), we aimed to
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evaluate trends in survival and early death (i.e., death
occurring within 30 d of diagnosis) among patients aged
0–39 years with AML in California, and investigate sociode-
mographic and selected clinical factors associated with poor
outcomes.
Patients and methods
Patients
Our data were obtained from the California Cancer Registry
(CCR), which participates in the Survival Epidemiology and
End Results (SEER) Programme of the National Cancer
Institute (NCI). Reporting of all malignant neoplasms is
compulsory in California, and the standard for completeness
of ascertainment is at least 98% (Hayat et al, 2007). In addi-
tion to relevant variables available in the SEER datasets, the
CCR provides information on hospital designation (i.e.,
whether the initial reporting hospital is affiliated with a
NCI-designated cancer centre), whether the patient has
undergone chemotherapy or haematopoietic stem cell trans-
plantation (HSCT) and neighbourhood socioeconomic status
(SES).
Ethics approval for human subject research was obtained
from the Cancer Prevention Institute of California Institu-
tional Review Board. As the analysis was based on state-man-
dated cancer registry data, the study was conducted in
accordance with the waivers of individual informed consent
and Health Insurance Portability and Accountability Act
authorization.
We identified all patients aged 0–39 years who were diag-
nosed with de novo AML between 1 January 1988 and 31
December 2011, and excluded those with acute promyelo-
cytic leukaemia, which has a much more favourable progno-
sis than the other subtypes of AML and was the focus of a
separate study (Abrah~ao et al, 2015a). Information on
patients with AML associated with Down syndrome (who
also have a better prognosis) was only available in the CCR
from 2010 onwards; prior to that, these cases were classified
as ‘AML not otherwise specified’. Therefore, it was not possi-
ble to study these patients separately.
To identify cases of AML diagnosed during 1988–2011, we
used the following morphology codes from the International
Classification of Diseases for Oncology, 3rd edition (ICD-O-3)
(World Health Organization, 2000): 9840, 9861, 9867, 9870–
9874, 9891, 9895–9898, 9910, 9920, and 9931. We excluded
patients diagnosed by autopsy or death certificate only
(n = 12), patients of non-Hispanic American Indian
(n = 20) or unknown (n = 18) race/ethnicity and patients
with a missing month of diagnosis (n = 22). Patients who
died on the day of diagnosis (n = 28) were included. Of the
4007 patients reviewed, 3935 (982%) were included in the
analyses. All the patients were followed from the date of
diagnosis until death, loss to follow-up or the end of the
study (31 December 2012), whichever occurred first.
Demographic and clinical variables
We examined early death and survival with a comprehensive
set of variables in order to identify the main factors associ-
ated with poorer prognosis among young patients (≤39 years
of age). Age is independently associated with survival after
AML, and a progressive survival decline is observed from
10 years of age (Horibe et al, 2001; Razzouk et al, 2006;
Walter et al, 2011; Gatta et al, 2014; Ofran & Rowe, 2014).
Based on these observations, we categorized age in four
groups (0–9, 10–19, 20–29, and 30–39 years). To evaluate
trends in outcomes, we used three calendar periods of diag-
nosis (1988–1995, 1996–2003, and 2004–2011). Race/ethnic-
ity was classified in 4 groups [non–Hispanic white (white),
non-Hispanic black (black), Hispanic, and non-Hispanic
Asian/Pacific Islander (Asian)]. Neighbourhood SES was
divided into quintiles by using a previous developed index
(Yost et al, 2001), which is based on block-level census data,
and is considered an adequate surrogate to SES at the indi-
vidual level (Glaser et al, 2014; Tao et al, 2014). Patients’
health insurance status was routinely reported by the CCR
from 1996 onwards and was categorized in 4 groups [unin-
sured, publicly insured, privately insured or unknown/not
otherwise specified (NOS)]. Binary variables were sex (male/
female) and initial care at hospitals affiliated with NCI-desig-
nated cancer centres (Y/N).
We provided descriptive information on chemotherapy
and HSCT, that, like all treatment data collected by the CCR,
is limited to the first course of treatment, with no details on
treatment regimens or intensity. Information on HSCT was
routinely reported from 2003 onwards; however, it was also
abstracted for patients diagnosed during 1996–2002, when
available.
Statistical analysis
Our analyses investigated how the following variables repre-
senting sociodemographic and clinical characteristics were
associated with early death and overall survival: age at diag-
nosis, treatment period, sex, race/ethnicity, neighbourhood
SES, health insurance status, and treatment facility. All of the
variables considered had a priori hypothesized or previously
observed (Bradley et al, 2011; Walter et al, 2011; Wolfson
et al, 2012; Pulte et al, 2013; Patel et al, 2015a; Percival et al,
2015) associations with early death or survival. We also
hypothesized that sociodemographic factors would have a
greater impact on survival in older versus younger patients
and investigated this hypothesis by analysing the hazard of
death by age group.
Early death. Chi-squared tests were used for testing whether
early death differed among groups for each covariate. The
Kruskal–Wallis test was also used for ordinal covariates (age
group, neighbourhood SES and calendar period). We used
multivariate logistic regression to obtain the odds ratios (ORs)
Survival Predictors After Acute Myeloid Leukaemia
ª 2016 John Wiley & Sons Ltd 293
British Journal of Haematology, 2016, 173, 292–302
for early death (death within 30 d of diagnosis) and the corre-
sponding 95% confidence intervals (95% CIs) associated with
sociodemographic and clinical characteristics. We used the
likelihood ratio test as an overall significance test for the asso-
ciation of each independent variable with early death.
Survival. We estimated the overall (all causes) survival at 1,
5, and 10 years by using the Kaplan–Meier method and
tested differences in survival across strata of each variable
with the log-rank test (the log-rank test for trend was also
estimated for ordinal variables). Twenty-eight patients who
died on the day of diagnosis were considered to have a sur-
vival time of 1 d.
The 5-year survival in the three calendar periods examined
and the 10-year survival in 1988–1995 and 1996–2003 were
estimated using the traditional cohort-based approach,
because most patients had been followed for at least 5 or
10 years, respectively, during these time periods. For patients
who had all been followed up for at least 10 years, the classi-
cal cohort approach provided survival estimates using all the
observed follow-up data. For patients with less than 5 (or
10) years of follow-up, we used the period approach (Bren-
ner et al, 2004) to obtain a short-term prediction of their
survival up to 5 (or 10) years after diagnosis on the assump-
tion that their partial probabilities of survival will be the
same as those observed during the most recent years for
which follow-up data were available.
We used multivariate Cox regression to obtain the hazard
ratios (HRs) and corresponding 95% CIs for each variable,
and the likelihood ratio test as an overall significance test for
the association of each independent variable with survival.
The proportional hazard assumption, assessed by looking at
Schoenfeld residuals, was met for all variables in the multi-
variate model. To investigate whether the association of sur-
vival with sociodemographic and clinical factors varied with
age, we fitted separate Cox models by age group (0–9, 10–19,
20–29 and 30–39 years) and tested for interactions between
age group and each variable using the likelihood ratio test.
Statistical analyses were performed using Stata 13 software
(StataCorp, College Station, TX, USA), and a 2-sided P value
of less than 005 was considered statistically significant.
Results
Sociodemographic and clinical characteristics
Among 3935 patients, the median age at diagnosis was
23 years (range, 0–39 years), with a slight predominance of
males (535%) (Table I). Most patients were white (41%) or
Hispanic (39%) and were treated at hospitals that were not
affiliated with NCI-designated cancer centres (74%). For
patients diagnosed during 1996–2011, 85% had health insur-
ance (46% had private insurance and 39% had public insur-
ance), 4% were uninsured and 11% had unknown or not
otherwise specified health insurance status.
Chemotherapy was administered to 93% of patients; it
was recommended, but not given, to 2% of patients, and
refused by 02% of patients (or their families). A total of 690
patients (26%) received HSCT; 324 (27%) of those diagnosed
during 1996–2003 and 366 (30%) of those diagnosed during
2004–2011. Leukaemia was the cause of death in 88% of
patients; a small percentage died of other (9%) or unknown
(3%) causes. Of the deaths resulting from other causes, 3%
were caused by infections (data not shown).
Early death
In total, 332 patients (84%) died within 30 d of diagnosis.
There was a trend towards a reduction in early death over
time, from 97% in 1988–1995 to 86% in 1996–2003 to
71% in 2004–2011 (P = 0062) (Table I). Overall, in unad-
justed analyses, early death was strongly associated with age,
hospital designation, neighbourhood SES, and health insur-
ance status (Table I). In multivariate analyses in which all
variates were mutually adjusted (Table II), the odds of early
death increased progressively with age: the OR for older
patients (aged 30–39 years) was increased by 70% relative to
that for younger patients (aged 0–9 years) (OR = 170, 95%
CI 122–238). Patients treated at hospitals not affiliated with
NCI-designated cancer centres had a higher risk of early
death compared with those treated at hospitals affiliated with
such centres (OR = 175, 95% CI 128–239). Uninsured
patients diagnosed during 1996–2011 had an approximately
3 times greater risk of early death than privately insured
patients (OR = 291, 95% CI 165–512); there was no evi-
dence of such a difference between publicly and privately
insured patients (P = 0849). Patients living in the lowest
SES neighbourhoods had a significantly greater risk of early
death than patients living in the highest SES neighbourhoods
(OR = 157, 95% CI 105–234).
Survival
Of 3935 patients included in the analysis, 2272 (58%) died
over the course of follow-up. Approximately 93% of patients
had confirmation of vital status within 18 months of the
study end date. The median time to death for deceased
patients was 09 years, the median follow-up time for surviv-
ing patients was 88 years, and the overall median follow-up
time using reverse censoring (Schemper & Smith, 1996) was
100 years. Overall survival improved substantially over time
for all ages and racial/ethnic groups. Five-year survival
increased from 329% (95% CI 303–355) in 1988–1995 to
50% (95% CI 470–529) in 2004–2011 (Table I). Based on
the log-rank test, there was evidence of an association
between worse survival and older age at diagnosis (Fig 1),
black race/ethnicity, receipt of initial care in hospitals not
affiliated with NCI-designated cancer centres, and, for
patients diagnosed during 1996–2011, lack of health insur-
ance. In a multivariate Cox regression analysis in which all
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variables were mutually adjusted (Table III), we found an
increased hazard of death for older patients compared with
younger patients (30–39 vs. 0–9 years of age) (HR = 155,
95% CI 138–174), for black patients compared with white
patients (HR = 127, 95% CI 108–149), and for patients
who received initial care at hospitals not affiliated with NCI-
designated cancer centres compared with those initially trea-
ted at such facilities (HR = 118, 95% CI 107–131). For
patients diagnosed during 1996–2011, the hazard of death
was higher among uninsured patients than among privately
insured patients (HR = 134, 95% CI 101–178), with no
evidence of a difference in hazard between privately and pub-
licly insured patients (P = 0429).
When we fitted separate Cox models by age at diagnosis
(Tables IV and V), we observed that the association between
the hazard of death and sociodemographic and clinical fac-
tors varied by age group. Table IV presents Cox models for
the factors available during 1988–2011 (all variables except
health insurance status) by age group at diagnosis. Table V
additionally includes health insurance status, but is limited
to patients diagnosed during 1996–2011. For patients aged
0–9 years, we found no association between the risk of death
and sociodemographic or clinical factors, whereas associa-
tions were found with advancing age (Table IV). Markedly,
for patients aged 30–39 years, the hazard of death was sub-
stantially higher among those who received initial care at
Table I. Patient characteristics, early death and overall survival in patients aged 0–39 years with acute myeloid leukaemia in California, 1988–
2011.
Characteristics
Total
N (%)
Early death
N (%) P*
1-year OS
(95% CI)
5-year OS
(95% CI)
10-year OS‡
(95% CI) P†
Total 3935 (100) 332 (84) 668 (653–683) 428 (412–444) 396 (380–413)
Calendar period
1988–1995 1303 (331) 126 (97) 00620/00626 593 (566–620) 329 (303–355) 307 (283–333) <00001/<00001
1996–2003 1299 (330) 111 (86) 681 (654–705) 458 (430–485) 424 (396–451)
2004–2011 1333 (339) 95 (71) 728 (703–751) 500 (470–529) 452 (425–479)
Age at diagnosis, years
0–9 964 (245) 55 (57) <00001/00003 732 (703–759) 524 (491–556) 500 (461–529) <00001/<00001
10–19 733 (186) 52 (71) 698 (663–730) 447 (409–484) 414 (376–452)
20–29 951 (242) 94 (99) 648 (616–677) 404 (372–437) 379 (346–411)
30–39 1287 (327) 131 (102) 617 (589–643) 362 (335–389) 326 (299–354)
Median 23 27
Race/ethnicity
Non–Hispanic white 1607 (408) 131 (82) 00230 654 (630–677) 443 (418–467) 408 (382–433) 00087
Non–Hispanic black 276 (70) 27 (98) 607 (546–661) 331 (274–388) 315 (258–372)
Hispanic 1545 (393) 147 (95) 682 (658–705) 428 (402–454) 396 (369–423)
Asian/Pacific Islander 507 (129) 27 (53) 702 (659–740) 428 (383–473) 403 (357–448)
Sex
Male 2106 (535) 188 (89) 02360 668 (647–688) 418 (396–440) 390 (368–412) 03151
Female 1829 (465) 144 (79) 667 (645–689) 439 (416–463) 404 (380–428)
Initial care at hospitals affiliated with NCI-designated cancer centres
Yes 1039 (264) 53 (51) <00001 723 (695–750) 494 (462–525) 468 (435–500) <00001
No 2896 (736) 279 (96) 648 (630–665) 404 (386–423) 371 (352–390)
Neighbourhood socioeconomic status (quintiles)
Lowest 20% 986 (251) 108 (110) 00180/00178 651 (620–684) 421 (389–454) 388 (354–421) 01446/00338
826 (210) 61 (79) 683 (650–714) 410 (375–445) 377 (342–412)
Middle 20% 783 (199) 64 (82) 648 (613–680) 403 (367–438) 371 (335–406)
714 (181) 57 (80) 680 (644–713) 462 (424–500) 429 (390–467)
Highest 20% 626 (159) 42 (67) 684 (646–719) 455 (414–494) 431 (390–471)
Health insurance status (limited to patients diagnosed in 1996–2011, N = 2632)
None 99 (38) 21 (212) <00001 563 (457–657) 379 (277–480) 379 (277–480) 00045
Public 1038 (394) 78 (75) 719 (690–745) 476 (444–509) 438 (403–472)
Private 1207 (459) 86 (71) 710 (683–735) 499 (470–528) 465 (435–495)
Unknown/NOS 288 (109) 21 (73) 679 (621–730) 426 (366–484) 371 (311–432)
OS, overall survival; CI, confidence interval; NOS, not otherwise specified; NCI, National Cancer Institute.
*The chi-squared was used to test whether early death differs among groups for each variable. For ordinal variables, the Kruskal–Wallis test also
is reported (value on the right).
†The log-rank was used to test differences in survival across strata for each variable. The log-rank test for trend also is reported for ordinal vari-
ables (value on the right).
‡Ten-year survival during 2004–2011 was estimated using the period approach.
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hospitals not affiliated with NCI-designated cancer centres
(HR = 131, 95% CI 108–158) (Table IV) and, during
1996–2011, among uninsured patients (HR = 178, 95% CI
114–276) (Table V). We also observed an increased risk of
death among black patients, particularly those aged 20–
29 years (HR = 170, 95% CI 121–239) (Table IV). How-
ever, despite observed differences in associations between the
explanatory variables and survival by age group, none of
these were found to be statistically significant when tested for
interactions between age group and each variable, and the
results should therefore be interpreted with caution.
Discussion
Our study found evidence of a reduction in early death and
an improvement in survival after AML over a 25-year period
Table II. Relationhip of sociodemographic and clinical factors to early death in patients aged 0–39 years with acute myeloid leukaemia in Califor-
nia, 1988–2011.
Characteristics
Adjusted OR1 (95% CI)
1988–2011 P-value*
Adjusted OR2 (95% CI)
1996–2011 P-value*
Adjusted OR3 (95% CI)
1996–2011 P-value*
Calendar period
1988–1995 138 (104–183) 00799 N/A 01552 N/A 02208
1996–2003 122 (092–163) 123 (092–164) 120 (090–161)
2004–2011 1 (reference) 1 (reference) 1 (reference)
Sex
Male 111 (088–140) 03656 121 (091–162) 01908 120 (090–161) 02153
Female 1 (reference) 1 (reference) 1 (reference)
Age at diagnosis, years
0–9 1 (reference) 00049 1 (reference) 01743 1 (reference) 03915
10–19 121 (082–140) 116 (090–276) 113 (070–181)
20–29 164 (116–234) 158 (103–242) 144 (093–221)
30–39 170 (122–238) 136 (089–206) 127 (084–194)
Race/ethnicity
Non-Hispanic white 1 (reference) 00599 1 (reference) 01533 1 (reference) 02791
Non-Hispanic black 115 (074–179) 107 (058–197) 106 (058–196)
Hispanic 114 (086–149) 122 (086–173) 112 (078–161)
Asian/Pacific Islander 065 (042–099) 066 (038–115) 066 (038–114)
Neighbourhood socioeconomic status (quintiles)
Lowest 20% 157 (105–234) 00934 158 (090–276) 04512 154 (087–272) 04411
104 (068–157) 129 (073–227) 128 (072–226)
Middle 20% 118 (078–177) 151 (086–173) 153 (087–269)
119 (078–181) 154 (087–270) 158 (090–280)
Highest 20% 1 (reference) 1 (reference) 1 (reference)
Initial care at hospitals affiliated with NCI-designated cancer centres
Yes 1 (reference) 00002 1 (reference) 00004 1 (reference) 00004
No 175 (128–239) 196 (132–292) 199 (133–297)
Health insurance status (limited to patients diagnosed in 1996–2011, N = 2632)
Uninsured N/A N/A 291 (165–512) 00046
Public N/A N/A 103 (073–146)
Private N/A N/A 1 (reference)
Unknown/NOS N/A N/A N/A N/A 104 (001–043)
OR, odds ratio; CI, confidence interval; NOS, not otherwise specified; NCI, National Cancer Institute. OR1, adjusted model without insurance
(1988–2011); OR2, adjusted model without insurance (1996–2011); OR3, adjusted model with insurance (1996–2011).
*Likelihood ratio test.
Fig 1. Overall survival after acute myeloid leukaemia by age group
at diagnosis, in California, 1988–2011 (percentages in the graph cor-
respond to 10-year survival).
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for patients of all age and racial/ethnic groups in California.
Overall, early death and survival were associated with several
sociodemographic and clinical factors, including age at diag-
nosis, race/ethnicity, neighbourhood SES, hospital designa-
tion, and health insurance status. Despite substantial
improvements, approximately half of the patients died in the
most recent treatment period (2004–2011).
We found worse survival among black patients than white
patients, consistent with previous studies of AML and acute
lymphoblastic leukaemia (ALL) (Sekeres et al, 2004; Aplenc
et al, 2006; Rubnitz et al, 2007; Bradley et al, 2011; Byrne
et al, 2011; Dores et al, 2012; Pulte et al, 2012, 2013; Patel
et al, 2015b). Results from several clinical trials at a single
institution in the US showed survival in black children with
AML to be similar to that in white children (Rubnitz et al,
2007). However, a recent trial at the same institution showed
a trend towards worse outcomes in black children compared
to those in white and Hispanic children (Rubnitz et al,
2007). It is not yet clear what factors accounted for the dis-
parities in survival among black patients with AML that were
observed in our and other studies. Black race/ethnicity has
been associated with both favourable and unfavourable cyto-
genetic subtypes (Sekeres et al, 2004; Rubnitz et al, 2007). It
is possible that pharmacogenetic differences between black
and white patients contribute to different responses to
chemotherapy (Pui et al, 2004; Rubnitz et al, 2007). Another
possibility is that black patients have had less access to
chemotherapy and/or HSCT. A recent study using CCR data
linked to hospital discharge data showed that the odds of
receipt of HSCT and chemotherapy were lower among black
than non-black patients (Patel et al, 2015a).
Interestingly, we found no evidence of differences in sur-
vival between Hispanic and white patients in any age group.
This differs from the results of two consecutive clinical trials
Table III. Relationship of sociodemographic and clinical factors to the hazard of death after acute myeloid leukaemia in patients aged 0–39 years
in California, 1988–2011.
Characteristics
Adjusted HR1 (95% CI)
1988–2011 P-value*
Adjusted HR2 (95% CI)
1996–2011 P-value*
Adjusted HR3 (95% CI)
1996–2011 P-value*
Calendar period
1988–1995 158 (143–176) <00001 N/A 00211 N/A 00460
1996–2003 114 (103–127) 114 (102–127) 112 (100–125)
2004–2011 10 (reference) 10 (reference 10 (reference)
Age at diagnosis, years
0–9 10 (reference) <00001 10 (reference) <00001 10 (reference) <00001
10–19 123 (107–140) 128 (108–152) 128 (107–151)
20–29 134 (118–152) 139 (118–164) 138 (117–162)
30–39 155 (138–174) 149 (128–174) 149 (128–174)
Race/ethnicity
Non-Hispanic white 10 (reference) 00318 10 (reference) 00505 10 (reference) 00629
Non-Hispanic black 127 (108–149) 133 (108–165) 134 (108–165)
Hispanic 105 (095–116) 110 (096–125) 108 (094–124)
Asian/Pacific Islander 098 (086–113) 100 (083–118) 100 (084–119)
Sex
Male 103 (095–112) 04806 099 (089–110) 08900 099 (089–110) 08349
Female 10 (reference) 10 (reference 10 (reference)
Neighbourhood socioeconomic status (quintiles)
Lowest 20% 114 (099–131) 01868 123 (101–149) 00490 122 (100–148) 00453
110 (095–127) 120 (100–146) 120 (099–145)
Middle 20% 113 (098–130) 130 (108–158) 131 (108–159)
101 (087–115) 107 (088–130) 107 (088–131)
Highest 20% 10 (reference) 10 (reference 10 (reference)
Initial care at hospitals affiliated with NCI-designated cancer centres
Yes 10 (reference) 00009 10 (reference 00004 10 (reference) 00002
No 118 (107–131) 126 (111–143) 127 (111–145)
Health insurance status (limited to patients diagnosed in 1996–2011, N = 2632)
None N/A N/A 134 (101–178)
Public N/A N/A 105 (093–119)
Private N/A N/A 10 (reference)
Unknown/NOS N/A N/A N/A N/A 127 (107–151) 00204
HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified; NCI, National Cancer Institute. HR1, adjusted model without insurance,
1988–2011; HR2, adjusted model without insurance, 1996–2011; HR3, adjusted model with insurance, 1996–2011.
*Likelihood ratio test.
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by the Children’s Oncology Group (patients aged 0–21 years)
(Aplenc et al, 2006), but is consistent with the population-
based study mentioned above (Patel et al, 2015a) that found
survival among Hispanics to be similar to that among white
patients after adjustment for age (all ages included), and with
paediatric clinical trials that showed favourable outcomes
among Hispanic patients with AML (Rubnitz et al, 2007).
These observations contrast with the worse survival observed
among Hispanic children and adolescents with ALL in the
US (Goggins & Lo, 2012; Lim et al, 2014; Pulte et al, 2013;
Abrah~ao et al, 2015b), and suggest that unfavourable biologi-
cal characteristics are associated with survival after ALL (Lim
et al, 2014) but may not contribute, to the same extent, to
the worse outcomes after AML. In fact, clinical trials have
shown favourable cytogenetic characteristics among Hispanic
children with AML (Rubnitz et al, 2007).
Clinical (Aplenc et al, 2006) and population-based studies
(Patel et al, 2015a) that looked at the association of race/eth-
nicity with survival lacked information on SES. Our informa-
tion on neighbourhood SES found a significant association
between lower SES and higher early death, but there was no
evidence of an association between neighbourhood SES and
survival. This suggests that some patients with lower neigh-
bourhood SES lacked access to optimal treatment during the
critical initial days after AML diagnosis.
Our findings showed that survival was better among
patients aged 0–9 years and there was no evidence of
increased hazard of death associated with sociodemographic
and clinical characteristics in this age group. However,
among older patients, particularly those aged 30–39 years, we
observed an association between increased risk of death and
several sociodemographic and clinical factors, including treat-
ment at hospitals not affiliated with NCI-designated cancer
centres, lack of health insurance and black race/ethnicity.
The diagnosis of AML in older patients may carry a worse
prognosis and probably requires more intensive chemother-
apy and, in some cases, HSCT. Consequently, these patients
possibly have a higher probability of treatment-related com-
plications (mainly haemorrhage and infection) requiring
more aggressive treatment and long-term supportive care.
Recent studies have shown that the biology of paediatric
AML differs from that of adult AML and that structural and
numerical chromosome alterations have prognostic implica-
tions (Grimwade et al, 1998; Harrison et al, 2010; Tarlock &
Meshinchi, 2015). For instance, core-binding factor AML
[CBF AML: t(8;21) and inv(16)/t(16;16)], which has a
favourable prognosis, is more frequent in children and ado-
lescents than in adults. In contrast, abnormalities of chromo-
somes 5 and 7 are more common in adults and are
associated with a dismal prognosis (Tarlock & Meshinchi,
2015). Additionally, somatic mutations in selected genes,
such as FLT3, NPM1 and CEBPA, are known to have prog-
nostic clinical significance in paediatric and adult AML.
Whereas double CEBPA and isolated NPM1 mutations are
Table IV. Relation of sociodemographic and clinical factors to the hazard of death after acute myeloid leukaemia by age group at diagnosis, Cali-
fornia, 1988–2011.
Characteristics
(total = 3935)
HR1 (95% CI)
0–9 years
N = 964 P-value*
HR2 (95% CI)
10–19 years
N = 733 P-value*
HR3 (95% CI)
20–29 years
N = 951 P-value*
HR4 (95% CI)
30–39 years
N = 1287 P-value*
Calendar period
1988–1995 184 (145–234) <00001 152 (119–193) 00034 129 (105–159) 00049 171 (144–204) <00001
1996–2003 136 (107–173) 127 (099–163) 095 (076–118) 114 (095–136)
2004–2011 10 (reference) 10 (reference) 10 (reference) 10 (reference)
Race/ethnicity
Non-Hispanic white 10 (reference) 02468 10 (reference) 07294 10 (reference) 00122 10 (reference) 00821
Non-Hispanic black 122 (086–174) 119 (081–174) 170 (121–239) 119 (092–154)
Hispanic 102 (082–128) 106 (083–135) 105 (086–130) 110 (093–130)
Asian/Pacific Islander 079 (057–109) 116 (084–160) 128 (099–164) 084 (067–105)
Sex
Male 093 (077–112) 04455 089 (073–108) 02287 117 (099–138) 00734 106 (092–121) 04152
Female 10 (reference) 10 (reference) 10 (reference) 10 (reference)
Neighbourhood socioeconomic status (quintiles)
Lowest 20% 088 (063–122) 04063 111 (080–153) 04579 126 (094–168) 00583 119 (094–151) 01260
107 (077–147) 096 (069–132) 103 (077–138) 121 (096–153)
Middle 20% 086 (063–120) 093 (066–130) 114 (086–152) 131 (105–153)
083 (059–117) 082 (058–116) 084 (062–114) 131 (104–164)
Highest 20% 10 (reference) 10 (reference) 10 (reference) 10 (reference)
Initial care at hospitals affiliated with NCI-designated cancer centres
Yes 10 (reference) 03314 10 (reference) 00220 10 (reference) 03310 10 (reference) 00042
No 110 (091–132) 129 (103–161) 111 (090–137) 131 (108–158)
HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified; NCI, National Cancer Institute.
*Likelihood ratio test.
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associated with a reduced risk of relapse and better survival
(Ho et al, 2009; Yoon et al, 2015), patients with internal tan-
dem mutations of FLT3 (FLT3-ITD mutations) have a higher
risk of relapse and worse survival and may benefit from
receipt of HSCT (Schlenk et al, 2008). Adult AML has a
higher prevalence of FLT3-ITD mutations compared to pae-
diatric AML (27% vs. 12%) (Tarlock & Meshinchi, 2015).
These cytogenetic and genomic differences may partly
account for the inferior outcomes we observed among older
patients and explain the association between worse survival
and sociodemographic and clinical factors. Hence, interven-
tions to improve timely access to high-quality complex ther-
apy and optimal supportive care for all individuals with
AML have the potential to reduce mortality and morbidity,
particularly among higher-risk and minority patients.
Other factors that may contribute to the worse outcomes
among older patients with AML include the lower participa-
tion of adolescents and young adults in clinical trials or
treatment at hospitals that are not affiliated with NCI-desig-
nated cancer centres compared with that of paediatric
patients (Bleyer & Barr, 2009). We had no information on
patients’ clinical trial enrolment, but our observations
support the results from a previous study (Wolfson et al,
2012) showing that adolescents and young adults with cancer
who were treated at hospitals affiliated with NCI-designated
cancer centres had better outcomes than those treated at hos-
pitals not affiliated with such centres.
Moreover, we found evidence of increased early death and
worse survival among uninsured patients compared to pri-
vately or publicly insured patients. These results agree with
recent studies that showed health insurance status to be inde-
pendently associated with the risk of death (Bradley et al,
2011; Robbins et al, 2014; Rosenberg et al, 2014), and high-
light the importance of health systems that provide timely
access to adequate treatment (chemotherapy and, when rec-
ommended, HSCT) and optimal supportive care, including
prophylaxis and control of invasive fungal infection.
Intensive chemotherapy regimens, improvements in sup-
portive care, development of risk-adapted treatment strate-
gies (through cytogenetic studies and early response to
treatment as measured by minimal residual disease) and pro-
vision of HSCT to a greater number of high-risk patients are
considered the primary causes of better outcomes in AML,
rather than novel therapeutic agents (Ferrara & Schiffer,
Table V. Relationship of sociodemographic and clinical factors to the hazard of death after acute myeloid leukaemia by age group at diagnosis,
including health insurance status, California, 1996–2011.
Characteristics
(total = 2632)
HR1 (95% CI)
0–9 years
N = 671 P-value*
HR2 (95% CI)
10–19 years
N = 510 P-value*
HR3 (95% CI)
20–29 years
N = 619 P-value*
HR4 (95% CI)
30–39 years
N = 832 P-value*
Calendar period
1996–2003 131 (102–168) 00308 128 (099–164) 00580 092 (074–115) 04640 113 (094–136) 02000
2004–2011 10 (reference) 10 (reference) 10 (reference) 10 (reference)
Race/ethnicity
Non-Hispanic white 10 (reference) 00821 10 (reference) 08872 10 (reference) 00392 10 (reference) 04981
Non-Hispanic black 163 (104–257) 123 (074–205) 195 (117–325) 111 (078–156)
Hispanic 127 (093–172) 105 (076–144) 117 (088–156) 099 (079–124)
Asian/Pacific Islander 087 (055–136) 101 (066–155) 140 (101–192) 083 (062–111)
Sex
Male 089 (070–112) 03220 084 (065–108) 01688 108 (086–135) 05054 106 (088–127) 05343
Female 10 (reference) 10 (reference) 10 (reference) 10 (reference)
Neighbourhood socioeconomic status (quintiles)
Lowest 20% 092 (059–143) 06758 112 (071–078) 07838 137 (092–204) 00281 134 (095–188) 00035
116 (076–177) 092 (059–144) 103 (069–153) 156 (114–215)
Middle 20% 102 (067–156) 099 (064–153) 121 (082–178) 176 (128–242)
092 (059–145) 087 (054–140) 077 (051–116) 160 (117–220)
Highest 20% 10 (reference) 10 (reference) 10 (reference) 10 (reference)
Initial care at hospitals affiliated with NCI-designated cancer centres
Yes 10 (reference) 03512 10 (reference) 00078 10 (reference) 01414 10 (reference) 00095
No 112 (088–143) 144 (109–190) 124 (093–166) 139 (108–180)
Health insurance status
None 160 (063–402) 04384 178 (085–375) 02399 094 (057–155) 01965 178 (114–276) 00986
Public 093 (069–125) 121 (090–164) 099 (077–127) 110 (090–136)
Private 10 (reference) 10 (reference) 10 (reference) 10 (reference)
Unknown/NOS 121 (083–175) 135 (092–199) 145 (102–207) 117 (086–159)
HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified; NCI, National Cancer Institute.
*Likelihood ratio test.
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2013). Although improvements in HSCT have led to a signif-
icant decrease in transplant-related morbidity and mortality
in patients with AML (Ferrara & Schiffer, 2013), the role of
HSCT remains controversial. With the progress in the use of
chemotherapy and the improvement in risk assessment over
the last 25 years, HSCT in first remission is not recom-
mended for AML patients that have a favourable prognosis
(CBF AML) (Carpenter et al, 2012), and the use of HSCT
may be limited to intermediate-risk patients who experience
relapse after undergoing initial therapy (Burnett et al, 2013).
Because AML is a complex disease characterized by mor-
phological and cytogenetic heterogeneity, we believe that
multiple factors may have contributed to the lower survival
we observed among older patients and those of black race/
ethnicity. Further improvements in disease outcomes will
also require the development of more effective and less toxic
agents for each subtype of the disease (precision medicine)
(Rubnitz & Inaba, 2012). Conventional genetic and, more
recently, genomic studies have played a key role in advancing
the cure for ALL over a period of almost 30 years (Evans
et al, 2013), and the same benefit is expected for AML. In
the new era of basket trials [clinical trial design based on the
hypothesis that the presence of a molecular marker predicts
response to a targeted therapy regardless of tumour histology
(Redig & Janne, 2015)] and big data infrastructure (including
access to electronic medical records and linkage of cancer
registry data with insurance claims information) (Meyer &
Basch, 2015), national and international collaborations are
fundamental to help to answer questions regarding treatment
efficacy, toxicity and long-term survival.
Our study has several limitations. Hospital designation
was limited to the location of care at the first reporting facil-
ity, so it is possible that some patients who were initially
treated at one type of facility were subsequently treated at
another. Nevertheless, the majority of our patients (90%)
received at least part of their treatment at the reporting hos-
pital. The CCR, like the majority of population-based cancer
registries, does not collect information on patients’ perfor-
mance status, baseline cytogenetic risk assessment or relapse.
Without these additional data, it was not possible to clearly
investigate whether there was an association between the
receipt of HSCT and survival. Although supplementary clini-
cal information would have contributed additional important
findings and explained some of the variability of our results,
our study provided relevant information on survival and
early death over a 25-year period in the most populous and
racial/ethnically diverse state of the United States, using
high-quality data. We have also provided important informa-
tion on factors that may have influenced AML outcomes. To
our knowledge, this is the first population-based study to
consider the association between neighbourhood SES and
outcomes (survival and early death) and to identify associa-
tions of several sociodemographic and clinical factors with
survival, both overall and stratified by age group among chil-
dren, adolescents and young adults with AML. Whereas
clinical trials are essential to develop guidelines for the best
therapeutic regimen (better efficacy with less toxicity), they
provide data in less than 3% of the cancer population
(Meyer & Basch, 2015), although this proportion is usually
higher among paediatric patients. In addition, clinical trials
commonly report relatively short outcomes (i.e., event-free
survival and 1–5 years overall survival). Our study included
up to 10 years of survival estimates on virtually all patients
in California, important information to evaluate long-term
outcomes and excess mortality after treatment.
In conclusion, survival after AML increased over time
among children, adolescents and young adults, but 5-year
survival was still only 50% or less in the most recent treat-
ment period (2004–2011). We identified subgroups with a
higher risk of death from the disease, including those aged
10–39 years, uninsured patients, those who received initial
care at hospitals not affiliated with NCI-designated cancer
centres and those of black race/ethnicity. At the population-
based level, strategies to address the high burden of AML,
especially among adolescents and young adults, may include
wider insurance coverage and treatment at specialized cancer
centres.
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Disparities found to affect survival for older
children, adolescents and young adults with
acute myeloid leukemia
FREMONT, CA (PRWEB) FEBRUARY 18, 2016
Acute leukemia is the leading cause of cancer death among
patients 39 years of age and younger. Without treatment, most
patients die within months, if not weeks, of diagnosis. The
Gve-year survival was only about 50% for the most recent
treatment period of 2004 – 2011.
In a study led by the Cancer Prevention Institute of
California(CPIC) and the London School of Hygiene and
Tropical Medicine, and published in the February issue of the
British Journal of Hematology, researchers analyzed 3,935
patients with acute myeloid leukemia (AML) up to 39 years of
age in California from 1988 – 2011.
For this study researchers used data from the California
Cancer Registry, which participates in the Surveillance,
Epidemiology and End Results (SEER) program of the National
Cancer Institute (NCI). To the authors’ knowledge, this is the
Grst population-based study that simultaneously examined the
in^uence of race/ethnicity, neighborhood socioeconomic
status, type of health insurance and treatment facility on
survival.
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Researchers found several subgroups of patients with worse
survival. They tended to fall into one of these groups:
    age group (10 – 39 years)
    lower neighborhood socioeconomic status
    black race/ethnicity
    receipt of initial care in hospitals not afGliated with the
NCI
    lack of health insurance
The diagnosis of AML in older children, adolescents and young
adults may require more intensive treatment, which may lead
to a higher probability of treatment-related complications.
Older children, adolescents and young adults are also less
likely to participate in clinical trials and more likely to receive
treatment at hospitals not afGliated with the NCI in comparison
to younger children.
A signiGcant association was found between lower socioeconomic neighborhoods and early
death suggesting that these patients lacked access to optimal treatments during the critical
days after initial diagnosis.
It is not clear what factors accounted for the disparities in survival among black patients.
Researchers speculate that genetics may contribute to the difference in chemotherapy
response or that black patients had less access to chemotherapy and other treatments such
as hematopoietic stem cell transplantation.
Recent studies have also shown the biology of pediatric AML differs from adult AML which
may lead to a favorable prognosis in younger patients.
Researchers also found evidence of increased early death and lower survival among
uninsured patients compared to privately or publicly insured patients. Health insurance
information was available in the California Cancer Registry for patients diagnosed from 1996
– 2011.
“Our study reveals that survival inequalities persist among vulnerable patients with acute
myeloid leukemia such as the uninsured, those of black race/ethnicity and adolescents and
young adults.” said Renata Abrahão MD, MSc, a visiting research scientist at CPIC and lead
author of the study. “This study can serve as a baseline to compare changes in survival that
may result from potential improvements in health insurance coverage following the
implementation of the Affordable Care Act (Obamacare).”
“Moreover, this study showed that survival after AML remains low among young patients
and highlights the need for new therapeutic regimens to treat this disease with various
subtypes. We emphasized the importance of linking population-based data with genetic and
clinical information contained in the patients’ medical records in order to better understand
the causes of survival inequalities.”
The work was supported by Children with Cancer UK.
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Department of Non-Communicable Disease Epidemiology, London School of Hygiene and
Tropical Medicine; Ruth Keogh of the Department of Medical Statistics, London School of
Hygiene and Tropical Medicine; Daphne Lichtensztajn of the Cancer Prevention Institute of
California; Rafael Marcos-Gragera of the Epidemiology Unity and Cancer Registry of Girona,
Girona Biomedical Research Institute; Bruno Medeiros of the Division of Hematology,
Stanford University School of Medicine; Michel Coleman of the Department of
Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical
Medicine; Raul Ribeiro of the Department of Oncology, Leukemia and Lymphoma Division, St.
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About the Cancer Prevention Institute of California
The Cancer Prevention Institute of California is the nation’s premier organization dedicated
to preventing cancer and to reducing its burden where it cannot yet be prevented. CPIC
tracks patterns of cancer throughout the entire population and identiGes those at risk for
developing cancer. Its research scientists are leaders in investigating the causes of cancer in
large populations to advance the development of prevention-focused interventions. CPIC’s
innovative cancer prevention research and education programs, together with the work of
the Stanford Cancer Institute, can make our vision of a world without cancer a reality. For
more information, visit CPIC’s ofGcial website at http://www.cpic.org.
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